Altered	15177686
replication	15177686
timing	15177686
of	15177686
the	15177686
HIRA	15177686
/	15177686
Tuple1	15177686
locus	15177686
in	15177686
the	15177686
DiGeorge	15177686
and	15177686
Velocardiofacial	15177686
syndromes	15177686
.	15177686

DiGeorge	15177686
and	15177686
Velocardiofacial	15177686
syndromes	15177686
(	15177686
DGS	15177686
/	15177686
VCFS	15177686
)	15177686
are	15177686
endowed	15177686
by	15177686
a	15177686
similar	15177686
complex	15177686
phenotype	15177686
including	15177686
cardiovascular	15177686
,	15177686
craniofacial	15177686
,	15177686
and	15177686
thymic	15177686
malformations	15177686
,	15177686
and	15177686
are	15177686
associated	15177686
with	15177686
heterozygous	15177686
deletions	15177686
of	15177686
22q11	15177686
chromosomal	15177686
band	15177686
.	15177686

The	15177686
Typically	15177686
Deleted	15177686
Region	15177686
in	15177686
the	15177686
22q11	15177686
.	15177686
21	15177686
subband	15177686
(	15177686
here	15177686
called	15177686
TDR22	15177686
)	15177686
is	15177686
very	15177686
gene	15177686
-	15177686
dense	15177686
,	15177686
and	15177686
the	15177686
extent	15177686
of	15177686
the	15177686
deletion	15177686
has	15177686
been	15177686
defined	15177686
precisely	15177686
in	15177686
several	15177686
studies	15177686
.	15177686

However	15177686
,	15177686
to	15177686
date	15177686
there	15177686
is	15177686
no	15177686
evidence	15177686
for	15177686
a	15177686
mechanism	15177686
of	15177686
haploinsufficiency	15177686
that	15177686
can	15177686
fully	15177686
explain	15177686
the	15177686
DGS	15177686
/	15177686
VCFS	15177686
phenotype	15177686
.	15177686

In	15177686
this	15177686
study	15177686
,	15177686
we	15177686
show	15177686
that	15177686
the	15177686
candidate	15177686
gene	15177686
HIRA	15177686
/	15177686
Tuple1	15177686
mapping	15177686
on	15177686
the	15177686
non	15177686
-	15177686
deleted	15177686
TDR22	15177686
,	15177686
in	15177686
DGS	15177686
/	15177686
VCFS	15177686
subjects	15177686
presents	15177686
a	15177686
delayed	15177686
replication	15177686
timing	15177686
.	15177686

Moreover	15177686
,	15177686
we	15177686
observed	15177686
an	15177686
increase	15177686
in	15177686
the	15177686
cell	15177686
ratio	15177686
showing	15177686
the	15177686
HIRA	15177686
/	15177686
Tuple1	15177686
locus	15177686
localised	15177686
toward	15177686
the	15177686
nuclear	15177686
periphery	15177686
.	15177686

It	15177686
is	15177686
known	15177686
that	15177686
replication	15177686
timing	15177686
and	15177686
nuclear	15177686
location	15177686
are	15177686
generally	15177686
correlated	15177686
to	15177686
the	15177686
transcription	15177686
activity	15177686
of	15177686
the	15177686
relative	15177686
DNA	15177686
region	15177686
.	15177686

We	15177686
propose	15177686
that	15177686
the	15177686
alteration	15177686
in	15177686
the	15177686
replication	15177686
/	15177686
nuclear	15177686
location	15177686
pattern	15177686
of	15177686
the	15177686
non	15177686
-	15177686
deleted	15177686
TDR22	15177686
indicates	15177686
an	15177686
altered	15177686
gene	15177686
regulation	15177686
hence	15177686
an	15177686
altered	15177686
transcritpion	15177686
in	15177686
DGS	15177686
/	15177686
VCFS	15177686
.	15177686
Manganese	17628794
superoxide	17628794
dismutase	17628794
(	17628794
Mn	17628794
-	17628794
SOD	17628794
)	17628794
gene	17628794
polymorphisms	17628794
in	17628794
urolithiasis	17628794
.	17628794

Polymorphism	17628794
in	17628794
manganese	17628794
superoxide	17628794
dismutase	17628794
gene	17628794
(	17628794
Mn	17628794
-	17628794
SOD	17628794
)	17628794
is	17628794
a	17628794
new	17628794
approach	17628794
to	17628794
identify	17628794
its	17628794
probable	17628794
association	17628794
with	17628794
urolithiasis	17628794
.	17628794

Oxidative	17628794
stress	17628794
may	17628794
be	17628794
involved	17628794
in	17628794
the	17628794
development	17628794
of	17628794
stone	17628794
formation	17628794
in	17628794
the	17628794
renal	17628794
system	17628794
.	17628794

MnSOD	17628794
is	17628794
one	17628794
of	17628794
the	17628794
primary	17628794
enzymes	17628794
that	17628794
directly	17628794
scavenges	17628794
potential	17628794
harmful	17628794
oxidizing	17628794
species	17628794
.	17628794

A	17628794
valine	17628794
(	17628794
Val	17628794
)	17628794
to	17628794
alanine	17628794
(	17628794
Ala	17628794
)	17628794
substitution	17628794
at	17628794
amino	17628794
acid	17628794
16	17628794
,	17628794
occurring	17628794
in	17628794
the	17628794
mitochondrial	17628794
targeting	17628794
sequence	17628794
of	17628794
the	17628794
MnSOD	17628794
gene	17628794
,	17628794
has	17628794
been	17628794
associated	17628794
with	17628794
an	17628794
increase	17628794
in	17628794
urolithiasis	17628794
risk	17628794
.	17628794

This	17628794
study	17628794
was	17628794
conducted	17628794
to	17628794
investigate	17628794
the	17628794
association	17628794
of	17628794
MnSOD	17628794
gene	17628794
polymorphism	17628794
with	17628794
the	17628794
risk	17628794
of	17628794
urolithiasis	17628794
.	17628794

We	17628794
investigated	17628794
the	17628794
MnSOD	17628794
in	17628794
66	17628794
stone	17628794
-	17628794
forming	17628794
adults	17628794
and	17628794
72	17628794
healthy	17628794
volunteers	17628794
.	17628794

DNA	17628794
was	17628794
isolated	17628794
from	17628794
peripheral	17628794
blood	17628794
and	17628794
genotyping	17628794
was	17628794
performed	17628794
with	17628794
PCR	17628794
-	17628794
based	17628794
methods	17628794
.	17628794

Then	17628794
PCR	17628794
products	17628794
were	17628794
cut	17628794
by	17628794
BsaW1	17628794
.	17628794

Products	17628794
were	17628794
run	17628794
on	17628794
3%	17628794
agarose	17628794
gel	17628794
,	17628794
246	17628794
bp	17628794
regions	17628794
were	17628794
1	17628794
-	17628794
Ala	17628794
-	17628794
9	17628794
,	17628794
164	17628794
and	17628794
82	17628794
bp	17628794
products	17628794
were	17628794
determined	17628794
as	17628794
2	17628794
Val	17628794
-	17628794
9	17628794
.	17628794

Chi	17628794
-	17628794
square	17628794
test	17628794
was	17628794
used	17628794
for	17628794
comparison	17628794
between	17628794
patients	17628794
and	17628794
controls	17628794
.	17628794

In	17628794
the	17628794
control	17628794
group	17628794
the	17628794
homozygote	17628794
Ala	17628794
allele	17628794
was	17628794
significantly	17628794
higher	17628794
than	17628794
in	17628794
the	17628794
patient	17628794
group	17628794
(	17628794
P	17628794
<	17628794
0	17628794
.	17628794
01	17628794
)	17628794
.	17628794

The	17628794
distribution	17628794
of	17628794
Ala	17628794
/	17628794
Val	17628794
and	17628794
homozygote	17628794
Val	17628794
alleles	17628794
in	17628794
the	17628794
patient	17628794
group	17628794
was	17628794
significantly	17628794
higher	17628794
than	17628794
in	17628794
the	17628794
control	17628794
group	17628794
(	17628794
P	17628794
<	17628794
0	17628794
.	17628794
05	17628794
)	17628794
.	17628794

MnSOD	17628794
genotype	17628794
determination	17628794
may	17628794
provide	17628794
a	17628794
tool	17628794
to	17628794
identify	17628794
individuals	17628794
who	17628794
are	17628794
at	17628794
risk	17628794
of	17628794
urolithiasis	17628794
.	17628794

This	17628794
experiment	17628794
also	17628794
provides	17628794
data	17628794
about	17628794
antioxidant	17628794
status	17628794
and	17628794
stone	17628794
formation	17628794
.	17628794
Identification	17395743
of	17395743
PVT1	17395743
as	17395743
a	17395743
candidate	17395743
gene	17395743
for	17395743
end	17395743
-	17395743
stage	17395743
renal	17395743
disease	17395743
in	17395743
type	17395743
2	17395743
diabetes	17395743
using	17395743
a	17395743
pooling	17395743
-	17395743
based	17395743
genome	17395743
-	17395743
wide	17395743
single	17395743
nucleotide	17395743
polymorphism	17395743
association	17395743
study	17395743
.	17395743

To	17395743
identify	17395743
genetic	17395743
variants	17395743
contributing	17395743
to	17395743
end	17395743
-	17395743
stage	17395743
renal	17395743
disease	17395743
(	17395743
ESRD	17395743
)	17395743
in	17395743
type	17395743
2	17395743
diabetes	17395743
,	17395743
we	17395743
performed	17395743
a	17395743
genome	17395743
-	17395743
wide	17395743
analysis	17395743
of	17395743
115	17395743
,	17395743
352	17395743
single	17395743
nucleotide	17395743
polymorphisms	17395743
(	17395743
SNPs	17395743
)	17395743
in	17395743
pools	17395743
of	17395743
105	17395743
unrelated	17395743
case	17395743
subjects	17395743
with	17395743
ESRD	17395743
and	17395743
102	17395743
unrelated	17395743
control	17395743
subjects	17395743
who	17395743
have	17395743
had	17395743
type	17395743
2	17395743
diabetes	17395743
for	17395743
>	17395743
or	17395743
=	17395743
10	17395743
years	17395743
without	17395743
macroalbuminuria	17395743
.	17395743

Using	17395743
a	17395743
sliding	17395743
window	17395743
statistic	17395743
of	17395743
ranked	17395743
SNPs	17395743
,	17395743
we	17395743
identified	17395743
a	17395743
200	17395743
-	17395743
kb	17395743
region	17395743
on	17395743
8q24	17395743
harboring	17395743
three	17395743
SNPs	17395743
showing	17395743
substantial	17395743
differences	17395743
in	17395743
allelic	17395743
frequency	17395743
between	17395743
case	17395743
and	17395743
control	17395743
pools	17395743
.	17395743

These	17395743
SNPs	17395743
were	17395743
genotyped	17395743
in	17395743
individuals	17395743
comprising	17395743
each	17395743
pool	17395743
,	17395743
and	17395743
strong	17395743
evidence	17395743
for	17395743
association	17395743
was	17395743
found	17395743
with	17395743
rs2720709	17395743
(	17395743
P	17395743
=	17395743
0	17395743
.	17395743
000021	17395743
;	17395743
odds	17395743
ratio	17395743
2	17395743
.	17395743
57	17395743
[	17395743
95%	17395743
CI	17395743
1	17395743
.	17395743
66	17395743
-	17395743
3	17395743
.	17395743
96	17395743
]	17395743
)	17395743
,	17395743
which	17395743
is	17395743
located	17395743
in	17395743
the	17395743
plasmacytoma	17395743
variant	17395743
translocation	17395743
gene	17395743
PVT1	17395743
.	17395743

We	17395743
sequenced	17395743
all	17395743
exons	17395743
,	17395743
exon	17395743
-	17395743
intron	17395743
boundaries	17395743
,	17395743
and	17395743
the	17395743
promoter	17395743
of	17395743
PVT1	17395743
and	17395743
identified	17395743
47	17395743
variants	17395743
,	17395743
11	17395743
of	17395743
which	17395743
represented	17395743
nonredundant	17395743
markers	17395743
with	17395743
minor	17395743
allele	17395743
frequency	17395743
>	17395743
or	17395743
=	17395743
0	17395743
.	17395743
05	17395743
.	17395743

We	17395743
subsequently	17395743
genotyped	17395743
these	17395743
11	17395743
variants	17395743
and	17395743
an	17395743
additional	17395743
87	17395743
SNPs	17395743
identified	17395743
through	17395743
public	17395743
databases	17395743
in	17395743
319	17395743
-	17395743
kb	17395743
flanking	17395743
rs2720709	17395743
(	17395743
approximately	17395743
1	17395743
SNP	17395743
/	17395743
3	17395743
.	17395743
5	17395743
kb	17395743
)	17395743
;	17395743
23	17395743
markers	17395743
were	17395743
associated	17395743
with	17395743
ESRD	17395743
at	17395743
P	17395743
<	17395743
0	17395743
.	17395743
01	17395743
.	17395743

The	17395743
strongest	17395743
evidence	17395743
for	17395743
association	17395743
was	17395743
found	17395743
for	17395743
rs2648875	17395743
(	17395743
P	17395743
=	17395743
0	17395743
.	17395743
0000018	17395743
;	17395743
2	17395743
.	17395743
97	17395743
[	17395743
1	17395743
.	17395743
90	17395743
-	17395743
4	17395743
.	17395743
65	17395743
]	17395743
)	17395743
,	17395743
which	17395743
maps	17395743
to	17395743
intron	17395743
8	17395743
of	17395743
PVT1	17395743
.	17395743

Together	17395743
,	17395743
these	17395743
results	17395743
suggest	17395743
that	17395743
PVT1	17395743
may	17395743
contribute	17395743
to	17395743
ESRD	17395743
susceptibility	17395743
in	17395743
diabetes	17395743
.	17395743
Roles	21666969
of	21666969
G1359A	21666969
polymorphism	21666969
of	21666969
the	21666969
cannabinoid	21666969
receptor	21666969
gene	21666969
(	21666969
CNR1	21666969
)	21666969
on	21666969
weight	21666969
loss	21666969
and	21666969
adipocytokines	21666969
after	21666969
a	21666969
hypocaloric	21666969
diet	21666969
.	21666969

BACKGROUND	21666969
:	21666969
A	21666969
intragenic	21666969
biallelic	21666969
polymorphism	21666969
(	21666969
1359	21666969
G	21666969
/	21666969
A	21666969
)	21666969
of	21666969
the	21666969
CB1	21666969
gene	21666969
resulting	21666969
in	21666969
the	21666969
substitution	21666969
of	21666969
the	21666969
G	21666969
to	21666969
A	21666969
at	21666969
nucleotide	21666969
position	21666969
1359	21666969
in	21666969
codon	21666969
435	21666969
(	21666969
Thr	21666969
)	21666969
,	21666969
was	21666969
reported	21666969
as	21666969
a	21666969
common	21666969
polymorphism	21666969
in	21666969
Caucasian	21666969
populations	21666969
.	21666969

Intervention	21666969
studies	21666969
with	21666969
this	21666969
polymorphism	21666969
have	21666969
not	21666969
been	21666969
realized	21666969
.	21666969

OBJECTIVE	21666969
:	21666969
We	21666969
decided	21666969
to	21666969
investigate	21666969
the	21666969
role	21666969
of	21666969
the	21666969
polymorphism	21666969
(	21666969
G1359A	21666969
)	21666969
of	21666969
CB1	21666969
receptor	21666969
gene	21666969
on	21666969
adipocytokines	21666969
response	21666969
and	21666969
weight	21666969
loss	21666969
secondary	21666969
to	21666969
a	21666969
lifestyle	21666969
modification	21666969
(	21666969
Mediterranean	21666969
hypocaloric	21666969
diet	21666969
and	21666969
exercise	21666969
)	21666969
in	21666969
obese	21666969
patients	21666969
.	21666969

DESIGN	21666969
:	21666969
A	21666969
population	21666969
of	21666969
94	21666969
patients	21666969
with	21666969
obesity	21666969
was	21666969
analyzed	21666969
.	21666969

Before	21666969
and	21666969
after	21666969
3	21666969
months	21666969
on	21666969
a	21666969
hypocaloric	21666969
diet	21666969
,	21666969
an	21666969
anthropometric	21666969
evaluation	21666969
,	21666969
an	21666969
assessment	21666969
of	21666969
nutritional	21666969
intake	21666969
and	21666969
a	21666969
biochemical	21666969
analysis	21666969
were	21666969
performed	21666969
.	21666969

The	21666969
statistical	21666969
analysis	21666969
was	21666969
performed	21666969
for	21666969
the	21666969
combined	21666969
G1359A	21666969
and	21666969
A1359A	21666969
as	21666969
a	21666969
group	21666969
and	21666969
wild	21666969
type	21666969
G1359G	21666969
as	21666969
second	21666969
group	21666969
,	21666969
with	21666969
a	21666969
dominant	21666969
model	21666969
.	21666969

Results	21666969
:	21666969
Forty	21666969
seven	21666969
patients	21666969
(	21666969
50%	21666969
)	21666969
had	21666969
the	21666969
genotype	21666969
G1359G	21666969
(	21666969
wild	21666969
type	21666969
group	21666969
)	21666969
and	21666969
47	21666969
(	21666969
50%	21666969
)	21666969
patients	21666969
G1359A	21666969
(	21666969
41	21666969
patients	21666969
,	21666969
43	21666969
.	21666969
6%	21666969
)	21666969
or	21666969
A1359A	21666969
(	21666969
6	21666969
patients	21666969
,	21666969
6	21666969
.	21666969
4%	21666969
)	21666969
(	21666969
mutant	21666969
type	21666969
group	21666969
)	21666969
had	21666969
the	21666969
genotype	21666969
.	21666969

In	21666969
wild	21666969
and	21666969
mutant	21666969
type	21666969
groups	21666969
,	21666969
weight	21666969
,	21666969
body	21666969
mass	21666969
index	21666969
,	21666969
fat	21666969
mass	21666969
,	21666969
waist	21666969
circumference	21666969
and	21666969
systolic	21666969
blood	21666969
pressure	21666969
decreased	21666969
.	21666969

In	21666969
mutant	21666969
type	21666969
group	21666969
,	21666969
resistin	21666969
(	21666969
4	21666969
.	21666969
15	21666969
1	21666969
.	21666969
7	21666969
ng	21666969
/	21666969
ml	21666969
vs	21666969
.	21666969

3	21666969
.	21666969
90	21666969
2	21666969
.	21666969
1	21666969
ng	21666969
/	21666969
ml	21666969
:	21666969
P	21666969
<	21666969
0	21666969
.	21666969
05	21666969
)	21666969
,	21666969
leptin	21666969
(	21666969
78	21666969
.	21666969
4	21666969
69	21666969
ng	21666969
/	21666969
ml	21666969
vs	21666969
66	21666969
.	21666969
2	21666969
32	21666969
ng	21666969
/	21666969
ml	21666969
:	21666969
P	21666969
<	21666969
0	21666969
.	21666969
05	21666969
)	21666969
and	21666969
IL	21666969
-	21666969
6	21666969
(	21666969
1	21666969
.	21666969
40	21666969
1	21666969
.	21666969
9	21666969
pg	21666969
/	21666969
ml	21666969
vs	21666969
0	21666969
.	21666969
81	21666969
1	21666969
.	21666969
5	21666969
pg	21666969
/	21666969
ml	21666969
:	21666969
P	21666969
<	21666969
0	21666969
.	21666969
05	21666969
)	21666969
levels	21666969
decreased	21666969
after	21666969
dietary	21666969
treatment	21666969
.	21666969

CONCLUSION	21666969
:	21666969
The	21666969
novel	21666969
finding	21666969
of	21666969
this	21666969
study	21666969
is	21666969
the	21666969
association	21666969
of	21666969
the	21666969
mutant	21666969
allele	21666969
(	21666969
A1359	21666969
)	21666969
with	21666969
a	21666969
decrease	21666969
of	21666969
resistin	21666969
,	21666969
leptin	21666969
and	21666969
interleukin	21666969
-	21666969
6	21666969
secondary	21666969
to	21666969
weight	21666969
loss	21666969
.	21666969
CRYBA3	15111599
/	15111599
A1	15111599
gene	15111599
mutation	15111599
associated	15111599
with	15111599
suture	15111599
-	15111599
sparing	15111599
autosomal	15111599
dominant	15111599
congenital	15111599
nuclear	15111599
cataract	15111599
:	15111599
a	15111599
novel	15111599
phenotype	15111599
.	15111599

PURPOSE	15111599
:	15111599
To	15111599
identify	15111599
the	15111599
genetic	15111599
defect	15111599
leading	15111599
to	15111599
the	15111599
congenital	15111599
nuclear	15111599
cataract	15111599
affecting	15111599
a	15111599
large	15111599
five	15111599
-	15111599
generation	15111599
Swiss	15111599
family	15111599
.	15111599

METHODS	15111599
:	15111599
Family	15111599
history	15111599
and	15111599
clinical	15111599
data	15111599
were	15111599
recorded	15111599
.	15111599

The	15111599
phenotype	15111599
was	15111599
documented	15111599
by	15111599
both	15111599
slit	15111599
lamp	15111599
and	15111599
Scheimpflug	15111599
photography	15111599
.	15111599

One	15111599
cortical	15111599
lens	15111599
was	15111599
evaluated	15111599
by	15111599
electron	15111599
microscopy	15111599
after	15111599
cataract	15111599
extraction	15111599
.	15111599

Lenticular	15111599
phenotyping	15111599
and	15111599
genotyping	15111599
were	15111599
performed	15111599
independently	15111599
with	15111599
short	15111599
tandem	15111599
repeat	15111599
polymorphism	15111599
.	15111599

Linkage	15111599
analysis	15111599
was	15111599
performed	15111599
,	15111599
and	15111599
candidate	15111599
genes	15111599
were	15111599
PCR	15111599
amplified	15111599
and	15111599
screened	15111599
for	15111599
mutations	15111599
on	15111599
both	15111599
strands	15111599
using	15111599
direct	15111599
sequencing	15111599
.	15111599

RESULTS	15111599
:	15111599
Affected	15111599
individuals	15111599
had	15111599
a	15111599
congenital	15111599
nuclear	15111599
lactescent	15111599
cataract	15111599
in	15111599
both	15111599
eyes	15111599
.	15111599

Linkage	15111599
was	15111599
observed	15111599
on	15111599
chromosome	15111599
17	15111599
for	15111599
DNA	15111599
marker	15111599
D17S1857	15111599
(	15111599
lod	15111599
score	15111599
:	15111599
3	15111599
.	15111599
44	15111599
at	15111599
theta	15111599
=	15111599
0	15111599
)	15111599
.	15111599

Direct	15111599
sequencing	15111599
of	15111599
CRYBA3	15111599
/	15111599
A1	15111599
,	15111599
which	15111599
maps	15111599
to	15111599
the	15111599
vicinity	15111599
,	15111599
revealed	15111599
an	15111599
in	15111599
-	15111599
frame	15111599
3	15111599
-	15111599
bp	15111599
deletion	15111599
in	15111599
exon	15111599
4	15111599
(	15111599
279delGAG	15111599
)	15111599
.	15111599

This	15111599
mutation	15111599
involved	15111599
a	15111599
deletion	15111599
of	15111599
glycine	15111599
-	15111599
91	15111599
,	15111599
cosegregated	15111599
in	15111599
all	15111599
affected	15111599
individuals	15111599
,	15111599
and	15111599
was	15111599
not	15111599
observed	15111599
in	15111599
unaffected	15111599
individuals	15111599
or	15111599
in	15111599
250	15111599
normal	15111599
control	15111599
subjects	15111599
from	15111599
the	15111599
same	15111599
ethnic	15111599
background	15111599
.	15111599

Electron	15111599
microscopy	15111599
showed	15111599
that	15111599
cortical	15111599
lens	15111599
fiber	15111599
morphology	15111599
was	15111599
normal	15111599
.	15111599

CONCLUSIONS	15111599
:	15111599
The	15111599
DeltaG91	15111599
mutation	15111599
in	15111599
CRYBA3	15111599
/	15111599
A1	15111599
is	15111599
associated	15111599
with	15111599
an	15111599
autosomal	15111599
dominant	15111599
congenital	15111599
nuclear	15111599
lactescent	15111599
cataract	15111599
.	15111599

A	15111599
splice	15111599
mutation	15111599
(	15111599
IVS3	15111599
+	15111599
1G	15111599
/	15111599
A	15111599
)	15111599
in	15111599
this	15111599
gene	15111599
has	15111599
been	15111599
reported	15111599
in	15111599
a	15111599
zonular	15111599
cataract	15111599
with	15111599
sutural	15111599
opacities	15111599
.	15111599

These	15111599
results	15111599
indicate	15111599
phenotypic	15111599
heterogeneity	15111599
related	15111599
to	15111599
mutations	15111599
in	15111599
this	15111599
gene	15111599
.	15111599
Mutations	17854040
associated	17854040
with	17854040
lamivudine	17854040
-	17854040
resistance	17854040
in	17854040
therapy	17854040
-	17854040
na	17854040
ve	17854040
hepatitis	17854040
B	17854040
virus	17854040
(	17854040
HBV	17854040
)	17854040
infected	17854040
patients	17854040
with	17854040
and	17854040
without	17854040
HIV	17854040
co	17854040
-	17854040
infection	17854040
:	17854040
implications	17854040
for	17854040
antiretroviral	17854040
therapy	17854040
in	17854040
HBV	17854040
and	17854040
HIV	17854040
co	17854040
-	17854040
infected	17854040
South	17854040
African	17854040
patients	17854040
.	17854040

This	17854040
was	17854040
an	17854040
exploratory	17854040
study	17854040
to	17854040
investigate	17854040
lamivudine	17854040
-	17854040
resistant	17854040
hepatitis	17854040
B	17854040
virus	17854040
(	17854040
HBV	17854040
)	17854040
strains	17854040
in	17854040
selected	17854040
lamivudine	17854040
-	17854040
na	17854040
ve	17854040
HBV	17854040
carriers	17854040
with	17854040
and	17854040
without	17854040
human	17854040
immunodeficiency	17854040
virus	17854040
(	17854040
HIV	17854040
)	17854040
co	17854040
-	17854040
infection	17854040
in	17854040
South	17854040
African	17854040
patients	17854040
.	17854040

Thirty	17854040
-	17854040
five	17854040
lamivudine	17854040
-	17854040
na	17854040
ve	17854040
HBV	17854040
infected	17854040
patients	17854040
with	17854040
or	17854040
without	17854040
HIV	17854040
co	17854040
-	17854040
infection	17854040
were	17854040
studied	17854040
:	17854040
15	17854040
chronic	17854040
HBV	17854040
mono	17854040
-	17854040
infected	17854040
patients	17854040
and	17854040
20	17854040
HBV	17854040
-	17854040
HIV	17854040
co	17854040
-	17854040
infected	17854040
patients	17854040
.	17854040

The	17854040
latter	17854040
group	17854040
was	17854040
further	17854040
sub	17854040
-	17854040
divided	17854040
into	17854040
13	17854040
occult	17854040
HBV	17854040
(	17854040
HBsAg	17854040
-	17854040
negative	17854040
)	17854040
and	17854040
7	17854040
overt	17854040
HBV	17854040
(	17854040
HBsAg	17854040
-	17854040
positive	17854040
)	17854040
patients	17854040
.	17854040

HBsAg	17854040
,	17854040
anti	17854040
-	17854040
HBs	17854040
,	17854040
anti	17854040
-	17854040
HBc	17854040
,	17854040
and	17854040
anti	17854040
-	17854040
HIV	17854040
1	17854040
/	17854040
2	17854040
were	17854040
determined	17854040
as	17854040
part	17854040
of	17854040
routine	17854040
diagnosis	17854040
using	17854040
Axsym	17854040
assays	17854040
(	17854040
Abbott	17854040
Laboratories	17854040
,	17854040
North	17854040
Chicago	17854040
,	17854040
IL	17854040
)	17854040
.	17854040

Serum	17854040
samples	17854040
were	17854040
PCR	17854040
amplified	17854040
with	17854040
HBV	17854040
reverse	17854040
transcriptase	17854040
(	17854040
RT	17854040
)	17854040
primers	17854040
,	17854040
followed	17854040
by	17854040
direct	17854040
sequencing	17854040
across	17854040
the	17854040
tyrosine	17854040
-	17854040
methionine	17854040
-	17854040
aspartate	17854040
-	17854040
aspartate	17854040
(	17854040
YMDD	17854040
)	17854040
motif	17854040
of	17854040
the	17854040
major	17854040
catalytic	17854040
region	17854040
in	17854040
the	17854040
C	17854040
domain	17854040
of	17854040
the	17854040
HBV	17854040
RT	17854040
enzyme	17854040
.	17854040

HBV	17854040
viral	17854040
load	17854040
was	17854040
performed	17854040
with	17854040
Amplicor	17854040
HBV	17854040
Monitor	17854040
test	17854040
v2	17854040
.	17854040
0	17854040
(	17854040
Roche	17854040
Diagnostics	17854040
,	17854040
Penzberg	17854040
,	17854040
Germany	17854040
)	17854040
.	17854040

HBV	17854040
lamivudine	17854040
-	17854040
resistant	17854040
strains	17854040
were	17854040
detected	17854040
in	17854040
3	17854040
of	17854040
15	17854040
mono	17854040
-	17854040
infected	17854040
chronic	17854040
hepatitis	17854040
B	17854040
patients	17854040
and	17854040
10	17854040
of	17854040
20	17854040
HBV	17854040
-	17854040
HIV	17854040
co	17854040
-	17854040
infected	17854040
patients	17854040
.	17854040

To	17854040
the	17854040
best	17854040
of	17854040
our	17854040
knowledge	17854040
,	17854040
this	17854040
constitutes	17854040
the	17854040
first	17854040
report	17854040
of	17854040
HBV	17854040
lamivudine	17854040
-	17854040
resistant	17854040
strains	17854040
in	17854040
therapy	17854040
-	17854040
na	17854040
ve	17854040
HBV	17854040
-	17854040
HIV	17854040
co	17854040
-	17854040
infected	17854040
patients	17854040
.	17854040

The	17854040
HBV	17854040
viral	17854040
loads	17854040
for	17854040
mono	17854040
-	17854040
infected	17854040
and	17854040
co	17854040
-	17854040
infected	17854040
patients	17854040
ranged	17854040
from	17854040
3	17854040
.	17854040
32	17854040
x	17854040
10	17854040
(	17854040
2	17854040
)	17854040
to	17854040
3	17854040
.	17854040
82	17854040
x	17854040
10	17854040
(	17854040
7	17854040
)	17854040
and	17854040
<	17854040
200	17854040
to	17854040
4	17854040
.	17854040
40	17854040
x	17854040
10	17854040
(	17854040
3	17854040
)	17854040
copies	17854040
/	17854040
ml	17854040
,	17854040
respectively	17854040
.	17854040

It	17854040
remains	17854040
to	17854040
be	17854040
seen	17854040
whether	17854040
such	17854040
pre	17854040
-	17854040
existing	17854040
antiviral	17854040
mutations	17854040
could	17854040
result	17854040
in	17854040
widespread	17854040
emergence	17854040
of	17854040
HBV	17854040
resistant	17854040
strains	17854040
when	17854040
lamivudine	17854040
-	17854040
containing	17854040
highly	17854040
active	17854040
antiretroviral	17854040
(	17854040
ARV	17854040
)	17854040
treatment	17854040
(	17854040
HAART	17854040
)	17854040
regimens	17854040
become	17854040
widely	17854040
applied	17854040
in	17854040
South	17854040
Africa	17854040
,	17854040
as	17854040
this	17854040
is	17854040
likely	17854040
to	17854040
have	17854040
potential	17854040
implications	17854040
in	17854040
the	17854040
management	17854040
of	17854040
HBV	17854040
-	17854040
HIV	17854040
co	17854040
-	17854040
infected	17854040
patients	17854040
.	17854040
Compound	15609295
heterozygosity	15609295
for	15609295
a	15609295
novel	15609295
nine	15609295
-	15609295
nucleotide	15609295
deletion	15609295
and	15609295
the	15609295
Asn45Ser	15609295
missense	15609295
mutation	15609295
in	15609295
the	15609295
glycoprotein	15609295
IX	15609295
gene	15609295
in	15609295
a	15609295
patient	15609295
with	15609295
Bernard	15609295
-	15609295
Soulier	15609295
syndrome	15609295
.	15609295

Bernard	15609295
-	15609295
Soulier	15609295
syndrome	15609295
(	15609295
BSS	15609295
)	15609295
is	15609295
a	15609295
rare	15609295
inherited	15609295
bleeding	15609295
disorder	15609295
due	15609295
to	15609295
quantitative	15609295
or	15609295
qualitative	15609295
abnormalities	15609295
in	15609295
the	15609295
platelet	15609295
glycoprotein	15609295
(	15609295
GP	15609295
)	15609295
Ib	15609295
/	15609295
IX	15609295
/	15609295
V	15609295
complex	15609295
,	15609295
the	15609295
major	15609295
von	15609295
Willebrand	15609295
factor	15609295
receptor	15609295
.	15609295

The	15609295
complex	15609295
comprises	15609295
four	15609295
subunits	15609295
,	15609295
each	15609295
encoded	15609295
by	15609295
a	15609295
separate	15609295
gene	15609295
.	15609295

Several	15609295
mutations	15609295
have	15609295
been	15609295
described	15609295
for	15609295
each	15609295
of	15609295
the	15609295
subunits	15609295
,	15609295
except	15609295
for	15609295
GPV	15609295
,	15609295
as	15609295
a	15609295
cause	15609295
of	15609295
BSS	15609295
.	15609295

We	15609295
describe	15609295
here	15609295
the	15609295
genetic	15609295
basis	15609295
of	15609295
the	15609295
disorder	15609295
in	15609295
a	15609295
child	15609295
with	15609295
BSS	15609295
.	15609295

Flow	15609295
-	15609295
cytometric	15609295
analysis	15609295
of	15609295
the	15609295
patient	15609295
'	15609295
s	15609295
platelets	15609295
showed	15609295
a	15609295
markedly	15609295
reduced	15609295
surface	15609295
expression	15609295
of	15609295
all	15609295
three	15609295
glycoproteins	15609295
of	15609295
the	15609295
GPIb	15609295
/	15609295
IX	15609295
/	15609295
V	15609295
complex	15609295
.	15609295

DNA	15609295
sequencing	15609295
analysis	15609295
showed	15609295
the	15609295
patient	15609295
to	15609295
be	15609295
a	15609295
compound	15609295
heterozygote	15609295
for	15609295
two	15609295
mutations	15609295
in	15609295
the	15609295
GPIX	15609295
gene	15609295
,	15609295
a	15609295
novel	15609295
nine	15609295
-	15609295
nucleotide	15609295
deletion	15609295
starting	15609295
at	15609295
position	15609295
1952	15609295
of	15609295
the	15609295
gene	15609295
that	15609295
changes	15609295
asparagine	15609295
86	15609295
for	15609295
alanine	15609295
and	15609295
eliminates	15609295
amino	15609295
acids	15609295
87	15609295
,	15609295
88	15609295
,	15609295
and	15609295
89	15609295
(	15609295
arginine	15609295
,	15609295
threonine	15609295
,	15609295
and	15609295
proline	15609295
)	15609295
and	15609295
a	15609295
previously	15609295
reported	15609295
point	15609295
mutation	15609295
that	15609295
changes	15609295
the	15609295
codon	15609295
asparagine	15609295
(	15609295
AAC	15609295
)	15609295
for	15609295
serine	15609295
(	15609295
AGC	15609295
)	15609295
at	15609295
residue	15609295
45	15609295
.	15609295

Her	15609295
mother	15609295
was	15609295
heterozygous	15609295
for	15609295
the	15609295
Asn45Ser	15609295
mutation	15609295
,	15609295
and	15609295
her	15609295
father	15609295
,	15609295
for	15609295
the	15609295
nine	15609295
-	15609295
nucleotide	15609295
deletion	15609295
.	15609295

Our	15609295
findings	15609295
suggest	15609295
that	15609295
the	15609295
additive	15609295
effects	15609295
of	15609295
both	15609295
mutations	15609295
in	15609295
the	15609295
GPIX	15609295
gene	15609295
are	15609295
responsible	15609295
for	15609295
the	15609295
BSS	15609295
phenotype	15609295
of	15609295
the	15609295
patient	15609295
.	15609295
Antipsychotic	16867021
-	16867021
like	16867021
profile	16867021
of	16867021
thioperamide	16867021
,	16867021
a	16867021
selective	16867021
H3	16867021
-	16867021
receptor	16867021
antagonist	16867021
in	16867021
mice	16867021
.	16867021

Experimental	16867021
and	16867021
clinical	16867021
evidence	16867021
points	16867021
to	16867021
a	16867021
role	16867021
of	16867021
central	16867021
histaminergic	16867021
system	16867021
in	16867021
the	16867021
pathogenesis	16867021
of	16867021
schizophrenia	16867021
.	16867021

The	16867021
present	16867021
study	16867021
was	16867021
designed	16867021
to	16867021
study	16867021
the	16867021
effect	16867021
of	16867021
histamine	16867021
H	16867021
(	16867021
3	16867021
)	16867021
-	16867021
receptor	16867021
ligands	16867021
on	16867021
neuroleptic	16867021
-	16867021
induced	16867021
catalepsy	16867021
,	16867021
apomorphine	16867021
-	16867021
induced	16867021
climbing	16867021
behavior	16867021
and	16867021
amphetamine	16867021
-	16867021
induced	16867021
locomotor	16867021
activities	16867021
in	16867021
mice	16867021
.	16867021

Catalepsy	16867021
was	16867021
induced	16867021
by	16867021
haloperidol	16867021
(	16867021
2	16867021
mg	16867021
/	16867021
kg	16867021
p	16867021
.	16867021
o	16867021
.	16867021
)	16867021
,	16867021
while	16867021
apomorphine	16867021
(	16867021
1	16867021
.	16867021
5	16867021
mg	16867021
/	16867021
kg	16867021
s	16867021
.	16867021
c	16867021
.	16867021
)	16867021
and	16867021
amphetamine	16867021
(	16867021
2	16867021
mg	16867021
/	16867021
kg	16867021
s	16867021
.	16867021
c	16867021
.	16867021
)	16867021
were	16867021
used	16867021
for	16867021
studying	16867021
climbing	16867021
behavior	16867021
and	16867021
locomotor	16867021
activities	16867021
,	16867021
respectively	16867021
.	16867021

(	16867021
R	16867021
)	16867021
-	16867021
alpha	16867021
-	16867021
methylhistamine	16867021
(	16867021
RAMH	16867021
)	16867021
(	16867021
5	16867021
microg	16867021
i	16867021
.	16867021
c	16867021
.	16867021
v	16867021
.	16867021
)	16867021
and	16867021
thioperamide	16867021
(	16867021
THP	16867021
)	16867021
(	16867021
15	16867021
mg	16867021
/	16867021
kg	16867021
i	16867021
.	16867021
p	16867021
.	16867021
)	16867021
,	16867021
per	16867021
se	16867021
did	16867021
not	16867021
cause	16867021
catalepsy	16867021
.	16867021

Administration	16867021
of	16867021
THP	16867021
(	16867021
3	16867021
.	16867021
75	16867021
,	16867021
7	16867021
.	16867021
5	16867021
and	16867021
15	16867021
mg	16867021
/	16867021
kg	16867021
i	16867021
.	16867021
p	16867021
.	16867021
)	16867021
1	16867021
h	16867021
prior	16867021
to	16867021
haloperidol	16867021
resulted	16867021
in	16867021
a	16867021
dose	16867021
-	16867021
dependent	16867021
increase	16867021
in	16867021
the	16867021
catalepsy	16867021
times	16867021
(	16867021
P	16867021
<	16867021
0	16867021
.	16867021
05	16867021
)	16867021
.	16867021

However	16867021
,	16867021
pretreatment	16867021
with	16867021
RAMH	16867021
significantly	16867021
reversed	16867021
such	16867021
an	16867021
effect	16867021
of	16867021
THP	16867021
(	16867021
15	16867021
mg	16867021
/	16867021
kg	16867021
i	16867021
.	16867021
p	16867021
.	16867021
)	16867021
.	16867021

RAMH	16867021
per	16867021
se	16867021
showed	16867021
significant	16867021
reduction	16867021
in	16867021
locomotor	16867021
time	16867021
,	16867021
distance	16867021
traveled	16867021
and	16867021
average	16867021
speed	16867021
but	16867021
THP	16867021
(	16867021
15	16867021
mg	16867021
/	16867021
kg	16867021
i	16867021
.	16867021
p	16867021
.	16867021
)	16867021
per	16867021
se	16867021
had	16867021
no	16867021
effect	16867021
on	16867021
these	16867021
parameters	16867021
.	16867021

On	16867021
amphetamine	16867021
-	16867021
induced	16867021
hyperactivity	16867021
,	16867021
THP	16867021
(	16867021
3	16867021
.	16867021
75	16867021
and	16867021
7	16867021
.	16867021
5	16867021
mg	16867021
/	16867021
kg	16867021
i	16867021
.	16867021
p	16867021
.	16867021
)	16867021
reduced	16867021
locomotor	16867021
time	16867021
,	16867021
distance	16867021
traveled	16867021
and	16867021
average	16867021
speed	16867021
(	16867021
P	16867021
<	16867021
0	16867021
.	16867021
05	16867021
)	16867021
.	16867021

Pretreatment	16867021
with	16867021
RAMH	16867021
(	16867021
5	16867021
microg	16867021
i	16867021
.	16867021
c	16867021
.	16867021
v	16867021
.	16867021
)	16867021
could	16867021
partially	16867021
reverse	16867021
such	16867021
effects	16867021
of	16867021
THP	16867021
(	16867021
3	16867021
.	16867021
75	16867021
mg	16867021
/	16867021
kg	16867021
i	16867021
.	16867021
p	16867021
.	16867021
)	16867021
.	16867021

Climbing	16867021
behavior	16867021
induced	16867021
by	16867021
apomorphine	16867021
was	16867021
reduced	16867021
in	16867021
animals	16867021
treated	16867021
with	16867021
THP	16867021
.	16867021

Such	16867021
an	16867021
effect	16867021
was	16867021
,	16867021
however	16867021
,	16867021
reversed	16867021
in	16867021
presence	16867021
of	16867021
RAMH	16867021
.	16867021

THP	16867021
exhibited	16867021
an	16867021
antipsychotic	16867021
-	16867021
like	16867021
profile	16867021
by	16867021
potentiating	16867021
haloperidol	16867021
-	16867021
induced	16867021
catalepsy	16867021
,	16867021
reducing	16867021
amphetamine	16867021
-	16867021
induced	16867021
hyperactivity	16867021
and	16867021
reducing	16867021
apomorphine	16867021
-	16867021
induced	16867021
climbing	16867021
in	16867021
mice	16867021
.	16867021

Such	16867021
effects	16867021
of	16867021
THP	16867021
were	16867021
reversed	16867021
by	16867021
RAMH	16867021
indicating	16867021
the	16867021
involvement	16867021
of	16867021
histamine	16867021
H	16867021
(	16867021
3	16867021
)	16867021
-	16867021
receptors	16867021
.	16867021

Findings	16867021
suggest	16867021
a	16867021
potential	16867021
for	16867021
H	16867021
(	16867021
3	16867021
)	16867021
-	16867021
receptor	16867021
antagonists	16867021
in	16867021
improving	16867021
the	16867021
refractory	16867021
cases	16867021
of	16867021
schizophrenia	16867021
.	16867021
Insulin	28260056
-	28260056
like	28260056
growth	28260056
factor	28260056
1	28260056
receptor	28260056
-	28260056
mediated	28260056
cell	28260056
survival	28260056
in	28260056
hypoxia	28260056
depends	28260056
on	28260056
the	28260056
promotion	28260056
of	28260056
autophagy	28260056
via	28260056
suppression	28260056
of	28260056
the	28260056
PI3K	28260056
/	28260056
Akt	28260056
/	28260056
mTOR	28260056
signaling	28260056
pathway	28260056
.	28260056

Hypoxia	28260056
is	28260056
widely	28260056
accepted	28260056
as	28260056
a	28260056
fundamental	28260056
biological	28260056
phenomenon	28260056
,	28260056
which	28260056
is	28260056
strongly	28260056
associated	28260056
with	28260056
tissue	28260056
damage	28260056
and	28260056
cell	28260056
viability	28260056
under	28260056
stress	28260056
conditions	28260056
.	28260056

Insulin	28260056
-	28260056
like	28260056
growth	28260056
factor	28260056
-	28260056
1	28260056
(	28260056
IGF	28260056
-	28260056
1	28260056
)	28260056
is	28260056
known	28260056
to	28260056
protect	28260056
tissues	28260056
from	28260056
multiple	28260056
types	28260056
of	28260056
damage	28260056
,	28260056
and	28260056
protect	28260056
cells	28260056
from	28260056
apoptosis	28260056
.	28260056

Hypoxia	28260056
is	28260056
a	28260056
regulatory	28260056
factor	28260056
of	28260056
the	28260056
IGF	28260056
system	28260056
,	28260056
however	28260056
the	28260056
role	28260056
of	28260056
the	28260056
IGF	28260056
-	28260056
1	28260056
receptor	28260056
(	28260056
IGF	28260056
-	28260056
1R	28260056
)	28260056
in	28260056
hypoxia	28260056
-	28260056
induced	28260056
apoptosis	28260056
remains	28260056
unclear	28260056
.	28260056

The	28260056
present	28260056
study	28260056
investigated	28260056
the	28260056
potential	28260056
mechanisms	28260056
associated	28260056
with	28260056
IGF	28260056
-	28260056
1R	28260056
-	28260056
associated	28260056
apoptosis	28260056
under	28260056
hypoxic	28260056
conditions	28260056
.	28260056

Mouse	28260056
embryonic	28260056
fibroblasts	28260056
exhibiting	28260056
disruption	28260056
or	28260056
overexpression	28260056
of	28260056
IGF	28260056
-	28260056
1R	28260056
(	28260056
R	28260056
-	28260056
cells	28260056
and	28260056
R	28260056
+	28260056
cells	28260056
)	28260056
were	28260056
used	28260056
to	28260056
examine	28260056
the	28260056
level	28260056
of	28260056
apoptosis	28260056
,	28260056
autophagy	28260056
,	28260056
and	28260056
production	28260056
of	28260056
reactive	28260056
oxygen	28260056
species	28260056
(	28260056
ROS	28260056
)	28260056
.	28260056

The	28260056
autophagy	28260056
inhibitor	28260056
3	28260056
-	28260056
methyladenine	28260056
was	28260056
used	28260056
to	28260056
assess	28260056
the	28260056
effect	28260056
of	28260056
autophagy	28260056
on	28260056
ROS	28260056
production	28260056
and	28260056
apoptosis	28260056
under	28260056
hypoxic	28260056
conditions	28260056
.	28260056

A	28260056
potential	28260056
downstream	28260056
signaling	28260056
pathway	28260056
involving	28260056
phosphatidylinositol	28260056
3	28260056
-	28260056
kinase	28260056
(	28260056
PI3K	28260056
)	28260056
/	28260056
threonine	28260056
protein	28260056
kinase	28260056
B	28260056
(	28260056
Akt	28260056
)	28260056
/	28260056
mammalian	28260056
target	28260056
of	28260056
rapamycin	28260056
(	28260056
mTOR	28260056
)	28260056
was	28260056
identifiedby	28260056
western	28260056
blot	28260056
analysis	28260056
.	28260056

The	28260056
results	28260056
demonstrated	28260056
that	28260056
hypoxia	28260056
induced	28260056
apoptosis	28260056
,	28260056
increased	28260056
ROS	28260056
production	28260056
,	28260056
and	28260056
promoted	28260056
autophagy	28260056
in	28260056
a	28260056
time	28260056
-	28260056
dependent	28260056
manner	28260056
relative	28260056
to	28260056
that	28260056
observed	28260056
under	28260056
normoxia	28260056
.	28260056

R	28260056
+	28260056
cells	28260056
exhibited	28260056
a	28260056
lower	28260056
percentage	28260056
of	28260056
apoptotic	28260056
cells	28260056
,	28260056
lower	28260056
ROS	28260056
production	28260056
,	28260056
and	28260056
higher	28260056
levels	28260056
of	28260056
autophagy	28260056
when	28260056
compared	28260056
to	28260056
that	28260056
of	28260056
R	28260056
-	28260056
cells	28260056
.	28260056

In	28260056
addition	28260056
,	28260056
inhibition	28260056
of	28260056
autophagy	28260056
led	28260056
to	28260056
increased	28260056
ROS	28260056
production	28260056
and	28260056
a	28260056
higher	28260056
percentage	28260056
of	28260056
apoptotic	28260056
cells	28260056
in	28260056
the	28260056
two	28260056
cell	28260056
types	28260056
.	28260056

Furthermore	28260056
,	28260056
IGF	28260056
-	28260056
1R	28260056
is	28260056
related	28260056
with	28260056
PI3K	28260056
/	28260056
Akt	28260056
/	28260056
mTOR	28260056
signaling	28260056
pathway	28260056
and	28260056
enhanced	28260056
autophagy	28260056
-	28260056
associated	28260056
protein	28260056
expression	28260056
,	28260056
which	28260056
was	28260056
verified	28260056
following	28260056
treatment	28260056
with	28260056
the	28260056
PI3K	28260056
inhibitor	28260056
LY294002	28260056
.	28260056

These	28260056
results	28260056
indicated	28260056
that	28260056
IGF	28260056
-	28260056
1R	28260056
may	28260056
increase	28260056
cell	28260056
viability	28260056
under	28260056
hypoxic	28260056
conditions	28260056
by	28260056
promoting	28260056
autophagy	28260056
and	28260056
scavenging	28260056
ROS	28260056
production	28260056
,	28260056
which	28260056
is	28260056
closed	28260056
with	28260056
PI3K	28260056
/	28260056
Akt	28260056
/	28260056
mTOR	28260056
signaling	28260056
pathway	28260056
.	28260056
Serum	26937641
Amyloid	26937641
A	26937641
Induces	26937641
Inflammation	26937641
,	26937641
Proliferation	26937641
and	26937641
Cell	26937641
Death	26937641
in	26937641
Activated	26937641
Hepatic	26937641
Stellate	26937641
Cells	26937641
.	26937641

Serum	26937641
amyloid	26937641
A	26937641
(	26937641
SAA	26937641
)	26937641
is	26937641
an	26937641
evolutionary	26937641
highly	26937641
conserved	26937641
acute	26937641
phase	26937641
protein	26937641
that	26937641
is	26937641
predominantly	26937641
secreted	26937641
by	26937641
hepatocytes	26937641
.	26937641

However	26937641
,	26937641
its	26937641
role	26937641
in	26937641
liver	26937641
injury	26937641
and	26937641
fibrogenesis	26937641
has	26937641
not	26937641
been	26937641
elucidated	26937641
so	26937641
far	26937641
.	26937641

In	26937641
this	26937641
study	26937641
,	26937641
we	26937641
determined	26937641
the	26937641
effects	26937641
of	26937641
SAA	26937641
on	26937641
hepatic	26937641
stellate	26937641
cells	26937641
(	26937641
HSCs	26937641
)	26937641
,	26937641
the	26937641
main	26937641
fibrogenic	26937641
cell	26937641
type	26937641
of	26937641
the	26937641
liver	26937641
.	26937641

Serum	26937641
amyloid	26937641
A	26937641
potently	26937641
activated	26937641
IkappaB	26937641
kinase	26937641
,	26937641
c	26937641
-	26937641
Jun	26937641
N	26937641
-	26937641
terminal	26937641
kinase	26937641
(	26937641
JNK	26937641
)	26937641
,	26937641
Erk	26937641
and	26937641
Akt	26937641
and	26937641
enhanced	26937641
NF	26937641
-	26937641
kappaB	26937641
-	26937641
dependent	26937641
luciferase	26937641
activity	26937641
in	26937641
primary	26937641
human	26937641
and	26937641
rat	26937641
HSCs	26937641
.	26937641

Serum	26937641
amyloid	26937641
A	26937641
induced	26937641
the	26937641
transcription	26937641
of	26937641
MCP	26937641
-	26937641
1	26937641
,	26937641
RANTES	26937641
and	26937641
MMP9	26937641
in	26937641
an	26937641
NF	26937641
-	26937641
kappaB	26937641
-	26937641
and	26937641
JNK	26937641
-	26937641
dependent	26937641
manner	26937641
.	26937641

Blockade	26937641
of	26937641
NF	26937641
-	26937641
kappaB	26937641
revealed	26937641
cytotoxic	26937641
effects	26937641
of	26937641
SAA	26937641
in	26937641
primary	26937641
HSCs	26937641
with	26937641
signs	26937641
of	26937641
apoptosis	26937641
such	26937641
as	26937641
caspase	26937641
3	26937641
and	26937641
PARP	26937641
cleavage	26937641
and	26937641
Annexin	26937641
V	26937641
staining	26937641
.	26937641

Serum	26937641
amyloid	26937641
A	26937641
induced	26937641
HSC	26937641
proliferation	26937641
,	26937641
which	26937641
depended	26937641
on	26937641
JNK	26937641
,	26937641
Erk	26937641
and	26937641
Akt	26937641
activity	26937641
.	26937641

In	26937641
primary	26937641
hepatocytes	26937641
,	26937641
SAA	26937641
also	26937641
activated	26937641
MAP	26937641
kinases	26937641
,	26937641
but	26937641
did	26937641
not	26937641
induce	26937641
relevant	26937641
cell	26937641
death	26937641
after	26937641
NF	26937641
-	26937641
kappaB	26937641
inhibition	26937641
.	26937641

In	26937641
two	26937641
models	26937641
of	26937641
hepatic	26937641
fibrogenesis	26937641
,	26937641
CCl4	26937641
treatment	26937641
and	26937641
bile	26937641
duct	26937641
ligation	26937641
,	26937641
hepatic	26937641
mRNA	26937641
levels	26937641
of	26937641
SAA1	26937641
and	26937641
SAA3	26937641
were	26937641
strongly	26937641
increased	26937641
.	26937641

In	26937641
conclusion	26937641
,	26937641
SAA	26937641
may	26937641
modulate	26937641
fibrogenic	26937641
responses	26937641
in	26937641
the	26937641
liver	26937641
in	26937641
a	26937641
positive	26937641
and	26937641
negative	26937641
fashion	26937641
by	26937641
inducing	26937641
inflammation	26937641
,	26937641
proliferation	26937641
and	26937641
cell	26937641
death	26937641
in	26937641
HSCs	26937641
.	26937641

Molecular	2491010
and	2491010
phenotypic	2491010
analysis	2491010
of	2491010
patients	2491010
with	2491010
deletions	2491010
within	2491010
the	2491010
deletion	2491010
-	2491010
rich	2491010
region	2491010
of	2491010
the	2491010
Duchenne	2491010
muscular	2491010
dystrophy	2491010
(	2491010
DMD	2491010
)	2491010
gene	2491010
.	2491010

Eighty	2491010
unrelated	2491010
individuals	2491010
with	2491010
Duchenne	2491010
muscular	2491010
dystrophy	2491010
(	2491010
DMD	2491010
)	2491010
or	2491010
Becker	2491010
muscular	2491010
dystrophy	2491010
(	2491010
BMD	2491010
)	2491010
were	2491010
found	2491010
to	2491010
have	2491010
deletions	2491010
in	2491010
the	2491010
major	2491010
deletion	2491010
-	2491010
rich	2491010
region	2491010
of	2491010
the	2491010
DMD	2491010
locus	2491010
.	2491010

This	2491010
region	2491010
includes	2491010
the	2491010
last	2491010
five	2491010
exons	2491010
detected	2491010
by	2491010
cDNA5b	2491010
-	2491010
7	2491010
,	2491010
all	2491010
exons	2491010
detected	2491010
by	2491010
cDNA8	2491010
,	2491010
and	2491010
the	2491010
first	2491010
two	2491010
exons	2491010
detected	2491010
by	2491010
cDNA9	2491010
.	2491010

These	2491010
80	2491010
individuals	2491010
account	2491010
for	2491010
approximately	2491010
75%	2491010
of	2491010
109	2491010
deletions	2491010
of	2491010
the	2491010
gene	2491010
,	2491010
detected	2491010
among	2491010
181	2491010
patients	2491010
analyzed	2491010
with	2491010
the	2491010
entire	2491010
dystrophin	2491010
cDNA	2491010
.	2491010

Endpoints	2491010
for	2491010
many	2491010
of	2491010
these	2491010
deletions	2491010
were	2491010
further	2491010
characterized	2491010
using	2491010
two	2491010
genomic	2491010
probes	2491010
,	2491010
p20	2491010
(	2491010
DXS269	2491010
;	2491010
Wapenaar	2491010
et	2491010
al	2491010
.	2491010
)	2491010
and	2491010
GMGX11	2491010
(	2491010
DXS239	2491010
;	2491010
present	2491010
paper	2491010
)	2491010
.	2491010

Clinical	2491010
findings	2491010
are	2491010
presented	2491010
for	2491010
all	2491010
80	2491010
patients	2491010
allowing	2491010
a	2491010
correlation	2491010
of	2491010
phenotypic	2491010
severity	2491010
with	2491010
the	2491010
genotype	2491010
.	2491010

Thirty	2491010
-	2491010
eight	2491010
independent	2491010
patients	2491010
were	2491010
old	2491010
enough	2491010
to	2491010
be	2491010
classified	2491010
as	2491010
DMD	2491010
,	2491010
BMD	2491010
,	2491010
or	2491010
intermediate	2491010
phenotype	2491010
and	2491010
had	2491010
deletions	2491010
of	2491010
exons	2491010
with	2491010
sequenced	2491010
intron	2491010
/	2491010
exon	2491010
boundaries	2491010
.	2491010

Of	2491010
these	2491010
,	2491010
eight	2491010
BMD	2491010
patients	2491010
and	2491010
one	2491010
intermediate	2491010
patient	2491010
had	2491010
gene	2491010
deletions	2491010
predicted	2491010
to	2491010
leave	2491010
the	2491010
reading	2491010
frame	2491010
intact	2491010
,	2491010
while	2491010
21	2491010
DMD	2491010
patients	2491010
,	2491010
7	2491010
intermediate	2491010
patients	2491010
,	2491010
and	2491010
1	2491010
BMD	2491010
patient	2491010
had	2491010
gene	2491010
deletions	2491010
predicted	2491010
to	2491010
disrupt	2491010
the	2491010
reading	2491010
frame	2491010
.	2491010

Thus	2491010
,	2491010
with	2491010
two	2491010
exceptions	2491010
,	2491010
frameshift	2491010
deletions	2491010
of	2491010
the	2491010
gene	2491010
resulted	2491010
in	2491010
more	2491010
severe	2491010
phenotype	2491010
than	2491010
did	2491010
in	2491010
-	2491010
frame	2491010
deletions	2491010
.	2491010

This	2491010
is	2491010
in	2491010
agreement	2491010
with	2491010
recent	2491010
findings	2491010
by	2491010
Baumbach	2491010
et	2491010
al	2491010
.	2491010

and	2491010
Koenig	2491010
et	2491010
al	2491010
.	2491010

but	2491010
is	2491010
in	2491010
contrast	2491010
to	2491010
findings	2491010
,	2491010
by	2491010
Malhotra	2491010
et	2491010
al	2491010
.	2491010

at	2491010
the	2491010
5	2491010
'	2491010
end	2491010
of	2491010
the	2491010
gene	2491010
.	2491010
Cardioprotective	19445921
effect	19445921
of	19445921
salvianolic	19445921
acid	19445921
A	19445921
on	19445921
isoproterenol	19445921
-	19445921
induced	19445921
myocardial	19445921
infarction	19445921
in	19445921
rats	19445921
.	19445921

The	19445921
present	19445921
study	19445921
was	19445921
designed	19445921
to	19445921
evaluate	19445921
the	19445921
cardioprotective	19445921
potential	19445921
of	19445921
salvianolic	19445921
acid	19445921
A	19445921
on	19445921
isoproterenol	19445921
-	19445921
induced	19445921
myocardial	19445921
infarction	19445921
in	19445921
rats	19445921
.	19445921

Hemodynamic	19445921
parameters	19445921
and	19445921
lead	19445921
II	19445921
electrocardiograph	19445921
were	19445921
monitored	19445921
and	19445921
recorded	19445921
continuously	19445921
.	19445921

Cardiac	19445921
marker	19445921
enzymes	19445921
and	19445921
antioxidative	19445921
parameters	19445921
in	19445921
serum	19445921
and	19445921
heart	19445921
tissues	19445921
were	19445921
measured	19445921
.	19445921

Assay	19445921
for	19445921
mitochondrial	19445921
respiratory	19445921
function	19445921
and	19445921
histopathological	19445921
examination	19445921
of	19445921
heart	19445921
tissues	19445921
were	19445921
performed	19445921
.	19445921

Isoproterenol	19445921
-	19445921
treated	19445921
rats	19445921
showed	19445921
significant	19445921
increases	19445921
in	19445921
the	19445921
levels	19445921
of	19445921
lactate	19445921
dehydrogenase	19445921
,	19445921
aspartate	19445921
transaminase	19445921
,	19445921
creatine	19445921
kinase	19445921
and	19445921
malondialdehyde	19445921
and	19445921
significant	19445921
decreases	19445921
in	19445921
the	19445921
activities	19445921
of	19445921
superoxide	19445921
dismutase	19445921
,	19445921
catalase	19445921
and	19445921
glutathione	19445921
peroxidase	19445921
in	19445921
serum	19445921
and	19445921
heart	19445921
.	19445921

These	19445921
rats	19445921
also	19445921
showed	19445921
declines	19445921
in	19445921
left	19445921
ventricular	19445921
systolic	19445921
pressure	19445921
,	19445921
maximum	19445921
and	19445921
minimum	19445921
rate	19445921
of	19445921
developed	19445921
left	19445921
ventricular	19445921
pressure	19445921
,	19445921
and	19445921
elevation	19445921
of	19445921
left	19445921
ventricular	19445921
end	19445921
-	19445921
diastolic	19445921
pressure	19445921
and	19445921
ST	19445921
-	19445921
segment	19445921
.	19445921

In	19445921
addition	19445921
,	19445921
mitochondrial	19445921
respiratory	19445921
dysfunction	19445921
characterized	19445921
by	19445921
decreased	19445921
respiratory	19445921
control	19445921
ratio	19445921
and	19445921
ADP	19445921
/	19445921
O	19445921
was	19445921
observed	19445921
in	19445921
isoproterenol	19445921
-	19445921
treated	19445921
rats	19445921
.	19445921

Administration	19445921
of	19445921
salvianolic	19445921
acid	19445921
A	19445921
for	19445921
a	19445921
period	19445921
of	19445921
8	19445921
days	19445921
significantly	19445921
attenuated	19445921
isoproterenol	19445921
-	19445921
induced	19445921
cardiac	19445921
dysfunction	19445921
and	19445921
myocardial	19445921
injury	19445921
and	19445921
improved	19445921
mitochondrial	19445921
respiratory	19445921
function	19445921
.	19445921

The	19445921
protective	19445921
role	19445921
of	19445921
salvianolic	19445921
acid	19445921
A	19445921
against	19445921
isoproterenol	19445921
-	19445921
induced	19445921
myocardial	19445921
damage	19445921
was	19445921
further	19445921
confirmed	19445921
by	19445921
histopathological	19445921
examination	19445921
.	19445921

The	19445921
results	19445921
of	19445921
our	19445921
study	19445921
suggest	19445921
that	19445921
salvianolic	19445921
acid	19445921
A	19445921
possessing	19445921
antioxidant	19445921
activity	19445921
has	19445921
a	19445921
significant	19445921
protective	19445921
effect	19445921
against	19445921
isoproterenol	19445921
-	19445921
induced	19445921
myocardial	19445921
infarction	19445921
.	19445921
A	16200390
genetic	16200390
analysis	16200390
of	16200390
serotonergic	16200390
biosynthetic	16200390
and	16200390
metabolic	16200390
enzymes	16200390
in	16200390
migraine	16200390
using	16200390
a	16200390
DNA	16200390
pooling	16200390
approach	16200390
.	16200390

Migraine	16200390
is	16200390
a	16200390
common	16200390
debilitating	16200390
primary	16200390
headache	16200390
disorder	16200390
with	16200390
significant	16200390
mental	16200390
,	16200390
physical	16200390
and	16200390
social	16200390
health	16200390
implications	16200390
.	16200390

The	16200390
brain	16200390
neurotransmitter	16200390
5	16200390
-	16200390
hydroxytryptamine	16200390
(	16200390
5	16200390
-	16200390
HT	16200390
;	16200390
serotonin	16200390
)	16200390
is	16200390
involved	16200390
in	16200390
nociceptive	16200390
pathways	16200390
and	16200390
has	16200390
been	16200390
implicated	16200390
in	16200390
the	16200390
pathophysiology	16200390
of	16200390
migraine	16200390
.	16200390

With	16200390
few	16200390
genetic	16200390
studies	16200390
investigating	16200390
biosynthetic	16200390
and	16200390
metabolic	16200390
enzymes	16200390
governing	16200390
the	16200390
rate	16200390
of	16200390
5	16200390
-	16200390
HT	16200390
activity	16200390
and	16200390
their	16200390
relationship	16200390
to	16200390
migraine	16200390
,	16200390
it	16200390
was	16200390
the	16200390
objective	16200390
of	16200390
this	16200390
study	16200390
to	16200390
assess	16200390
genetic	16200390
variants	16200390
within	16200390
the	16200390
human	16200390
tryptophan	16200390
hydroxylase	16200390
(	16200390
TPH	16200390
)	16200390
,	16200390
amino	16200390
acid	16200390
decarboxylase	16200390
(	16200390
AADC	16200390
)	16200390
and	16200390
monoamine	16200390
oxidase	16200390
A	16200390
(	16200390
MAOA	16200390
)	16200390
genes	16200390
in	16200390
migraine	16200390
susceptibility	16200390
.	16200390

This	16200390
objective	16200390
was	16200390
undertaken	16200390
using	16200390
a	16200390
high	16200390
-	16200390
throughput	16200390
DNA	16200390
pooling	16200390
experimental	16200390
design	16200390
,	16200390
which	16200390
proved	16200390
to	16200390
be	16200390
a	16200390
very	16200390
accurate	16200390
,	16200390
sensitive	16200390
and	16200390
specific	16200390
method	16200390
of	16200390
estimating	16200390
allele	16200390
frequencies	16200390
for	16200390
single	16200390
nucleotide	16200390
polymorphism	16200390
,	16200390
insertion	16200390
deletion	16200390
and	16200390
variable	16200390
number	16200390
tandem	16200390
repeat	16200390
loci	16200390
.	16200390

Application	16200390
of	16200390
DNA	16200390
pooling	16200390
to	16200390
a	16200390
wide	16200390
array	16200390
of	16200390
genetic	16200390
loci	16200390
provides	16200390
greater	16200390
scope	16200390
in	16200390
the	16200390
assessment	16200390
of	16200390
population	16200390
-	16200390
based	16200390
genetic	16200390
association	16200390
study	16200390
designs	16200390
.	16200390

Despite	16200390
the	16200390
application	16200390
of	16200390
this	16200390
high	16200390
-	16200390
throughput	16200390
genotyping	16200390
method	16200390
,	16200390
negative	16200390
results	16200390
from	16200390
the	16200390
two	16200390
-	16200390
stage	16200390
DNA	16200390
pooling	16200390
design	16200390
used	16200390
to	16200390
screen	16200390
loci	16200390
within	16200390
the	16200390
TPH	16200390
,	16200390
AADC	16200390
and	16200390
MAOA	16200390
genes	16200390
did	16200390
not	16200390
support	16200390
their	16200390
role	16200390
in	16200390
migraine	16200390
susceptibility	16200390
.	16200390
Inappropriate	9746003
use	9746003
of	9746003
carbamazepine	9746003
and	9746003
vigabatrin	9746003
in	9746003
typical	9746003
absence	9746003
seizures	9746003
.	9746003

Carbamazepine	9746003
and	9746003
vigabatrin	9746003
are	9746003
contraindicated	9746003
in	9746003
typical	9746003
absence	9746003
seizures	9746003
.	9746003

Of	9746003
18	9746003
consecutive	9746003
referrals	9746003
of	9746003
children	9746003
with	9746003
resistant	9746003
typical	9746003
absences	9746003
only	9746003
,	9746003
eight	9746003
were	9746003
erroneously	9746003
treated	9746003
with	9746003
carbamazepine	9746003
either	9746003
as	9746003
monotherapy	9746003
or	9746003
as	9746003
an	9746003
add	9746003
-	9746003
on	9746003
.	9746003

Vigabatrin	9746003
was	9746003
also	9746003
used	9746003
in	9746003
the	9746003
treatment	9746003
of	9746003
two	9746003
children	9746003
.	9746003

Frequency	9746003
of	9746003
absences	9746003
increased	9746003
in	9746003
four	9746003
children	9746003
treated	9746003
with	9746003
carbamazepine	9746003
and	9746003
two	9746003
of	9746003
these	9746003
developed	9746003
myoclonic	9746003
jerks	9746003
,	9746003
which	9746003
resolved	9746003
on	9746003
withdrawal	9746003
of	9746003
carbamazepine	9746003
.	9746003

Absences	9746003
were	9746003
aggravated	9746003
in	9746003
both	9746003
cases	9746003
where	9746003
vigabatrin	9746003
was	9746003
added	9746003
on	9746003
to	9746003
concurrent	9746003
treatment	9746003
.	9746003

Optimal	9746003
control	9746003
of	9746003
the	9746003
absences	9746003
was	9746003
achieved	9746003
with	9746003
sodium	9746003
valproate	9746003
,	9746003
lamotrigine	9746003
,	9746003
or	9746003
ethosuximide	9746003
alone	9746003
or	9746003
in	9746003
combination	9746003
.	9746003
Safety	15859361
of	15859361
celecoxib	15859361
in	15859361
patients	15859361
with	15859361
adverse	15859361
skin	15859361
reactions	15859361
to	15859361
acetaminophen	15859361
(	15859361
paracetamol	15859361
)	15859361
and	15859361
nimesulide	15859361
associated	15859361
or	15859361
not	15859361
with	15859361
common	15859361
non	15859361
-	15859361
steroidal	15859361
anti	15859361
-	15859361
inflammatory	15859361
drugs	15859361
.	15859361

BACKGROUND	15859361
:	15859361
Acetaminophen	15859361
(	15859361
paracetamol	15859361
-	15859361
-	15859361
P	15859361
)	15859361
and	15859361
Nimesulide	15859361
(	15859361
N	15859361
)	15859361
are	15859361
widely	15859361
used	15859361
analgesic	15859361
-	15859361
antipyretic	15859361
/	15859361
anti	15859361
-	15859361
inflammatory	15859361
drugs	15859361
.	15859361

The	15859361
rate	15859361
of	15859361
adverse	15859361
hypersensitivity	15859361
reactions	15859361
to	15859361
these	15859361
agents	15859361
is	15859361
generally	15859361
low	15859361
.	15859361

On	15859361
the	15859361
contrary	15859361
non	15859361
-	15859361
steroidal	15859361
anti	15859361
-	15859361
inflammatory	15859361
drugs	15859361
(	15859361
NSAIDs	15859361
)	15859361
are	15859361
commonly	15859361
involved	15859361
in	15859361
such	15859361
reactions	15859361
.	15859361

Celecoxib	15859361
(	15859361
CE	15859361
)	15859361
is	15859361
a	15859361
novel	15859361
drug	15859361
,	15859361
with	15859361
high	15859361
selectivity	15859361
and	15859361
affinity	15859361
for	15859361
COX	15859361
-	15859361
2	15859361
enzyme	15859361
.	15859361

OBJECTIVE	15859361
:	15859361
We	15859361
evaluated	15859361
the	15859361
tolerability	15859361
of	15859361
CE	15859361
in	15859361
a	15859361
group	15859361
of	15859361
patients	15859361
with	15859361
documented	15859361
history	15859361
of	15859361
adverse	15859361
cutaneous	15859361
reactions	15859361
to	15859361
P	15859361
and	15859361
N	15859361
associated	15859361
or	15859361
not	15859361
to	15859361
classic	15859361
NSAIDs	15859361
.	15859361

METHODS	15859361
:	15859361
We	15859361
studied	15859361
9	15859361
patients	15859361
with	15859361
hypersensitivity	15859361
to	15859361
P	15859361
and	15859361
N	15859361
with	15859361
or	15859361
without	15859361
associated	15859361
reactions	15859361
to	15859361
classic	15859361
NSAIDs	15859361
.	15859361

The	15859361
diagnosis	15859361
of	15859361
P	15859361
and	15859361
N	15859361
-	15859361
induced	15859361
skin	15859361
reactions	15859361
was	15859361
based	15859361
in	15859361
vivo	15859361
challenge	15859361
.	15859361

The	15859361
placebo	15859361
was	15859361
blindly	15859361
administered	15859361
at	15859361
the	15859361
beginning	15859361
of	15859361
each	15859361
challenge	15859361
.	15859361

After	15859361
three	15859361
days	15859361
,	15859361
a	15859361
cumulative	15859361
dosage	15859361
of	15859361
200	15859361
mg	15859361
of	15859361
CE	15859361
in	15859361
refracted	15859361
doses	15859361
were	15859361
given	15859361
.	15859361

After	15859361
2	15859361
-	15859361
3	15859361
days	15859361
,	15859361
a	15859361
single	15859361
dose	15859361
of	15859361
200	15859361
mg	15859361
was	15859361
administered	15859361
.	15859361

All	15859361
patients	15859361
were	15859361
observed	15859361
for	15859361
6	15859361
hours	15859361
after	15859361
each	15859361
challenge	15859361
,	15859361
and	15859361
controlled	15859361
again	15859361
after	15859361
24	15859361
hours	15859361
to	15859361
exclude	15859361
delayed	15859361
reactions	15859361
.	15859361

The	15859361
challenge	15859361
was	15859361
considered	15859361
positive	15859361
if	15859361
one	15859361
or	15859361
more	15859361
of	15859361
the	15859361
following	15859361
appeared	15859361
:	15859361
erythema	15859361
,	15859361
rush	15859361
or	15859361
urticaria	15859361
-	15859361
angioedema	15859361
.	15859361

RESULTS	15859361
:	15859361
No	15859361
reaction	15859361
was	15859361
observed	15859361
with	15859361
placebo	15859361
and	15859361
eight	15859361
patients	15859361
(	15859361
88	15859361
.	15859361
8%	15859361
)	15859361
tolerated	15859361
CE	15859361
.	15859361

Only	15859361
one	15859361
patient	15859361
developed	15859361
a	15859361
moderate	15859361
angioedema	15859361
of	15859361
the	15859361
lips	15859361
.	15859361

CONCLUSION	15859361
:	15859361
Only	15859361
one	15859361
hypersensitivity	15859361
reaction	15859361
to	15859361
CE	15859361
was	15859361
documented	15859361
among	15859361
9	15859361
P	15859361
and	15859361
N	15859361
-	15859361
highly	15859361
NSAIDs	15859361
intolerant	15859361
patients	15859361
.	15859361

Thus	15859361
,	15859361
we	15859361
conclude	15859361
that	15859361
CE	15859361
is	15859361
a	15859361
reasonably	15859361
safe	15859361
alternative	15859361
to	15859361
be	15859361
used	15859361
in	15859361
subjects	15859361
who	15859361
do	15859361
not	15859361
tolerate	15859361
P	15859361
and	15859361
N	15859361
.	15859361
Genetic	28411266
Variation	28411266
at	28411266
the	28411266
Sulfonylurea	28411266
Receptor	28411266
,	28411266
Type	28411266
2	28411266
Diabetes	28411266
,	28411266
and	28411266
Coronary	28411266
Heart	28411266
Disease	28411266
.	28411266

Despite	28411266
widespread	28411266
clinical	28411266
use	28411266
in	28411266
the	28411266
treatment	28411266
of	28411266
type	28411266
2	28411266
diabetes	28411266
,	28411266
the	28411266
impact	28411266
of	28411266
sulfonylurea	28411266
therapy	28411266
on	28411266
cardiovascular	28411266
outcomes	28411266
remains	28411266
uncertain	28411266
.	28411266

Studies	28411266
of	28411266
naturally	28411266
occurring	28411266
genetic	28411266
variation	28411266
can	28411266
be	28411266
used	28411266
to	28411266
anticipate	28411266
the	28411266
expected	28411266
clinical	28411266
consequences	28411266
of	28411266
a	28411266
pharmacological	28411266
therapy	28411266
.	28411266

A	28411266
common	28411266
missense	28411266
variant	28411266
in	28411266
the	28411266
gene	28411266
encoding	28411266
a	28411266
component	28411266
of	28411266
the	28411266
sulfonylurea	28411266
receptor	28411266
(	28411266
ABCC8	28411266
p	28411266
.	28411266
A1369S	28411266
)	28411266
promotes	28411266
closure	28411266
of	28411266
the	28411266
target	28411266
channel	28411266
of	28411266
sulfonylurea	28411266
therapy	28411266
and	28411266
is	28411266
associated	28411266
with	28411266
increased	28411266
insulin	28411266
secretion	28411266
,	28411266
thus	28411266
mimicking	28411266
the	28411266
effects	28411266
of	28411266
sulfonylurea	28411266
therapy	28411266
.	28411266

Using	28411266
individual	28411266
-	28411266
level	28411266
data	28411266
from	28411266
120	28411266
,	28411266
286	28411266
participants	28411266
in	28411266
the	28411266
UK	28411266
Biobank	28411266
and	28411266
summary	28411266
association	28411266
results	28411266
from	28411266
four	28411266
large	28411266
-	28411266
scale	28411266
genome	28411266
-	28411266
wide	28411266
association	28411266
studies	28411266
,	28411266
we	28411266
examined	28411266
the	28411266
impact	28411266
of	28411266
this	28411266
variant	28411266
on	28411266
cardiometabolic	28411266
traits	28411266
,	28411266
type	28411266
2	28411266
diabetes	28411266
,	28411266
and	28411266
coronary	28411266
heart	28411266
disease	28411266
.	28411266

The	28411266
p	28411266
.	28411266
A1369S	28411266
variant	28411266
was	28411266
associated	28411266
with	28411266
a	28411266
significantly	28411266
lower	28411266
risk	28411266
of	28411266
type	28411266
2	28411266
diabetes	28411266
(	28411266
odds	28411266
ratio	28411266
[	28411266
OR	28411266
]	28411266
0	28411266
.	28411266
93	28411266
;	28411266
95%	28411266
CI	28411266
0	28411266
.	28411266
91	28411266
,	28411266
0	28411266
.	28411266
95	28411266
;	28411266
P	28411266
=	28411266
1	28411266
.	28411266
2	28411266
x	28411266
10	28411266
(	28411266
-	28411266
11	28411266
)	28411266
)	28411266
.	28411266

The	28411266
variant	28411266
was	28411266
associated	28411266
with	28411266
increased	28411266
BMI	28411266
(	28411266
+	28411266
0	28411266
.	28411266
062	28411266
kg	28411266
/	28411266
m	28411266
(	28411266
2	28411266
)	28411266
;	28411266
95%	28411266
CI	28411266
0	28411266
.	28411266
037	28411266
,	28411266
0	28411266
.	28411266
086	28411266
;	28411266
P	28411266
=	28411266
8	28411266
.	28411266
1	28411266
x	28411266
10	28411266
(	28411266
-	28411266
7	28411266
)	28411266
)	28411266
but	28411266
lower	28411266
waist	28411266
-	28411266
to	28411266
-	28411266
hip	28411266
ratio	28411266
adjusted	28411266
for	28411266
BMI	28411266
,	28411266
a	28411266
marker	28411266
of	28411266
abdominal	28411266
fat	28411266
distribution	28411266
.	28411266

Furthermore	28411266
,	28411266
p	28411266
.	28411266
A1369S	28411266
was	28411266
associated	28411266
with	28411266
a	28411266
reduced	28411266
risk	28411266
of	28411266
coronary	28411266
heart	28411266
disease	28411266
(	28411266
OR	28411266
0	28411266
.	28411266
98	28411266
;	28411266
95%	28411266
CI	28411266
0	28411266
.	28411266
96	28411266
,	28411266
0	28411266
.	28411266
99	28411266
;	28411266
P	28411266
=	28411266
5	28411266
.	28411266
9	28411266
x	28411266
10	28411266
(	28411266
-	28411266
4	28411266
)	28411266
)	28411266
.	28411266

These	28411266
results	28411266
suggest	28411266
that	28411266
,	28411266
despite	28411266
a	28411266
known	28411266
association	28411266
with	28411266
increased	28411266
weight	28411266
,	28411266
long	28411266
-	28411266
term	28411266
sulfonylurea	28411266
therapy	28411266
may	28411266
reduce	28411266
the	28411266
risk	28411266
of	28411266
coronary	28411266
heart	28411266
disease	28411266
.	28411266
Brat	21238926
promotes	21238926
stem	21238926
cell	21238926
differentiation	21238926
via	21238926
control	21238926
of	21238926
a	21238926
bistable	21238926
switch	21238926
that	21238926
restricts	21238926
BMP	21238926
signaling	21238926
.	21238926

Drosophila	21238926
ovarian	21238926
germline	21238926
stem	21238926
cells	21238926
(	21238926
GSCs	21238926
)	21238926
are	21238926
maintained	21238926
by	21238926
Dpp	21238926
signaling	21238926
and	21238926
the	21238926
Pumilio	21238926
(	21238926
Pum	21238926
)	21238926
and	21238926
Nanos	21238926
(	21238926
Nos	21238926
)	21238926
translational	21238926
repressors	21238926
.	21238926

Upon	21238926
division	21238926
,	21238926
Dpp	21238926
signaling	21238926
is	21238926
extinguished	21238926
,	21238926
and	21238926
Nos	21238926
is	21238926
downregulated	21238926
in	21238926
one	21238926
daughter	21238926
cell	21238926
,	21238926
causing	21238926
it	21238926
to	21238926
switch	21238926
to	21238926
a	21238926
differentiating	21238926
cystoblast	21238926
(	21238926
CB	21238926
)	21238926
.	21238926

However	21238926
,	21238926
downstream	21238926
effectors	21238926
of	21238926
Pum	21238926
-	21238926
Nos	21238926
remain	21238926
unknown	21238926
,	21238926
and	21238926
how	21238926
CBs	21238926
lose	21238926
their	21238926
responsiveness	21238926
to	21238926
Dpp	21238926
is	21238926
unclear	21238926
.	21238926

Here	21238926
,	21238926
we	21238926
identify	21238926
Brain	21238926
Tumor	21238926
(	21238926
Brat	21238926
)	21238926
as	21238926
a	21238926
potent	21238926
differentiation	21238926
factor	21238926
and	21238926
target	21238926
of	21238926
Pum	21238926
-	21238926
Nos	21238926
regulation	21238926
.	21238926

Brat	21238926
is	21238926
excluded	21238926
from	21238926
GSCs	21238926
by	21238926
Pum	21238926
-	21238926
Nos	21238926
but	21238926
functions	21238926
with	21238926
Pum	21238926
in	21238926
CBs	21238926
to	21238926
translationally	21238926
repress	21238926
distinct	21238926
targets	21238926
,	21238926
including	21238926
the	21238926
Mad	21238926
and	21238926
dMyc	21238926
mRNAs	21238926
.	21238926

Regulation	21238926
of	21238926
both	21238926
targets	21238926
simultaneously	21238926
lowers	21238926
cellular	21238926
responsiveness	21238926
to	21238926
Dpp	21238926
signaling	21238926
,	21238926
forcing	21238926
the	21238926
cell	21238926
to	21238926
become	21238926
refractory	21238926
to	21238926
the	21238926
self	21238926
-	21238926
renewal	21238926
signal	21238926
.	21238926

Mathematical	21238926
modeling	21238926
elucidates	21238926
bistability	21238926
of	21238926
cell	21238926
fate	21238926
in	21238926
the	21238926
Brat	21238926
-	21238926
mediated	21238926
system	21238926
,	21238926
revealing	21238926
how	21238926
autoregulation	21238926
of	21238926
GSC	21238926
number	21238926
can	21238926
arise	21238926
from	21238926
Brat	21238926
coupling	21238926
extracellular	21238926
Dpp	21238926
regulation	21238926
to	21238926
intracellular	21238926
interpretation	21238926
.	21238926
Inhibitory	28260110
effect	28260110
of	28260110
emodin	28260110
on	28260110
fatty	28260110
acid	28260110
synthase	28260110
,	28260110
colon	28260110
cancer	28260110
proliferation	28260110
and	28260110
apoptosis	28260110
.	28260110

Fatty	28260110
acid	28260110
synthase	28260110
(	28260110
FASN	28260110
)	28260110
is	28260110
a	28260110
key	28260110
anabolic	28260110
enzyme	28260110
for	28260110
de	28260110
novo	28260110
fatty	28260110
acid	28260110
synthesis	28260110
,	28260110
which	28260110
is	28260110
important	28260110
in	28260110
the	28260110
development	28260110
of	28260110
colon	28260110
carcinoma	28260110
.	28260110

The	28260110
high	28260110
expression	28260110
of	28260110
FASN	28260110
is	28260110
considered	28260110
a	28260110
promising	28260110
molecular	28260110
target	28260110
for	28260110
colon	28260110
cancer	28260110
therapy	28260110
.	28260110

Emodin	28260110
,	28260110
a	28260110
naturally	28260110
occurring	28260110
anthraquinone	28260110
,	28260110
exhibits	28260110
an	28260110
anticancer	28260110
effect	28260110
in	28260110
various	28260110
types	28260110
of	28260110
human	28260110
cancer	28260110
,	28260110
including	28260110
colon	28260110
cancer	28260110
;	28260110
however	28260110
,	28260110
the	28260110
molecular	28260110
mechanisms	28260110
remain	28260110
to	28260110
be	28260110
fully	28260110
elucidated	28260110
.	28260110

Cell	28260110
viability	28260110
was	28260110
evaluated	28260110
using	28260110
a	28260110
Cell	28260110
Counting	28260110
Kit	28260110
-	28260110
8	28260110
assay	28260110
.	28260110

The	28260110
apoptosis	28260110
rate	28260110
of	28260110
cells	28260110
was	28260110
quantified	28260110
via	28260110
flow	28260110
cytometry	28260110
following	28260110
Annexin	28260110
V	28260110
/	28260110
propidium	28260110
iodide	28260110
staining	28260110
.	28260110

FASN	28260110
activity	28260110
was	28260110
measured	28260110
by	28260110
monitoring	28260110
oxidation	28260110
of	28260110
nicotinamide	28260110
adenine	28260110
dinucleotide	28260110
phosphate	28260110
at	28260110
a	28260110
wavelength	28260110
of	28260110
340	28260110
nm	28260110
,	28260110
and	28260110
intracellular	28260110
free	28260110
fatty	28260110
acid	28260110
levels	28260110
were	28260110
detected	28260110
using	28260110
a	28260110
Free	28260110
Fatty	28260110
Acid	28260110
Quantification	28260110
kit	28260110
.	28260110

Western	28260110
blot	28260110
analysis	28260110
and	28260110
reverse	28260110
transcription	28260110
-	28260110
polymerase	28260110
chain	28260110
reaction	28260110
were	28260110
used	28260110
to	28260110
detect	28260110
target	28260110
gene	28260110
and	28260110
protein	28260110
expression	28260110
.	28260110

The	28260110
present	28260110
study	28260110
was	28260110
performed	28260110
to	28260110
investigate	28260110
whether	28260110
the	28260110
gene	28260110
expression	28260110
of	28260110
FASN	28260110
and	28260110
its	28260110
enzymatic	28260110
activity	28260110
are	28260110
regulated	28260110
by	28260110
emodin	28260110
in	28260110
a	28260110
human	28260110
colon	28260110
cancer	28260110
cell	28260110
line	28260110
.	28260110

Emodin	28260110
markedly	28260110
inhibited	28260110
the	28260110
proliferation	28260110
of	28260110
HCT116	28260110
cells	28260110
and	28260110
a	28260110
higher	28260110
protein	28260110
level	28260110
of	28260110
FASN	28260110
was	28260110
expressed	28260110
,	28260110
compared	28260110
with	28260110
that	28260110
in	28260110
SW480	28260110
,	28260110
SNU	28260110
-	28260110
C2A	28260110
or	28260110
SNU	28260110
-	28260110
C5	28260110
cells	28260110
.	28260110

Emodin	28260110
significantly	28260110
downregulated	28260110
the	28260110
protein	28260110
expression	28260110
of	28260110
FASN	28260110
in	28260110
HCT116	28260110
cells	28260110
,	28260110
which	28260110
was	28260110
caused	28260110
by	28260110
protein	28260110
degradation	28260110
due	28260110
to	28260110
elevated	28260110
protein	28260110
ubiquitination	28260110
.	28260110

Emodin	28260110
also	28260110
inhibited	28260110
intracellular	28260110
FASN	28260110
enzymatic	28260110
activity	28260110
and	28260110
reduced	28260110
the	28260110
levels	28260110
of	28260110
intracellular	28260110
free	28260110
fatty	28260110
acids	28260110
.	28260110

Emodin	28260110
enhanced	28260110
antiproliferation	28260110
and	28260110
apoptosis	28260110
in	28260110
a	28260110
dose	28260110
-	28260110
and	28260110
time	28260110
-	28260110
dependent	28260110
manner	28260110
.	28260110

The	28260110
combined	28260110
treatment	28260110
of	28260110
emodin	28260110
and	28260110
cerulenin	28260110
,	28260110
a	28260110
commercial	28260110
FASN	28260110
inhibitor	28260110
,	28260110
had	28260110
an	28260110
additive	28260110
effect	28260110
on	28260110
these	28260110
activities	28260110
.	28260110

Palmitate	28260110
,	28260110
the	28260110
final	28260110
product	28260110
of	28260110
the	28260110
FASN	28260110
reaction	28260110
,	28260110
rescued	28260110
emodin	28260110
-	28260110
induced	28260110
viability	28260110
and	28260110
apoptosis	28260110
.	28260110

In	28260110
addition	28260110
,	28260110
emodin	28260110
altered	28260110
FASN	28260110
-	28260110
involved	28260110
signaling	28260110
pathways	28260110
,	28260110
including	28260110
phosphatidylinositol	28260110
3	28260110
-	28260110
kinase	28260110
/	28260110
Akt	28260110
and	28260110
mitogen	28260110
-	28260110
activated	28260110
protein	28260110
kinases	28260110
/	28260110
extracellular	28260110
signal	28260110
-	28260110
regulated	28260110
kinases	28260110
1	28260110
/	28260110
2	28260110
.	28260110

These	28260110
results	28260110
suggested	28260110
that	28260110
emodin	28260110
-	28260110
regulated	28260110
cell	28260110
growth	28260110
and	28260110
apoptosis	28260110
were	28260110
mediated	28260110
by	28260110
inhibiting	28260110
FASN	28260110
and	28260110
provide	28260110
a	28260110
molecular	28260110
basis	28260110
for	28260110
colon	28260110
cancer	28260110
therapy	28260110
.	28260110
Circulating	27090298
Fatty	27090298
Acid	27090298
Synthase	27090298
in	27090298
pregnant	27090298
women	27090298
:	27090298
Relationship	27090298
to	27090298
blood	27090298
pressure	27090298
,	27090298
maternal	27090298
metabolism	27090298
and	27090298
newborn	27090298
parameters	27090298
.	27090298

The	27090298
enzyme	27090298
FASN	27090298
(	27090298
fatty	27090298
acid	27090298
synthase	27090298
)	27090298
is	27090298
potentially	27090298
related	27090298
with	27090298
hypertension	27090298
and	27090298
metabolic	27090298
dysfunction	27090298
.	27090298

FASN	27090298
is	27090298
highly	27090298
expressed	27090298
in	27090298
the	27090298
human	27090298
placenta	27090298
.	27090298

We	27090298
aimed	27090298
to	27090298
investigate	27090298
the	27090298
relationship	27090298
circulating	27090298
FASN	27090298
has	27090298
with	27090298
blood	27090298
pressure	27090298
,	27090298
maternal	27090298
metabolism	27090298
and	27090298
newborn	27090298
parameters	27090298
in	27090298
healthy	27090298
pregnant	27090298
women	27090298
.	27090298

Circulating	27090298
FASN	27090298
was	27090298
assessed	27090298
in	27090298
115	27090298
asymptomatic	27090298
pregnant	27090298
women	27090298
in	27090298
the	27090298
second	27090298
trimester	27090298
of	27090298
gestation	27090298
along	27090298
with	27090298
C	27090298
-	27090298
peptide	27090298
,	27090298
fasting	27090298
glucose	27090298
and	27090298
insulin	27090298
,	27090298
post	27090298
-	27090298
load	27090298
glucose	27090298
lipids	27090298
,	27090298
HMW	27090298
-	27090298
adiponectin	27090298
and	27090298
blood	27090298
pressure	27090298
(	27090298
the	27090298
latter	27090298
was	27090298
assessed	27090298
in	27090298
each	27090298
trimester	27090298
of	27090298
gestation	27090298
)	27090298
.	27090298

At	27090298
birth	27090298
,	27090298
newborns	27090298
and	27090298
placentas	27090298
were	27090298
weighed	27090298
.	27090298

FASN	27090298
expression	27090298
was	27090298
also	27090298
able	27090298
to	27090298
be	27090298
assessed	27090298
in	27090298
80	27090298
placentas	27090298
.	27090298

Higher	27090298
circulating	27090298
FASN	27090298
was	27090298
associated	27090298
with	27090298
lower	27090298
systolic	27090298
blood	27090298
pressure	27090298
(	27090298
SBP	27090298
)	27090298
,	27090298
with	27090298
a	27090298
more	27090298
favourable	27090298
metabolic	27090298
phenotype	27090298
(	27090298
lower	27090298
fasting	27090298
glucose	27090298
and	27090298
insulin	27090298
,	27090298
post	27090298
load	27090298
glucose	27090298
,	27090298
HbAc1	27090298
,	27090298
HOMA	27090298
-	27090298
IR	27090298
and	27090298
C	27090298
-	27090298
peptide	27090298
)	27090298
,	27090298
and	27090298
with	27090298
lower	27090298
placental	27090298
and	27090298
birth	27090298
weight	27090298
(	27090298
all	27090298
p	27090298
<	27090298
0	27090298
.	27090298
05	27090298
to	27090298
p	27090298
<	27090298
0	27090298
.	27090298
001	27090298
)	27090298
.	27090298

Placental	27090298
FASN	27090298
expression	27090298
related	27090298
positively	27090298
to	27090298
circulating	27090298
FASN	27090298
(	27090298
p	27090298
<	27090298
0	27090298
.	27090298
005	27090298
)	27090298
and	27090298
negatively	27090298
to	27090298
placental	27090298
weight	27090298
(	27090298
p	27090298
<	27090298
0	27090298
.	27090298
05	27090298
)	27090298
.	27090298

Our	27090298
observations	27090298
suggest	27090298
a	27090298
physiological	27090298
role	27090298
of	27090298
placental	27090298
FASN	27090298
in	27090298
human	27090298
pregnancy	27090298
.	27090298

Future	27090298
studies	27090298
will	27090298
clarify	27090298
whether	27090298
circulating	27090298
FASN	27090298
of	27090298
placental	27090298
origin	27090298
does	27090298
actually	27090298
regulate	27090298
placental	27090298
and	27090298
fetal	27090298
growth	27090298
,	27090298
and	27090298
(	27090298
thereby	27090298
)	27090298
has	27090298
a	27090298
favourable	27090298
influence	27090298
on	27090298
the	27090298
pregnant	27090298
mother	27090298
'	27090298
s	27090298
insulin	27090298
sensitivity	27090298
and	27090298
blood	27090298
pressure	27090298
.	27090298
Syncope	20859899
caused	20859899
by	20859899
hyperkalemia	20859899
during	20859899
use	20859899
of	20859899
a	20859899
combined	20859899
therapy	20859899
with	20859899
the	20859899
angiotensin	20859899
-	20859899
converting	20859899
enzyme	20859899
inhibitor	20859899
and	20859899
spironolactone	20859899
.	20859899

A	20859899
76	20859899
year	20859899
-	20859899
old	20859899
woman	20859899
with	20859899
a	20859899
history	20859899
of	20859899
coronary	20859899
artery	20859899
bypass	20859899
grafting	20859899
and	20859899
prior	20859899
myocardial	20859899
infarction	20859899
was	20859899
transferred	20859899
to	20859899
the	20859899
emergency	20859899
room	20859899
with	20859899
loss	20859899
of	20859899
consciousness	20859899
due	20859899
to	20859899
marked	20859899
bradycardia	20859899
caused	20859899
by	20859899
hyperkalemia	20859899
.	20859899

The	20859899
concentration	20859899
of	20859899
serum	20859899
potassium	20859899
was	20859899
high	20859899
,	20859899
and	20859899
normal	20859899
sinus	20859899
rhythm	20859899
was	20859899
restored	20859899
after	20859899
correction	20859899
of	20859899
the	20859899
serum	20859899
potassium	20859899
level	20859899
.	20859899

The	20859899
cause	20859899
of	20859899
hyperkalemia	20859899
was	20859899
considered	20859899
to	20859899
be	20859899
several	20859899
doses	20859899
of	20859899
spiranolactone	20859899
,	20859899
an	20859899
aldosterone	20859899
antagonist	20859899
,	20859899
in	20859899
addition	20859899
to	20859899
the	20859899
long	20859899
-	20859899
term	20859899
intake	20859899
of	20859899
ramipril	20859899
,	20859899
an	20859899
ACE	20859899
inhibitor	20859899
.	20859899

This	20859899
case	20859899
is	20859899
a	20859899
good	20859899
example	20859899
of	20859899
electrolyte	20859899
imbalance	20859899
causing	20859899
acute	20859899
life	20859899
-	20859899
threatening	20859899
cardiac	20859899
events	20859899
.	20859899

Clinicians	20859899
should	20859899
be	20859899
alert	20859899
to	20859899
the	20859899
possibility	20859899
of	20859899
hyperkalemia	20859899
,	20859899
especially	20859899
in	20859899
elderly	20859899
patients	20859899
using	20859899
ACE	20859899
/	20859899
ARB	20859899
in	20859899
combination	20859899
with	20859899
potassium	20859899
sparing	20859899
agents	20859899
and	20859899
who	20859899
have	20859899
mild	20859899
renal	20859899
disturbance	20859899
.	20859899
The	21070631
dopamine	21070631
b	21070631
-	21070631
hydroxylase	21070631
-	21070631
1021C	21070631
/	21070631
T	21070631
polymorphism	21070631
is	21070631
associated	21070631
with	21070631
the	21070631
risk	21070631
of	21070631
Alzheimer	21070631
'	21070631
s	21070631
disease	21070631
in	21070631
the	21070631
Epistasis	21070631
Project	21070631
.	21070631

BACKGROUND	21070631
:	21070631
The	21070631
loss	21070631
of	21070631
noradrenergic	21070631
neurones	21070631
of	21070631
the	21070631
locus	21070631
coeruleus	21070631
is	21070631
a	21070631
major	21070631
feature	21070631
of	21070631
Alzheimer	21070631
'	21070631
s	21070631
disease	21070631
(	21070631
AD	21070631
)	21070631
.	21070631

Dopamine	21070631
b	21070631
-	21070631
hydroxylase	21070631
(	21070631
DBH	21070631
)	21070631
catalyses	21070631
the	21070631
conversion	21070631
of	21070631
dopamine	21070631
to	21070631
noradrenaline	21070631
.	21070631

Interactions	21070631
have	21070631
been	21070631
reported	21070631
between	21070631
the	21070631
low	21070631
-	21070631
activity	21070631
-	21070631
1021T	21070631
allele	21070631
(	21070631
rs1611115	21070631
)	21070631
of	21070631
DBH	21070631
and	21070631
polymorphisms	21070631
of	21070631
the	21070631
pro	21070631
-	21070631
inflammatory	21070631
cytokine	21070631
genes	21070631
,	21070631
IL1A	21070631
and	21070631
IL6	21070631
,	21070631
contributing	21070631
to	21070631
the	21070631
risk	21070631
of	21070631
AD	21070631
.	21070631

We	21070631
therefore	21070631
examined	21070631
the	21070631
associations	21070631
with	21070631
AD	21070631
of	21070631
the	21070631
DBH	21070631
-	21070631
1021T	21070631
allele	21070631
and	21070631
of	21070631
the	21070631
above	21070631
interactions	21070631
in	21070631
the	21070631
Epistasis	21070631
Project	21070631
,	21070631
with	21070631
1757	21070631
cases	21070631
of	21070631
AD	21070631
and	21070631
6294	21070631
elderly	21070631
controls	21070631
.	21070631

METHODS	21070631
:	21070631
We	21070631
genotyped	21070631
eight	21070631
single	21070631
nucleotide	21070631
polymorphisms	21070631
(	21070631
SNPs	21070631
)	21070631
in	21070631
the	21070631
three	21070631
genes	21070631
,	21070631
DBH	21070631
,	21070631
IL1A	21070631
and	21070631
IL6	21070631
.	21070631

We	21070631
used	21070631
logistic	21070631
regression	21070631
models	21070631
and	21070631
synergy	21070631
factor	21070631
analysis	21070631
to	21070631
examine	21070631
potential	21070631
interactions	21070631
and	21070631
associations	21070631
with	21070631
AD	21070631
.	21070631

RESULTS	21070631
:	21070631
We	21070631
found	21070631
that	21070631
the	21070631
presence	21070631
of	21070631
the	21070631
-	21070631
1021T	21070631
allele	21070631
was	21070631
associated	21070631
with	21070631
AD	21070631
:	21070631
odds	21070631
ratio	21070631
=	21070631
1	21070631
.	21070631
2	21070631
(	21070631
95%	21070631
confidence	21070631
interval	21070631
:	21070631
1	21070631
.	21070631
06	21070631
-	21070631
1	21070631
.	21070631
4	21070631
,	21070631
p	21070631
=	21070631
0	21070631
.	21070631
005	21070631
)	21070631
.	21070631

This	21070631
association	21070631
was	21070631
nearly	21070631
restricted	21070631
to	21070631
men	21070631
<	21070631
75	21070631
years	21070631
old	21070631
:	21070631
odds	21070631
ratio	21070631
=	21070631
2	21070631
.	21070631
2	21070631
(	21070631
1	21070631
.	21070631
4	21070631
-	21070631
3	21070631
.	21070631
3	21070631
,	21070631
0	21070631
.	21070631
0004	21070631
)	21070631
.	21070631

We	21070631
also	21070631
found	21070631
an	21070631
interaction	21070631
between	21070631
the	21070631
presence	21070631
of	21070631
DBH	21070631
-	21070631
1021T	21070631
and	21070631
the	21070631
-	21070631
889TT	21070631
genotype	21070631
(	21070631
rs1800587	21070631
)	21070631
of	21070631
IL1A	21070631
:	21070631
synergy	21070631
factor	21070631
=	21070631
1	21070631
.	21070631
9	21070631
(	21070631
1	21070631
.	21070631
2	21070631
-	21070631
3	21070631
.	21070631
1	21070631
,	21070631
0	21070631
.	21070631
005	21070631
)	21070631
.	21070631

All	21070631
these	21070631
results	21070631
were	21070631
consistent	21070631
between	21070631
North	21070631
Europe	21070631
and	21070631
North	21070631
Spain	21070631
.	21070631

CONCLUSIONS	21070631
:	21070631
Extensive	21070631
,	21070631
previous	21070631
evidence	21070631
(	21070631
reviewed	21070631
here	21070631
)	21070631
indicates	21070631
an	21070631
important	21070631
role	21070631
for	21070631
noradrenaline	21070631
in	21070631
the	21070631
control	21070631
of	21070631
inflammation	21070631
in	21070631
the	21070631
brain	21070631
.	21070631

Thus	21070631
,	21070631
the	21070631
-	21070631
1021T	21070631
allele	21070631
with	21070631
presumed	21070631
low	21070631
activity	21070631
may	21070631
be	21070631
associated	21070631
with	21070631
misregulation	21070631
of	21070631
inflammation	21070631
,	21070631
which	21070631
could	21070631
contribute	21070631
to	21070631
the	21070631
onset	21070631
of	21070631
AD	21070631
.	21070631

We	21070631
suggest	21070631
that	21070631
such	21070631
misregulation	21070631
is	21070631
the	21070631
predominant	21070631
mechanism	21070631
of	21070631
the	21070631
association	21070631
we	21070631
report	21070631
here	21070631
.	21070631
Association	18439317
between	18439317
promoter	18439317
-	18439317
1607	18439317
polymorphism	18439317
of	18439317
MMP1	18439317
and	18439317
lumbar	18439317
disc	18439317
disease	18439317
in	18439317
Southern	18439317
Chinese	18439317
.	18439317

BACKGROUND	18439317
:	18439317
Matrix	18439317
metalloproteinases	18439317
(	18439317
MMPs	18439317
)	18439317
are	18439317
involved	18439317
in	18439317
the	18439317
degradation	18439317
of	18439317
the	18439317
extracellular	18439317
matrix	18439317
of	18439317
the	18439317
intervertebral	18439317
disc	18439317
.	18439317

A	18439317
SNP	18439317
for	18439317
guanine	18439317
insertion	18439317
/	18439317
deletion	18439317
(	18439317
G	18439317
/	18439317
D	18439317
)	18439317
,	18439317
the	18439317
-	18439317
1607	18439317
promoter	18439317
polymorphism	18439317
,	18439317
of	18439317
the	18439317
MMP1	18439317
gene	18439317
was	18439317
found	18439317
significantly	18439317
affecting	18439317
promoter	18439317
activity	18439317
and	18439317
corresponding	18439317
transcription	18439317
level	18439317
.	18439317

Hence	18439317
it	18439317
is	18439317
a	18439317
good	18439317
candidate	18439317
for	18439317
genetic	18439317
studies	18439317
in	18439317
DDD	18439317
.	18439317

METHODS	18439317
:	18439317
Southern	18439317
Chinese	18439317
volunteers	18439317
between	18439317
18	18439317
and	18439317
55	18439317
years	18439317
were	18439317
recruited	18439317
from	18439317
the	18439317
population	18439317
.	18439317

DDD	18439317
in	18439317
the	18439317
lumbar	18439317
spine	18439317
was	18439317
defined	18439317
by	18439317
MRI	18439317
using	18439317
Schneiderman	18439317
'	18439317
s	18439317
classification	18439317
.	18439317

Genomic	18439317
DNA	18439317
was	18439317
isolated	18439317
from	18439317
the	18439317
leukocytes	18439317
and	18439317
genotyping	18439317
was	18439317
performed	18439317
using	18439317
the	18439317
Sequenom	18439317
platform	18439317
.	18439317

Association	18439317
and	18439317
Hardy	18439317
-	18439317
Weinberg	18439317
equilibrium	18439317
checking	18439317
were	18439317
assessed	18439317
by	18439317
Chi	18439317
-	18439317
square	18439317
test	18439317
and	18439317
Mann	18439317
-	18439317
Whitney	18439317
U	18439317
test	18439317
.	18439317

RESULTS	18439317
:	18439317
Our	18439317
results	18439317
showed	18439317
substantial	18439317
evidence	18439317
of	18439317
association	18439317
between	18439317
-	18439317
1607	18439317
promoter	18439317
polymorphism	18439317
of	18439317
MMP1	18439317
and	18439317
DDD	18439317
in	18439317
the	18439317
Southern	18439317
Chinese	18439317
subjects	18439317
.	18439317

D	18439317
allelic	18439317
was	18439317
significantly	18439317
associated	18439317
with	18439317
DDD	18439317
(	18439317
p	18439317
value	18439317
=	18439317
0	18439317
.	18439317
027	18439317
,	18439317
odds	18439317
ratio	18439317
=	18439317
1	18439317
.	18439317
41	18439317
with	18439317
95%	18439317
CI	18439317
=	18439317
1	18439317
.	18439317
04	18439317
-	18439317
1	18439317
.	18439317
90	18439317
)	18439317
while	18439317
Genotypic	18439317
association	18439317
on	18439317
the	18439317
presence	18439317
of	18439317
D	18439317
allele	18439317
was	18439317
also	18439317
significantly	18439317
associated	18439317
with	18439317
DDD	18439317
(	18439317
p	18439317
value	18439317
=	18439317
0	18439317
.	18439317
046	18439317
,	18439317
odds	18439317
ratio	18439317
=	18439317
1	18439317
.	18439317
50	18439317
with	18439317
95%	18439317
CI	18439317
=	18439317
1	18439317
.	18439317
01	18439317
-	18439317
2	18439317
.	18439317
24	18439317
)	18439317
.	18439317

Further	18439317
age	18439317
stratification	18439317
showed	18439317
significant	18439317
genotypic	18439317
as	18439317
well	18439317
as	18439317
allelic	18439317
association	18439317
in	18439317
the	18439317
group	18439317
of	18439317
over	18439317
40	18439317
years	18439317
(	18439317
genotypic	18439317
:	18439317
p	18439317
value	18439317
=	18439317
0	18439317
.	18439317
035	18439317
,	18439317
odds	18439317
ratio	18439317
=	18439317
1	18439317
.	18439317
617	18439317
with	18439317
95%	18439317
CI	18439317
=	18439317
1	18439317
.	18439317
033	18439317
-	18439317
2	18439317
.	18439317
529	18439317
;	18439317
allelic	18439317
:	18439317
p	18439317
value	18439317
=	18439317
0	18439317
.	18439317
033	18439317
,	18439317
odds	18439317
ratio	18439317
=	18439317
1	18439317
.	18439317
445	18439317
with	18439317
95%	18439317
CI	18439317
=	18439317
1	18439317
.	18439317
029	18439317
-	18439317
2	18439317
.	18439317
029	18439317
)	18439317
.	18439317

Disc	18439317
bulge	18439317
,	18439317
annular	18439317
tears	18439317
and	18439317
the	18439317
Schmorl	18439317
'	18439317
s	18439317
nodes	18439317
were	18439317
not	18439317
associated	18439317
with	18439317
the	18439317
D	18439317
allele	18439317
.	18439317

CONCLUSION	18439317
:	18439317
We	18439317
demonstrated	18439317
that	18439317
individuals	18439317
with	18439317
the	18439317
presence	18439317
of	18439317
D	18439317
allele	18439317
for	18439317
the	18439317
-	18439317
1607	18439317
promoter	18439317
polymorphism	18439317
of	18439317
MMP1	18439317
are	18439317
about	18439317
1	18439317
.	18439317
5	18439317
times	18439317
more	18439317
susceptible	18439317
to	18439317
develop	18439317
DDD	18439317
when	18439317
compared	18439317
with	18439317
those	18439317
having	18439317
G	18439317
allele	18439317
only	18439317
.	18439317

Further	18439317
association	18439317
was	18439317
identified	18439317
in	18439317
individuals	18439317
over	18439317
40	18439317
years	18439317
of	18439317
age	18439317
.	18439317

Disc	18439317
bulge	18439317
,	18439317
annular	18439317
tear	18439317
as	18439317
well	18439317
as	18439317
Schmorl	18439317
'	18439317
s	18439317
nodes	18439317
were	18439317
not	18439317
associated	18439317
with	18439317
this	18439317
polymorphism	18439317
.	18439317
Recurrent	15602202
acute	15602202
interstitial	15602202
nephritis	15602202
induced	15602202
by	15602202
azithromycin	15602202
.	15602202

A	15602202
14	15602202
-	15602202
year	15602202
-	15602202
old	15602202
girl	15602202
is	15602202
reported	15602202
with	15602202
recurrent	15602202
,	15602202
azithromycin	15602202
-	15602202
induced	15602202
,	15602202
acute	15602202
interstitial	15602202
nephritis	15602202
.	15602202

The	15602202
second	15602202
episode	15602202
was	15602202
more	15602202
severe	15602202
than	15602202
the	15602202
first	15602202
;	15602202
and	15602202
although	15602202
both	15602202
were	15602202
treated	15602202
with	15602202
intensive	15602202
corticosteroid	15602202
therapy	15602202
,	15602202
renal	15602202
function	15602202
remained	15602202
impaired	15602202
.	15602202

Although	15602202
most	15602202
cases	15602202
of	15602202
antibiotic	15602202
induced	15602202
acute	15602202
interstitial	15602202
nephritis	15602202
are	15602202
benign	15602202
and	15602202
self	15602202
-	15602202
limited	15602202
,	15602202
some	15602202
patients	15602202
are	15602202
at	15602202
risk	15602202
for	15602202
permanent	15602202
renal	15602202
injury	15602202
.	15602202
CFI	26900322
-	26900322
rs7356506	26900322
polymorphisms	26900322
associated	26900322
with	26900322
Vogt	26900322
-	26900322
Koyanagi	26900322
-	26900322
Harada	26900322
syndrome	26900322
.	26900322

PURPOSE	26900322
:	26900322
Complement	26900322
factor	26900322
I	26900322
(	26900322
CFI	26900322
)	26900322
plays	26900322
an	26900322
important	26900322
role	26900322
in	26900322
complement	26900322
activation	26900322
pathways	26900322
and	26900322
is	26900322
known	26900322
to	26900322
affect	26900322
the	26900322
development	26900322
of	26900322
uveitis	26900322
.	26900322

The	26900322
present	26900322
study	26900322
was	26900322
performed	26900322
to	26900322
investigate	26900322
the	26900322
existence	26900322
of	26900322
an	26900322
association	26900322
between	26900322
CFI	26900322
genetic	26900322
polymorphisms	26900322
and	26900322
Vogt	26900322
-	26900322
Koyanagi	26900322
-	26900322
Harada	26900322
(	26900322
VKH	26900322
)	26900322
syndrome	26900322
.	26900322

METHODS	26900322
:	26900322
A	26900322
total	26900322
of	26900322
100	26900322
patients	26900322
diagnosed	26900322
with	26900322
VKH	26900322
syndrome	26900322
and	26900322
300	26900322
healthy	26900322
controls	26900322
were	26900322
recruited	26900322
for	26900322
the	26900322
study	26900322
.	26900322

Two	26900322
milliliters	26900322
of	26900322
peripheral	26900322
blood	26900322
were	26900322
collected	26900322
in	26900322
a	26900322
sterile	26900322
anticoagulative	26900322
tube	26900322
.	26900322

CFI	26900322
-	26900322
rs7356506	26900322
polymorphisms	26900322
were	26900322
genotyped	26900322
using	26900322
Sequenom	26900322
MassARRAY	26900322
technology	26900322
.	26900322

Allele	26900322
and	26900322
genotype	26900322
frequencies	26900322
were	26900322
compared	26900322
between	26900322
patients	26900322
and	26900322
controls	26900322
using	26900322
a	26900322
X	26900322
(	26900322
2	26900322
)	26900322
test	26900322
.	26900322

The	26900322
analyses	26900322
were	26900322
stratified	26900322
for	26900322
recurrent	26900322
status	26900322
,	26900322
complicated	26900322
cataract	26900322
status	26900322
,	26900322
and	26900322
steroid	26900322
-	26900322
sensitive	26900322
status	26900322
.	26900322

RESULTS	26900322
:	26900322
No	26900322
significant	26900322
association	26900322
was	26900322
found	26900322
between	26900322
CFI	26900322
-	26900322
rs7356506	26900322
polymorphisms	26900322
and	26900322
VKH	26900322
syndrome	26900322
.	26900322

However	26900322
,	26900322
patients	26900322
with	26900322
recurrent	26900322
VKH	26900322
syndrome	26900322
had	26900322
lower	26900322
frequencies	26900322
of	26900322
the	26900322
G	26900322
allele	26900322
and	26900322
GG	26900322
homozygosity	26900322
in	26900322
CFI	26900322
-	26900322
rs7356506	26900322
when	26900322
compared	26900322
to	26900322
the	26900322
controls	26900322
(	26900322
p	26900322
=	26900322
0	26900322
.	26900322
016	26900322
,	26900322
odds	26900322
ratio	26900322
[	26900322
OR	26900322
]	26900322
=	26900322
0	26900322
.	26900322
429	26900322
,	26900322
95%	26900322
confidence	26900322
interval	26900322
[	26900322
CI	26900322
]	26900322
=	26900322
0	26900322
.	26900322
212	26900322
-	26900322
0	26900322
.	26900322
871	26900322
;	26900322
p	26900322
=	26900322
0	26900322
.	26900322
014	26900322
,	26900322
OR	26900322
=	26900322
0	26900322
.	26900322
364	26900322
,	26900322
95%	26900322
CI	26900322
=	26900322
0	26900322
.	26900322
158	26900322
-	26900322
0	26900322
.	26900322
837	26900322
,	26900322
respectively	26900322
)	26900322
.	26900322

Furthermore	26900322
,	26900322
there	26900322
were	26900322
significant	26900322
decreases	26900322
in	26900322
the	26900322
frequencies	26900322
of	26900322
the	26900322
G	26900322
allele	26900322
and	26900322
GG	26900322
homozygosity	26900322
in	26900322
CFI	26900322
-	26900322
rs7356506	26900322
in	26900322
patients	26900322
with	26900322
VKH	26900322
syndrome	26900322
with	26900322
complicated	26900322
cataract	26900322
compared	26900322
to	26900322
the	26900322
controls	26900322
(	26900322
p	26900322
<	26900322
0	26900322
.	26900322
001	26900322
,	26900322
OR	26900322
=	26900322
0	26900322
.	26900322
357	26900322
,	26900322
95%	26900322
CI	26900322
=	26900322
0	26900322
.	26900322
197	26900322
-	26900322
0	26900322
.	26900322
648	26900322
;	26900322
p	26900322
<	26900322
0	26900322
.	26900322
001	26900322
,	26900322
OR	26900322
=	26900322
0	26900322
.	26900322
273	26900322
,	26900322
95%	26900322
CI	26900322
=	26900322
0	26900322
.	26900322
135	26900322
-	26900322
0	26900322
.	26900322
551	26900322
,	26900322
respectively	26900322
)	26900322
.	26900322

Nevertheless	26900322
,	26900322
no	26900322
significant	26900322
association	26900322
with	26900322
patients	26900322
with	26900322
VKH	26900322
syndrome	26900322
in	26900322
steroid	26900322
-	26900322
sensitive	26900322
statuses	26900322
was	26900322
detected	26900322
for	26900322
CFI	26900322
-	26900322
rs7356506	26900322
polymorphisms	26900322
.	26900322

CONCLUSIONS	26900322
:	26900322
Our	26900322
results	26900322
indicate	26900322
that	26900322
CFI	26900322
polymorphisms	26900322
are	26900322
not	26900322
significantly	26900322
associated	26900322
with	26900322
VKH	26900322
syndrome	26900322
;	26900322
nevertheless	26900322
,	26900322
we	26900322
identified	26900322
a	26900322
trend	26900322
for	26900322
the	26900322
association	26900322
of	26900322
CFI	26900322
-	26900322
7356506	26900322
with	26900322
VKH	26900322
syndrome	26900322
that	26900322
depends	26900322
on	26900322
the	26900322
recurrent	26900322
status	26900322
and	26900322
the	26900322
complicated	26900322
cataract	26900322
status	26900322
but	26900322
not	26900322
on	26900322
the	26900322
steroid	26900322
-	26900322
sensitive	26900322
status	26900322
.	26900322
The	19108278
biological	19108278
properties	19108278
of	19108278
the	19108278
optical	19108278
isomers	19108278
of	19108278
propranolol	19108278
and	19108278
their	19108278
effects	19108278
on	19108278
cardiac	19108278
arrhythmias	19108278
.	19108278

1	19108278
.	19108278

The	19108278
optical	19108278
isomers	19108278
of	19108278
propranolol	19108278
have	19108278
been	19108278
compared	19108278
for	19108278
their	19108278
beta	19108278
-	19108278
blocking	19108278
and	19108278
antiarrhythmic	19108278
activities	19108278
.	19108278
2	19108278
.	19108278

In	19108278
blocking	19108278
the	19108278
positive	19108278
inotropic	19108278
and	19108278
chronotropic	19108278
responses	19108278
to	19108278
isoprenaline	19108278
,	19108278
(	19108278
+	19108278
)	19108278
-	19108278
propranolol	19108278
had	19108278
less	19108278
than	19108278
one	19108278
hundredth	19108278
the	19108278
potency	19108278
of	19108278
(	19108278
-	19108278
)	19108278
-	19108278
propranolol	19108278
.	19108278

At	19108278
dose	19108278
levels	19108278
of	19108278
(	19108278
+	19108278
)	19108278
-	19108278
propranolol	19108278
which	19108278
attenuated	19108278
the	19108278
responses	19108278
to	19108278
isoprenaline	19108278
,	19108278
there	19108278
was	19108278
a	19108278
significant	19108278
prolongation	19108278
of	19108278
the	19108278
PR	19108278
interval	19108278
of	19108278
the	19108278
electrocardiogram	19108278
.	19108278
3	19108278
.	19108278

The	19108278
metabolic	19108278
responses	19108278
to	19108278
isoprenaline	19108278
in	19108278
dogs	19108278
(	19108278
an	19108278
increase	19108278
in	19108278
circulating	19108278
glucose	19108278
,	19108278
lactate	19108278
and	19108278
free	19108278
fatty	19108278
acids	19108278
)	19108278
were	19108278
all	19108278
blocked	19108278
by	19108278
(	19108278
-	19108278
)	19108278
-	19108278
propranolol	19108278
.	19108278

(	19108278
+	19108278
)	19108278
-	19108278
Propranolol	19108278
had	19108278
no	19108278
effect	19108278
on	19108278
fatty	19108278
acid	19108278
mobilization	19108278
but	19108278
significantly	19108278
reduced	19108278
the	19108278
increments	19108278
in	19108278
both	19108278
lactate	19108278
and	19108278
glucose	19108278
.	19108278
4	19108278
.	19108278

Both	19108278
isomers	19108278
of	19108278
propranolol	19108278
possessed	19108278
similar	19108278
depressant	19108278
potency	19108278
on	19108278
isolated	19108278
atrial	19108278
muscle	19108278
taken	19108278
from	19108278
guinea	19108278
-	19108278
pigs	19108278
.	19108278
5	19108278
.	19108278

The	19108278
isomers	19108278
of	19108278
propranolol	19108278
exhibited	19108278
similar	19108278
local	19108278
anaesthetic	19108278
potencies	19108278
on	19108278
an	19108278
isolated	19108278
frog	19108278
nerve	19108278
preparation	19108278
at	19108278
a	19108278
level	19108278
approximately	19108278
three	19108278
times	19108278
that	19108278
of	19108278
procaine	19108278
.	19108278

The	19108278
racemic	19108278
compound	19108278
was	19108278
significantly	19108278
less	19108278
potent	19108278
than	19108278
either	19108278
isomer	19108278
.	19108278
6	19108278
.	19108278

Both	19108278
isomers	19108278
of	19108278
propranolol	19108278
were	19108278
capable	19108278
of	19108278
preventing	19108278
adrenaline	19108278
-	19108278
induced	19108278
cardiac	19108278
arrhythmias	19108278
in	19108278
cats	19108278
anaesthetized	19108278
with	19108278
halothane	19108278
,	19108278
but	19108278
the	19108278
mean	19108278
dose	19108278
of	19108278
(	19108278
-	19108278
)	19108278
-	19108278
propranolol	19108278
was	19108278
0	19108278
.	19108278
09	19108278
+	19108278
/	19108278
-	19108278
0	19108278
.	19108278
02	19108278
mg	19108278
/	19108278
kg	19108278
whereas	19108278
that	19108278
of	19108278
(	19108278
+	19108278
)	19108278
-	19108278
propranolol	19108278
was	19108278
4	19108278
.	19108278
2	19108278
+	19108278
/	19108278
-	19108278
1	19108278
.	19108278
2	19108278
mg	19108278
/	19108278
kg	19108278
.	19108278

At	19108278
the	19108278
effective	19108278
dose	19108278
level	19108278
of	19108278
(	19108278
+	19108278
)	19108278
-	19108278
propranolol	19108278
there	19108278
was	19108278
a	19108278
significant	19108278
prolongation	19108278
of	19108278
the	19108278
PR	19108278
interval	19108278
of	19108278
the	19108278
electrocardiogram	19108278
.	19108278

Blockade	19108278
of	19108278
arrhythmias	19108278
with	19108278
both	19108278
isomers	19108278
was	19108278
surmountable	19108278
by	19108278
increasing	19108278
the	19108278
dose	19108278
of	19108278
adrenaline	19108278
.	19108278
7	19108278
.	19108278

Both	19108278
isomers	19108278
of	19108278
propranolol	19108278
were	19108278
also	19108278
capable	19108278
of	19108278
reversing	19108278
ventricular	19108278
tachycardia	19108278
caused	19108278
by	19108278
ouabain	19108278
in	19108278
anaesthetized	19108278
cats	19108278
and	19108278
dogs	19108278
.	19108278

The	19108278
dose	19108278
of	19108278
(	19108278
-	19108278
)	19108278
-	19108278
propranolol	19108278
was	19108278
significantly	19108278
smaller	19108278
than	19108278
that	19108278
of	19108278
(	19108278
+	19108278
)	19108278
-	19108278
propranolol	19108278
in	19108278
both	19108278
species	19108278
but	19108278
much	19108278
higher	19108278
than	19108278
that	19108278
required	19108278
to	19108278
produce	19108278
evidence	19108278
of	19108278
beta	19108278
-	19108278
blockade	19108278
.	19108278
8	19108278
.	19108278

The	19108278
implications	19108278
of	19108278
these	19108278
results	19108278
are	19108278
discussed	19108278
.	19108278
Combination	19082493
of	19082493
polymorphisms	19082493
within	19082493
5	19082493
'	19082493
and	19082493
3	19082493
'	19082493
untranslated	19082493
regions	19082493
of	19082493
thymidylate	19082493
synthase	19082493
gene	19082493
modulates	19082493
survival	19082493
in	19082493
5	19082493
fluorouracil	19082493
-	19082493
treated	19082493
colorectal	19082493
cancer	19082493
patients	19082493
.	19082493

In	19082493
the	19082493
present	19082493
study	19082493
we	19082493
explored	19082493
the	19082493
effect	19082493
of	19082493
three	19082493
polymorphisms	19082493
of	19082493
the	19082493
TS	19082493
gene	19082493
on	19082493
overall	19082493
and	19082493
progression	19082493
-	19082493
free	19082493
survival	19082493
of	19082493
colorectal	19082493
cancer	19082493
(	19082493
CRC	19082493
)	19082493
patients	19082493
subjected	19082493
to	19082493
5FU	19082493
chemotherapy	19082493
.	19082493

A	19082493
28	19082493
bp	19082493
variable	19082493
number	19082493
of	19082493
tandem	19082493
repeats	19082493
(	19082493
VNTR	19082493
)	19082493
,	19082493
a	19082493
G	19082493
/	19082493
C	19082493
single	19082493
nucleotide	19082493
polymorphism	19082493
(	19082493
SNP	19082493
)	19082493
,	19082493
and	19082493
a	19082493
deletion	19082493
of	19082493
6	19082493
bp	19082493
at	19082493
position	19082493
1494	19082493
were	19082493
studied	19082493
.	19082493

The	19082493
possible	19082493
combined	19082493
effect	19082493
of	19082493
these	19082493
DNA	19082493
polymorphisms	19082493
on	19082493
the	19082493
clinical	19082493
outcome	19082493
of	19082493
patients	19082493
was	19082493
also	19082493
evaluated	19082493
.	19082493

A	19082493
retrospective	19082493
study	19082493
was	19082493
carried	19082493
out	19082493
on	19082493
paraffin	19082493
-	19082493
embedded	19082493
sections	19082493
from	19082493
113	19082493
patients	19082493
diagnosed	19082493
of	19082493
advanced	19082493
CRC	19082493
.	19082493

TS	19082493
genotyping	19082493
methods	19082493
were	19082493
polymerase	19082493
chain	19082493
reaction	19082493
(	19082493
PCR	19082493
)	19082493
for	19082493
VNTR	19082493
and	19082493
PCR	19082493
,	19082493
followed	19082493
by	19082493
restriction	19082493
length	19082493
fragment	19082493
polymorphism	19082493
(	19082493
PCR	19082493
-	19082493
RFLP	19082493
)	19082493
for	19082493
SNP	19082493
and	19082493
ins	19082493
/	19082493
del	19082493
6	19082493
bp	19082493
.	19082493

To	19082493
study	19082493
the	19082493
combined	19082493
effect	19082493
of	19082493
TS	19082493
polymorphisms	19082493
,	19082493
four	19082493
categories	19082493
were	19082493
defined	19082493
accordingly	19082493
to	19082493
the	19082493
level	19082493
of	19082493
expression	19082493
attributed	19082493
to	19082493
SNP	19082493
and	19082493
ins	19082493
/	19082493
del	19082493
6	19082493
bp	19082493
genotypes	19082493
:	19082493
C_allele	19082493
6	19082493
-	19082493
,	19082493
C_6	19082493
+	19082493
/	19082493
6	19082493
+	19082493
,	19082493
G_allele6	19082493
-	19082493
and	19082493
G_6	19082493
+	19082493
/	19082493
6	19082493
+	19082493
.	19082493

VNTR	19082493
and	19082493
ins	19082493
/	19082493
del	19082493
6	19082493
bp	19082493
genotypes	19082493
varied	19082493
with	19082493
tumour	19082493
anatomical	19082493
site	19082493
:	19082493
2R	19082493
/	19082493
2R	19082493
genotype	19082493
was	19082493
rare	19082493
in	19082493
left	19082493
-	19082493
sided	19082493
tumours	19082493
(	19082493
7	19082493
.	19082493
0%	19082493
vs	19082493
.	19082493

26	19082493
.	19082493
3%	19082493
of	19082493
right	19082493
-	19082493
sided	19082493
and	19082493
24	19082493
.	19082493
1%	19082493
of	19082493
rectal	19082493
cancers	19082493
;	19082493
P	19082493
<	19082493
0	19082493
.	19082493
01	19082493
)	19082493
,	19082493
where	19082493
the	19082493
variant	19082493
allele	19082493
6	19082493
-	19082493
was	19082493
very	19082493
frequent	19082493
(	19082493
69	19082493
.	19082493
0%	19082493
)	19082493
.	19082493

Instead	19082493
,	19082493
most	19082493
patients	19082493
with	19082493
right	19082493
-	19082493
sided	19082493
tumours	19082493
were	19082493
wild	19082493
-	19082493
type	19082493
homozygous	19082493
6	19082493
+	19082493
/	19082493
6	19082493
+	19082493
(	19082493
63	19082493
.	19082493
9%	19082493
)	19082493
(	19082493
P	19082493
<	19082493
0	19082493
.	19082493
01	19082493
)	19082493
.	19082493

Heterozygous	19082493
6	19082493
+	19082493
/	19082493
6	19082493
-	19082493
genotype	19082493
was	19082493
more	19082493
frequent	19082493
among	19082493
tumours	19082493
classified	19082493
as	19082493
C	19082493
(	19082493
50	19082493
.	19082493
0%	19082493
)	19082493
and	19082493
D	19082493
(	19082493
76	19082493
.	19082493
5%	19082493
)	19082493
Dukes	19082493
stages	19082493
(	19082493
P	19082493
=	19082493
0	19082493
.	19082493
05	19082493
)	19082493
.	19082493

None	19082493
of	19082493
the	19082493
studied	19082493
polymorphisms	19082493
alone	19082493
affected	19082493
overall	19082493
or	19082493
progression	19082493
-	19082493
free	19082493
survival	19082493
(	19082493
PFS	19082493
)	19082493
.	19082493

C_6	19082493
+	19082493
/	19082493
6	19082493
+	19082493
and	19082493
G_6	19082493
+	19082493
/	19082493
6	19082493
+	19082493
combined	19082493
genotypes	19082493
were	19082493
respectively	19082493
associated	19082493
to	19082493
the	19082493
best	19082493
and	19082493
worst	19082493
PFS	19082493
(	19082493
P	19082493
=	19082493
0	19082493
.	19082493
03	19082493
when	19082493
compared	19082493
with	19082493
each	19082493
other	19082493
)	19082493
,	19082493
while	19082493
combinations	19082493
carrying	19082493
the	19082493
allele	19082493
6	19082493
-	19082493
determined	19082493
an	19082493
intermediate	19082493
evolution	19082493
that	19082493
might	19082493
be	19082493
indicative	19082493
of	19082493
a	19082493
variable	19082493
response	19082493
to	19082493
chemotherapy	19082493
.	19082493

The	19082493
rate	19082493
of	19082493
Dukes	19082493
B	19082493
stage	19082493
tumours	19082493
was	19082493
unexpectedly	19082493
high	19082493
(	19082493
59	19082493
.	19082493
1%	19082493
)	19082493
among	19082493
patients	19082493
with	19082493
the	19082493
unfavourable	19082493
G_6	19082493
+	19082493
/	19082493
6	19082493
+	19082493
combination	19082493
.	19082493

In	19082493
our	19082493
study	19082493
the	19082493
combination	19082493
of	19082493
high	19082493
TS	19082493
expression	19082493
genotypes	19082493
G_6	19082493
+	19082493
/	19082493
6	19082493
+	19082493
identifies	19082493
a	19082493
group	19082493
of	19082493
high	19082493
risk	19082493
within	19082493
CRC	19082493
patients	19082493
treated	19082493
with	19082493
5FU	19082493
.	19082493
Polymorphisms	19880293
in	19880293
the	19880293
FOXP3	19880293
gene	19880293
in	19880293
Han	19880293
Chinese	19880293
psoriasis	19880293
patients	19880293
.	19880293

BACKGROUND	19880293
:	19880293
Psoriasis	19880293
is	19880293
a	19880293
common	19880293
dermatological	19880293
disorder	19880293
,	19880293
in	19880293
which	19880293
autoimmunity	19880293
plays	19880293
an	19880293
important	19880293
role	19880293
.	19880293

CD4	19880293
(	19880293
+	19880293
)	19880293
CD25	19880293
(	19880293
+	19880293
)	19880293
regulatory	19880293
T	19880293
cells	19880293
(	19880293
T	19880293
-	19880293
regs	19880293
)	19880293
have	19880293
been	19880293
suggested	19880293
to	19880293
be	19880293
involved	19880293
in	19880293
the	19880293
pathogenesis	19880293
of	19880293
some	19880293
autoimmune	19880293
diseases	19880293
.	19880293

T	19880293
-	19880293
regs	19880293
express	19880293
the	19880293
fork	19880293
head	19880293
/	19880293
winged	19880293
helix	19880293
transcription	19880293
factor	19880293
,	19880293
FOXP3	19880293
,	19880293
which	19880293
appears	19880293
to	19880293
be	19880293
of	19880293
key	19880293
importance	19880293
in	19880293
the	19880293
development	19880293
and	19880293
function	19880293
of	19880293
T	19880293
-	19880293
regs	19880293
.	19880293

Studies	19880293
have	19880293
found	19880293
that	19880293
single	19880293
-	19880293
nucleotide	19880293
polymorphisms	19880293
(	19880293
SNPs	19880293
)	19880293
in	19880293
the	19880293
FOXP3	19880293
gene	19880293
contribute	19880293
to	19880293
susceptibility	19880293
to	19880293
some	19880293
autoimmune	19880293
disorders	19880293
.	19880293

However	19880293
,	19880293
information	19880293
about	19880293
FOXP3	19880293
gene	19880293
in	19880293
psoriasis	19880293
is	19880293
limited	19880293
.	19880293

OBJECTIVE	19880293
:	19880293
This	19880293
study	19880293
evaluated	19880293
the	19880293
association	19880293
between	19880293
FOXP3	19880293
gene	19880293
SNPs	19880293
and	19880293
susceptibility	19880293
to	19880293
psoriasis	19880293
in	19880293
a	19880293
Han	19880293
Chinese	19880293
population	19880293
.	19880293

METHODS	19880293
:	19880293
In	19880293
a	19880293
hospital	19880293
-	19880293
based	19880293
case	19880293
-	19880293
control	19880293
study	19880293
,	19880293
524	19880293
patients	19880293
with	19880293
psoriasis	19880293
and	19880293
549	19880293
psoriasis	19880293
-	19880293
free	19880293
controls	19880293
were	19880293
recruited	19880293
according	19880293
to	19880293
age	19880293
and	19880293
gender	19880293
.	19880293

We	19880293
investigated	19880293
four	19880293
SNPs	19880293
in	19880293
the	19880293
FOXP3	19880293
gene	19880293
(	19880293
-	19880293
6054	19880293
,	19880293
deletion	19880293
/	19880293
ATT	19880293
;	19880293
-	19880293
3279	19880293
,	19880293
A	19880293
/	19880293
C	19880293
;	19880293
-	19880293
924	19880293
,	19880293
A	19880293
/	19880293
G	19880293
;	19880293
IVS9	19880293
+	19880293
459	19880293
,	19880293
A	19880293
/	19880293
G	19880293
)	19880293
in	19880293
psoriatic	19880293
patients	19880293
,	19880293
and	19880293
assessed	19880293
allele	19880293
and	19880293
genotype	19880293
frequencies	19880293
in	19880293
psoriatic	19880293
patients	19880293
(	19880293
237	19880293
females	19880293
,	19880293
287	19880293
males	19880293
)	19880293
and	19880293
normal	19880293
controls	19880293
(	19880293
272	19880293
females	19880293
,	19880293
277	19880293
males	19880293
)	19880293
.	19880293

The	19880293
polymorphisms	19880293
were	19880293
genotyped	19880293
using	19880293
the	19880293
PCR	19880293
sequence	19880293
-	19880293
specific	19880293
primer	19880293
(	19880293
PCR	19880293
-	19880293
SSP	19880293
)	19880293
technique	19880293
and	19880293
PCR	19880293
-	19880293
restriction	19880293
fragment	19880293
length	19880293
polymorphism	19880293
(	19880293
RFLP	19880293
)	19880293
analysis	19880293
.	19880293

RESULTS	19880293
:	19880293
We	19880293
found	19880293
that	19880293
increased	19880293
risk	19880293
of	19880293
psoriasis	19880293
was	19880293
associated	19880293
with	19880293
the	19880293
FOXP3	19880293
-	19880293
3279	19880293
AC	19880293
genotype	19880293
(	19880293
adjusted	19880293
OR	19880293
,	19880293
1	19880293
.	19880293
32	19880293
;	19880293
95%	19880293
CI	19880293
,	19880293
1	19880293
.	19880293
01	19880293
-	19880293
1	19880293
.	19880293
74	19880293
)	19880293
and	19880293
the	19880293
combined	19880293
AC	19880293
+	19880293
AA	19880293
genotype	19880293
(	19880293
adjusted	19880293
OR	19880293
,	19880293
1	19880293
.	19880293
38	19880293
;	19880293
95%	19880293
CI	19880293
,	19880293
1	19880293
.	19880293
07	19880293
-	19880293
1	19880293
.	19880293
78	19880293
)	19880293
,	19880293
compared	19880293
with	19880293
the	19880293
-	19880293
3279	19880293
CC	19880293
genotype	19880293
.	19880293

We	19880293
also	19880293
found	19880293
that	19880293
an	19880293
increased	19880293
risk	19880293
of	19880293
psoriasis	19880293
was	19880293
associated	19880293
with	19880293
the	19880293
FOXP3	19880293
IVS9	19880293
+	19880293
459	19880293
GG	19880293
genotype	19880293
(	19880293
adjusted	19880293
OR	19880293
,	19880293
2	19880293
.	19880293
24	19880293
;	19880293
95%	19880293
CI	19880293
,	19880293
1	19880293
.	19880293
41	19880293
-	19880293
3	19880293
.	19880293
58	19880293
)	19880293
.	19880293

However	19880293
,	19880293
the	19880293
combined	19880293
GA	19880293
+	19880293
GG	19880293
genotype	19880293
showed	19880293
no	19880293
such	19880293
tendency	19880293
(	19880293
adjusted	19880293
OR	19880293
=	19880293
1	19880293
.	19880293
28	19880293
;	19880293
95%	19880293
CI	19880293
,	19880293
1	19880293
.	19880293
00	19880293
-	19880293
1	19880293
.	19880293
64	19880293
)	19880293
,	19880293
compared	19880293
with	19880293
the	19880293
IVS9	19880293
+	19880293
459	19880293
AA	19880293
genotype	19880293
.	19880293

There	19880293
was	19880293
no	19880293
evidence	19880293
of	19880293
an	19880293
increased	19880293
risk	19880293
associated	19880293
with	19880293
the	19880293
FOXP3	19880293
-	19880293
6054	19880293
deletion	19880293
/	19880293
ATT	19880293
or	19880293
FOXP3	19880293
-	19880293
924	19880293
A	19880293
/	19880293
G	19880293
genotype	19880293
.	19880293

In	19880293
combined	19880293
genotype	19880293
analyses	19880293
,	19880293
the	19880293
FOXP3	19880293
-	19880293
3279	19880293
AC	19880293
+	19880293
AA	19880293
genotype	19880293
was	19880293
more	19880293
obviously	19880293
associated	19880293
in	19880293
males	19880293
(	19880293
adjusted	19880293
OR	19880293
=	19880293
1	19880293
.	19880293
60	19880293
,	19880293
95%	19880293
CI	19880293
=	19880293
1	19880293
.	19880293
11	19880293
-	19880293
2	19880293
.	19880293
31	19880293
)	19880293
and	19880293
severe	19880293
psoriasis	19880293
patients	19880293
(	19880293
PASI	19880293
score	19880293
>	19880293
20	19880293
;	19880293
adjusted	19880293
OR	19880293
=	19880293
1	19880293
.	19880293
97	19880293
,	19880293
95%	19880293
CI	19880293
=	19880293
1	19880293
.	19880293
41	19880293
-	19880293
2	19880293
.	19880293
75	19880293
)	19880293
.	19880293

Meanwhile	19880293
,	19880293
the	19880293
FOXP3	19880293
IVS9	19880293
+	19880293
459	19880293
GA	19880293
+	19880293
GG	19880293
genotype	19880293
was	19880293
also	19880293
associated	19880293
with	19880293
severe	19880293
psoriasis	19880293
patients	19880293
(	19880293
adjusted	19880293
OR	19880293
=	19880293
1	19880293
.	19880293
69	19880293
,	19880293
95%	19880293
CI	19880293
=	19880293
1	19880293
.	19880293
21	19880293
-	19880293
2	19880293
.	19880293
36	19880293
)	19880293
.	19880293

CONCLUSIONS	19880293
:	19880293
FOXP3	19880293
polymorphisms	19880293
appear	19880293
to	19880293
contribute	19880293
to	19880293
the	19880293
risk	19880293
of	19880293
psoriasis	19880293
in	19880293
a	19880293
Han	19880293
Chinese	19880293
population	19880293
.	19880293

Larger	19880293
studies	19880293
are	19880293
needed	19880293
to	19880293
confirm	19880293
these	19880293
findings	19880293
.	19880293
Late	22836123
-	22836123
onset	22836123
scleroderma	22836123
renal	22836123
crisis	22836123
induced	22836123
by	22836123
tacrolimus	22836123
and	22836123
prednisolone	22836123
:	22836123
a	22836123
case	22836123
report	22836123
.	22836123

Scleroderma	22836123
renal	22836123
crisis	22836123
(	22836123
SRC	22836123
)	22836123
is	22836123
a	22836123
rare	22836123
complication	22836123
of	22836123
systemic	22836123
sclerosis	22836123
(	22836123
SSc	22836123
)	22836123
but	22836123
can	22836123
be	22836123
severe	22836123
enough	22836123
to	22836123
require	22836123
temporary	22836123
or	22836123
permanent	22836123
renal	22836123
replacement	22836123
therapy	22836123
.	22836123

Moderate	22836123
to	22836123
high	22836123
dose	22836123
corticosteroid	22836123
use	22836123
is	22836123
recognized	22836123
as	22836123
a	22836123
major	22836123
risk	22836123
factor	22836123
for	22836123
SRC	22836123
.	22836123

Furthermore	22836123
,	22836123
there	22836123
have	22836123
been	22836123
reports	22836123
of	22836123
thrombotic	22836123
microangiopathy	22836123
precipitated	22836123
by	22836123
cyclosporine	22836123
in	22836123
patients	22836123
with	22836123
SSc	22836123
.	22836123

In	22836123
this	22836123
article	22836123
,	22836123
we	22836123
report	22836123
a	22836123
patient	22836123
with	22836123
SRC	22836123
induced	22836123
by	22836123
tacrolimus	22836123
and	22836123
corticosteroids	22836123
.	22836123

The	22836123
aim	22836123
of	22836123
this	22836123
work	22836123
is	22836123
to	22836123
call	22836123
attention	22836123
to	22836123
the	22836123
risk	22836123
of	22836123
tacrolimus	22836123
use	22836123
in	22836123
patients	22836123
with	22836123
SSc	22836123
.	22836123
A	20846357
novel	20846357
mutation	20846357
in	20846357
the	20846357
connexin	20846357
26	20846357
gene	20846357
(	20846357
GJB2	20846357
)	20846357
in	20846357
a	20846357
child	20846357
with	20846357
clinical	20846357
and	20846357
histological	20846357
features	20846357
of	20846357
keratitis	20846357
-	20846357
ichthyosis	20846357
-	20846357
deafness	20846357
(	20846357
KID	20846357
)	20846357
syndrome	20846357
.	20846357

BACKGROUND	20846357
:	20846357
Keratitis	20846357
-	20846357
ichthyosis	20846357
-	20846357
deafness	20846357
(	20846357
KID	20846357
)	20846357
syndrome	20846357
is	20846357
a	20846357
rare	20846357
congenital	20846357
ectodermal	20846357
disorder	20846357
,	20846357
caused	20846357
by	20846357
heterozygous	20846357
missense	20846357
mutation	20846357
in	20846357
GJB2	20846357
,	20846357
encoding	20846357
the	20846357
gap	20846357
junction	20846357
protein	20846357
connexin	20846357
26	20846357
.	20846357

The	20846357
commonest	20846357
mutation	20846357
is	20846357
the	20846357
p	20846357
.	20846357
Asp50Asn	20846357
mutation	20846357
,	20846357
and	20846357
only	20846357
a	20846357
few	20846357
other	20846357
mutations	20846357
have	20846357
been	20846357
described	20846357
to	20846357
date	20846357
.	20846357

AIM	20846357
:	20846357
To	20846357
report	20846357
the	20846357
fatal	20846357
clinical	20846357
course	20846357
and	20846357
characterize	20846357
the	20846357
genetic	20846357
background	20846357
of	20846357
a	20846357
premature	20846357
male	20846357
neonate	20846357
with	20846357
the	20846357
clinical	20846357
and	20846357
histological	20846357
features	20846357
of	20846357
KID	20846357
syndrome	20846357
.	20846357

METHODS	20846357
:	20846357
Genomic	20846357
DNA	20846357
was	20846357
extracted	20846357
from	20846357
peripheral	20846357
blood	20846357
and	20846357
used	20846357
for	20846357
PCR	20846357
amplification	20846357
of	20846357
the	20846357
GJB2	20846357
gene	20846357
.	20846357

Direct	20846357
sequencing	20846357
was	20846357
used	20846357
for	20846357
mutation	20846357
analysis	20846357
.	20846357

RESULTS	20846357
:	20846357
The	20846357
clinical	20846357
features	20846357
included	20846357
hearing	20846357
impairment	20846357
,	20846357
ichthyosiform	20846357
erythroderma	20846357
with	20846357
hyperkeratotic	20846357
plaques	20846357
,	20846357
palmoplantar	20846357
keratoderma	20846357
,	20846357
alopecia	20846357
of	20846357
the	20846357
scalp	20846357
and	20846357
eyelashes	20846357
,	20846357
and	20846357
a	20846357
thick	20846357
vernix	20846357
caseosa	20846357
-	20846357
like	20846357
covering	20846357
of	20846357
the	20846357
scalp	20846357
.	20846357

On	20846357
histological	20846357
analysis	20846357
,	20846357
features	20846357
characteristic	20846357
of	20846357
KID	20846357
syndrome	20846357
,	20846357
such	20846357
as	20846357
acanthosis	20846357
and	20846357
papillomatosis	20846357
of	20846357
the	20846357
epidermis	20846357
with	20846357
basket	20846357
-	20846357
weave	20846357
hyperkeratosis	20846357
,	20846357
were	20846357
seen	20846357
.	20846357

The	20846357
skin	20846357
symptoms	20846357
were	20846357
treated	20846357
successfully	20846357
with	20846357
acitretin	20846357
0	20846357
.	20846357
5	20846357
mg	20846357
/	20846357
kg	20846357
.	20846357

The	20846357
boy	20846357
developed	20846357
intraventricular	20846357
and	20846357
intracerebral	20846357
haemorrhage	20846357
,	20846357
leading	20846357
to	20846357
hydrocephalus	20846357
.	20846357

His	20846357
condition	20846357
was	20846357
further	20846357
complicated	20846357
by	20846357
septicaemia	20846357
and	20846357
meningitis	20846357
caused	20846357
by	20846357
infection	20846357
with	20846357
extended	20846357
-	20846357
spectrum	20846357
beta	20846357
-	20846357
lactamase	20846357
-	20846357
producing	20846357
Klebsiella	20846357
pneumoniae	20846357
.	20846357

Severe	20846357
respiratory	20846357
failure	20846357
followed	20846357
,	20846357
and	20846357
the	20846357
child	20846357
died	20846357
at	20846357
46	20846357
weeks	20846357
of	20846357
gestational	20846357
age	20846357
(	20846357
13	20846357
weeks	20846357
postnatally	20846357
)	20846357
.	20846357

Sequencing	20846357
of	20846357
the	20846357
GJB2	20846357
gene	20846357
showed	20846357
that	20846357
the	20846357
child	20846357
was	20846357
heterozygous	20846357
for	20846357
a	20846357
novel	20846357
nucleotide	20846357
change	20846357
,	20846357
c	20846357
.	20846357
263C	20846357
>	20846357
T	20846357
,	20846357
in	20846357
exon	20846357
2	20846357
,	20846357
leading	20846357
to	20846357
a	20846357
substitution	20846357
of	20846357
alanine	20846357
for	20846357
valine	20846357
at	20846357
position	20846357
88	20846357
(	20846357
p	20846357
.	20846357
Ala88Val	20846357
)	20846357
.	20846357

CONCLUSIONS	20846357
:	20846357
This	20846357
study	20846357
has	20846357
identified	20846357
a	20846357
new	20846357
heterozygous	20846357
de	20846357
novo	20846357
mutation	20846357
in	20846357
the	20846357
Cx26	20846357
gene	20846357
(	20846357
c	20846357
.	20846357
263C	20846357
>	20846357
T	20846357
;	20846357
p	20846357
.	20846357
Ala88Val	20846357
)	20846357
leading	20846357
to	20846357
KID	20846357
syndrome	20846357
.	20846357
Mono	16181814
-	16181814
allelic	16181814
POLG	16181814
expression	16181814
resulting	16181814
from	16181814
nonsense	16181814
-	16181814
mediated	16181814
decay	16181814
and	16181814
alternative	16181814
splicing	16181814
in	16181814
a	16181814
patient	16181814
with	16181814
Alpers	16181814
syndrome	16181814
.	16181814

Alpers	16181814
syndrome	16181814
is	16181814
an	16181814
autosomal	16181814
recessive	16181814
mitochondrial	16181814
DNA	16181814
depletion	16181814
disorder	16181814
that	16181814
affects	16181814
children	16181814
and	16181814
young	16181814
adults	16181814
.	16181814

It	16181814
is	16181814
characterized	16181814
by	16181814
a	16181814
progressive	16181814
,	16181814
fatal	16181814
brain	16181814
and	16181814
liver	16181814
disease	16181814
.	16181814

This	16181814
syndrome	16181814
has	16181814
been	16181814
associated	16181814
with	16181814
mutations	16181814
in	16181814
POLG	16181814
,	16181814
the	16181814
gene	16181814
encoding	16181814
the	16181814
mitochondrial	16181814
DNA	16181814
polymerase	16181814
(	16181814
pol	16181814
gamma	16181814
)	16181814
.	16181814

Most	16181814
patients	16181814
with	16181814
Alpers	16181814
syndrome	16181814
have	16181814
been	16181814
found	16181814
to	16181814
be	16181814
compound	16181814
heterozygotes	16181814
,	16181814
carrying	16181814
two	16181814
pathogenic	16181814
mutations	16181814
in	16181814
trans	16181814
at	16181814
the	16181814
POLG	16181814
locus	16181814
.	16181814

POLG	16181814
is	16181814
a	16181814
nuclear	16181814
-	16181814
encoded	16181814
gene	16181814
whose	16181814
protein	16181814
product	16181814
is	16181814
imported	16181814
into	16181814
mitochondria	16181814
,	16181814
where	16181814
it	16181814
is	16181814
essential	16181814
for	16181814
mtDNA	16181814
replication	16181814
and	16181814
repair	16181814
.	16181814

We	16181814
studied	16181814
the	16181814
skin	16181814
fibroblasts	16181814
of	16181814
a	16181814
patient	16181814
with	16181814
Alpers	16181814
syndrome	16181814
having	16181814
the	16181814
genotype	16181814
E873stop	16181814
/	16181814
A467T	16181814
.	16181814

The	16181814
E873stop	16181814
mutation	16181814
produces	16181814
a	16181814
premature	16181814
termination	16181814
codon	16181814
(	16181814
TAG	16181814
)	16181814
in	16181814
exon	16181814
17	16181814
.	16181814

The	16181814
A467T	16181814
mutation	16181814
produces	16181814
a	16181814
threonine	16181814
to	16181814
alanine	16181814
substitution	16181814
at	16181814
a	16181814
highly	16181814
conserved	16181814
site	16181814
in	16181814
exon	16181814
7	16181814
.	16181814

The	16181814
allele	16181814
bearing	16181814
the	16181814
stop	16181814
codon	16181814
(	16181814
E873	16181814
-	16181814
TAG	16181814
)	16181814
is	16181814
predicted	16181814
to	16181814
produce	16181814
a	16181814
truncated	16181814
,	16181814
catalytically	16181814
inactive	16181814
polymerase	16181814
.	16181814

However	16181814
,	16181814
only	16181814
full	16181814
-	16181814
length	16181814
pol	16181814
gamma	16181814
protein	16181814
was	16181814
detected	16181814
by	16181814
Western	16181814
blot	16181814
analysis	16181814
.	16181814

Here	16181814
,	16181814
we	16181814
show	16181814
that	16181814
transcripts	16181814
containing	16181814
this	16181814
stop	16181814
codon	16181814
undergo	16181814
nonsense	16181814
-	16181814
associated	16181814
alternative	16181814
splicing	16181814
and	16181814
nonsense	16181814
-	16181814
mediated	16181814
decay	16181814
.	16181814

More	16181814
than	16181814
95%	16181814
of	16181814
the	16181814
functional	16181814
POLG	16181814
mRNA	16181814
was	16181814
derived	16181814
from	16181814
the	16181814
allele	16181814
bearing	16181814
the	16181814
A467T	16181814
mutation	16181814
and	16181814
less	16181814
than	16181814
5%	16181814
contained	16181814
the	16181814
E873stop	16181814
mutation	16181814
.	16181814

These	16181814
events	16181814
ensured	16181814
that	16181814
virtually	16181814
all	16181814
POLG	16181814
protein	16181814
in	16181814
the	16181814
cell	16181814
was	16181814
expressed	16181814
from	16181814
the	16181814
A467T	16181814
allele	16181814
.	16181814

Therefore	16181814
,	16181814
the	16181814
Alpers	16181814
phenotype	16181814
in	16181814
this	16181814
patient	16181814
was	16181814
a	16181814
consequence	16181814
of	16181814
a	16181814
single	16181814
-	16181814
copy	16181814
gene	16181814
dose	16181814
of	16181814
the	16181814
A467T	16181814
allele	16181814
,	16181814
and	16181814
selective	16181814
elimination	16181814
of	16181814
transcripts	16181814
bearing	16181814
the	16181814
E873stop	16181814
mutation	16181814
.	16181814
Metallothionein	20046642
induction	20046642
reduces	20046642
caspase	20046642
-	20046642
3	20046642
activity	20046642
and	20046642
TNFalpha	20046642
levels	20046642
with	20046642
preservation	20046642
of	20046642
cognitive	20046642
function	20046642
and	20046642
intact	20046642
hippocampal	20046642
neurons	20046642
in	20046642
carmustine	20046642
-	20046642
treated	20046642
rats	20046642
.	20046642

Hippocampal	20046642
integrity	20046642
is	20046642
essential	20046642
for	20046642
cognitive	20046642
functions	20046642
.	20046642

On	20046642
the	20046642
other	20046642
hand	20046642
,	20046642
induction	20046642
of	20046642
metallothionein	20046642
(	20046642
MT	20046642
)	20046642
by	20046642
ZnSO	20046642
(	20046642
4	20046642
)	20046642
and	20046642
its	20046642
role	20046642
in	20046642
neuroprotection	20046642
has	20046642
been	20046642
documented	20046642
.	20046642

The	20046642
present	20046642
study	20046642
aimed	20046642
to	20046642
explore	20046642
the	20046642
effect	20046642
of	20046642
MT	20046642
induction	20046642
on	20046642
carmustine	20046642
(	20046642
BCNU	20046642
)	20046642
-	20046642
induced	20046642
hippocampal	20046642
cognitive	20046642
dysfunction	20046642
in	20046642
rats	20046642
.	20046642

A	20046642
total	20046642
of	20046642
60	20046642
male	20046642
Wistar	20046642
albino	20046642
rats	20046642
were	20046642
randomly	20046642
divided	20046642
into	20046642
four	20046642
groups	20046642
(	20046642
15	20046642
/	20046642
group	20046642
)	20046642
:	20046642
The	20046642
control	20046642
group	20046642
injected	20046642
with	20046642
single	20046642
doses	20046642
of	20046642
normal	20046642
saline	20046642
(	20046642
i	20046642
.	20046642
c	20046642
.	20046642
v	20046642
)	20046642
followed	20046642
24	20046642
h	20046642
later	20046642
by	20046642
BCNU	20046642
solvent	20046642
(	20046642
i	20046642
.	20046642
v	20046642
)	20046642
.	20046642

The	20046642
second	20046642
group	20046642
administered	20046642
ZnSO	20046642
(	20046642
4	20046642
)	20046642
(	20046642
0	20046642
.	20046642
1	20046642
micromol	20046642
/	20046642
10	20046642
microl	20046642
normal	20046642
saline	20046642
,	20046642
i	20046642
.	20046642
c	20046642
.	20046642
v	20046642
,	20046642
once	20046642
)	20046642
then	20046642
BCNU	20046642
solvent	20046642
(	20046642
i	20046642
.	20046642
v	20046642
)	20046642
after	20046642
24	20046642
h	20046642
.	20046642

Third	20046642
group	20046642
received	20046642
BCNU	20046642
(	20046642
20	20046642
mg	20046642
/	20046642
kg	20046642
,	20046642
i	20046642
.	20046642
v	20046642
,	20046642
once	20046642
)	20046642
24	20046642
h	20046642
after	20046642
injection	20046642
with	20046642
normal	20046642
saline	20046642
(	20046642
i	20046642
.	20046642
c	20046642
.	20046642
v	20046642
)	20046642
.	20046642

Fourth	20046642
group	20046642
received	20046642
a	20046642
single	20046642
dose	20046642
of	20046642
ZnSO	20046642
(	20046642
4	20046642
)	20046642
(	20046642
0	20046642
.	20046642
1	20046642
micromol	20046642
/	20046642
10	20046642
microl	20046642
normal	20046642
saline	20046642
,	20046642
i	20046642
.	20046642
c	20046642
.	20046642
v	20046642
)	20046642
then	20046642
BCNU	20046642
(	20046642
20	20046642
mg	20046642
/	20046642
kg	20046642
,	20046642
i	20046642
.	20046642
v	20046642
,	20046642
once	20046642
)	20046642
after	20046642
24	20046642
h	20046642
.	20046642

The	20046642
obtained	20046642
data	20046642
revealed	20046642
that	20046642
BCNU	20046642
administration	20046642
resulted	20046642
in	20046642
deterioration	20046642
of	20046642
learning	20046642
and	20046642
short	20046642
-	20046642
term	20046642
memory	20046642
(	20046642
STM	20046642
)	20046642
,	20046642
as	20046642
measured	20046642
by	20046642
using	20046642
radial	20046642
arm	20046642
water	20046642
maze	20046642
,	20046642
accompanied	20046642
with	20046642
decreased	20046642
hippocampal	20046642
glutathione	20046642
reductase	20046642
(	20046642
GR	20046642
)	20046642
activity	20046642
and	20046642
reduced	20046642
glutathione	20046642
(	20046642
GSH	20046642
)	20046642
content	20046642
.	20046642

Also	20046642
,	20046642
BCNU	20046642
administration	20046642
increased	20046642
serum	20046642
tumor	20046642
necrosis	20046642
factor	20046642
-	20046642
alpha	20046642
(	20046642
TNFalpha	20046642
)	20046642
,	20046642
hippocampal	20046642
MT	20046642
and	20046642
malondialdehyde	20046642
(	20046642
MDA	20046642
)	20046642
contents	20046642
as	20046642
well	20046642
as	20046642
caspase	20046642
-	20046642
3	20046642
activity	20046642
in	20046642
addition	20046642
to	20046642
histological	20046642
alterations	20046642
.	20046642

ZnSO	20046642
(	20046642
4	20046642
)	20046642
pretreatment	20046642
counteracted	20046642
BCNU	20046642
-	20046642
induced	20046642
inhibition	20046642
of	20046642
GR	20046642
and	20046642
depletion	20046642
of	20046642
GSH	20046642
and	20046642
resulted	20046642
in	20046642
significant	20046642
reduction	20046642
in	20046642
the	20046642
levels	20046642
of	20046642
MDA	20046642
and	20046642
TNFalpha	20046642
as	20046642
well	20046642
as	20046642
the	20046642
activity	20046642
of	20046642
caspase	20046642
-	20046642
3	20046642
.	20046642

The	20046642
histological	20046642
features	20046642
were	20046642
improved	20046642
in	20046642
hippocampus	20046642
of	20046642
rats	20046642
treated	20046642
with	20046642
ZnSO	20046642
(	20046642
4	20046642
)	20046642
+	20046642
BCNU	20046642
compared	20046642
to	20046642
only	20046642
BCNU	20046642
-	20046642
treated	20046642
animals	20046642
.	20046642

In	20046642
conclusion	20046642
,	20046642
MT	20046642
induction	20046642
halts	20046642
BCNU	20046642
-	20046642
induced	20046642
hippocampal	20046642
toxicity	20046642
as	20046642
it	20046642
prevented	20046642
GR	20046642
inhibition	20046642
and	20046642
GSH	20046642
depletion	20046642
and	20046642
counteracted	20046642
the	20046642
increased	20046642
levels	20046642
of	20046642
TNFalpha	20046642
,	20046642
MDA	20046642
and	20046642
caspase	20046642
-	20046642
3	20046642
activity	20046642
with	20046642
subsequent	20046642
preservation	20046642
of	20046642
cognition	20046642
.	20046642
Identification	19370764
and	19370764
molecular	19370764
characterization	19370764
of	19370764
six	19370764
novel	19370764
mutations	19370764
in	19370764
the	19370764
UDP	19370764
-	19370764
N	19370764
-	19370764
acetylglucosamine	19370764
-	19370764
1	19370764
-	19370764
phosphotransferase	19370764
gamma	19370764
subunit	19370764
(	19370764
GNPTG	19370764
)	19370764
gene	19370764
in	19370764
patients	19370764
with	19370764
mucolipidosis	19370764
III	19370764
gamma	19370764
.	19370764

Mucolipidosis	19370764
type	19370764
III	19370764
(	19370764
MLIII	19370764
)	19370764
is	19370764
an	19370764
autosomal	19370764
recessive	19370764
disorder	19370764
affecting	19370764
lysosomal	19370764
hydrolase	19370764
trafficking	19370764
.	19370764

In	19370764
a	19370764
study	19370764
of	19370764
10	19370764
patients	19370764
from	19370764
seven	19370764
families	19370764
with	19370764
a	19370764
clinical	19370764
phenotype	19370764
and	19370764
enzymatic	19370764
diagnosis	19370764
of	19370764
MLIII	19370764
,	19370764
six	19370764
novel	19370764
GNPTG	19370764
gene	19370764
mutations	19370764
were	19370764
identified	19370764
.	19370764

These	19370764
included	19370764
missense	19370764
(	19370764
p	19370764
.	19370764
T286M	19370764
)	19370764
and	19370764
nonsense	19370764
(	19370764
p	19370764
.	19370764
W111X	19370764
)	19370764
mutations	19370764
and	19370764
a	19370764
transition	19370764
in	19370764
the	19370764
obligate	19370764
AG	19370764
-	19370764
dinucleotide	19370764
of	19370764
the	19370764
intron	19370764
8	19370764
acceptor	19370764
splice	19370764
site	19370764
(	19370764
c	19370764
.	19370764
610	19370764
-	19370764
2A	19370764
>	19370764
G	19370764
)	19370764
.	19370764

Three	19370764
microdeletions	19370764
were	19370764
also	19370764
identified	19370764
,	19370764
two	19370764
of	19370764
which	19370764
(	19370764
c	19370764
.	19370764
611delG	19370764
and	19370764
c	19370764
.	19370764
640_667del28	19370764
)	19370764
were	19370764
located	19370764
within	19370764
the	19370764
coding	19370764
region	19370764
whereas	19370764
one	19370764
(	19370764
c	19370764
.	19370764
609	19370764
+	19370764
28_610	19370764
-	19370764
16del	19370764
)	19370764
was	19370764
located	19370764
entirely	19370764
within	19370764
intron	19370764
8	19370764
.	19370764

RT	19370764
-	19370764
PCR	19370764
analysis	19370764
of	19370764
the	19370764
c	19370764
.	19370764
610	19370764
-	19370764
2A	19370764
>	19370764
G	19370764
transition	19370764
demonstrated	19370764
that	19370764
the	19370764
change	19370764
altered	19370764
splicing	19370764
,	19370764
leading	19370764
to	19370764
the	19370764
production	19370764
of	19370764
two	19370764
distinct	19370764
aberrantly	19370764
spliced	19370764
forms	19370764
,	19370764
viz	19370764
.	19370764

the	19370764
skipping	19370764
of	19370764
exon	19370764
9	19370764
(	19370764
p	19370764
.	19370764
G204_K247del	19370764
)	19370764
or	19370764
the	19370764
retention	19370764
of	19370764
introns	19370764
8	19370764
and	19370764
9	19370764
(	19370764
p	19370764
.	19370764
G204VfsX28	19370764
)	19370764
.	19370764

RT	19370764
-	19370764
PCR	19370764
analysis	19370764
,	19370764
performed	19370764
on	19370764
a	19370764
patient	19370764
homozygous	19370764
for	19370764
the	19370764
intronic	19370764
deletion	19370764
(	19370764
c	19370764
.	19370764
609	19370764
+	19370764
28_610	19370764
-	19370764
16del	19370764
)	19370764
,	19370764
failed	19370764
to	19370764
detect	19370764
any	19370764
GNPTG	19370764
RNA	19370764
transcripts	19370764
.	19370764

To	19370764
determine	19370764
whether	19370764
c	19370764
.	19370764
609	19370764
+	19370764
28_610	19370764
-	19370764
16del	19370764
allele	19370764
-	19370764
derived	19370764
transcripts	19370764
were	19370764
subject	19370764
to	19370764
nonsense	19370764
-	19370764
mediated	19370764
mRNA	19370764
decay	19370764
(	19370764
NMD	19370764
)	19370764
,	19370764
patient	19370764
fibroblasts	19370764
were	19370764
incubated	19370764
with	19370764
the	19370764
protein	19370764
synthesis	19370764
inhibitor	19370764
anisomycin	19370764
.	19370764

An	19370764
RT	19370764
-	19370764
PCR	19370764
fragment	19370764
retaining	19370764
43	19370764
bp	19370764
of	19370764
intron	19370764
8	19370764
was	19370764
consistently	19370764
detected	19370764
suggesting	19370764
that	19370764
the	19370764
33	19370764
-	19370764
bp	19370764
genomic	19370764
deletion	19370764
had	19370764
elicited	19370764
NMD	19370764
.	19370764

Quantitative	19370764
real	19370764
-	19370764
time	19370764
PCR	19370764
and	19370764
GNPTG	19370764
western	19370764
blot	19370764
analysis	19370764
confirmed	19370764
that	19370764
the	19370764
homozygous	19370764
microdeletion	19370764
p	19370764
.	19370764
G204VfsX17	19370764
had	19370764
elicited	19370764
NMD	19370764
resulting	19370764
in	19370764
failure	19370764
to	19370764
synthesize	19370764
GNPTG	19370764
protein	19370764
.	19370764

Analysis	19370764
of	19370764
the	19370764
sequences	19370764
surrounding	19370764
the	19370764
microdeletion	19370764
breakpoints	19370764
revealed	19370764
either	19370764
intrinsic	19370764
repetitivity	19370764
of	19370764
the	19370764
deleted	19370764
region	19370764
or	19370764
short	19370764
direct	19370764
repeats	19370764
adjacent	19370764
to	19370764
the	19370764
breakpoint	19370764
junctions	19370764
.	19370764

This	19370764
is	19370764
consistent	19370764
with	19370764
these	19370764
repeats	19370764
having	19370764
mediated	19370764
the	19370764
microdeletions	19370764
via	19370764
replication	19370764
slippage	19370764
and	19370764
supports	19370764
the	19370764
view	19370764
that	19370764
the	19370764
mutational	19370764
spectrum	19370764
of	19370764
the	19370764
GNPTG	19370764
gene	19370764
is	19370764
strongly	19370764
influenced	19370764
by	19370764
the	19370764
properties	19370764
of	19370764
the	19370764
local	19370764
DNA	19370764
sequence	19370764
environment	19370764
.	19370764
Curcumin	25119790
prevents	25119790
maleate	25119790
-	25119790
induced	25119790
nephrotoxicity	25119790
:	25119790
relation	25119790
to	25119790
hemodynamic	25119790
alterations	25119790
,	25119790
oxidative	25119790
stress	25119790
,	25119790
mitochondrial	25119790
oxygen	25119790
consumption	25119790
and	25119790
activity	25119790
of	25119790
respiratory	25119790
complex	25119790
I	25119790
.	25119790

The	25119790
potential	25119790
protective	25119790
effect	25119790
of	25119790
the	25119790
dietary	25119790
antioxidant	25119790
curcumin	25119790
(	25119790
120	25119790
mg	25119790
/	25119790
Kg	25119790
/	25119790
day	25119790
for	25119790
6	25119790
days	25119790
)	25119790
against	25119790
the	25119790
renal	25119790
injury	25119790
induced	25119790
by	25119790
maleate	25119790
was	25119790
evaluated	25119790
.	25119790

Tubular	25119790
proteinuria	25119790
and	25119790
oxidative	25119790
stress	25119790
were	25119790
induced	25119790
by	25119790
a	25119790
single	25119790
injection	25119790
of	25119790
maleate	25119790
(	25119790
400	25119790
mg	25119790
/	25119790
kg	25119790
)	25119790
in	25119790
rats	25119790
.	25119790

Maleate	25119790
-	25119790
induced	25119790
renal	25119790
injury	25119790
included	25119790
increase	25119790
in	25119790
renal	25119790
vascular	25119790
resistance	25119790
and	25119790
in	25119790
the	25119790
urinary	25119790
excretion	25119790
of	25119790
total	25119790
protein	25119790
,	25119790
glucose	25119790
,	25119790
sodium	25119790
,	25119790
neutrophil	25119790
gelatinase	25119790
-	25119790
associated	25119790
lipocalin	25119790
(	25119790
NGAL	25119790
)	25119790
and	25119790
N	25119790
-	25119790
acetyl	25119790
b	25119790
-	25119790
D	25119790
-	25119790
glucosaminidase	25119790
(	25119790
NAG	25119790
)	25119790
,	25119790
upregulation	25119790
of	25119790
kidney	25119790
injury	25119790
molecule	25119790
(	25119790
KIM	25119790
)	25119790
-	25119790
1	25119790
,	25119790
decrease	25119790
in	25119790
renal	25119790
blood	25119790
flow	25119790
and	25119790
claudin	25119790
-	25119790
2	25119790
expression	25119790
besides	25119790
of	25119790
necrosis	25119790
and	25119790
apoptosis	25119790
of	25119790
tubular	25119790
cells	25119790
on	25119790
24	25119790
h	25119790
.	25119790

Oxidative	25119790
stress	25119790
was	25119790
determined	25119790
by	25119790
measuring	25119790
the	25119790
oxidation	25119790
of	25119790
lipids	25119790
and	25119790
proteins	25119790
and	25119790
diminution	25119790
in	25119790
renal	25119790
Nrf2	25119790
levels	25119790
.	25119790

Studies	25119790
were	25119790
also	25119790
conducted	25119790
in	25119790
renal	25119790
epithelial	25119790
LLC	25119790
-	25119790
PK1	25119790
cells	25119790
and	25119790
in	25119790
mitochondria	25119790
isolated	25119790
from	25119790
kidneys	25119790
of	25119790
all	25119790
the	25119790
experimental	25119790
groups	25119790
.	25119790

Maleate	25119790
induced	25119790
cell	25119790
damage	25119790
and	25119790
reactive	25119790
oxygen	25119790
species	25119790
(	25119790
ROS	25119790
)	25119790
production	25119790
in	25119790
LLC	25119790
-	25119790
PK1	25119790
cells	25119790
in	25119790
culture	25119790
.	25119790

In	25119790
addition	25119790
,	25119790
maleate	25119790
treatment	25119790
reduced	25119790
oxygen	25119790
consumption	25119790
in	25119790
ADP	25119790
-	25119790
stimulated	25119790
mitochondria	25119790
and	25119790
diminished	25119790
respiratory	25119790
control	25119790
index	25119790
when	25119790
using	25119790
malate	25119790
/	25119790
glutamate	25119790
as	25119790
substrate	25119790
.	25119790

The	25119790
activities	25119790
of	25119790
both	25119790
complex	25119790
I	25119790
and	25119790
aconitase	25119790
were	25119790
also	25119790
diminished	25119790
.	25119790

All	25119790
the	25119790
above	25119790
-	25119790
described	25119790
alterations	25119790
were	25119790
prevented	25119790
by	25119790
curcumin	25119790
.	25119790

It	25119790
is	25119790
concluded	25119790
that	25119790
curcumin	25119790
is	25119790
able	25119790
to	25119790
attenuate	25119790
in	25119790
vivo	25119790
maleate	25119790
-	25119790
induced	25119790
nephropathy	25119790
and	25119790
in	25119790
vitro	25119790
cell	25119790
damage	25119790
.	25119790

The	25119790
in	25119790
vivo	25119790
protection	25119790
was	25119790
associated	25119790
to	25119790
the	25119790
prevention	25119790
of	25119790
oxidative	25119790
stress	25119790
and	25119790
preservation	25119790
of	25119790
mitochondrial	25119790
oxygen	25119790
consumption	25119790
and	25119790
activity	25119790
of	25119790
respiratory	25119790
complex	25119790
I	25119790
,	25119790
and	25119790
the	25119790
in	25119790
vitro	25119790
protection	25119790
was	25119790
associated	25119790
to	25119790
the	25119790
prevention	25119790
of	25119790
ROS	25119790
production	25119790
.	25119790
A	15485686
novel	15485686
SCN5A	15485686
mutation	15485686
manifests	15485686
as	15485686
a	15485686
malignant	15485686
form	15485686
of	15485686
long	15485686
QT	15485686
syndrome	15485686
with	15485686
perinatal	15485686
onset	15485686
of	15485686
tachycardia	15485686
/	15485686
bradycardia	15485686
.	15485686

OBJECTIVE	15485686
:	15485686
Congenital	15485686
long	15485686
QT	15485686
syndrome	15485686
(	15485686
LQTS	15485686
)	15485686
with	15485686
in	15485686
utero	15485686
onset	15485686
of	15485686
the	15485686
rhythm	15485686
disturbances	15485686
is	15485686
associated	15485686
with	15485686
a	15485686
poor	15485686
prognosis	15485686
.	15485686

In	15485686
this	15485686
study	15485686
we	15485686
investigated	15485686
a	15485686
newborn	15485686
patient	15485686
with	15485686
fetal	15485686
bradycardia	15485686
,	15485686
2	15485686
:	15485686
1	15485686
atrioventricular	15485686
block	15485686
and	15485686
ventricular	15485686
tachycardia	15485686
soon	15485686
after	15485686
birth	15485686
.	15485686

METHODS	15485686
:	15485686
Mutational	15485686
analysis	15485686
and	15485686
DNA	15485686
sequencing	15485686
were	15485686
conducted	15485686
in	15485686
a	15485686
newborn	15485686
.	15485686

The	15485686
2	15485686
:	15485686
1	15485686
atrioventricular	15485686
block	15485686
improved	15485686
to	15485686
1	15485686
:	15485686
1	15485686
conduction	15485686
only	15485686
after	15485686
intravenous	15485686
lidocaine	15485686
infusion	15485686
or	15485686
a	15485686
high	15485686
dose	15485686
of	15485686
mexiletine	15485686
,	15485686
which	15485686
also	15485686
controlled	15485686
the	15485686
ventricular	15485686
tachycardia	15485686
.	15485686

RESULTS	15485686
:	15485686
A	15485686
novel	15485686
,	15485686
spontaneous	15485686
LQTS	15485686
-	15485686
3	15485686
mutation	15485686
was	15485686
identified	15485686
in	15485686
the	15485686
transmembrane	15485686
segment	15485686
6	15485686
of	15485686
domain	15485686
IV	15485686
of	15485686
the	15485686
Na	15485686
(	15485686
v	15485686
)	15485686
1	15485686
.	15485686
5	15485686
cardiac	15485686
sodium	15485686
channel	15485686
,	15485686
with	15485686
a	15485686
G	15485686
-	15485686
-	15485686
>	15485686
A	15485686
substitution	15485686
at	15485686
codon	15485686
1763	15485686
,	15485686
which	15485686
changed	15485686
a	15485686
valine	15485686
(	15485686
GTG	15485686
)	15485686
to	15485686
a	15485686
methionine	15485686
(	15485686
ATG	15485686
)	15485686
.	15485686

The	15485686
proband	15485686
was	15485686
heterozygous	15485686
but	15485686
the	15485686
mutation	15485686
was	15485686
absent	15485686
in	15485686
the	15485686
parents	15485686
and	15485686
the	15485686
sister	15485686
.	15485686

Expression	15485686
of	15485686
this	15485686
mutant	15485686
channel	15485686
in	15485686
tsA201	15485686
mammalian	15485686
cells	15485686
by	15485686
site	15485686
-	15485686
directed	15485686
mutagenesis	15485686
revealed	15485686
a	15485686
persistent	15485686
tetrodotoxin	15485686
-	15485686
sensitive	15485686
but	15485686
lidocaine	15485686
-	15485686
resistant	15485686
current	15485686
that	15485686
was	15485686
associated	15485686
with	15485686
a	15485686
positive	15485686
shift	15485686
of	15485686
the	15485686
steady	15485686
-	15485686
state	15485686
inactivation	15485686
curve	15485686
,	15485686
steeper	15485686
activation	15485686
curve	15485686
and	15485686
faster	15485686
recovery	15485686
from	15485686
inactivation	15485686
.	15485686

We	15485686
also	15485686
found	15485686
a	15485686
similar	15485686
electrophysiological	15485686
profile	15485686
for	15485686
the	15485686
neighboring	15485686
V1764M	15485686
mutant	15485686
.	15485686

But	15485686
,	15485686
the	15485686
other	15485686
neighboring	15485686
I1762A	15485686
mutant	15485686
had	15485686
no	15485686
persistent	15485686
current	15485686
and	15485686
was	15485686
still	15485686
associated	15485686
with	15485686
a	15485686
positive	15485686
shift	15485686
of	15485686
inactivation	15485686
.	15485686

CONCLUSIONS	15485686
:	15485686
These	15485686
findings	15485686
suggest	15485686
that	15485686
the	15485686
Na	15485686
(	15485686
v	15485686
)	15485686
1	15485686
.	15485686
5	15485686
/	15485686
V1763M	15485686
channel	15485686
dysfunction	15485686
and	15485686
possible	15485686
neighboring	15485686
mutants	15485686
contribute	15485686
to	15485686
a	15485686
persistent	15485686
inward	15485686
current	15485686
due	15485686
to	15485686
altered	15485686
inactivation	15485686
kinetics	15485686
and	15485686
clinically	15485686
congenital	15485686
LQTS	15485686
with	15485686
perinatal	15485686
onset	15485686
of	15485686
arrhythmias	15485686
that	15485686
responded	15485686
to	15485686
lidocaine	15485686
and	15485686
mexiletine	15485686
.	15485686
Photochemoprevention	15748645
of	15748645
ultraviolet	15748645
B	15748645
signaling	15748645
and	15748645
photocarcinogenesis	15748645
.	15748645

Exposure	15748645
to	15748645
solar	15748645
radiation	15748645
,	15748645
particularly	15748645
its	15748645
ultraviolet	15748645
(	15748645
UV	15748645
)	15748645
B	15748645
component	15748645
,	15748645
has	15748645
a	15748645
variety	15748645
of	15748645
harmful	15748645
effects	15748645
on	15748645
human	15748645
health	15748645
.	15748645

Some	15748645
of	15748645
these	15748645
effects	15748645
include	15748645
sunburn	15748645
cell	15748645
formation	15748645
,	15748645
basal	15748645
and	15748645
squamous	15748645
cell	15748645
cancers	15748645
,	15748645
melanoma	15748645
,	15748645
cataracts	15748645
,	15748645
photoaging	15748645
of	15748645
the	15748645
skin	15748645
,	15748645
and	15748645
immune	15748645
suppression	15748645
.	15748645

Amongst	15748645
these	15748645
various	15748645
adverse	15748645
effects	15748645
of	15748645
UV	15748645
radiation	15748645
,	15748645
skin	15748645
cancer	15748645
is	15748645
of	15748645
the	15748645
greatest	15748645
concern	15748645
.	15748645

Over	15748645
the	15748645
years	15748645
,	15748645
changes	15748645
in	15748645
lifestyle	15748645
has	15748645
led	15748645
to	15748645
a	15748645
significant	15748645
increase	15748645
in	15748645
the	15748645
amount	15748645
of	15748645
UV	15748645
radiation	15748645
that	15748645
people	15748645
receive	15748645
,	15748645
and	15748645
this	15748645
consequently	15748645
has	15748645
led	15748645
to	15748645
a	15748645
surge	15748645
in	15748645
the	15748645
incidence	15748645
of	15748645
skin	15748645
cancer	15748645
.	15748645

The	15748645
development	15748645
of	15748645
skin	15748645
cancer	15748645
is	15748645
a	15748645
complex	15748645
multistage	15748645
phenomenon	15748645
involving	15748645
three	15748645
distinct	15748645
stages	15748645
exemplified	15748645
by	15748645
initiation	15748645
,	15748645
promotion	15748645
and	15748645
progression	15748645
stages	15748645
.	15748645

Each	15748645
of	15748645
these	15748645
stages	15748645
is	15748645
mediated	15748645
via	15748645
alterations	15748645
in	15748645
various	15748645
cellular	15748645
,	15748645
biochemical	15748645
,	15748645
and	15748645
molecular	15748645
changes	15748645
.	15748645

Initiation	15748645
,	15748645
the	15748645
first	15748645
step	15748645
in	15748645
the	15748645
carcinogenesis	15748645
process	15748645
is	15748645
essentially	15748645
an	15748645
irreversible	15748645
step	15748645
in	15748645
which	15748645
genetic	15748645
alterations	15748645
occur	15748645
in	15748645
genes	15748645
that	15748645
ultimately	15748645
leads	15748645
to	15748645
DNA	15748645
modification	15748645
and	15748645
fixation	15748645
of	15748645
mutation	15748645
.	15748645

Tumor	15748645
promotion	15748645
is	15748645
the	15748645
essential	15748645
process	15748645
in	15748645
cancer	15748645
development	15748645
involving	15748645
clonal	15748645
expansion	15748645
of	15748645
initiated	15748645
cells	15748645
giving	15748645
rise	15748645
to	15748645
pre	15748645
-	15748645
malignant	15748645
and	15748645
then	15748645
to	15748645
malignant	15748645
lesions	15748645
,	15748645
essentially	15748645
by	15748645
alterations	15748645
in	15748645
signal	15748645
transduction	15748645
pathways	15748645
.	15748645

Tumor	15748645
progression	15748645
involves	15748645
the	15748645
conversion	15748645
of	15748645
pre	15748645
-	15748645
malignant	15748645
and	15748645
malignant	15748645
lesions	15748645
into	15748645
an	15748645
invasive	15748645
and	15748645
potentially	15748645
metastatic	15748645
malignant	15748645
tumor	15748645
.	15748645

All	15748645
these	15748645
processes	15748645
for	15748645
skin	15748645
cancer	15748645
development	15748645
involve	15748645
stimulation	15748645
of	15748645
DNA	15748645
synthesis	15748645
,	15748645
DNA	15748645
damage	15748645
and	15748645
proliferation	15748645
,	15748645
inflammation	15748645
,	15748645
immunosuppression	15748645
,	15748645
epidermal	15748645
hyperplasia	15748645
,	15748645
cell	15748645
cycle	15748645
dysregulation	15748645
,	15748645
depletion	15748645
of	15748645
antioxidant	15748645
defenses	15748645
,	15748645
impairment	15748645
of	15748645
signal	15748645
transduction	15748645
pathways	15748645
,	15748645
induction	15748645
of	15748645
cyclooxygenase	15748645
,	15748645
increase	15748645
in	15748645
prostaglandin	15748645
synthesis	15748645
,	15748645
and	15748645
induction	15748645
of	15748645
ornithine	15748645
decarboxylase	15748645
.	15748645

Photochemoprevention	15748645
has	15748645
been	15748645
appreciated	15748645
as	15748645
a	15748645
viable	15748645
approach	15748645
to	15748645
reduce	15748645
the	15748645
occurrence	15748645
of	15748645
skin	15748645
cancer	15748645
and	15748645
in	15748645
recent	15748645
years	15748645
,	15748645
the	15748645
use	15748645
of	15748645
agents	15748645
,	15748645
especially	15748645
botanical	15748645
antioxidants	15748645
,	15748645
present	15748645
in	15748645
the	15748645
common	15748645
diet	15748645
and	15748645
beverages	15748645
consumed	15748645
by	15748645
human	15748645
population	15748645
have	15748645
gained	15748645
considerable	15748645
attention	15748645
as	15748645
photochemopreventive	15748645
agents	15748645
for	15748645
human	15748645
use	15748645
.	15748645

Many	15748645
such	15748645
agents	15748645
have	15748645
also	15748645
found	15748645
a	15748645
place	15748645
in	15748645
skin	15748645
care	15748645
products	15748645
.	15748645

Although	15748645
this	15748645
is	15748645
more	15748645
common	15748645
in	15748645
oriental	15748645
countries	15748645
,	15748645
its	15748645
popularity	15748645
is	15748645
significantly	15748645
growing	15748645
in	15748645
western	15748645
countries	15748645
.	15748645

In	15748645
this	15748645
article	15748645
,	15748645
we	15748645
have	15748645
summarized	15748645
the	15748645
available	15748645
information	15748645
of	15748645
laboratory	15748645
studies	15748645
on	15748645
UVB	15748645
-	15748645
mediated	15748645
signaling	15748645
that	15748645
can	15748645
be	15748645
exploited	15748645
as	15748645
targets	15748645
for	15748645
photochemoprevention	15748645
.	15748645

We	15748645
suggest	15748645
that	15748645
the	15748645
use	15748645
of	15748645
skin	15748645
care	15748645
products	15748645
supplemented	15748645
with	15748645
proven	15748645
chemopreventive	15748645
agents	15748645
in	15748645
conjunction	15748645
with	15748645
the	15748645
use	15748645
of	15748645
sunscreens	15748645
along	15748645
with	15748645
educational	15748645
efforts	15748645
may	15748645
be	15748645
an	15748645
effective	15748645
strategy	15748645
for	15748645
reducing	15748645
UV	15748645
-	15748645
induced	15748645
photodamage	15748645
and	15748645
skin	15748645
cancer	15748645
in	15748645
humans	15748645
.	15748645

The	15748645
mechanistic	15748645
basis	15748645
for	15748645
the	15748645
use	15748645
of	15748645
such	15748645
products	15748645
is	15748645
discussed	15748645
.	15748645
Association	20534142
of	20534142
obesity	20534142
risk	20534142
SNPs	20534142
in	20534142
PCSK1	20534142
with	20534142
insulin	20534142
sensitivity	20534142
and	20534142
proinsulin	20534142
conversion	20534142
.	20534142

BACKGROUND	20534142
:	20534142
Prohormone	20534142
convertase	20534142
1	20534142
is	20534142
involved	20534142
in	20534142
maturation	20534142
of	20534142
peptides	20534142
.	20534142

Rare	20534142
mutations	20534142
in	20534142
gene	20534142
PCSK1	20534142
,	20534142
encoding	20534142
this	20534142
enzyme	20534142
,	20534142
cause	20534142
childhood	20534142
obesity	20534142
and	20534142
abnormal	20534142
glucose	20534142
homeostasis	20534142
with	20534142
elevated	20534142
proinsulin	20534142
concentrations	20534142
.	20534142

Common	20534142
single	20534142
nucleotide	20534142
polymorphisms	20534142
(	20534142
SNPs	20534142
)	20534142
within	20534142
this	20534142
gene	20534142
,	20534142
rs6232	20534142
and	20534142
rs6235	20534142
,	20534142
are	20534142
associated	20534142
with	20534142
obesity	20534142
.	20534142

We	20534142
studied	20534142
whether	20534142
these	20534142
SNPs	20534142
influence	20534142
the	20534142
prediabetic	20534142
traits	20534142
insulin	20534142
resistance	20534142
,	20534142
beta	20534142
-	20534142
cell	20534142
dysfunction	20534142
,	20534142
or	20534142
glucose	20534142
intolerance	20534142
.	20534142

METHODS	20534142
:	20534142
We	20534142
genotyped	20534142
1498	20534142
German	20534142
subjects	20534142
for	20534142
SNPs	20534142
rs6232	20534142
and	20534142
rs6235	20534142
within	20534142
PCSK1	20534142
.	20534142

The	20534142
subjects	20534142
were	20534142
metabolically	20534142
characterized	20534142
by	20534142
oral	20534142
glucose	20534142
tolerance	20534142
test	20534142
with	20534142
glucose	20534142
,	20534142
insulin	20534142
,	20534142
proinsulin	20534142
,	20534142
and	20534142
C	20534142
-	20534142
peptide	20534142
measurements	20534142
.	20534142

A	20534142
subgroup	20534142
of	20534142
512	20534142
subjects	20534142
underwent	20534142
a	20534142
hyperinsulinemic	20534142
-	20534142
euglycemic	20534142
clamp	20534142
.	20534142

RESULTS	20534142
:	20534142
The	20534142
minor	20534142
allele	20534142
frequencies	20534142
were	20534142
25	20534142
.	20534142
8%	20534142
for	20534142
SNP	20534142
rs6235	20534142
and	20534142
6	20534142
.	20534142
0%	20534142
for	20534142
rs6232	20534142
.	20534142

After	20534142
adjustment	20534142
for	20534142
sex	20534142
and	20534142
age	20534142
,	20534142
we	20534142
found	20534142
no	20534142
association	20534142
of	20534142
SNPs	20534142
rs6235	20534142
and	20534142
rs6232	20534142
with	20534142
BMI	20534142
or	20534142
other	20534142
weight	20534142
-	20534142
related	20534142
traits	20534142
(	20534142
all	20534142
p	20534142
>	20534142
or	20534142
=	20534142
0	20534142
.	20534142
07	20534142
)	20534142
.	20534142

Both	20534142
minor	20534142
alleles	20534142
,	20534142
adjusted	20534142
for	20534142
sex	20534142
,	20534142
age	20534142
,	20534142
BMI	20534142
and	20534142
insulin	20534142
sensitivity	20534142
were	20534142
associated	20534142
with	20534142
elevated	20534142
AUCproinsulin	20534142
and	20534142
AUCproinsulin	20534142
/	20534142
AUCinsulin	20534142
(	20534142
rs6235	20534142
:	20534142
p	20534142
(	20534142
additive	20534142
)	20534142
model	20534142
<	20534142
or	20534142
=	20534142
0	20534142
.	20534142
009	20534142
,	20534142
effect	20534142
sizes	20534142
8	20534142
/	20534142
8%	20534142
,	20534142
rs6232	20534142
:	20534142
pdominant	20534142
model	20534142
<	20534142
or	20534142
=	20534142
0	20534142
.	20534142
01	20534142
,	20534142
effect	20534142
sizes	20534142
10	20534142
/	20534142
21%	20534142
)	20534142
.	20534142

Insulin	20534142
secretion	20534142
was	20534142
not	20534142
affected	20534142
by	20534142
the	20534142
variants	20534142
(	20534142
different	20534142
secretion	20534142
parameters	20534142
,	20534142
all	20534142
p	20534142
>	20534142
or	20534142
=	20534142
0	20534142
.	20534142
08	20534142
)	20534142
.	20534142

The	20534142
minor	20534142
allele	20534142
of	20534142
SNP	20534142
rs6232	20534142
was	20534142
additionally	20534142
associated	20534142
with	20534142
15%	20534142
higher	20534142
OGTT	20534142
-	20534142
derived	20534142
and	20534142
19%	20534142
higher	20534142
clamp	20534142
-	20534142
derived	20534142
insulin	20534142
sensitivity	20534142
(	20534142
pdom	20534142
<	20534142
or	20534142
=	20534142
0	20534142
.	20534142
0047	20534142
)	20534142
,	20534142
4	20534142
.	20534142
5%	20534142
lower	20534142
HOMAIR	20534142
(	20534142
pdom	20534142
=	20534142
0	20534142
.	20534142
02	20534142
)	20534142
and	20534142
3	20534142
.	20534142
5%	20534142
lower	20534142
120	20534142
-	20534142
min	20534142
glucose	20534142
(	20534142
pdom	20534142
=	20534142
0	20534142
.	20534142
0003	20534142
)	20534142
independently	20534142
of	20534142
BMI	20534142
and	20534142
proinsulin	20534142
conversion	20534142
.	20534142

SNP	20534142
rs6235	20534142
was	20534142
not	20534142
associated	20534142
with	20534142
parameters	20534142
of	20534142
glucose	20534142
metabolism	20534142
.	20534142

CONCLUSIONS	20534142
:	20534142
Like	20534142
rare	20534142
mutations	20534142
in	20534142
PCSK1	20534142
,	20534142
the	20534142
more	20534142
common	20534142
variants	20534142
tested	20534142
determine	20534142
glucose	20534142
-	20534142
stimulated	20534142
proinsulin	20534142
conversion	20534142
,	20534142
but	20534142
not	20534142
insulin	20534142
secretion	20534142
.	20534142

In	20534142
addition	20534142
,	20534142
rs6232	20534142
,	20534142
encoding	20534142
the	20534142
amino	20534142
acid	20534142
exchange	20534142
N221D	20534142
,	20534142
influences	20534142
insulin	20534142
sensitivity	20534142
and	20534142
glucose	20534142
homeostasis	20534142
.	20534142
Metalloprotease	28148288
-	28148288
disintegrin	28148288
ADAM12	28148288
actively	28148288
promotes	28148288
the	28148288
stem	28148288
cell	28148288
-	28148288
like	28148288
phenotype	28148288
in	28148288
claudin	28148288
-	28148288
low	28148288
breast	28148288
cancer	28148288
.	28148288

BACKGROUND	28148288
:	28148288
ADAM12	28148288
is	28148288
upregulated	28148288
in	28148288
human	28148288
breast	28148288
cancers	28148288
and	28148288
is	28148288
a	28148288
predictor	28148288
of	28148288
chemoresistance	28148288
in	28148288
estrogen	28148288
receptor	28148288
-	28148288
negative	28148288
tumors	28148288
.	28148288

ADAM12	28148288
is	28148288
induced	28148288
during	28148288
epithelial	28148288
-	28148288
to	28148288
-	28148288
mesenchymal	28148288
transition	28148288
,	28148288
a	28148288
feature	28148288
associated	28148288
with	28148288
claudin	28148288
-	28148288
low	28148288
breast	28148288
tumors	28148288
,	28148288
which	28148288
are	28148288
enriched	28148288
in	28148288
cancer	28148288
stem	28148288
cell	28148288
(	28148288
CSC	28148288
)	28148288
markers	28148288
.	28148288

It	28148288
is	28148288
currently	28148288
unknown	28148288
whether	28148288
ADAM12	28148288
plays	28148288
an	28148288
active	28148288
role	28148288
in	28148288
promoting	28148288
the	28148288
CSC	28148288
phenotype	28148288
in	28148288
breast	28148288
cancer	28148288
cells	28148288
.	28148288

METHODS	28148288
:	28148288
ADAM12	28148288
expression	28148288
was	28148288
downregulated	28148288
in	28148288
representative	28148288
claudin	28148288
-	28148288
low	28148288
breast	28148288
cancer	28148288
cell	28148288
lines	28148288
,	28148288
SUM159PT	28148288
and	28148288
Hs578T	28148288
,	28148288
using	28148288
siRNA	28148288
transfection	28148288
or	28148288
inducible	28148288
shRNA	28148288
expression	28148288
.	28148288

Cell	28148288
characteristics	28148288
commonly	28148288
associated	28148288
with	28148288
the	28148288
CSC	28148288
phenotype	28148288
in	28148288
vitro	28148288
(	28148288
cell	28148288
migration	28148288
,	28148288
invasion	28148288
,	28148288
anoikis	28148288
resistance	28148288
,	28148288
mammosphere	28148288
formation	28148288
,	28148288
ALDH	28148288
activity	28148288
,	28148288
and	28148288
expression	28148288
of	28148288
the	28148288
CD44	28148288
and	28148288
CD24	28148288
cell	28148288
surface	28148288
markers	28148288
)	28148288
and	28148288
in	28148288
vivo	28148288
(	28148288
tumor	28148288
formation	28148288
in	28148288
mice	28148288
using	28148288
limiting	28148288
dilution	28148288
transplantation	28148288
assays	28148288
)	28148288
were	28148288
evaluated	28148288
.	28148288

RNA	28148288
sequencing	28148288
was	28148288
performed	28148288
to	28148288
identify	28148288
global	28148288
gene	28148288
expression	28148288
changes	28148288
after	28148288
ADAM12	28148288
knockdown	28148288
.	28148288

RESULTS	28148288
:	28148288
We	28148288
found	28148288
that	28148288
sorted	28148288
SUM159PT	28148288
cell	28148288
populations	28148288
with	28148288
high	28148288
ADAM12	28148288
levels	28148288
had	28148288
elevated	28148288
expression	28148288
of	28148288
CSC	28148288
markers	28148288
and	28148288
an	28148288
increased	28148288
ability	28148288
to	28148288
form	28148288
mammospheres	28148288
.	28148288

ADAM12	28148288
knockdown	28148288
reduced	28148288
cell	28148288
migration	28148288
and	28148288
invasion	28148288
,	28148288
decreased	28148288
anoikis	28148288
resistance	28148288
,	28148288
and	28148288
compromised	28148288
mammosphere	28148288
formation	28148288
.	28148288

ADAM12	28148288
knockdown	28148288
also	28148288
diminished	28148288
ALDEFLUOR	28148288
(	28148288
+	28148288
)	28148288
and	28148288
CD44	28148288
(	28148288
hi	28148288
)	28148288
/	28148288
CD24	28148288
(	28148288
-	28148288
/	28148288
lo	28148288
)	28148288
CSC	28148288
-	28148288
enriched	28148288
populations	28148288
in	28148288
vitro	28148288
and	28148288
reduced	28148288
tumorigenesis	28148288
in	28148288
mice	28148288
in	28148288
vivo	28148288
.	28148288

RNA	28148288
sequencing	28148288
identified	28148288
a	28148288
significant	28148288
overlap	28148288
between	28148288
ADAM12	28148288
-	28148288
and	28148288
Epidermal	28148288
Growth	28148288
Factor	28148288
Receptor	28148288
(	28148288
EGFR	28148288
)	28148288
-	28148288
regulated	28148288
genes	28148288
.	28148288

Consequently	28148288
,	28148288
ADAM12	28148288
knockdown	28148288
lowered	28148288
the	28148288
basal	28148288
activation	28148288
level	28148288
of	28148288
EGFR	28148288
,	28148288
and	28148288
this	28148288
effect	28148288
was	28148288
abolished	28148288
by	28148288
batimastat	28148288
,	28148288
a	28148288
metalloproteinase	28148288
inhibitor	28148288
.	28148288

Furthermore	28148288
,	28148288
incubation	28148288
of	28148288
cells	28148288
with	28148288
exogenously	28148288
added	28148288
EGF	28148288
prevented	28148288
the	28148288
downregulation	28148288
of	28148288
CD44	28148288
(	28148288
hi	28148288
)	28148288
/	28148288
CD24	28148288
(	28148288
-	28148288
/	28148288
lo	28148288
)	28148288
cell	28148288
population	28148288
by	28148288
ADAM12	28148288
knockdown	28148288
.	28148288

CONCLUSIONS	28148288
:	28148288
These	28148288
results	28148288
indicate	28148288
that	28148288
ADAM12	28148288
actively	28148288
supports	28148288
the	28148288
CSC	28148288
phenotype	28148288
in	28148288
claudin	28148288
-	28148288
low	28148288
breast	28148288
cancer	28148288
cells	28148288
via	28148288
modulation	28148288
of	28148288
the	28148288
EGFR	28148288
pathway	28148288
.	28148288
An	18356633
evaluation	18356633
of	18356633
amikacin	18356633
nephrotoxicity	18356633
in	18356633
the	18356633
hematology	18356633
/	18356633
oncology	18356633
population	18356633
.	18356633

Amikacin	18356633
is	18356633
an	18356633
aminoglycoside	18356633
commonly	18356633
used	18356633
to	18356633
provide	18356633
empirical	18356633
double	18356633
gram	18356633
-	18356633
negative	18356633
treatment	18356633
for	18356633
febrile	18356633
neutropenia	18356633
and	18356633
other	18356633
suspected	18356633
infections	18356633
.	18356633

Strategies	18356633
of	18356633
extended	18356633
-	18356633
interval	18356633
and	18356633
conventional	18356633
dosing	18356633
have	18356633
been	18356633
utilized	18356633
extensively	18356633
in	18356633
the	18356633
general	18356633
medical	18356633
population	18356633
;	18356633
however	18356633
,	18356633
data	18356633
are	18356633
lacking	18356633
to	18356633
support	18356633
a	18356633
dosing	18356633
strategy	18356633
in	18356633
the	18356633
hematology	18356633
/	18356633
oncology	18356633
population	18356633
.	18356633

To	18356633
evaluate	18356633
amikacin	18356633
-	18356633
associated	18356633
nephrotoxicity	18356633
in	18356633
an	18356633
adult	18356633
hematology	18356633
/	18356633
oncology	18356633
population	18356633
,	18356633
a	18356633
prospective	18356633
,	18356633
randomized	18356633
,	18356633
open	18356633
-	18356633
label	18356633
trial	18356633
was	18356633
conducted	18356633
at	18356633
a	18356633
university	18356633
-	18356633
affiliated	18356633
medical	18356633
center	18356633
.	18356633

Forty	18356633
patients	18356633
with	18356633
a	18356633
diagnosis	18356633
consistent	18356633
with	18356633
a	18356633
hematologic	18356633
/	18356633
oncologic	18356633
disorder	18356633
that	18356633
required	18356633
treatment	18356633
with	18356633
an	18356633
aminoglycoside	18356633
were	18356633
randomized	18356633
to	18356633
either	18356633
conventional	18356633
or	18356633
extended	18356633
-	18356633
interval	18356633
amikacin	18356633
.	18356633

The	18356633
occurrence	18356633
of	18356633
nephrotoxicity	18356633
by	18356633
means	18356633
of	18356633
an	18356633
increase	18356633
in	18356633
serum	18356633
creatinine	18356633
and	18356633
evaluation	18356633
of	18356633
efficacy	18356633
via	18356633
amikacin	18356633
serum	18356633
concentrations	18356633
with	18356633
respective	18356633
pathogens	18356633
were	18356633
assessed	18356633
.	18356633

The	18356633
occurrence	18356633
of	18356633
nephrotoxicity	18356633
was	18356633
similar	18356633
between	18356633
the	18356633
conventional	18356633
and	18356633
extended	18356633
-	18356633
interval	18356633
groups	18356633
,	18356633
at	18356633
10%	18356633
and	18356633
5%	18356633
,	18356633
respectively	18356633
(	18356633
P	18356633
=	18356633
1	18356633
.	18356633
00	18356633
)	18356633
.	18356633

Six	18356633
patients	18356633
in	18356633
the	18356633
conventional	18356633
group	18356633
had	18356633
a	18356633
positive	18356633
culture	18356633
,	18356633
compared	18356633
with	18356633
none	18356633
in	18356633
the	18356633
extended	18356633
-	18356633
interval	18356633
group	18356633
(	18356633
P	18356633
=	18356633
0	18356633
.	18356633
002	18356633
)	18356633
.	18356633

The	18356633
occurrence	18356633
of	18356633
nephrotoxicity	18356633
was	18356633
similar	18356633
between	18356633
the	18356633
two	18356633
dosing	18356633
regimens	18356633
,	18356633
but	18356633
the	18356633
distribution	18356633
of	18356633
risk	18356633
factors	18356633
was	18356633
variable	18356633
between	18356633
the	18356633
two	18356633
groups	18356633
.	18356633

Efficacy	18356633
could	18356633
not	18356633
be	18356633
assessed	18356633
.	18356633
Homozygous	16391785
deletion	16391785
and	16391785
reduced	16391785
expression	16391785
of	16391785
the	16391785
DOCK8	16391785
gene	16391785
in	16391785
human	16391785
lung	16391785
cancer	16391785
.	16391785

A	16391785
homozygous	16391785
deletion	16391785
of	16391785
the	16391785
DOCK8	16391785
(	16391785
dedicator	16391785
of	16391785
cytokinesis	16391785
8	16391785
)	16391785
locus	16391785
at	16391785
chromosome	16391785
9p24	16391785
was	16391785
found	16391785
in	16391785
a	16391785
lung	16391785
cancer	16391785
cell	16391785
line	16391785
by	16391785
array	16391785
-	16391785
CGH	16391785
analysis	16391785
.	16391785

Cloning	16391785
of	16391785
the	16391785
full	16391785
-	16391785
length	16391785
DOCK8	16391785
cDNA	16391785
led	16391785
us	16391785
to	16391785
define	16391785
that	16391785
the	16391785
DOCK8	16391785
gene	16391785
encodes	16391785
a	16391785
protein	16391785
consisting	16391785
of	16391785
2	16391785
,	16391785
099	16391785
amino	16391785
acids	16391785
.	16391785

DOCK8	16391785
was	16391785
expressed	16391785
in	16391785
a	16391785
variety	16391785
of	16391785
human	16391785
organs	16391785
,	16391785
including	16391785
the	16391785
lungs	16391785
,	16391785
and	16391785
was	16391785
also	16391785
expressed	16391785
in	16391785
type	16391785
II	16391785
alveolar	16391785
,	16391785
bronchiolar	16391785
epithelial	16391785
and	16391785
bronchial	16391785
epithelial	16391785
cells	16391785
,	16391785
which	16391785
are	16391785
considered	16391785
as	16391785
being	16391785
progenitors	16391785
for	16391785
lung	16391785
cancer	16391785
cells	16391785
.	16391785

DOCK8	16391785
expression	16391785
was	16391785
reduced	16391785
in	16391785
62	16391785
/	16391785
71	16391785
(	16391785
87%	16391785
)	16391785
primary	16391785
lung	16391785
cancers	16391785
compared	16391785
with	16391785
normal	16391785
lung	16391785
tissue	16391785
,	16391785
and	16391785
the	16391785
reduction	16391785
occurred	16391785
irrespective	16391785
of	16391785
the	16391785
histological	16391785
type	16391785
of	16391785
lung	16391785
cancer	16391785
.	16391785

5	16391785
-	16391785
Aza	16391785
-	16391785
2	16391785
'	16391785
-	16391785
deoxy	16391785
-	16391785
cytidine	16391785
and	16391785
/	16391785
or	16391785
Trichostatin	16391785
A	16391785
treatments	16391785
induced	16391785
DOCK8	16391785
expression	16391785
in	16391785
lung	16391785
cancer	16391785
cell	16391785
lines	16391785
with	16391785
reduced	16391785
DOCK8	16391785
expression	16391785
.	16391785

Therefore	16391785
,	16391785
epigenetic	16391785
mechanisms	16391785
,	16391785
including	16391785
DNA	16391785
methylation	16391785
and	16391785
histone	16391785
deacetylation	16391785
,	16391785
were	16391785
indicated	16391785
to	16391785
be	16391785
involved	16391785
in	16391785
DOCK8	16391785
down	16391785
-	16391785
regulation	16391785
in	16391785
lung	16391785
cancer	16391785
cells	16391785
.	16391785

Further	16391785
screening	16391785
revealed	16391785
homozygous	16391785
deletions	16391785
of	16391785
the	16391785
DOCK8	16391785
gene	16391785
in	16391785
a	16391785
gastric	16391785
and	16391785
a	16391785
breast	16391785
cancer	16391785
cell	16391785
line	16391785
.	16391785

DOCK	16391785
family	16391785
proteins	16391785
have	16391785
been	16391785
shown	16391785
to	16391785
play	16391785
roles	16391785
in	16391785
regulation	16391785
of	16391785
migration	16391785
,	16391785
morphology	16391785
,	16391785
adhesion	16391785
and	16391785
growth	16391785
of	16391785
cells	16391785
.	16391785

Thus	16391785
,	16391785
the	16391785
present	16391785
results	16391785
suggest	16391785
that	16391785
genetic	16391785
and	16391785
epigenetic	16391785
inactivation	16391785
of	16391785
DOCK8	16391785
is	16391785
involved	16391785
in	16391785
the	16391785
development	16391785
and	16391785
/	16391785
or	16391785
progression	16391785
of	16391785
lung	16391785
and	16391785
other	16391785
cancers	16391785
by	16391785
disturbing	16391785
such	16391785
regulations	16391785
.	16391785
Ectodermal	16781314
dysplasia	16781314
-	16781314
skin	16781314
fragility	16781314
syndrome	16781314
resulting	16781314
from	16781314
a	16781314
new	16781314
homozygous	16781314
mutation	16781314
,	16781314
888delC	16781314
,	16781314
in	16781314
the	16781314
desmosomal	16781314
protein	16781314
plakophilin	16781314
1	16781314
.	16781314

We	16781314
report	16781314
an	16781314
unusual	16781314
case	16781314
of	16781314
an	16781314
inherited	16781314
disorder	16781314
of	16781314
the	16781314
desmosomal	16781314
protein	16781314
plakophilin	16781314
1	16781314
,	16781314
resulting	16781314
in	16781314
ectodermal	16781314
dysplasia	16781314
-	16781314
skin	16781314
fragility	16781314
syndrome	16781314
.	16781314

The	16781314
affected	16781314
6	16781314
-	16781314
year	16781314
-	16781314
old	16781314
boy	16781314
had	16781314
red	16781314
skin	16781314
at	16781314
birth	16781314
and	16781314
subsequently	16781314
developed	16781314
skin	16781314
fragility	16781314
,	16781314
progressive	16781314
plantar	16781314
keratoderma	16781314
,	16781314
nail	16781314
dystrophy	16781314
,	16781314
and	16781314
alopecia	16781314
.	16781314

Skin	16781314
biopsy	16781314
revealed	16781314
widening	16781314
of	16781314
intercellular	16781314
spaces	16781314
in	16781314
the	16781314
epidermis	16781314
and	16781314
a	16781314
reduced	16781314
number	16781314
of	16781314
small	16781314
,	16781314
poorly	16781314
formed	16781314
desmosomes	16781314
.	16781314

Mutation	16781314
analysis	16781314
of	16781314
the	16781314
plakophilin	16781314
1	16781314
gene	16781314
PKP1	16781314
revealed	16781314
a	16781314
homozygous	16781314
deletion	16781314
of	16781314
C	16781314
at	16781314
nucleotide	16781314
888	16781314
within	16781314
exon	16781314
5	16781314
.	16781314

This	16781314
mutation	16781314
differs	16781314
from	16781314
the	16781314
PKP1	16781314
gene	16781314
pathology	16781314
reported	16781314
in	16781314
8	16781314
previously	16781314
published	16781314
individuals	16781314
with	16781314
this	16781314
rare	16781314
genodermatosis	16781314
.	16781314

However	16781314
,	16781314
all	16781314
cases	16781314
show	16781314
similar	16781314
clinical	16781314
features	16781314
,	16781314
highlighting	16781314
the	16781314
importance	16781314
of	16781314
functional	16781314
plakophilin	16781314
1	16781314
in	16781314
maintaining	16781314
desmosomal	16781314
adhesion	16781314
in	16781314
skin	16781314
,	16781314
as	16781314
well	16781314
as	16781314
the	16781314
role	16781314
of	16781314
this	16781314
protein	16781314
in	16781314
aspects	16781314
of	16781314
ectodermal	16781314
development	16781314
.	16781314
Disruption	24632946
of	24632946
the	24632946
temporally	24632946
regulated	24632946
cloaca	24632946
endodermal	24632946
b	24632946
-	24632946
catenin	24632946
signaling	24632946
causes	24632946
anorectal	24632946
malformations	24632946
.	24632946

The	24632946
cloaca	24632946
is	24632946
temporally	24632946
formed	24632946
and	24632946
eventually	24632946
divided	24632946
by	24632946
the	24632946
urorectal	24632946
septum	24632946
(	24632946
URS	24632946
)	24632946
during	24632946
urogenital	24632946
and	24632946
anorectal	24632946
organ	24632946
development	24632946
.	24632946

Although	24632946
congenital	24632946
malformations	24632946
,	24632946
such	24632946
as	24632946
anorectal	24632946
malformations	24632946
(	24632946
ARMs	24632946
)	24632946
,	24632946
are	24632946
frequently	24632946
observed	24632946
during	24632946
this	24632946
process	24632946
,	24632946
the	24632946
underlying	24632946
pathogenic	24632946
mechanisms	24632946
remain	24632946
unclear	24632946
.	24632946

b	24632946
-	24632946
Catenin	24632946
is	24632946
a	24632946
critical	24632946
component	24632946
of	24632946
canonical	24632946
Wnt	24632946
signaling	24632946
and	24632946
is	24632946
essential	24632946
for	24632946
the	24632946
regulation	24632946
of	24632946
cell	24632946
differentiation	24632946
and	24632946
morphogenesis	24632946
during	24632946
embryogenesis	24632946
.	24632946

The	24632946
expression	24632946
of	24632946
b	24632946
-	24632946
catenin	24632946
is	24632946
observed	24632946
in	24632946
endodermal	24632946
epithelia	24632946
,	24632946
including	24632946
URS	24632946
epithelia	24632946
.	24632946

We	24632946
modulated	24632946
the	24632946
b	24632946
-	24632946
catenin	24632946
gene	24632946
conditionally	24632946
in	24632946
endodermal	24632946
epithelia	24632946
by	24632946
utilizing	24632946
tamoxifen	24632946
-	24632946
inducible	24632946
Cre	24632946
driver	24632946
line	24632946
(	24632946
Shh	24632946
(	24632946
CreERT2	24632946
)	24632946
)	24632946
.	24632946

Both	24632946
b	24632946
-	24632946
catenin	24632946
loss	24632946
-	24632946
and	24632946
gain	24632946
-	24632946
of	24632946
-	24632946
function	24632946
(	24632946
LOF	24632946
and	24632946
GOF	24632946
)	24632946
mutants	24632946
displayed	24632946
abnormal	24632946
clefts	24632946
in	24632946
the	24632946
perineal	24632946
region	24632946
and	24632946
hypoplastic	24632946
elongation	24632946
of	24632946
the	24632946
URS	24632946
.	24632946

The	24632946
mutants	24632946
also	24632946
displayed	24632946
reduced	24632946
cell	24632946
proliferation	24632946
in	24632946
the	24632946
URS	24632946
mesenchyme	24632946
.	24632946

In	24632946
addition	24632946
,	24632946
the	24632946
b	24632946
-	24632946
catenin	24632946
GOF	24632946
mutants	24632946
displayed	24632946
reduced	24632946
apoptosis	24632946
and	24632946
subsequently	24632946
increased	24632946
apoptosis	24632946
in	24632946
the	24632946
URS	24632946
epithelium	24632946
.	24632946

This	24632946
instability	24632946
possibly	24632946
resulted	24632946
in	24632946
reduced	24632946
expression	24632946
levels	24632946
of	24632946
differentiation	24632946
markers	24632946
,	24632946
such	24632946
as	24632946
keratin	24632946
1	24632946
and	24632946
filaggrin	24632946
,	24632946
in	24632946
the	24632946
perineal	24632946
epithelia	24632946
.	24632946

The	24632946
expression	24632946
of	24632946
bone	24632946
morphogenetic	24632946
protein	24632946
(	24632946
Bmp	24632946
)	24632946
genes	24632946
,	24632946
such	24632946
as	24632946
Bmp4	24632946
and	24632946
Bmp7	24632946
,	24632946
was	24632946
also	24632946
ectopically	24632946
induced	24632946
in	24632946
the	24632946
epithelia	24632946
of	24632946
the	24632946
URS	24632946
in	24632946
the	24632946
b	24632946
-	24632946
catenin	24632946
GOF	24632946
mutants	24632946
.	24632946

The	24632946
expression	24632946
of	24632946
the	24632946
Msx2	24632946
gene	24632946
and	24632946
phosphorylated	24632946
-	24632946
Smad1	24632946
/	24632946
5	24632946
/	24632946
8	24632946
,	24632946
possible	24632946
readouts	24632946
of	24632946
Bmp	24632946
signaling	24632946
,	24632946
was	24632946
also	24632946
increased	24632946
in	24632946
the	24632946
mutants	24632946
.	24632946

Moreover	24632946
,	24632946
we	24632946
introduced	24632946
an	24632946
additional	24632946
mutation	24632946
for	24632946
a	24632946
Bmp	24632946
receptor	24632946
gene	24632946
:	24632946
BmprIA	24632946
.	24632946

The	24632946
Shh	24632946
(	24632946
CreERT2	24632946
/	24632946
+	24632946
)	24632946
;	24632946
b	24632946
-	24632946
catenin	24632946
(	24632946
flox	24632946
(	24632946
ex3	24632946
)	24632946
/	24632946
+	24632946
)	24632946
;	24632946
BmprIA	24632946
(	24632946
flox	24632946
/	24632946
-	24632946
)	24632946
mutants	24632946
displayed	24632946
partial	24632946
restoration	24632946
of	24632946
URS	24632946
elongation	24632946
compared	24632946
with	24632946
the	24632946
b	24632946
-	24632946
catenin	24632946
GOF	24632946
mutants	24632946
.	24632946

These	24632946
results	24632946
indicate	24632946
that	24632946
some	24632946
ARM	24632946
phenotypes	24632946
in	24632946
the	24632946
b	24632946
-	24632946
catenin	24632946
GOF	24632946
mutants	24632946
were	24632946
caused	24632946
by	24632946
abnormal	24632946
Bmp	24632946
signaling	24632946
.	24632946

The	24632946
current	24632946
analysis	24632946
revealed	24632946
the	24632946
close	24632946
relation	24632946
of	24632946
endodermal	24632946
b	24632946
-	24632946
catenin	24632946
signaling	24632946
to	24632946
the	24632946
ARM	24632946
phenotypes	24632946
.	24632946

These	24632946
results	24632946
are	24632946
considered	24632946
to	24632946
shed	24632946
light	24632946
on	24632946
the	24632946
pathogenic	24632946
mechanisms	24632946
of	24632946
human	24632946
ARMs	24632946
.	24632946
An	29049388
inducible	29049388
mouse	29049388
model	29049388
of	29049388
podocin	29049388
-	29049388
mutation	29049388
-	29049388
related	29049388
nephrotic	29049388
syndrome	29049388
.	29049388

Mutations	29049388
in	29049388
the	29049388
NPHS2	29049388
gene	29049388
,	29049388
encoding	29049388
podocin	29049388
,	29049388
cause	29049388
hereditary	29049388
nephrotic	29049388
syndrome	29049388
.	29049388

The	29049388
most	29049388
common	29049388
podocin	29049388
mutation	29049388
,	29049388
R138Q	29049388
,	29049388
is	29049388
associated	29049388
with	29049388
early	29049388
disease	29049388
onset	29049388
and	29049388
rapid	29049388
progression	29049388
to	29049388
end	29049388
-	29049388
stage	29049388
renal	29049388
disease	29049388
.	29049388

Knock	29049388
-	29049388
in	29049388
mice	29049388
carrying	29049388
a	29049388
R140Q	29049388
mutation	29049388
,	29049388
the	29049388
mouse	29049388
analogue	29049388
of	29049388
human	29049388
R138Q	29049388
,	29049388
show	29049388
developmental	29049388
arrest	29049388
of	29049388
podocytes	29049388
and	29049388
lethal	29049388
renal	29049388
failure	29049388
at	29049388
neonatal	29049388
age	29049388
.	29049388

Here	29049388
we	29049388
created	29049388
a	29049388
conditional	29049388
podocin	29049388
knock	29049388
-	29049388
in	29049388
model	29049388
named	29049388
NPHS2	29049388
R140Q	29049388
/	29049388
-	29049388
,	29049388
using	29049388
a	29049388
tamoxifen	29049388
-	29049388
inducible	29049388
Cre	29049388
recombinase	29049388
,	29049388
which	29049388
permits	29049388
to	29049388
study	29049388
the	29049388
effects	29049388
of	29049388
the	29049388
mutation	29049388
in	29049388
postnatal	29049388
life	29049388
.	29049388

Within	29049388
the	29049388
first	29049388
week	29049388
of	29049388
R140Q	29049388
hemizygosity	29049388
induction	29049388
the	29049388
animals	29049388
developed	29049388
proteinuria	29049388
,	29049388
which	29049388
peaked	29049388
after	29049388
4	29049388
-	29049388
5	29049388
weeks	29049388
.	29049388

Subsequently	29049388
the	29049388
animals	29049388
developed	29049388
progressive	29049388
renal	29049388
failure	29049388
,	29049388
with	29049388
a	29049388
median	29049388
survival	29049388
time	29049388
of	29049388
12	29049388
(	29049388
95%	29049388
CI	29049388
:	29049388
11	29049388
-	29049388
13	29049388
)	29049388
weeks	29049388
.	29049388

Foot	29049388
process	29049388
fusion	29049388
was	29049388
observed	29049388
within	29049388
one	29049388
week	29049388
,	29049388
progressing	29049388
to	29049388
severe	29049388
and	29049388
global	29049388
effacement	29049388
in	29049388
the	29049388
course	29049388
of	29049388
the	29049388
disease	29049388
.	29049388

The	29049388
number	29049388
of	29049388
podocytes	29049388
per	29049388
glomerulus	29049388
gradually	29049388
diminished	29049388
to	29049388
18%	29049388
compared	29049388
to	29049388
healthy	29049388
controls	29049388
12	29049388
-	29049388
16	29049388
weeks	29049388
after	29049388
induction	29049388
.	29049388

The	29049388
fraction	29049388
of	29049388
segmentally	29049388
sclerosed	29049388
glomeruli	29049388
was	29049388
25%	29049388
,	29049388
85%	29049388
and	29049388
97%	29049388
at	29049388
2	29049388
,	29049388
4	29049388
and	29049388
8	29049388
weeks	29049388
,	29049388
respectively	29049388
.	29049388

Severe	29049388
tubulointerstitial	29049388
fibrosis	29049388
was	29049388
present	29049388
at	29049388
later	29049388
disease	29049388
stage	29049388
and	29049388
was	29049388
correlated	29049388
quantitatively	29049388
with	29049388
the	29049388
level	29049388
of	29049388
proteinuria	29049388
at	29049388
early	29049388
disease	29049388
stages	29049388
.	29049388

While	29049388
R140Q	29049388
podocin	29049388
mRNA	29049388
expression	29049388
was	29049388
elevated	29049388
,	29049388
protein	29049388
abundance	29049388
was	29049388
reduced	29049388
by	29049388
more	29049388
than	29049388
50%	29049388
within	29049388
one	29049388
week	29049388
following	29049388
induction	29049388
.	29049388

Whereas	29049388
miRNA21	29049388
expression	29049388
persistently	29049388
increased	29049388
during	29049388
the	29049388
first	29049388
4	29049388
weeks	29049388
,	29049388
miRNA	29049388
-	29049388
193a	29049388
expression	29049388
peaked	29049388
2	29049388
weeks	29049388
after	29049388
induction	29049388
.	29049388

In	29049388
conclusion	29049388
,	29049388
the	29049388
inducible	29049388
R140Q	29049388
-	29049388
podocin	29049388
mouse	29049388
model	29049388
is	29049388
an	29049388
auspicious	29049388
model	29049388
of	29049388
the	29049388
most	29049388
common	29049388
genetic	29049388
cause	29049388
of	29049388
human	29049388
nephrotic	29049388
syndrome	29049388
,	29049388
with	29049388
a	29049388
spontaneous	29049388
disease	29049388
course	29049388
strongly	29049388
reminiscent	29049388
of	29049388
the	29049388
human	29049388
disorder	29049388
.	29049388

This	29049388
model	29049388
constitutes	29049388
a	29049388
valuable	29049388
tool	29049388
to	29049388
test	29049388
the	29049388
efficacy	29049388
of	29049388
novel	29049388
pharmacological	29049388
interventions	29049388
aimed	29049388
to	29049388
improve	29049388
podocyte	29049388
function	29049388
and	29049388
viability	29049388
and	29049388
attenuate	29049388
proteinuria	29049388
,	29049388
glomerulosclerosis	29049388
and	29049388
progressive	29049388
renal	29049388
failure	29049388
.	29049388
Cerebrospinal	20959502
fluid	20959502
penetration	20959502
of	20959502
high	20959502
-	20959502
dose	20959502
daptomycin	20959502
in	20959502
suspected	20959502
Staphylococcus	20959502
aureus	20959502
meningitis	20959502
.	20959502

OBJECTIVE	20959502
:	20959502
To	20959502
report	20959502
a	20959502
case	20959502
of	20959502
methicillin	20959502
-	20959502
sensitive	20959502
Staphylococcus	20959502
aureus	20959502
(	20959502
MSSA	20959502
)	20959502
bacteremia	20959502
with	20959502
suspected	20959502
MSSA	20959502
meningitis	20959502
treated	20959502
with	20959502
high	20959502
-	20959502
dose	20959502
daptomycin	20959502
assessed	20959502
with	20959502
concurrent	20959502
serum	20959502
and	20959502
cerebrospinal	20959502
fluid	20959502
(	20959502
CSF	20959502
)	20959502
concentrations	20959502
.	20959502

CASE	20959502
SUMMARY	20959502
:	20959502
A	20959502
54	20959502
-	20959502
year	20959502
-	20959502
old	20959502
male	20959502
presented	20959502
to	20959502
the	20959502
emergency	20959502
department	20959502
with	20959502
generalized	20959502
weakness	20959502
and	20959502
presumed	20959502
health	20959502
-	20959502
care	20959502
-	20959502
associated	20959502
pneumonia	20959502
shown	20959502
on	20959502
chest	20959502
radiograph	20959502
.	20959502

Treatment	20959502
was	20959502
empirically	20959502
initiated	20959502
with	20959502
vancomycin	20959502
,	20959502
levofloxacin	20959502
,	20959502
and	20959502
piperacillin	20959502
/	20959502
tazobactam	20959502
.	20959502

Blood	20959502
cultures	20959502
revealed	20959502
S	20959502
.	20959502

aureus	20959502
susceptible	20959502
to	20959502
oxacillin	20959502
.	20959502

Empiric	20959502
antibiotic	20959502
treatment	20959502
was	20959502
narrowed	20959502
to	20959502
nafcillin	20959502
on	20959502
day	20959502
4	20959502
.	20959502

On	20959502
day	20959502
8	20959502
,	20959502
the	20959502
patient	20959502
developed	20959502
acute	20959502
renal	20959502
failure	20959502
(	20959502
serum	20959502
creatinine	20959502
1	20959502
.	20959502
9	20959502
mg	20959502
/	20959502
dL	20959502
,	20959502
increased	20959502
from	20959502
1	20959502
.	20959502
2	20959502
mg	20959502
/	20959502
dL	20959502
the	20959502
previous	20959502
day	20959502
and	20959502
0	20959502
.	20959502
8	20959502
mg	20959502
/	20959502
dL	20959502
on	20959502
admission	20959502
)	20959502
.	20959502

The	20959502
patient	20959502
'	20959502
s	20959502
Glasgow	20959502
Coma	20959502
Score	20959502
was	20959502
3	20959502
,	20959502
with	20959502
normal	20959502
findings	20959502
shown	20959502
on	20959502
computed	20959502
tomography	20959502
scan	20959502
of	20959502
the	20959502
head	20959502
72	20959502
hours	20959502
following	20959502
an	20959502
episode	20959502
of	20959502
cardiac	20959502
arrest	20959502
on	20959502
day	20959502
10	20959502
.	20959502

The	20959502
patient	20959502
experienced	20959502
relapsing	20959502
MSSA	20959502
bacteremia	20959502
on	20959502
day	20959502
9	20959502
,	20959502
increasing	20959502
the	20959502
suspicion	20959502
for	20959502
a	20959502
central	20959502
nervous	20959502
system	20959502
(	20959502
CNS	20959502
)	20959502
infection	20959502
.	20959502

Nafcillin	20959502
was	20959502
discontinued	20959502
and	20959502
daptomycin	20959502
9	20959502
mg	20959502
/	20959502
kg	20959502
daily	20959502
was	20959502
initiated	20959502
for	20959502
suspected	20959502
meningitis	20959502
and	20959502
was	20959502
continued	20959502
until	20959502
the	20959502
patient	20959502
'	20959502
s	20959502
death	20959502
on	20959502
day	20959502
16	20959502
.	20959502

Daptomycin	20959502
serum	20959502
and	20959502
CSF	20959502
trough	20959502
concentrations	20959502
were	20959502
11	20959502
.	20959502
21	20959502
ug	20959502
/	20959502
mL	20959502
and	20959502
0	20959502
.	20959502
52	20959502
ug	20959502
/	20959502
mL	20959502
,	20959502
respectively	20959502
,	20959502
prior	20959502
to	20959502
the	20959502
third	20959502
dose	20959502
.	20959502

Lumbar	20959502
puncture	20959502
results	20959502
were	20959502
inconclusive	20959502
and	20959502
no	20959502
further	20959502
blood	20959502
cultures	20959502
were	20959502
positive	20959502
for	20959502
MSSA	20959502
.	20959502

Creatine	20959502
kinase	20959502
levels	20959502
were	20959502
normal	20959502
prior	20959502
to	20959502
daptomycin	20959502
therapy	20959502
and	20959502
were	20959502
not	20959502
reassessed	20959502
.	20959502

DISCUSSION	20959502
:	20959502
Daptomycin	20959502
was	20959502
initiated	20959502
in	20959502
our	20959502
patient	20959502
secondary	20959502
to	20959502
possible	20959502
nafcillin	20959502
-	20959502
induced	20959502
acute	20959502
interstitial	20959502
nephritis	20959502
and	20959502
relapsing	20959502
bacteremia	20959502
.	20959502

At	20959502
a	20959502
dose	20959502
of	20959502
9	20959502
mg	20959502
/	20959502
kg	20959502
,	20959502
resultant	20959502
penetration	20959502
of	20959502
5%	20959502
was	20959502
higher	20959502
than	20959502
in	20959502
previous	20959502
reports	20959502
,	20959502
more	20959502
consistent	20959502
with	20959502
inflamed	20959502
meninges	20959502
.	20959502

CONCLUSIONS	20959502
:	20959502
High	20959502
-	20959502
dose	20959502
daptomycin	20959502
may	20959502
be	20959502
an	20959502
alternative	20959502
option	20959502
for	20959502
MSSA	20959502
bacteremia	20959502
with	20959502
or	20959502
without	20959502
a	20959502
CNS	20959502
source	20959502
in	20959502
patients	20959502
who	20959502
have	20959502
failed	20959502
or	20959502
cannot	20959502
tolerate	20959502
standard	20959502
therapy	20959502
.	20959502

Further	20959502
clinical	20959502
evaluation	20959502
in	20959502
patients	20959502
with	20959502
confirmed	20959502
meningitis	20959502
is	20959502
warranted	20959502
.	20959502
Reversible	19346865
inferior	19346865
colliculus	19346865
lesion	19346865
in	19346865
metronidazole	19346865
-	19346865
induced	19346865
encephalopathy	19346865
:	19346865
magnetic	19346865
resonance	19346865
findings	19346865
on	19346865
diffusion	19346865
-	19346865
weighted	19346865
and	19346865
fluid	19346865
attenuated	19346865
inversion	19346865
recovery	19346865
imaging	19346865
.	19346865

OBJECTIVE	19346865
:	19346865
This	19346865
is	19346865
to	19346865
present	19346865
reversible	19346865
inferior	19346865
colliculus	19346865
lesions	19346865
in	19346865
metronidazole	19346865
-	19346865
induced	19346865
encephalopathy	19346865
,	19346865
to	19346865
focus	19346865
on	19346865
the	19346865
diffusion	19346865
-	19346865
weighted	19346865
imaging	19346865
(	19346865
DWI	19346865
)	19346865
and	19346865
fluid	19346865
attenuated	19346865
inversion	19346865
recovery	19346865
(	19346865
FLAIR	19346865
)	19346865
imaging	19346865
.	19346865

MATERIALS	19346865
AND	19346865
METHODS	19346865
:	19346865
From	19346865
November	19346865
2005	19346865
to	19346865
September	19346865
2007	19346865
,	19346865
8	19346865
patients	19346865
(	19346865
5	19346865
men	19346865
and	19346865
3	19346865
women	19346865
)	19346865
were	19346865
diagnosed	19346865
as	19346865
having	19346865
metronidazole	19346865
-	19346865
induced	19346865
encephalopathy	19346865
(	19346865
age	19346865
range	19346865
;	19346865
43	19346865
-	19346865
78	19346865
years	19346865
)	19346865
.	19346865

They	19346865
had	19346865
been	19346865
taking	19346865
metronidazole	19346865
(	19346865
total	19346865
dosage	19346865
,	19346865
45	19346865
-	19346865
120	19346865
g	19346865
;	19346865
duration	19346865
,	19346865
30	19346865
days	19346865
to	19346865
2	19346865
months	19346865
)	19346865
to	19346865
treat	19346865
the	19346865
infection	19346865
in	19346865
various	19346865
organs	19346865
.	19346865

Initial	19346865
brain	19346865
magnetic	19346865
resonance	19346865
imaging	19346865
(	19346865
MRI	19346865
)	19346865
were	19346865
obtained	19346865
after	19346865
the	19346865
hospitalization	19346865
,	19346865
including	19346865
DWI	19346865
(	19346865
8	19346865
/	19346865
8	19346865
)	19346865
,	19346865
apparent	19346865
diffusion	19346865
coefficient	19346865
(	19346865
ADC	19346865
)	19346865
map	19346865
(	19346865
4	19346865
/	19346865
8	19346865
)	19346865
,	19346865
FLAIR	19346865
(	19346865
7	19346865
/	19346865
8	19346865
)	19346865
,	19346865
and	19346865
T2	19346865
-	19346865
weighted	19346865
image	19346865
(	19346865
8	19346865
/	19346865
8	19346865
)	19346865
.	19346865

Follow	19346865
-	19346865
up	19346865
MRIs	19346865
were	19346865
performed	19346865
on	19346865
5	19346865
patients	19346865
from	19346865
third	19346865
to	19346865
14th	19346865
days	19346865
after	19346865
discontinuation	19346865
of	19346865
metronidazole	19346865
administration	19346865
.	19346865

Findings	19346865
of	19346865
initial	19346865
and	19346865
follow	19346865
-	19346865
up	19346865
MRIs	19346865
were	19346865
retrospectively	19346865
evaluated	19346865
by	19346865
2	19346865
neuroradiologists	19346865
by	19346865
consensus	19346865
,	19346865
to	19346865
analyze	19346865
the	19346865
presence	19346865
of	19346865
abnormal	19346865
signal	19346865
intensities	19346865
,	19346865
their	19346865
locations	19346865
,	19346865
and	19346865
signal	19346865
changes	19346865
on	19346865
follow	19346865
-	19346865
up	19346865
images	19346865
.	19346865

RESULTS	19346865
:	19346865
Initial	19346865
MRIs	19346865
showed	19346865
abnormal	19346865
high	19346865
signal	19346865
intensities	19346865
on	19346865
DWI	19346865
and	19346865
FLAIR	19346865
(	19346865
or	19346865
T2	19346865
-	19346865
weighted	19346865
image	19346865
)	19346865
at	19346865
the	19346865
dentate	19346865
nucleus	19346865
(	19346865
8	19346865
/	19346865
8	19346865
)	19346865
,	19346865
inferior	19346865
colliculus	19346865
(	19346865
6	19346865
/	19346865
8	19346865
)	19346865
,	19346865
corpus	19346865
callosum	19346865
(	19346865
2	19346865
/	19346865
8	19346865
)	19346865
,	19346865
pons	19346865
(	19346865
2	19346865
/	19346865
8	19346865
)	19346865
,	19346865
medulla	19346865
(	19346865
1	19346865
/	19346865
8	19346865
)	19346865
,	19346865
and	19346865
bilateral	19346865
cerebral	19346865
white	19346865
matter	19346865
(	19346865
1	19346865
/	19346865
8	19346865
)	19346865
.	19346865

High	19346865
-	19346865
signal	19346865
intensity	19346865
lesions	19346865
on	19346865
DWI	19346865
tended	19346865
to	19346865
show	19346865
low	19346865
signal	19346865
intensity	19346865
on	19346865
ADC	19346865
map	19346865
(	19346865
3	19346865
/	19346865
4	19346865
)	19346865
,	19346865
but	19346865
in	19346865
one	19346865
patient	19346865
,	19346865
high	19346865
signal	19346865
intensity	19346865
was	19346865
shown	19346865
at	19346865
bilateral	19346865
dentate	19346865
nuclei	19346865
on	19346865
not	19346865
only	19346865
DWI	19346865
but	19346865
also	19346865
ADC	19346865
map	19346865
.	19346865

All	19346865
the	19346865
lesions	19346865
in	19346865
dentate	19346865
,	19346865
inferior	19346865
colliculus	19346865
,	19346865
pons	19346865
,	19346865
and	19346865
medullas	19346865
had	19346865
been	19346865
resolved	19346865
completely	19346865
on	19346865
follow	19346865
-	19346865
up	19346865
MRIs	19346865
in	19346865
5	19346865
patients	19346865
,	19346865
but	19346865
in	19346865
1	19346865
patient	19346865
of	19346865
them	19346865
,	19346865
corpus	19346865
callosal	19346865
lesion	19346865
persisted	19346865
.	19346865

CONCLUSIONS	19346865
:	19346865
Reversible	19346865
inferior	19346865
colliculus	19346865
lesions	19346865
could	19346865
be	19346865
considered	19346865
as	19346865
the	19346865
characteristic	19346865
for	19346865
metronidazole	19346865
-	19346865
induced	19346865
encephalopathy	19346865
,	19346865
next	19346865
to	19346865
the	19346865
dentate	19346865
nucleus	19346865
involvement	19346865
.	19346865
Mutations	19037252
in	19037252
phospholipase	19037252
C	19037252
epsilon	19037252
1	19037252
are	19037252
not	19037252
sufficient	19037252
to	19037252
cause	19037252
diffuse	19037252
mesangial	19037252
sclerosis	19037252
.	19037252

Diffuse	19037252
mesangial	19037252
sclerosis	19037252
occurs	19037252
as	19037252
an	19037252
isolated	19037252
abnormality	19037252
or	19037252
as	19037252
a	19037252
part	19037252
of	19037252
a	19037252
syndrome	19037252
.	19037252

Recently	19037252
,	19037252
mutations	19037252
in	19037252
phospholipase	19037252
C	19037252
epsilon	19037252
1	19037252
(	19037252
PLCE1	19037252
)	19037252
were	19037252
found	19037252
to	19037252
cause	19037252
a	19037252
nonsyndromic	19037252
,	19037252
autosomal	19037252
recessive	19037252
form	19037252
of	19037252
this	19037252
disease	19037252
.	19037252

Here	19037252
we	19037252
describe	19037252
three	19037252
children	19037252
from	19037252
one	19037252
consanguineous	19037252
kindred	19037252
of	19037252
Pakistani	19037252
origin	19037252
with	19037252
diffuse	19037252
mesangial	19037252
sclerosis	19037252
who	19037252
presented	19037252
with	19037252
congenital	19037252
or	19037252
infantile	19037252
nephrotic	19037252
syndrome	19037252
.	19037252

Homozygous	19037252
mutations	19037252
in	19037252
PLCE1	19037252
(	19037252
also	19037252
known	19037252
as	19037252
KIAA1516	19037252
,	19037252
PLCE	19037252
,	19037252
or	19037252
NPHS3	19037252
)	19037252
were	19037252
identified	19037252
following	19037252
genome	19037252
-	19037252
wide	19037252
mapping	19037252
of	19037252
single	19037252
-	19037252
nucleotide	19037252
polymorphisms	19037252
.	19037252

All	19037252
affected	19037252
children	19037252
were	19037252
homozygous	19037252
for	19037252
a	19037252
four	19037252
-	19037252
basepair	19037252
deletion	19037252
in	19037252
exon	19037252
3	19037252
,	19037252
which	19037252
created	19037252
a	19037252
premature	19037252
translational	19037252
stop	19037252
codon	19037252
.	19037252

Analysis	19037252
of	19037252
the	19037252
asymptomatic	19037252
father	19037252
of	19037252
two	19037252
of	19037252
the	19037252
children	19037252
revealed	19037252
that	19037252
he	19037252
was	19037252
also	19037252
homozygous	19037252
for	19037252
the	19037252
same	19037252
mutation	19037252
.	19037252

We	19037252
conclude	19037252
this	19037252
nonpenetrance	19037252
may	19037252
be	19037252
due	19037252
to	19037252
compensatory	19037252
mutations	19037252
at	19037252
a	19037252
second	19037252
locus	19037252
and	19037252
that	19037252
mutation	19037252
within	19037252
PLCE1	19037252
is	19037252
not	19037252
always	19037252
sufficient	19037252
to	19037252
cause	19037252
diffuse	19037252
mesangial	19037252
sclerosis	19037252
.	19037252
TIPE2	25946186
Inhibits	25946186
Lung	25946186
Cancer	25946186
Growth	25946186
Attributing	25946186
to	25946186
Promotion	25946186
of	25946186
Apoptosis	25946186
by	25946186
Regulating	25946186
Some	25946186
Apoptotic	25946186
Molecules	25946186
Expression	25946186
.	25946186

Recent	25946186
studies	25946186
found	25946186
that	25946186
TIPE2	25946186
was	25946186
involved	25946186
in	25946186
cancer	25946186
development	25946186
.	25946186

However	25946186
,	25946186
little	25946186
is	25946186
known	25946186
about	25946186
TIPE2	25946186
in	25946186
lung	25946186
cancer	25946186
.	25946186

Our	25946186
study	25946186
aims	25946186
to	25946186
clarify	25946186
the	25946186
role	25946186
of	25946186
TIPE2	25946186
in	25946186
lung	25946186
carcinogenesis	25946186
.	25946186

We	25946186
examined	25946186
the	25946186
expression	25946186
of	25946186
TIPE2	25946186
in	25946186
lung	25946186
squamous	25946186
cancer	25946186
(	25946186
LSC	25946186
)	25946186
,	25946186
small	25946186
cell	25946186
lung	25946186
cancer	25946186
and	25946186
lung	25946186
adenocarcinoma	25946186
(	25946186
AdC	25946186
)	25946186
tissues	25946186
and	25946186
found	25946186
that	25946186
TIPE2	25946186
expression	25946186
was	25946186
lost	25946186
in	25946186
small	25946186
cell	25946186
lung	25946186
cancer	25946186
,	25946186
compared	25946186
with	25946186
adjacent	25946186
non	25946186
-	25946186
tumor	25946186
tissues	25946186
.	25946186

Overexpression	25946186
of	25946186
TIPE2	25946186
significantly	25946186
inhibited	25946186
the	25946186
growth	25946186
of	25946186
lung	25946186
cancer	25946186
cell	25946186
H446	25946186
in	25946186
vitro	25946186
and	25946186
even	25946186
suppressed	25946186
tumor	25946186
formation	25946186
in	25946186
vivo	25946186
.	25946186

Flow	25946186
cytometry	25946186
analysis	25946186
found	25946186
TIPE2	25946186
overexpression	25946186
promoted	25946186
apoptosis	25946186
of	25946186
H446	25946186
.	25946186

In	25946186
TIPE2	25946186
over	25946186
-	25946186
expression	25946186
cells	25946186
,	25946186
caspase	25946186
-	25946186
3	25946186
,	25946186
caspase	25946186
-	25946186
9	25946186
,	25946186
and	25946186
Bax	25946186
were	25946186
significantly	25946186
up	25946186
-	25946186
regulated	25946186
while	25946186
Bcl	25946186
-	25946186
2	25946186
was	25946186
down	25946186
-	25946186
regulated	25946186
.	25946186

Moreover	25946186
,	25946186
coincident	25946186
results	25946186
were	25946186
shown	25946186
by	25946186
immunohistochemistry	25946186
in	25946186
tumors	25946186
from	25946186
nude	25946186
mice	25946186
.	25946186

TIPE2	25946186
inhibited	25946186
the	25946186
phosphorylation	25946186
of	25946186
Akt	25946186
,	25946186
while	25946186
promoting	25946186
the	25946186
phosphorylation	25946186
of	25946186
P38	25946186
,	25946186
but	25946186
had	25946186
no	25946186
effect	25946186
on	25946186
IkBa	25946186
and	25946186
ERK	25946186
pathway	25946186
.	25946186

Taken	25946186
together	25946186
,	25946186
TIPE2	25946186
promoted	25946186
lung	25946186
cancer	25946186
cell	25946186
apoptosis	25946186
through	25946186
affecting	25946186
apoptosis	25946186
-	25946186
related	25946186
molecules	25946186
caspase	25946186
-	25946186
3	25946186
,	25946186
caspase	25946186
-	25946186
9	25946186
,	25946186
Bcl	25946186
-	25946186
2	25946186
and	25946186
Bax	25946186
,	25946186
possibly	25946186
via	25946186
regulating	25946186
P38	25946186
and	25946186
Akt	25946186
pathways	25946186
,	25946186
indicating	25946186
that	25946186
TIPE2	25946186
might	25946186
be	25946186
a	25946186
novel	25946186
marker	25946186
for	25946186
lung	25946186
cancer	25946186
diagnosis	25946186
and	25946186
therapy	25946186
.	25946186
An	17683901
improved	17683901
tetra	17683901
-	17683901
primer	17683901
PCR	17683901
approach	17683901
for	17683901
the	17683901
detection	17683901
of	17683901
the	17683901
FGFR3	17683901
G380R	17683901
mutation	17683901
responsible	17683901
for	17683901
achondroplasia	17683901
.	17683901

Achondroplasia	17683901
is	17683901
the	17683901
most	17683901
common	17683901
form	17683901
of	17683901
dwarfism	17683901
and	17683901
has	17683901
an	17683901
incidence	17683901
of	17683901
approximately	17683901
1	17683901
/	17683901
7500	17683901
.	17683901

In	17683901
more	17683901
than	17683901
98%	17683901
of	17683901
cases	17683901
,	17683901
the	17683901
disease	17683901
is	17683901
associated	17683901
with	17683901
a	17683901
G	17683901
to	17683901
A	17683901
or	17683901
G	17683901
to	17683901
C	17683901
substitution	17683901
at	17683901
nucleotide	17683901
position	17683901
1138	17683901
(	17683901
p	17683901
.	17683901
G380R	17683901
)	17683901
of	17683901
the	17683901
fibroblast	17683901
growth	17683901
factor	17683901
receptor	17683901
3	17683901
(	17683901
FGFR3	17683901
)	17683901
gene	17683901
.	17683901

We	17683901
have	17683901
developed	17683901
a	17683901
sensitive	17683901
single	17683901
tube	17683901
tetra	17683901
-	17683901
primer	17683901
PCR	17683901
assay	17683901
to	17683901
detect	17683901
both	17683901
the	17683901
c	17683901
.	17683901
1138G	17683901
>	17683901
A	17683901
and	17683901
c	17683901
.	17683901
1138G	17683901
>	17683901
C	17683901
mutations	17683901
and	17683901
can	17683901
successfully	17683901
distinguish	17683901
DNA	17683901
samples	17683901
that	17683901
are	17683901
homozygous	17683901
and	17683901
heterozygous	17683901
for	17683901
the	17683901
c	17683901
.	17683901
1138G	17683901
>	17683901
A	17683901
mutation	17683901
.	17683901

Titration	17683901
studies	17683901
showed	17683901
that	17683901
the	17683901
assay	17683901
could	17683901
reliably	17683901
detect	17683901
one	17683901
copy	17683901
of	17683901
the	17683901
mutant	17683901
allele	17683901
in	17683901
a	17683901
mix	17683901
of	17683901
100	17683901
wild	17683901
-	17683901
type	17683901
alleles	17683901
.	17683901

The	17683901
assay	17683901
has	17683901
been	17683901
tested	17683901
in	17683901
50	17683901
healthy	17683901
controls	17683901
,	17683901
3	17683901
known	17683901
patients	17683901
with	17683901
achondroplasia	17683901
,	17683901
and	17683901
5	17683901
amniotic	17683901
fluids	17683901
suspected	17683901
of	17683901
having	17683901
achondroplasia	17683901
and	17683901
for	17683901
whom	17683901
we	17683901
had	17683901
previously	17683901
determined	17683901
the	17683901
genotypes	17683901
for	17683901
the	17683901
c	17683901
.	17683901
1138G	17683901
>	17683901
A	17683901
mutation	17683901
by	17683901
PCR	17683901
-	17683901
RFLP	17683901
.	17683901

We	17683901
have	17683901
observed	17683901
complete	17683901
concordance	17683901
between	17683901
methods	17683901
.	17683901

Our	17683901
tetra	17683901
-	17683901
primer	17683901
PCR	17683901
assay	17683901
is	17683901
sensitive	17683901
,	17683901
low	17683901
-	17683901
cost	17683901
,	17683901
and	17683901
easy	17683901
to	17683901
use	17683901
method	17683901
for	17683901
FGFR3	17683901
p	17683901
.	17683901
G380R	17683901
genotyping	17683901
,	17683901
which	17683901
could	17683901
be	17683901
used	17683901
even	17683901
in	17683901
""""	17683901
low	17683901
-	17683901
tech	17683901
""""	17683901
laboratories	17683901
.	17683901
Gartanin	27491646
induces	27491646
cell	27491646
cycle	27491646
arrest	27491646
and	27491646
autophagy	27491646
and	27491646
suppresses	27491646
migration	27491646
involving	27491646
PI3K	27491646
/	27491646
Akt	27491646
/	27491646
mTOR	27491646
and	27491646
MAPK	27491646
signalling	27491646
pathway	27491646
in	27491646
human	27491646
glioma	27491646
cells	27491646
.	27491646

In	27491646
central	27491646
nervous	27491646
system	27491646
,	27491646
glioma	27491646
is	27491646
the	27491646
most	27491646
common	27491646
primary	27491646
brain	27491646
tumour	27491646
.	27491646

The	27491646
diffuse	27491646
migration	27491646
and	27491646
rapid	27491646
proliferation	27491646
are	27491646
main	27491646
obstacles	27491646
for	27491646
successful	27491646
treatment	27491646
.	27491646

Gartanin	27491646
,	27491646
a	27491646
natural	27491646
xanthone	27491646
of	27491646
mangosteen	27491646
,	27491646
suppressed	27491646
proliferation	27491646
,	27491646
migration	27491646
and	27491646
colony	27491646
formation	27491646
in	27491646
a	27491646
time	27491646
-	27491646
and	27491646
concentration	27491646
-	27491646
dependent	27491646
manner	27491646
in	27491646
T98G	27491646
glioma	27491646
cells	27491646
but	27491646
not	27491646
in	27491646
mouse	27491646
normal	27491646
neuronal	27491646
HT22	27491646
cells	27491646
.	27491646

Gartanin	27491646
,	27491646
at	27491646
low	27491646
micromole	27491646
,	27491646
led	27491646
to	27491646
cell	27491646
cycle	27491646
arrest	27491646
in	27491646
G1	27491646
phase	27491646
accompanied	27491646
by	27491646
inhibited	27491646
expression	27491646
level	27491646
of	27491646
G1	27491646
cell	27491646
cycle	27491646
regulatory	27491646
proteins	27491646
cyclin	27491646
D1	27491646
,	27491646
while	27491646
increased	27491646
expression	27491646
level	27491646
of	27491646
cyclin	27491646
-	27491646
dependent	27491646
kinase	27491646
inhibitor	27491646
p27Kip1	27491646
.	27491646

In	27491646
addition	27491646
,	27491646
the	27491646
secretion	27491646
and	27491646
activity	27491646
of	27491646
matrix	27491646
metalloproteinases	27491646
2	27491646
/	27491646
9	27491646
(	27491646
MMP	27491646
-	27491646
2	27491646
/	27491646
-	27491646
9	27491646
)	27491646
were	27491646
significantly	27491646
suppressed	27491646
in	27491646
T98G	27491646
cells	27491646
treated	27491646
with	27491646
gartanin	27491646
,	27491646
and	27491646
it	27491646
might	27491646
result	27491646
from	27491646
modulating	27491646
mitogen	27491646
-	27491646
activated	27491646
protein	27491646
kinases	27491646
(	27491646
MAPK	27491646
)	27491646
signalling	27491646
pathway	27491646
in	27491646
T98G	27491646
glioma	27491646
cells	27491646
.	27491646

Moreover	27491646
,	27491646
gartanin	27491646
significantly	27491646
induced	27491646
autophagy	27491646
in	27491646
T98G	27491646
cells	27491646
and	27491646
increased	27491646
GFP	27491646
-	27491646
LC3	27491646
punctate	27491646
fluorescence	27491646
accompanied	27491646
by	27491646
the	27491646
increased	27491646
expression	27491646
level	27491646
of	27491646
Beclin	27491646
1	27491646
and	27491646
LC3	27491646
-	27491646
II	27491646
,	27491646
while	27491646
suppressed	27491646
expression	27491646
level	27491646
of	27491646
p62	27491646
.	27491646

Gartanin	27491646
treatment	27491646
resulted	27491646
in	27491646
obvious	27491646
inhibition	27491646
of	27491646
PI3K	27491646
/	27491646
Akt	27491646
/	27491646
mTOR	27491646
signalling	27491646
pathway	27491646
,	27491646
which	27491646
is	27491646
important	27491646
in	27491646
modulating	27491646
autophagy	27491646
.	27491646

Notably	27491646
,	27491646
gartanin	27491646
-	27491646
mediated	27491646
anti	27491646
-	27491646
viability	27491646
was	27491646
significantly	27491646
abrogated	27491646
by	27491646
autophagy	27491646
inhibitors	27491646
including	27491646
3	27491646
-	27491646
methyladenine	27491646
(	27491646
3	27491646
-	27491646
MA	27491646
)	27491646
and	27491646
chloroquine	27491646
(	27491646
CQ	27491646
)	27491646
.	27491646

These	27491646
results	27491646
indicate	27491646
that	27491646
anti	27491646
-	27491646
proliferation	27491646
effect	27491646
of	27491646
gartanin	27491646
in	27491646
T98G	27491646
cells	27491646
is	27491646
most	27491646
likely	27491646
via	27491646
cell	27491646
cycle	27491646
arrest	27491646
modulated	27491646
by	27491646
autophagy	27491646
,	27491646
which	27491646
is	27491646
regulated	27491646
by	27491646
PI3K	27491646
/	27491646
Akt	27491646
/	27491646
mTOR	27491646
signalling	27491646
pathway	27491646
,	27491646
while	27491646
anti	27491646
-	27491646
migration	27491646
effect	27491646
is	27491646
most	27491646
likely	27491646
via	27491646
suppression	27491646
of	27491646
MMP	27491646
-	27491646
2	27491646
/	27491646
-	27491646
9	27491646
activity	27491646
which	27491646
is	27491646
involved	27491646
in	27491646
MAPK	27491646
signalling	27491646
pathway	27491646
.	27491646
Angiotensin	19484664
converting	19484664
enzyme	19484664
gene	19484664
polymorphism	19484664
in	19484664
Turkish	19484664
asthmatic	19484664
patients	19484664
.	19484664

Asthma	19484664
is	19484664
a	19484664
chronic	19484664
inflammatory	19484664
disease	19484664
of	19484664
the	19484664
airways	19484664
.	19484664

Several	19484664
candidate	19484664
genes	19484664
have	19484664
been	19484664
identified	19484664
with	19484664
a	19484664
potential	19484664
role	19484664
in	19484664
the	19484664
pathogenesis	19484664
of	19484664
asthma	19484664
,	19484664
including	19484664
the	19484664
angiotensin	19484664
converting	19484664
enzyme	19484664
(	19484664
ACE	19484664
)	19484664
gene	19484664
.	19484664

We	19484664
aimed	19484664
to	19484664
investigate	19484664
the	19484664
frequency	19484664
of	19484664
an	19484664
ACE	19484664
gene	19484664
polymorphism	19484664
in	19484664
Turkish	19484664
asthmatic	19484664
patients	19484664
and	19484664
to	19484664
determine	19484664
its	19484664
impact	19484664
on	19484664
clinical	19484664
parameters	19484664
and	19484664
disease	19484664
severity	19484664
.	19484664

Ninety	19484664
-	19484664
seven	19484664
asthmatic	19484664
patients	19484664
(	19484664
M	19484664
/	19484664
F	19484664
25	19484664
/	19484664
72	19484664
,	19484664
mean	19484664
age	19484664
39	19484664
+	19484664
/	19484664
-	19484664
13	19484664
years	19484664
)	19484664
and	19484664
96	19484664
healthy	19484664
subjects	19484664
(	19484664
M	19484664
/	19484664
F	19484664
26	19484664
/	19484664
70	19484664
,	19484664
mean	19484664
age	19484664
38	19484664
+	19484664
/	19484664
-	19484664
12	19484664
years	19484664
)	19484664
were	19484664
included	19484664
.	19484664

At	19484664
baseline	19484664
,	19484664
all	19484664
participants	19484664
completed	19484664
a	19484664
questionnaire	19484664
on	19484664
demographics	19484664
,	19484664
symptoms	19484664
,	19484664
triggering	19484664
factors	19484664
,	19484664
severity	19484664
of	19484664
asthma	19484664
,	19484664
and	19484664
the	19484664
presence	19484664
of	19484664
atopism	19484664
.	19484664

Blood	19484664
samples	19484664
were	19484664
obtained	19484664
from	19484664
all	19484664
patients	19484664
and	19484664
genomic	19484664
DNA	19484664
was	19484664
isolated	19484664
.	19484664

The	19484664
frequency	19484664
of	19484664
the	19484664
ACE	19484664
genotypes	19484664
(	19484664
I	19484664
=	19484664
insertion	19484664
and	19484664
D	19484664
=	19484664
deletion	19484664
)	19484664
among	19484664
asthmatics	19484664
and	19484664
controls	19484664
were	19484664
compared	19484664
:	19484664
asthmatics	19484664
showed	19484664
a	19484664
40	19484664
.	19484664
2%	19484664
prevalence	19484664
of	19484664
the	19484664
DD	19484664
genotype	19484664
(	19484664
n	19484664
=	19484664
39	19484664
)	19484664
,	19484664
ID	19484664
was	19484664
45	19484664
.	19484664
4%	19484664
(	19484664
n	19484664
=	19484664
44	19484664
)	19484664
,	19484664
and	19484664
II	19484664
was	19484664
14	19484664
.	19484664
4%	19484664
(	19484664
n	19484664
=	19484664
14	19484664
.	19484664
4	19484664
)	19484664
.	19484664

In	19484664
the	19484664
control	19484664
subjects	19484664
,	19484664
the	19484664
frequency	19484664
of	19484664
DD	19484664
was	19484664
18	19484664
.	19484664
8%	19484664
(	19484664
n	19484664
=	19484664
18	19484664
)	19484664
,	19484664
ID	19484664
was	19484664
50%	19484664
(	19484664
n	19484664
=	19484664
48	19484664
)	19484664
and	19484664
II	19484664
was	19484664
31	19484664
.	19484664
3%	19484664
(	19484664
n	19484664
=	19484664
30	19484664
)	19484664
.	19484664

The	19484664
DD	19484664
ACE	19484664
genotype	19484664
was	19484664
significantly	19484664
more	19484664
frequent	19484664
in	19484664
asthmatics	19484664
compared	19484664
with	19484664
controls	19484664
(	19484664
p	19484664
<	19484664
0	19484664
.	19484664
001	19484664
)	19484664
.	19484664

Asthmatics	19484664
with	19484664
the	19484664
ID	19484664
ACE	19484664
genotype	19484664
showed	19484664
a	19484664
higher	19484664
frequency	19484664
of	19484664
drug	19484664
allergies	19484664
,	19484664
although	19484664
this	19484664
was	19484664
not	19484664
statistically	19484664
significant	19484664
(	19484664
p	19484664
=	19484664
0	19484664
.	19484664
08	19484664
)	19484664
.	19484664

Asthmatics	19484664
with	19484664
the	19484664
DD	19484664
genotype	19484664
appeared	19484664
to	19484664
have	19484664
a	19484664
higher	19484664
incidence	19484664
of	19484664
asthmatic	19484664
episode	19484664
exacerbations	19484664
due	19484664
to	19484664
viral	19484664
infections	19484664
,	19484664
but	19484664
again	19484664
this	19484664
was	19484664
not	19484664
statistically	19484664
significant	19484664
(	19484664
p	19484664
=	19484664
0	19484664
.	19484664
08	19484664
)	19484664
.	19484664

Patients	19484664
with	19484664
mild	19484664
or	19484664
moderate	19484664
-	19484664
severe	19484664
asthma	19484664
had	19484664
similar	19484664
frequencies	19484664
of	19484664
these	19484664
mutations	19484664
.	19484664

We	19484664
found	19484664
a	19484664
higher	19484664
frequency	19484664
of	19484664
the	19484664
ACE	19484664
DD	19484664
gene	19484664
mutation	19484664
in	19484664
Turkish	19484664
asthmatic	19484664
patients	19484664
compared	19484664
with	19484664
non	19484664
-	19484664
asthmatics	19484664
,	19484664
suggesting	19484664
that	19484664
this	19484664
ACE	19484664
gene	19484664
polymorphism	19484664
may	19484664
be	19484664
a	19484664
risk	19484664
factor	19484664
for	19484664
asthma	19484664
but	19484664
does	19484664
not	19484664
increase	19484664
the	19484664
severity	19484664
of	19484664
the	19484664
disease	19484664
.	19484664
Valproate	17074608
-	17074608
induced	17074608
chorea	17074608
and	17074608
encephalopathy	17074608
in	17074608
atypical	17074608
nonketotic	17074608
hyperglycinemia	17074608
.	17074608

Nonketotic	17074608
hyperglycinemia	17074608
is	17074608
a	17074608
disorder	17074608
of	17074608
amino	17074608
acid	17074608
metabolism	17074608
in	17074608
which	17074608
a	17074608
defect	17074608
in	17074608
the	17074608
glycine	17074608
cleavage	17074608
system	17074608
leads	17074608
to	17074608
an	17074608
accumulation	17074608
of	17074608
glycine	17074608
in	17074608
the	17074608
brain	17074608
and	17074608
other	17074608
body	17074608
compartments	17074608
.	17074608

In	17074608
the	17074608
classical	17074608
form	17074608
it	17074608
presents	17074608
as	17074608
neonatal	17074608
apnea	17074608
,	17074608
intractable	17074608
seizures	17074608
,	17074608
and	17074608
hypotonia	17074608
,	17074608
followed	17074608
by	17074608
significant	17074608
psychomotor	17074608
retardation	17074608
.	17074608

An	17074608
important	17074608
subset	17074608
of	17074608
children	17074608
with	17074608
nonketotic	17074608
hyperglycinemia	17074608
are	17074608
atypical	17074608
variants	17074608
who	17074608
present	17074608
in	17074608
a	17074608
heterogeneous	17074608
manner	17074608
.	17074608

This	17074608
report	17074608
describes	17074608
a	17074608
patient	17074608
with	17074608
mild	17074608
language	17074608
delay	17074608
and	17074608
mental	17074608
retardation	17074608
,	17074608
who	17074608
was	17074608
found	17074608
to	17074608
have	17074608
nonketotic	17074608
hyperglycinemia	17074608
following	17074608
her	17074608
presentation	17074608
with	17074608
acute	17074608
encephalopathy	17074608
and	17074608
chorea	17074608
shortly	17074608
after	17074608
initiation	17074608
of	17074608
valproate	17074608
therapy	17074608
.	17074608
Two	1671881
distinct	1671881
mutations	1671881
at	1671881
a	1671881
single	1671881
BamHI	1671881
site	1671881
in	1671881
phenylketonuria	1671881
.	1671881

Classical	1671881
phenylketonuria	1671881
is	1671881
an	1671881
autosomal	1671881
recessive	1671881
disease	1671881
caused	1671881
by	1671881
a	1671881
deficiency	1671881
of	1671881
hepatic	1671881
phenylalanine	1671881
hydroxylase	1671881
(	1671881
PAH	1671881
)	1671881
.	1671881

The	1671881
abolition	1671881
of	1671881
an	1671881
invariant	1671881
BamHI	1671881
site	1671881
located	1671881
in	1671881
the	1671881
coding	1671881
sequence	1671881
of	1671881
the	1671881
PAH	1671881
gene	1671881
(	1671881
exon	1671881
7	1671881
)	1671881
led	1671881
to	1671881
the	1671881
recognition	1671881
of	1671881
two	1671881
new	1671881
point	1671881
mutations	1671881
at	1671881
codon	1671881
272	1671881
and	1671881
273	1671881
(	1671881
272gly	1671881
-	1671881
-	1671881
-	1671881
-	1671881
stop	1671881
and	1671881
273ser	1671881
-	1671881
-	1671881
-	1671881
-	1671881
phe	1671881
,	1671881
respectively	1671881
)	1671881
.	1671881

Both	1671881
mutations	1671881
were	1671881
detected	1671881
in	1671881
north	1671881
eastern	1671881
France	1671881
or	1671881
Belgium	1671881
and	1671881
occurred	1671881
on	1671881
the	1671881
background	1671881
of	1671881
RFLP	1671881
haplotype	1671881
7	1671881
alleles	1671881
.	1671881

The	1671881
present	1671881
study	1671881
supports	1671881
the	1671881
view	1671881
that	1671881
the	1671881
clinical	1671881
heterogeneity	1671881
in	1671881
PKU	1671881
is	1671881
accounted	1671881
for	1671881
by	1671881
the	1671881
large	1671881
variety	1671881
of	1671881
mutant	1671881
genotypes	1671881
associated	1671881
with	1671881
PAH	1671881
deficiencies	1671881
.	1671881
Fatal	20129423
carbamazepine	20129423
induced	20129423
fulminant	20129423
eosinophilic	20129423
(	20129423
hypersensitivity	20129423
)	20129423
myocarditis	20129423
:	20129423
emphasis	20129423
on	20129423
anatomical	20129423
and	20129423
histological	20129423
characteristics	20129423
,	20129423
mechanisms	20129423
and	20129423
genetics	20129423
of	20129423
drug	20129423
hypersensitivity	20129423
and	20129423
differential	20129423
diagnosis	20129423
.	20129423

The	20129423
most	20129423
severe	20129423
adverse	20129423
reactions	20129423
to	20129423
carbamazepine	20129423
have	20129423
been	20129423
observed	20129423
in	20129423
the	20129423
haemopoietic	20129423
system	20129423
,	20129423
the	20129423
liver	20129423
and	20129423
the	20129423
cardiovascular	20129423
system	20129423
.	20129423

A	20129423
frequently	20129423
fatal	20129423
,	20129423
although	20129423
exceptionally	20129423
rare	20129423
side	20129423
effect	20129423
of	20129423
carbamazepine	20129423
is	20129423
necrotizing	20129423
eosinophilic	20129423
(	20129423
hypersensitivity	20129423
)	20129423
myocarditis	20129423
.	20129423

We	20129423
report	20129423
a	20129423
case	20129423
of	20129423
hypersensitivity	20129423
myocarditis	20129423
secondary	20129423
to	20129423
administration	20129423
of	20129423
carbamazepine	20129423
.	20129423

Acute	20129423
hypersensitivity	20129423
myocarditis	20129423
was	20129423
not	20129423
suspected	20129423
clinically	20129423
,	20129423
and	20129423
the	20129423
diagnosis	20129423
was	20129423
made	20129423
post	20129423
-	20129423
mortem	20129423
.	20129423

Histology	20129423
revealed	20129423
diffuse	20129423
infiltration	20129423
of	20129423
the	20129423
myocardium	20129423
by	20129423
eosinophils	20129423
and	20129423
lymphocytes	20129423
with	20129423
myocyte	20129423
damage	20129423
.	20129423

Clinically	20129423
,	20129423
death	20129423
was	20129423
due	20129423
to	20129423
cardiogenic	20129423
shock	20129423
.	20129423

To	20129423
best	20129423
of	20129423
our	20129423
knowledge	20129423
this	20129423
is	20129423
the	20129423
second	20129423
case	20129423
of	20129423
fatal	20129423
carbamazepine	20129423
induced	20129423
myocarditis	20129423
reported	20129423
in	20129423
English	20129423
literature	20129423
.	20129423
Bach1	27959382
siRNA	27959382
attenuates	27959382
bleomycin	27959382
-	27959382
induced	27959382
pulmonary	27959382
fibrosis	27959382
by	27959382
modulating	27959382
oxidative	27959382
stress	27959382
in	27959382
mice	27959382
.	27959382

Oxidative	27959382
stress	27959382
plays	27959382
an	27959382
essential	27959382
role	27959382
in	27959382
inflammation	27959382
and	27959382
fibrosis	27959382
.	27959382

Bach1	27959382
is	27959382
an	27959382
important	27959382
transcriptional	27959382
repressor	27959382
that	27959382
acts	27959382
by	27959382
modulating	27959382
oxidative	27959382
stress	27959382
and	27959382
represents	27959382
a	27959382
potential	27959382
target	27959382
in	27959382
the	27959382
treatment	27959382
of	27959382
pulmonary	27959382
fibrosis	27959382
(	27959382
PF	27959382
)	27959382
.	27959382

In	27959382
this	27959382
study	27959382
,	27959382
we	27959382
knocked	27959382
down	27959382
Bach1	27959382
using	27959382
adenovirus	27959382
-	27959382
mediated	27959382
small	27959382
interfering	27959382
RNA	27959382
(	27959382
siRNA	27959382
)	27959382
to	27959382
determine	27959382
whether	27959382
the	27959382
use	27959382
of	27959382
Bach1	27959382
siRNA	27959382
is	27959382
an	27959382
effective	27959382
therapeutic	27959382
strategy	27959382
in	27959382
mice	27959382
with	27959382
bleomycin	27959382
(	27959382
BLM	27959382
)	27959382
-	27959382
induced	27959382
PF	27959382
.	27959382

Mouse	27959382
lung	27959382
fibroblasts	27959382
(	27959382
MLFs	27959382
)	27959382
were	27959382
incubated	27959382
with	27959382
transforming	27959382
growth	27959382
factor	27959382
(	27959382
TGF	27959382
)	27959382
-	27959382
b1	27959382
(	27959382
5	27959382
ng	27959382
/	27959382
ml	27959382
)	27959382
and	27959382
subsequently	27959382
infected	27959382
with	27959382
recombined	27959382
adenovirus	27959382
-	27959382
like	27959382
Bach1	27959382
siRNA1	27959382
and	27959382
Bach1	27959382
siRNA2	27959382
,	27959382
while	27959382
an	27959382
empty	27959382
adenovirus	27959382
vector	27959382
was	27959382
used	27959382
as	27959382
the	27959382
negative	27959382
control	27959382
.	27959382

The	27959382
selected	27959382
Bach1	27959382
siRNA	27959382
with	27959382
higher	27959382
interference	27959382
efficiency	27959382
was	27959382
used	27959382
for	27959382
the	27959382
animal	27959382
experiments	27959382
.	27959382

A	27959382
mouse	27959382
model	27959382
of	27959382
BLM	27959382
-	27959382
induced	27959382
PF	27959382
was	27959382
established	27959382
,	27959382
and	27959382
Bach1	27959382
siRNA	27959382
(	27959382
1x109	27959382
pfu	27959382
)	27959382
was	27959382
administered	27959382
to	27959382
the	27959382
mice	27959382
via	27959382
the	27959382
tail	27959382
vein	27959382
.	27959382

The	27959382
results	27959382
revealed	27959382
that	27959382
the	27959382
Bach1	27959382
mRNA	27959382
and	27959382
protein	27959382
levels	27959382
were	27959382
significantly	27959382
downregulated	27959382
by	27959382
Bach1	27959382
siRNA	27959382
.	27959382

Furthermore	27959382
,	27959382
the	27959382
MLFs	27959382
infected	27959382
with	27959382
Bach1	27959382
siRNA	27959382
exhibited	27959382
increased	27959382
mRNA	27959382
and	27959382
protein	27959382
expression	27959382
levels	27959382
of	27959382
heme	27959382
oxygenase	27959382
-	27959382
1	27959382
and	27959382
glutathione	27959382
peroxidase	27959382
1	27959382
,	27959382
but	27959382
decreased	27959382
levels	27959382
of	27959382
TGF	27959382
-	27959382
b1	27959382
and	27959382
interleukin	27959382
-	27959382
6	27959382
in	27959382
the	27959382
cell	27959382
supernatants	27959382
compared	27959382
with	27959382
the	27959382
cells	27959382
exposed	27959382
to	27959382
TGF	27959382
-	27959382
b1	27959382
alone	27959382
.	27959382

Bach1	27959382
knockdown	27959382
by	27959382
siRNA	27959382
also	27959382
enhanced	27959382
the	27959382
expression	27959382
of	27959382
antioxidant	27959382
factors	27959382
,	27959382
but	27959382
suppressed	27959382
that	27959382
of	27959382
fibrosis	27959382
-	27959382
related	27959382
cytokines	27959382
in	27959382
mice	27959382
compared	27959382
with	27959382
the	27959382
BLM	27959382
group	27959382
.	27959382

Finally	27959382
,	27959382
the	27959382
inflammatory	27959382
infiltration	27959382
of	27959382
alveolar	27959382
and	27959382
interstitial	27959382
cells	27959382
and	27959382
the	27959382
destruction	27959382
of	27959382
lung	27959382
structure	27959382
were	27959382
significantly	27959382
attenuated	27959382
in	27959382
the	27959382
mide	27959382
administered	27959382
Bach1	27959382
siRNA	27959382
compared	27959382
with	27959382
those	27959382
in	27959382
the	27959382
BLM	27959382
group	27959382
.	27959382

On	27959382
the	27959382
whole	27959382
,	27959382
our	27959382
findings	27959382
demonstrate	27959382
that	27959382
Bach1	27959382
siRNA	27959382
exerts	27959382
protective	27959382
effects	27959382
against	27959382
BLM	27959382
-	27959382
induced	27959382
PF	27959382
in	27959382
mice	27959382
.	27959382

Our	27959382
data	27959382
may	27959382
provide	27959382
the	27959382
basis	27959382
for	27959382
the	27959382
development	27959382
of	27959382
novel	27959382
targeted	27959382
therapeutic	27959382
strategies	27959382
for	27959382
PF	27959382
.	27959382
Acute	15686794
low	15686794
back	15686794
pain	15686794
during	15686794
intravenous	15686794
administration	15686794
of	15686794
amiodarone	15686794
:	15686794
a	15686794
report	15686794
of	15686794
two	15686794
cases	15686794
.	15686794

Amiodarone	15686794
represents	15686794
an	15686794
effective	15686794
antiarrhythmic	15686794
drug	15686794
for	15686794
cardioversion	15686794
of	15686794
recent	15686794
-	15686794
onset	15686794
atrial	15686794
fibrillation	15686794
(	15686794
AF	15686794
)	15686794
and	15686794
maintenance	15686794
of	15686794
sinus	15686794
rhythm	15686794
.	15686794

We	15686794
briefly	15686794
describe	15686794
two	15686794
patients	15686794
suffering	15686794
from	15686794
recent	15686794
-	15686794
onset	15686794
atrial	15686794
fibrillation	15686794
,	15686794
who	15686794
experienced	15686794
an	15686794
acute	15686794
devastating	15686794
low	15686794
back	15686794
pain	15686794
a	15686794
few	15686794
minutes	15686794
after	15686794
initiation	15686794
of	15686794
intravenous	15686794
amiodarone	15686794
loading	15686794
.	15686794

Notably	15686794
,	15686794
this	15686794
side	15686794
effect	15686794
has	15686794
not	15686794
been	15686794
ever	15686794
reported	15686794
in	15686794
the	15686794
medical	15686794
literature	15686794
.	15686794

Clinicians	15686794
should	15686794
be	15686794
aware	15686794
of	15686794
this	15686794
reaction	15686794
since	15686794
prompt	15686794
termination	15686794
of	15686794
parenteral	15686794
administration	15686794
leads	15686794
to	15686794
complete	15686794
resolution	15686794
.	15686794
Long	27959387
-	27959387
term	27959387
exposure	27959387
of	27959387
MCF	27959387
-	27959387
7	27959387
breast	27959387
cancer	27959387
cells	27959387
to	27959387
ethanol	27959387
stimulates	27959387
oncogenic	27959387
features	27959387
.	27959387

Alcohol	27959387
consumption	27959387
is	27959387
a	27959387
risk	27959387
factor	27959387
for	27959387
breast	27959387
cancer	27959387
.	27959387

Little	27959387
is	27959387
known	27959387
regarding	27959387
the	27959387
mechanism	27959387
,	27959387
although	27959387
it	27959387
is	27959387
assumed	27959387
that	27959387
acetaldehyde	27959387
or	27959387
estrogen	27959387
mediated	27959387
pathways	27959387
play	27959387
a	27959387
role	27959387
.	27959387

We	27959387
previously	27959387
showed	27959387
that	27959387
long	27959387
-	27959387
term	27959387
exposure	27959387
to	27959387
2	27959387
.	27959387
5	27959387
mM	27959387
ethanol	27959387
(	27959387
blood	27959387
alcohol	27959387
~	27959387
0	27959387
.	27959387
012%	27959387
)	27959387
of	27959387
MCF	27959387
-	27959387
12A	27959387
,	27959387
a	27959387
human	27959387
normal	27959387
epithelial	27959387
breast	27959387
cell	27959387
line	27959387
,	27959387
induced	27959387
epithelial	27959387
mesenchymal	27959387
transition	27959387
(	27959387
EMT	27959387
)	27959387
and	27959387
oncogenic	27959387
transformation	27959387
.	27959387

In	27959387
this	27959387
study	27959387
,	27959387
we	27959387
investigated	27959387
in	27959387
the	27959387
human	27959387
breast	27959387
cancer	27959387
cell	27959387
line	27959387
MCF	27959387
-	27959387
7	27959387
,	27959387
whether	27959387
a	27959387
similar	27959387
exposure	27959387
to	27959387
ethanol	27959387
at	27959387
concentrations	27959387
ranging	27959387
up	27959387
to	27959387
peak	27959387
blood	27959387
levels	27959387
in	27959387
heavy	27959387
drinkers	27959387
would	27959387
increase	27959387
malignant	27959387
progression	27959387
.	27959387

Short	27959387
-	27959387
term	27959387
(	27959387
1	27959387
-	27959387
week	27959387
)	27959387
incubation	27959387
to	27959387
ethanol	27959387
at	27959387
as	27959387
low	27959387
as	27959387
1	27959387
-	27959387
5	27959387
mM	27959387
(	27959387
corresponding	27959387
to	27959387
blood	27959387
alcohol	27959387
concentration	27959387
of	27959387
~	27959387
0	27959387
.	27959387
0048	27959387
-	27959387
0	27959387
.	27959387
024%	27959387
)	27959387
upregulated	27959387
the	27959387
stem	27959387
cell	27959387
related	27959387
proteins	27959387
Oct4	27959387
and	27959387
Nanog	27959387
,	27959387
but	27959387
they	27959387
were	27959387
reduced	27959387
after	27959387
exposure	27959387
at	27959387
25	27959387
mM	27959387
.	27959387

Long	27959387
-	27959387
term	27959387
(	27959387
4	27959387
-	27959387
week	27959387
)	27959387
exposure	27959387
to	27959387
25	27959387
mM	27959387
ethanol	27959387
upregulated	27959387
the	27959387
Oct4	27959387
and	27959387
Nanog	27959387
proteins	27959387
,	27959387
as	27959387
well	27959387
as	27959387
the	27959387
malignancy	27959387
marker	27959387
Ceacam6	27959387
.	27959387

DNA	27959387
microarray	27959387
analysis	27959387
in	27959387
cells	27959387
exposed	27959387
for	27959387
1	27959387
week	27959387
showed	27959387
upregulated	27959387
expression	27959387
of	27959387
metallothionein	27959387
genes	27959387
,	27959387
particularly	27959387
MT1X	27959387
.	27959387

Long	27959387
-	27959387
term	27959387
exposure	27959387
upregulated	27959387
expression	27959387
of	27959387
some	27959387
malignancy	27959387
related	27959387
genes	27959387
(	27959387
STEAP4	27959387
,	27959387
SERPINA3	27959387
,	27959387
SAMD9	27959387
,	27959387
GDF15	27959387
,	27959387
KRT15	27959387
,	27959387
ITGB6	27959387
,	27959387
TP63	27959387
,	27959387
and	27959387
PGR	27959387
,	27959387
as	27959387
well	27959387
as	27959387
the	27959387
CEACAM	27959387
,	27959387
interferon	27959387
related	27959387
,	27959387
and	27959387
HLA	27959387
gene	27959387
families	27959387
)	27959387
.	27959387

Some	27959387
of	27959387
these	27959387
findings	27959387
were	27959387
validated	27959387
by	27959387
RT	27959387
-	27959387
PCR	27959387
.	27959387

A	27959387
similar	27959387
treatment	27959387
also	27959387
modulated	27959387
numerous	27959387
microRNAs	27959387
(	27959387
miRs	27959387
)	27959387
including	27959387
one	27959387
regulator	27959387
of	27959387
Oct4	27959387
as	27959387
well	27959387
as	27959387
miRs	27959387
involved	27959387
in	27959387
oncogenesis	27959387
and	27959387
/	27959387
or	27959387
malignancy	27959387
,	27959387
with	27959387
only	27959387
a	27959387
few	27959387
estrogen	27959387
-	27959387
induced	27959387
miRs	27959387
.	27959387

Long	27959387
-	27959387
term	27959387
25	27959387
mM	27959387
ethanol	27959387
also	27959387
induced	27959387
a	27959387
5	27959387
.	27959387
6	27959387
-	27959387
fold	27959387
upregulation	27959387
of	27959387
anchorage	27959387
-	27959387
independent	27959387
growth	27959387
,	27959387
an	27959387
indicator	27959387
of	27959387
malignant	27959387
-	27959387
like	27959387
features	27959387
.	27959387

Exposure	27959387
to	27959387
acetaldehyde	27959387
resulted	27959387
in	27959387
little	27959387
or	27959387
no	27959387
effect	27959387
comparable	27959387
to	27959387
that	27959387
of	27959387
ethanol	27959387
.	27959387

The	27959387
previously	27959387
shown	27959387
alcohol	27959387
induction	27959387
of	27959387
oncogenic	27959387
transformation	27959387
of	27959387
normal	27959387
breast	27959387
cells	27959387
is	27959387
now	27959387
complemented	27959387
by	27959387
the	27959387
current	27959387
results	27959387
suggesting	27959387
alcohol	27959387
'	27959387
s	27959387
potential	27959387
involvement	27959387
in	27959387
malignant	27959387
progression	27959387
of	27959387
breast	27959387
cancer	27959387
.	27959387
Pheochromocytoma	15811908
unmasked	15811908
by	15811908
amisulpride	15811908
and	15811908
tiapride	15811908
.	15811908

OBJECTIVE	15811908
:	15811908
To	15811908
describe	15811908
the	15811908
unmasking	15811908
of	15811908
pheochromocytoma	15811908
in	15811908
a	15811908
patient	15811908
treated	15811908
with	15811908
amisulpride	15811908
and	15811908
tiapride	15811908
.	15811908

CASE	15811908
SUMMARY	15811908
:	15811908
A	15811908
42	15811908
-	15811908
year	15811908
-	15811908
old	15811908
white	15811908
man	15811908
developed	15811908
acute	15811908
hypertension	15811908
with	15811908
severe	15811908
headache	15811908
and	15811908
vomiting	15811908
2	15811908
hours	15811908
after	15811908
the	15811908
first	15811908
doses	15811908
of	15811908
amisulpride	15811908
100	15811908
mg	15811908
and	15811908
tiapride	15811908
100	15811908
mg	15811908
.	15811908

Both	15811908
drugs	15811908
were	15811908
immediately	15811908
discontinued	15811908
,	15811908
and	15811908
the	15811908
patient	15811908
recovered	15811908
after	15811908
subsequent	15811908
nicardipine	15811908
and	15811908
verapamil	15811908
treatment	15811908
.	15811908

Abdominal	15811908
ultrasound	15811908
showed	15811908
an	15811908
adrenal	15811908
mass	15811908
,	15811908
and	15811908
postoperative	15811908
histologic	15811908
examination	15811908
confirmed	15811908
the	15811908
diagnosis	15811908
of	15811908
pheochromocytoma	15811908
.	15811908

DISCUSSION	15811908
:	15811908
Drug	15811908
-	15811908
induced	15811908
symptoms	15811908
of	15811908
pheochromocytoma	15811908
are	15811908
often	15811908
associated	15811908
with	15811908
the	15811908
use	15811908
of	15811908
substituted	15811908
benzamide	15811908
drugs	15811908
,	15811908
but	15811908
the	15811908
underlying	15811908
mechanism	15811908
is	15811908
unknown	15811908
.	15811908

In	15811908
our	15811908
case	15811908
,	15811908
use	15811908
of	15811908
the	15811908
Naranjo	15811908
probability	15811908
scale	15811908
indicated	15811908
a	15811908
possible	15811908
relationship	15811908
between	15811908
the	15811908
hypertensive	15811908
crisis	15811908
and	15811908
amisulpride	15811908
and	15811908
tiapride	15811908
therapy	15811908
.	15811908

CONCLUSIONS	15811908
:	15811908
As	15811908
of	15811908
March	15811908
24	15811908
,	15811908
2005	15811908
,	15811908
this	15811908
is	15811908
the	15811908
first	15811908
reported	15811908
case	15811908
of	15811908
amisulpride	15811908
-	15811908
and	15811908
tiapride	15811908
-	15811908
induced	15811908
hypertensive	15811908
crisis	15811908
in	15811908
a	15811908
patient	15811908
with	15811908
pheochromocytoma	15811908
.	15811908

Physicians	15811908
and	15811908
other	15811908
healthcare	15811908
professionals	15811908
should	15811908
be	15811908
aware	15811908
of	15811908
this	15811908
potential	15811908
adverse	15811908
effect	15811908
of	15811908
tiapride	15811908
and	15811908
amisulpride	15811908
.	15811908
IL	24743235
-	24743235
3	24743235
and	24743235
CSF	24743235
-	24743235
1	24743235
interact	24743235
to	24743235
promote	24743235
generation	24743235
of	24743235
CD11c	24743235
+	24743235
IL	24743235
-	24743235
10	24743235
-	24743235
producing	24743235
macrophages	24743235
.	24743235

Unraveling	24743235
the	24743235
mechanisms	24743235
of	24743235
hematopoiesis	24743235
regulated	24743235
by	24743235
multiple	24743235
cytokines	24743235
remains	24743235
a	24743235
challenge	24743235
in	24743235
hematology	24743235
.	24743235

IL	24743235
-	24743235
3	24743235
is	24743235
an	24743235
allergic	24743235
cytokine	24743235
with	24743235
the	24743235
multilineage	24743235
potential	24743235
,	24743235
while	24743235
CSF	24743235
-	24743235
1	24743235
is	24743235
produced	24743235
in	24743235
the	24743235
steady	24743235
state	24743235
with	24743235
restricted	24743235
lineage	24743235
coverage	24743235
.	24743235

Here	24743235
,	24743235
we	24743235
uncovered	24743235
an	24743235
instructive	24743235
role	24743235
of	24743235
CSF	24743235
-	24743235
1	24743235
in	24743235
IL	24743235
-	24743235
3	24743235
-	24743235
mediated	24743235
hematopoiesis	24743235
.	24743235

CSF	24743235
-	24743235
1	24743235
significantly	24743235
promoted	24743235
IL	24743235
-	24743235
3	24743235
-	24743235
driven	24743235
CD11c	24743235
+	24743235
cell	24743235
expansion	24743235
and	24743235
dampened	24743235
basophil	24743235
and	24743235
mast	24743235
cell	24743235
generation	24743235
from	24743235
C57BL	24743235
/	24743235
6	24743235
bone	24743235
marrow	24743235
.	24743235

Further	24743235
studies	24743235
indicated	24743235
that	24743235
the	24743235
CSF	24743235
-	24743235
1	24743235
/	24743235
CSF	24743235
-	24743235
1R	24743235
axis	24743235
contributed	24743235
significantly	24743235
to	24743235
IL	24743235
-	24743235
3	24743235
-	24743235
induced	24743235
CD11c	24743235
+	24743235
cell	24743235
generation	24743235
through	24743235
enhancing	24743235
c	24743235
-	24743235
Fos	24743235
-	24743235
associated	24743235
monopoiesis	24743235
.	24743235

CD11c	24743235
+	24743235
cells	24743235
induced	24743235
by	24743235
IL	24743235
-	24743235
3	24743235
or	24743235
IL	24743235
-	24743235
3	24743235
/	24743235
CSF	24743235
-	24743235
1	24743235
were	24743235
competent	24743235
in	24743235
cellular	24743235
maturation	24743235
and	24743235
endocytosis	24743235
.	24743235

Both	24743235
IL	24743235
-	24743235
3	24743235
and	24743235
IL	24743235
-	24743235
3	24743235
/	24743235
CSF	24743235
-	24743235
1	24743235
cells	24743235
lacked	24743235
classical	24743235
dendritic	24743235
cell	24743235
appearance	24743235
and	24743235
resembled	24743235
macrophages	24743235
in	24743235
morphology	24743235
.	24743235

Both	24743235
populations	24743235
produced	24743235
a	24743235
high	24743235
level	24743235
of	24743235
IL	24743235
-	24743235
10	24743235
,	24743235
in	24743235
addition	24743235
to	24743235
IL	24743235
-	24743235
1	24743235
,	24743235
IL	24743235
-	24743235
6	24743235
and	24743235
TNFa	24743235
,	24743235
in	24743235
response	24743235
to	24743235
LPS	24743235
,	24743235
and	24743235
were	24743235
relatively	24743235
poor	24743235
T	24743235
cell	24743235
stimulators	24743235
.	24743235

Collectively	24743235
,	24743235
these	24743235
findings	24743235
reveal	24743235
a	24743235
role	24743235
for	24743235
CSF	24743235
-	24743235
1	24743235
in	24743235
mediating	24743235
the	24743235
IL	24743235
-	24743235
3	24743235
hematopoietic	24743235
pathway	24743235
through	24743235
monopoiesis	24743235
,	24743235
which	24743235
regulates	24743235
expansion	24743235
of	24743235
CD11c	24743235
+	24743235
macrophages	24743235
.	24743235
Analysis	28512644
of	28512644
Serum	28512644
Cytokines	28512644
and	28512644
Single	28512644
-	28512644
Nucleotide	28512644
Polymorphisms	28512644
of	28512644
SOD1	28512644
,	28512644
SOD2	28512644
,	28512644
and	28512644
CAT	28512644
in	28512644
Erysipelas	28512644
Patients	28512644
.	28512644

Increased	28512644
free	28512644
radical	28512644
production	28512644
had	28512644
been	28512644
documented	28512644
in	28512644
group	28512644
A	28512644
(	28512644
beta	28512644
-	28512644
hemolytic	28512644
)	28512644
streptococcus	28512644
infection	28512644
cases	28512644
.	28512644

Comparing	28512644
71	28512644
erysipelas	28512644
patients	28512644
to	28512644
55	28512644
age	28512644
-	28512644
matched	28512644
healthy	28512644
individuals	28512644
,	28512644
we	28512644
sought	28512644
for	28512644
CAT	28512644
,	28512644
SOD1	28512644
,	28512644
and	28512644
SOD2	28512644
single	28512644
polymorphism	28512644
mutation	28512644
(	28512644
SNPs	28512644
)	28512644
interactions	28512644
with	28512644
erysipelas	28512644
'	28512644
predisposition	28512644
and	28512644
serum	28512644
cytokine	28512644
levels	28512644
in	28512644
the	28512644
acute	28512644
and	28512644
recovery	28512644
phases	28512644
of	28512644
erysipelas	28512644
infection	28512644
.	28512644

Whereas	28512644
female	28512644
patients	28512644
had	28512644
a	28512644
higher	28512644
predisposition	28512644
to	28512644
erysipelas	28512644
,	28512644
male	28512644
patients	28512644
were	28512644
prone	28512644
to	28512644
having	28512644
a	28512644
facial	28512644
localization	28512644
of	28512644
the	28512644
infection	28512644
.	28512644

The	28512644
presence	28512644
of	28512644
SOD1	28512644
G7958	28512644
,	28512644
SOD2	28512644
T2734	28512644
,	28512644
and	28512644
CAT	28512644
C262	28512644
alleles	28512644
was	28512644
linked	28512644
to	28512644
erysipelas	28512644
'	28512644
predisposition	28512644
.	28512644

T	28512644
and	28512644
C	28512644
alleles	28512644
of	28512644
SOD2	28512644
T2734C	28512644
individually	28512644
were	28512644
linked	28512644
to	28512644
patients	28512644
with	28512644
bullous	28512644
and	28512644
erythematous	28512644
erysipelas	28512644
,	28512644
respectively	28512644
.	28512644

G	28512644
and	28512644
A	28512644
alleles	28512644
of	28512644
SOD1	28512644
G7958A	28512644
individually	28512644
were	28512644
associated	28512644
with	28512644
lower	28512644
limbs	28512644
and	28512644
higher	28512644
body	28512644
part	28512644
localizations	28512644
of	28512644
the	28512644
infection	28512644
,	28512644
respectively	28512644
.	28512644

Serum	28512644
levels	28512644
of	28512644
IL	28512644
-	28512644
1beta	28512644
,	28512644
CCL11	28512644
,	28512644
IL	28512644
-	28512644
2Ralpha	28512644
,	28512644
CXCL9	28512644
,	28512644
TRAIL	28512644
,	28512644
PDGF	28512644
-	28512644
BB	28512644
,	28512644
and	28512644
CCL4	28512644
were	28512644
associated	28512644
with	28512644
symptoms	28512644
accompanying	28512644
the	28512644
infection	28512644
,	28512644
while	28512644
IL	28512644
-	28512644
6	28512644
,	28512644
IL	28512644
-	28512644
9	28512644
,	28512644
IL	28512644
-	28512644
10	28512644
,	28512644
IL	28512644
-	28512644
13	28512644
,	28512644
IL	28512644
-	28512644
15	28512644
,	28512644
IL	28512644
-	28512644
17	28512644
,	28512644
G	28512644
-	28512644
CSF	28512644
,	28512644
and	28512644
VEGF	28512644
were	28512644
associated	28512644
with	28512644
predisposition	28512644
and	28512644
recurrence	28512644
of	28512644
erysipelas	28512644
.	28512644

While	28512644
variations	28512644
of	28512644
IL	28512644
-	28512644
1beta	28512644
,	28512644
IL	28512644
-	28512644
7	28512644
,	28512644
IL	28512644
-	28512644
8	28512644
,	28512644
IL	28512644
-	28512644
17	28512644
,	28512644
CCL5	28512644
,	28512644
and	28512644
HGF	28512644
were	28512644
associated	28512644
with	28512644
the	28512644
SOD2	28512644
T2734C	28512644
SNP	28512644
,	28512644
variations	28512644
of	28512644
PDFG	28512644
-	28512644
BB	28512644
and	28512644
CCL2	28512644
were	28512644
associated	28512644
with	28512644
the	28512644
CAT	28512644
C262T	28512644
SNP	28512644
.	28512644
XRCC1	21682595
Arg399Gln	21682595
gene	21682595
polymorphism	21682595
and	21682595
the	21682595
risk	21682595
of	21682595
systemic	21682595
lupus	21682595
erythematosus	21682595
in	21682595
the	21682595
Polish	21682595
population	21682595
.	21682595

It	21682595
has	21682595
been	21682595
shown	21682595
that	21682595
DNA	21682595
repair	21682595
is	21682595
reduced	21682595
in	21682595
patients	21682595
with	21682595
systemic	21682595
lupus	21682595
erythematosus	21682595
(	21682595
SLE	21682595
)	21682595
and	21682595
that	21682595
the	21682595
X	21682595
-	21682595
ray	21682595
repair	21682595
cross	21682595
-	21682595
complementing	21682595
(	21682595
XRCC1	21682595
)	21682595
Arg399Gln	21682595
(	21682595
rs25487	21682595
)	21682595
polymorphism	21682595
may	21682595
contribute	21682595
to	21682595
DNA	21682595
repair	21682595
.	21682595

We	21682595
evaluated	21682595
the	21682595
frequency	21682595
of	21682595
the	21682595
XRCC1	21682595
Arg399Gln	21682595
substitution	21682595
in	21682595
patients	21682595
with	21682595
SLE	21682595
(	21682595
n	21682595
=	21682595
265	21682595
)	21682595
and	21682595
controls	21682595
(	21682595
n	21682595
=	21682595
360	21682595
)	21682595
in	21682595
a	21682595
sample	21682595
of	21682595
the	21682595
Polish	21682595
population	21682595
.	21682595

The	21682595
odds	21682595
ratio	21682595
(	21682595
OR	21682595
)	21682595
for	21682595
SLE	21682595
patients	21682595
with	21682595
the	21682595
Gln	21682595
/	21682595
Gln	21682595
versus	21682595
Gln	21682595
/	21682595
Arg	21682595
or	21682595
Arg	21682595
/	21682595
Arg	21682595
genotypes	21682595
was	21682595
1	21682595
.	21682595
553	21682595
(	21682595
95%	21682595
confidence	21682595
interval	21682595
[	21682595
CI	21682595
]	21682595
=	21682595
0	21682595
.	21682595
9573	21682595
-	21682595
2	21682595
.	21682595
520	21682595
;	21682595
p	21682595
=	21682595
0	21682595
.	21682595
0729	21682595
)	21682595
.	21682595

OR	21682595
for	21682595
the	21682595
Gln	21682595
/	21682595
Gln	21682595
or	21682595
Gln	21682595
/	21682595
Arg	21682595
versus	21682595
Arg	21682595
/	21682595
Arg	21682595
genotype	21682595
was	21682595
1	21682595
.	21682595
551	21682595
(	21682595
95%	21682595
CI	21682595
=	21682595
1	21682595
.	21682595
122	21682595
-	21682595
2	21682595
.	21682595
144	21682595
,	21682595
p	21682595
=	21682595
0	21682595
.	21682595
0077	21682595
)	21682595
.	21682595

The	21682595
OR	21682595
for	21682595
the	21682595
399	21682595
Gln	21682595
allele	21682595
in	21682595
patients	21682595
with	21682595
SLE	21682595
was	21682595
1	21682595
.	21682595
406	21682595
(	21682595
95%	21682595
CI	21682595
=	21682595
1	21682595
.	21682595
111	21682595
-	21682595
1	21682595
.	21682595
779	21682595
,	21682595
p	21682595
=	21682595
0	21682595
.	21682595
0045	21682595
)	21682595
.	21682595

There	21682595
was	21682595
also	21682595
a	21682595
statistically	21682595
significant	21682595
p	21682595
-	21682595
value	21682595
of	21682595
the	21682595
(	21682595
2	21682595
)	21682595
test	21682595
for	21682595
the	21682595
trend	21682595
observed	21682595
in	21682595
the	21682595
XRCC1	21682595
Arg399Gln	21682595
polymorphism	21682595
(	21682595
ptrend	21682595
=	21682595
0	21682595
.	21682595
0048	21682595
)	21682595
.	21682595

We	21682595
also	21682595
found	21682595
a	21682595
significant	21682595
contribution	21682595
of	21682595
the	21682595
Gln	21682595
/	21682595
Gln	21682595
or	21682595
Arg	21682595
/	21682595
Gln	21682595
versus	21682595
Arg	21682595
/	21682595
Arg	21682595
genotype	21682595
to	21682595
the	21682595
presence	21682595
of	21682595
either	21682595
the	21682595
malar	21682595
rash	21682595
or	21682595
photosensitivity	21682595
manifestations	21682595
of	21682595
SLE	21682595
OR	21682595
=	21682595
2	21682595
.	21682595
241	21682595
(	21682595
1	21682595
.	21682595
328	21682595
-	21682595
3	21682595
.	21682595
781	21682595
,	21682595
p	21682595
=	21682595
0	21682595
.	21682595
0023	21682595
,	21682595
pcorr	21682595
=	21682595
0	21682595
.	21682595
0414	21682595
)	21682595
.	21682595

Moreover	21682595
,	21682595
the	21682595
meta	21682595
-	21682595
analysis	21682595
of	21682595
Taiwanese	21682595
Han	21682595
Chinese	21682595
,	21682595
Brazilian	21682595
,	21682595
and	21682595
Polish	21682595
populations	21682595
showed	21682595
that	21682595
the	21682595
Gln	21682595
/	21682595
Gln	21682595
or	21682595
Gln	21682595
/	21682595
Arg	21682595
genotype	21682595
and	21682595
Gln	21682595
allele	21682595
were	21682595
associated	21682595
with	21682595
SLE	21682595
incidence	21682595
.	21682595

OR	21682595
for	21682595
the	21682595
Gln	21682595
/	21682595
Gln	21682595
or	21682595
Gln	21682595
/	21682595
Arg	21682595
versus	21682595
Arg	21682595
/	21682595
Arg	21682595
genotype	21682595
was	21682595
1	21682595
.	21682595
440	21682595
(	21682595
95%	21682595
CI	21682595
=	21682595
1	21682595
.	21682595
15	21682595
-	21682595
1	21682595
.	21682595
80	21682595
,	21682595
p	21682595
=	21682595
0	21682595
.	21682595
0019	21682595
)	21682595
and	21682595
OR	21682595
for	21682595
the	21682595
Gln	21682595
allele	21682595
was	21682595
1	21682595
.	21682595
27	21682595
(	21682595
95%	21682595
CI	21682595
=	21682595
1	21682595
.	21682595
08	21682595
-	21682595
1	21682595
.	21682595
51	21682595
,	21682595
p	21682595
=	21682595
0	21682595
.	21682595
0051	21682595
)	21682595
.	21682595

Our	21682595
studies	21682595
may	21682595
confirm	21682595
that	21682595
the	21682595
XRCC1	21682595
Arg399Gln	21682595
polymorphism	21682595
may	21682595
increase	21682595
the	21682595
risk	21682595
of	21682595
incidence	21682595
of	21682595
SLE	21682595
and	21682595
the	21682595
occurrence	21682595
of	21682595
some	21682595
SLE	21682595
manifestations	21682595
.	21682595
Succinylcholine	15893386
-	15893386
induced	15893386
masseter	15893386
muscle	15893386
rigidity	15893386
during	15893386
bronchoscopic	15893386
removal	15893386
of	15893386
a	15893386
tracheal	15893386
foreign	15893386
body	15893386
.	15893386

Masseter	15893386
muscle	15893386
rigidity	15893386
during	15893386
general	15893386
anesthesia	15893386
is	15893386
considered	15893386
an	15893386
early	15893386
warning	15893386
sign	15893386
of	15893386
a	15893386
possible	15893386
episode	15893386
of	15893386
malignant	15893386
hyperthermia	15893386
.	15893386

The	15893386
decision	15893386
whether	15893386
to	15893386
continue	15893386
or	15893386
discontinue	15893386
the	15893386
procedure	15893386
depends	15893386
on	15893386
the	15893386
urgency	15893386
of	15893386
the	15893386
surgery	15893386
and	15893386
severity	15893386
of	15893386
masseter	15893386
muscle	15893386
rigidity	15893386
.	15893386

Here	15893386
,	15893386
we	15893386
describe	15893386
a	15893386
case	15893386
of	15893386
severe	15893386
masseter	15893386
muscle	15893386
rigidity	15893386
(	15893386
jaw	15893386
of	15893386
steel	15893386
)	15893386
after	15893386
succinylcholine	15893386
(	15893386
Sch	15893386
)	15893386
administration	15893386
during	15893386
general	15893386
anesthetic	15893386
management	15893386
for	15893386
rigid	15893386
bronchoscopic	15893386
removal	15893386
of	15893386
a	15893386
tracheal	15893386
foreign	15893386
body	15893386
.	15893386

Anesthesia	15893386
was	15893386
continued	15893386
uneventfully	15893386
with	15893386
propofol	15893386
infusion	15893386
while	15893386
all	15893386
facilities	15893386
were	15893386
available	15893386
to	15893386
detect	15893386
and	15893386
treat	15893386
malignant	15893386
hyperthermia	15893386
.	15893386
Evaluation	15198485
of	15198485
the	15198485
Lys198Asn	15198485
and	15198485
-	15198485
134delA	15198485
genetic	15198485
polymorphisms	15198485
of	15198485
the	15198485
endothelin	15198485
-	15198485
1	15198485
gene	15198485
.	15198485

Endothelin	15198485
-	15198485
1	15198485
(	15198485
ET	15198485
-	15198485
1	15198485
)	15198485
is	15198485
a	15198485
potent	15198485
vasoconstrictor	15198485
and	15198485
shows	15198485
various	15198485
pharmacological	15198485
responses	15198485
.	15198485

Two	15198485
single	15198485
nucleotide	15198485
polymorphisms	15198485
in	15198485
the	15198485
ET	15198485
-	15198485
1	15198485
gene	15198485
(	15198485
EDN1	15198485
)	15198485
have	15198485
been	15198485
reported	15198485
to	15198485
be	15198485
associated	15198485
with	15198485
blood	15198485
pressure	15198485
(	15198485
BP	15198485
)	15198485
.	15198485

One	15198485
is	15198485
the	15198485
Lys198Asn	15198485
polymorphism	15198485
,	15198485
which	15198485
showed	15198485
a	15198485
positive	15198485
association	15198485
with	15198485
BP	15198485
in	15198485
overweight	15198485
people	15198485
.	15198485

Another	15198485
is	15198485
the	15198485
3A	15198485
/	15198485
4A	15198485
polymorphism	15198485
(	15198485
-	15198485
134delA	15198485
)	15198485
located	15198485
in	15198485
the	15198485
5	15198485
'	15198485
-	15198485
untranslated	15198485
region	15198485
.	15198485

In	15198485
this	15198485
study	15198485
,	15198485
we	15198485
investigated	15198485
the	15198485
expression	15198485
of	15198485
the	15198485
Lys198Asn	15198485
polymorphism	15198485
in	15198485
ET	15198485
-	15198485
1	15198485
in	15198485
vitro	15198485
,	15198485
as	15198485
well	15198485
as	15198485
the	15198485
association	15198485
between	15198485
either	15198485
of	15198485
the	15198485
two	15198485
polymorphisms	15198485
and	15198485
the	15198485
plasma	15198485
ET	15198485
-	15198485
1	15198485
level	15198485
.	15198485

We	15198485
expressed	15198485
both	15198485
the	15198485
major	15198485
(	15198485
Lys	15198485
-	15198485
type	15198485
)	15198485
and	15198485
minor	15198485
type	15198485
(	15198485
Asn	15198485
-	15198485
type	15198485
)	15198485
preproET	15198485
-	15198485
1	15198485
in	15198485
three	15198485
different	15198485
cell	15198485
lines	15198485
,	15198485
and	15198485
measured	15198485
the	15198485
levels	15198485
of	15198485
ET	15198485
-	15198485
1	15198485
and	15198485
big	15198485
ET	15198485
-	15198485
1	15198485
in	15198485
the	15198485
culture	15198485
supernatant	15198485
.	15198485

There	15198485
was	15198485
no	15198485
significant	15198485
difference	15198485
in	15198485
the	15198485
levels	15198485
of	15198485
ET	15198485
-	15198485
1	15198485
or	15198485
big	15198485
ET	15198485
-	15198485
1	15198485
between	15198485
the	15198485
Asn	15198485
-	15198485
type	15198485
and	15198485
Lys	15198485
-	15198485
type	15198485
transfectant	15198485
.	15198485

In	15198485
the	15198485
association	15198485
study	15198485
,	15198485
the	15198485
plasma	15198485
levels	15198485
of	15198485
ET	15198485
-	15198485
1	15198485
in	15198485
54	15198485
hypertensive	15198485
patients	15198485
having	15198485
an	15198485
amino	15198485
acid	15198485
substitution	15198485
from	15198485
Lys	15198485
to	15198485
Asn	15198485
at	15198485
position	15198485
198	15198485
were	15198485
not	15198485
different	15198485
from	15198485
those	15198485
of	15198485
hypertensives	15198485
without	15198485
the	15198485
substitution	15198485
.	15198485

However	15198485
,	15198485
we	15198485
found	15198485
a	15198485
significant	15198485
difference	15198485
in	15198485
ET	15198485
-	15198485
1	15198485
levels	15198485
between	15198485
individuals	15198485
with	15198485
the	15198485
3A	15198485
/	15198485
3A	15198485
and	15198485
3A	15198485
/	15198485
4A	15198485
genotypes	15198485
.	15198485

Our	15198485
transient	15198485
expression	15198485
study	15198485
indicates	15198485
that	15198485
the	15198485
Lys198Asn	15198485
polymorphism	15198485
may	15198485
not	15198485
directly	15198485
affect	15198485
ET	15198485
-	15198485
1	15198485
and	15198485
big	15198485
ET	15198485
-	15198485
1	15198485
production	15198485
.	15198485

Another	15198485
variant	15198485
in	15198485
the	15198485
EDN1	15198485
gene	15198485
in	15198485
linkage	15198485
disequilibrium	15198485
with	15198485
the	15198485
Lys198Asn	15198485
polymorphism	15198485
may	15198485
be	15198485
responsible	15198485
for	15198485
the	15198485
association	15198485
with	15198485
BP	15198485
,	15198485
or	15198485
the	15198485
interaction	15198485
between	15198485
the	15198485
EDN1	15198485
Lys198Asn	15198485
polymorphism	15198485
and	15198485
other	15198485
factors	15198485
such	15198485
as	15198485
obesity	15198485
may	15198485
be	15198485
involved	15198485
in	15198485
the	15198485
mechanisms	15198485
elevating	15198485
BP	15198485
in	15198485
vivo	15198485
.	15198485
Polymorphisms	15983230
in	15983230
the	15983230
SLC2A2	15983230
(	15983230
GLUT2	15983230
)	15983230
gene	15983230
are	15983230
associated	15983230
with	15983230
the	15983230
conversion	15983230
from	15983230
impaired	15983230
glucose	15983230
tolerance	15983230
to	15983230
type	15983230
2	15983230
diabetes	15983230
:	15983230
the	15983230
Finnish	15983230
Diabetes	15983230
Prevention	15983230
Study	15983230
.	15983230

Impaired	15983230
insulin	15983230
secretion	15983230
is	15983230
a	15983230
fundamental	15983230
defect	15983230
in	15983230
type	15983230
2	15983230
diabetes	15983230
.	15983230

The	15983230
aim	15983230
of	15983230
this	15983230
study	15983230
was	15983230
to	15983230
investigate	15983230
whether	15983230
single	15983230
nucleotide	15983230
polymorphisms	15983230
(	15983230
SNPs	15983230
)	15983230
in	15983230
the	15983230
genes	15983230
regulating	15983230
insulin	15983230
secretion	15983230
(	15983230
SLC2A2	15983230
[	15983230
encoding	15983230
GLUT2	15983230
]	15983230
,	15983230
GCK	15983230
,	15983230
TCF1	15983230
[	15983230
encoding	15983230
HNF	15983230
-	15983230
1alpha	15983230
]	15983230
,	15983230
HNF4A	15983230
,	15983230
GIP	15983230
,	15983230
and	15983230
GLP1R	15983230
)	15983230
are	15983230
associated	15983230
with	15983230
the	15983230
conversion	15983230
from	15983230
impaired	15983230
glucose	15983230
tolerance	15983230
(	15983230
IGT	15983230
)	15983230
to	15983230
type	15983230
2	15983230
diabetes	15983230
in	15983230
participants	15983230
of	15983230
the	15983230
Finnish	15983230
Diabetes	15983230
Prevention	15983230
Study	15983230
.	15983230

With	15983230
the	15983230
exception	15983230
of	15983230
SLC2A2	15983230
,	15983230
other	15983230
genes	15983230
were	15983230
not	15983230
associated	15983230
with	15983230
the	15983230
risk	15983230
of	15983230
type	15983230
2	15983230
diabetes	15983230
.	15983230

All	15983230
four	15983230
SNPs	15983230
of	15983230
SLC2A2	15983230
predicted	15983230
the	15983230
conversion	15983230
to	15983230
diabetes	15983230
,	15983230
and	15983230
rs5393	15983230
(	15983230
AA	15983230
genotype	15983230
)	15983230
increased	15983230
the	15983230
risk	15983230
of	15983230
type	15983230
2	15983230
diabetes	15983230
in	15983230
the	15983230
entire	15983230
study	15983230
population	15983230
by	15983230
threefold	15983230
(	15983230
odds	15983230
ratio	15983230
3	15983230
.	15983230
04	15983230
,	15983230
95%	15983230
CI	15983230
1	15983230
.	15983230
34	15983230
-	15983230
6	15983230
.	15983230
88	15983230
,	15983230
P	15983230
=	15983230
0	15983230
.	15983230
008	15983230
)	15983230
.	15983230

The	15983230
risk	15983230
for	15983230
type	15983230
2	15983230
diabetes	15983230
in	15983230
the	15983230
AA	15983230
genotype	15983230
carriers	15983230
was	15983230
increased	15983230
in	15983230
the	15983230
control	15983230
group	15983230
(	15983230
5	15983230
.	15983230
56	15983230
[	15983230
1	15983230
.	15983230
78	15983230
-	15983230
17	15983230
.	15983230
39	15983230
]	15983230
,	15983230
P	15983230
=	15983230
0	15983230
.	15983230
003	15983230
)	15983230
but	15983230
not	15983230
in	15983230
the	15983230
intervention	15983230
group	15983230
.	15983230

We	15983230
conclude	15983230
that	15983230
the	15983230
SNPs	15983230
of	15983230
SLC2A2	15983230
predict	15983230
the	15983230
conversion	15983230
to	15983230
diabetes	15983230
in	15983230
obese	15983230
subjects	15983230
with	15983230
IGT	15983230
.	15983230
Identification	16005363
of	16005363
a	16005363
novel	16005363
WFS1	16005363
mutation	16005363
(	16005363
AFF344	16005363
-	16005363
345ins	16005363
)	16005363
in	16005363
Japanese	16005363
patients	16005363
with	16005363
Wolfram	16005363
syndrome	16005363
.	16005363

Wolfram	16005363
syndrome	16005363
(	16005363
WFS	16005363
)	16005363
is	16005363
an	16005363
autosomal	16005363
recessive	16005363
disorder	16005363
characterized	16005363
by	16005363
early	16005363
onset	16005363
diabetes	16005363
mellitus	16005363
,	16005363
progressive	16005363
optic	16005363
atrophy	16005363
,	16005363
sensorineural	16005363
deafness	16005363
and	16005363
diabetes	16005363
insipidus	16005363
.	16005363

Affected	16005363
individuals	16005363
may	16005363
also	16005363
have	16005363
renal	16005363
tract	16005363
abnormalities	16005363
as	16005363
well	16005363
as	16005363
neurogical	16005363
and	16005363
psychiatric	16005363
syndromes	16005363
.	16005363

WFS1	16005363
encoding	16005363
a	16005363
transmembrane	16005363
protein	16005363
was	16005363
identified	16005363
as	16005363
the	16005363
gene	16005363
responsible	16005363
for	16005363
WFS	16005363
.	16005363

We	16005363
report	16005363
herein	16005363
a	16005363
Japanese	16005363
family	16005363
,	16005363
of	16005363
which	16005363
two	16005363
members	16005363
had	16005363
this	16005363
syndrome	16005363
.	16005363

In	16005363
the	16005363
WFS1	16005363
gene	16005363
of	16005363
these	16005363
patients	16005363
,	16005363
we	16005363
identified	16005363
a	16005363
novel	16005363
mutation	16005363
,	16005363
a	16005363
nine	16005363
nucleotide	16005363
insertion	16005363
(	16005363
AFF344	16005363
-	16005363
345ins	16005363
)	16005363
.	16005363

In	16005363
addition	16005363
,	16005363
one	16005363
of	16005363
these	16005363
patients	16005363
had	16005363
preclinical	16005363
hypopituitarism	16005363
,	16005363
which	16005363
is	16005363
an	16005363
unusual	16005363
feature	16005363
of	16005363
WFS	16005363
.	16005363

As	16005363
only	16005363
the	16005363
two	16005363
family	16005363
members	16005363
homozygous	16005363
for	16005363
the	16005363
mutation	16005363
showed	16005363
WFS	16005363
,	16005363
these	16005363
data	16005363
support	16005363
the	16005363
notion	16005363
that	16005363
this	16005363
mutation	16005363
is	16005363
the	16005363
cause	16005363
of	16005363
WFS	16005363
.	16005363
hOGG1	19881468
Ser326Cys	19881468
polymorphism	19881468
and	19881468
risk	19881468
of	19881468
lung	19881468
cancer	19881468
by	19881468
histological	19881468
type	19881468
.	19881468

Human	19881468
8	19881468
-	19881468
oxoguanine	19881468
DNA	19881468
glycosylase	19881468
1	19881468
(	19881468
hOGG1	19881468
)	19881468
has	19881468
a	19881468
major	19881468
role	19881468
in	19881468
the	19881468
repair	19881468
of	19881468
8	19881468
-	19881468
hydroxyguanine	19881468
,	19881468
a	19881468
major	19881468
promutagenic	19881468
DNA	19881468
lesion	19881468
.	19881468

The	19881468
genetic	19881468
polymorphism	19881468
rs1052133	19881468
,	19881468
which	19881468
leads	19881468
to	19881468
substitution	19881468
of	19881468
the	19881468
amino	19881468
acid	19881468
at	19881468
codon	19881468
326	19881468
from	19881468
Ser	19881468
to	19881468
Cys	19881468
,	19881468
shows	19881468
functional	19881468
differences	19881468
,	19881468
namely	19881468
a	19881468
decrease	19881468
in	19881468
enzyme	19881468
activity	19881468
in	19881468
hOGG1	19881468
-	19881468
Cys326	19881468
.	19881468

Although	19881468
several	19881468
studies	19881468
have	19881468
investigated	19881468
the	19881468
association	19881468
between	19881468
rs1052133	19881468
and	19881468
lung	19881468
cancer	19881468
susceptibility	19881468
,	19881468
the	19881468
effect	19881468
of	19881468
this	19881468
locus	19881468
on	19881468
lung	19881468
cancer	19881468
according	19881468
to	19881468
histology	19881468
remains	19881468
unclear	19881468
.	19881468

We	19881468
therefore	19881468
conducted	19881468
a	19881468
case	19881468
-	19881468
control	19881468
study	19881468
with	19881468
515	19881468
incident	19881468
lung	19881468
cancer	19881468
cases	19881468
and	19881468
1030	19881468
age	19881468
-	19881468
and	19881468
sex	19881468
-	19881468
matched	19881468
controls	19881468
without	19881468
cancer	19881468
,	19881468
and	19881468
further	19881468
conducted	19881468
a	19881468
meta	19881468
-	19881468
analysis	19881468
.	19881468

In	19881468
overall	19881468
analysis	19881468
,	19881468
the	19881468
homozygous	19881468
Cys	19881468
/	19881468
Cys	19881468
genotype	19881468
showed	19881468
a	19881468
significant	19881468
association	19881468
with	19881468
lung	19881468
cancer	19881468
compared	19881468
to	19881468
Ser	19881468
allele	19881468
carrier	19881468
status	19881468
(	19881468
odds	19881468
ratio	19881468
(	19881468
OR	19881468
)	19881468
=	19881468
1	19881468
.	19881468
31	19881468
,	19881468
95%	19881468
confidence	19881468
interval	19881468
(	19881468
CI	19881468
)	19881468
=	19881468
1	19881468
.	19881468
02	19881468
-	19881468
1	19881468
.	19881468
69	19881468
)	19881468
.	19881468

By	19881468
histology	19881468
-	19881468
based	19881468
analysis	19881468
,	19881468
the	19881468
Cys	19881468
/	19881468
Cys	19881468
genotype	19881468
showed	19881468
a	19881468
significantly	19881468
positive	19881468
association	19881468
with	19881468
small	19881468
-	19881468
cell	19881468
carcinoma	19881468
(	19881468
OR	19881468
=	19881468
2	19881468
.	19881468
40	19881468
,	19881468
95%	19881468
CI	19881468
=	19881468
1	19881468
.	19881468
32	19881468
-	19881468
4	19881468
.	19881468
49	19881468
)	19881468
and	19881468
marginally	19881468
significant	19881468
association	19881468
with	19881468
adenocarcinoma	19881468
(	19881468
OR	19881468
=	19881468
1	19881468
.	19881468
32	19881468
,	19881468
95%	19881468
CI	19881468
=	19881468
0	19881468
.	19881468
98	19881468
-	19881468
1	19881468
.	19881468
77	19881468
)	19881468
.	19881468

A	19881468
meta	19881468
-	19881468
analysis	19881468
of	19881468
previous	19881468
and	19881468
our	19881468
present	19881468
study	19881468
revealed	19881468
that	19881468
this	19881468
polymorphism	19881468
is	19881468
positively	19881468
associated	19881468
with	19881468
adenocarcinoma	19881468
,	19881468
although	19881468
suggestive	19881468
associations	19881468
were	19881468
also	19881468
found	19881468
for	19881468
squamous	19881468
-	19881468
and	19881468
small	19881468
-	19881468
cell	19881468
lung	19881468
cancers	19881468
.	19881468

These	19881468
results	19881468
indicate	19881468
that	19881468
rs1052133	19881468
contributes	19881468
to	19881468
the	19881468
risk	19881468
of	19881468
adenocarcinoma	19881468
of	19881468
lung	19881468
.	19881468
Thyroid	24914936
hormone	24914936
receptor	24914936
a	24914936
mutation	24914936
causes	24914936
a	24914936
severe	24914936
and	24914936
thyroxine	24914936
-	24914936
resistant	24914936
skeletal	24914936
dysplasia	24914936
in	24914936
female	24914936
mice	24914936
.	24914936

A	24914936
new	24914936
genetic	24914936
disorder	24914936
has	24914936
been	24914936
identified	24914936
that	24914936
results	24914936
from	24914936
mutation	24914936
of	24914936
THRA	24914936
,	24914936
encoding	24914936
thyroid	24914936
hormone	24914936
receptor	24914936
a1	24914936
(	24914936
TRa1	24914936
)	24914936
.	24914936

Affected	24914936
children	24914936
have	24914936
a	24914936
high	24914936
serum	24914936
T3	24914936
:	24914936
T4	24914936
ratio	24914936
and	24914936
variable	24914936
degrees	24914936
of	24914936
intellectual	24914936
deficit	24914936
and	24914936
constipation	24914936
but	24914936
exhibit	24914936
a	24914936
consistently	24914936
severe	24914936
skeletal	24914936
dysplasia	24914936
.	24914936

In	24914936
an	24914936
attempt	24914936
to	24914936
improve	24914936
developmental	24914936
delay	24914936
and	24914936
alleviate	24914936
symptoms	24914936
of	24914936
hypothyroidism	24914936
,	24914936
patients	24914936
are	24914936
receiving	24914936
varying	24914936
doses	24914936
and	24914936
durations	24914936
of	24914936
T4	24914936
treatment	24914936
,	24914936
but	24914936
responses	24914936
have	24914936
been	24914936
inconsistent	24914936
so	24914936
far	24914936
.	24914936

Thra1	24914936
(	24914936
PV	24914936
/	24914936
+	24914936
)	24914936
mice	24914936
express	24914936
a	24914936
similar	24914936
potent	24914936
dominant	24914936
-	24914936
negative	24914936
mutant	24914936
TRa1	24914936
to	24914936
affected	24914936
individuals	24914936
,	24914936
and	24914936
thus	24914936
represent	24914936
an	24914936
excellent	24914936
disease	24914936
model	24914936
.	24914936

We	24914936
hypothesized	24914936
that	24914936
Thra1	24914936
(	24914936
PV	24914936
/	24914936
+	24914936
)	24914936
mice	24914936
could	24914936
be	24914936
used	24914936
to	24914936
predict	24914936
the	24914936
skeletal	24914936
outcome	24914936
of	24914936
human	24914936
THRA	24914936
mutations	24914936
and	24914936
determine	24914936
whether	24914936
prolonged	24914936
treatment	24914936
with	24914936
a	24914936
supraphysiological	24914936
dose	24914936
of	24914936
T4	24914936
ameliorates	24914936
the	24914936
skeletal	24914936
abnormalities	24914936
.	24914936

Adult	24914936
female	24914936
Thra1	24914936
(	24914936
PV	24914936
/	24914936
+	24914936
)	24914936
mice	24914936
had	24914936
short	24914936
stature	24914936
,	24914936
grossly	24914936
abnormal	24914936
bone	24914936
morphology	24914936
but	24914936
normal	24914936
bone	24914936
strength	24914936
despite	24914936
high	24914936
bone	24914936
mass	24914936
.	24914936

Although	24914936
T4	24914936
treatment	24914936
suppressed	24914936
TSH	24914936
secretion	24914936
,	24914936
it	24914936
had	24914936
no	24914936
effect	24914936
on	24914936
skeletal	24914936
maturation	24914936
,	24914936
linear	24914936
growth	24914936
,	24914936
or	24914936
bone	24914936
mineralization	24914936
,	24914936
thus	24914936
demonstrating	24914936
profound	24914936
tissue	24914936
resistance	24914936
to	24914936
thyroid	24914936
hormone	24914936
.	24914936

Despite	24914936
this	24914936
,	24914936
prolonged	24914936
T4	24914936
treatment	24914936
abnormally	24914936
increased	24914936
bone	24914936
stiffness	24914936
and	24914936
strength	24914936
,	24914936
suggesting	24914936
the	24914936
potential	24914936
for	24914936
detrimental	24914936
consequences	24914936
in	24914936
the	24914936
long	24914936
term	24914936
.	24914936

Our	24914936
studies	24914936
establish	24914936
that	24914936
TRa1	24914936
has	24914936
an	24914936
essential	24914936
role	24914936
in	24914936
the	24914936
developing	24914936
and	24914936
adult	24914936
skeleton	24914936
and	24914936
predict	24914936
that	24914936
patients	24914936
with	24914936
different	24914936
THRA	24914936
mutations	24914936
will	24914936
display	24914936
variable	24914936
responses	24914936
to	24914936
T4	24914936
treatment	24914936
,	24914936
which	24914936
depend	24914936
on	24914936
the	24914936
severity	24914936
of	24914936
the	24914936
causative	24914936
mutation	24914936
.	24914936
Variation	22859398
in	22859398
IL10	22859398
and	22859398
other	22859398
genes	22859398
involved	22859398
in	22859398
the	22859398
immune	22859398
response	22859398
and	22859398
in	22859398
oxidation	22859398
and	22859398
prostate	22859398
cancer	22859398
recurrence	22859398
.	22859398

BACKGROUND	22859398
:	22859398
To	22859398
evaluate	22859398
the	22859398
association	22859398
of	22859398
variation	22859398
in	22859398
genes	22859398
involved	22859398
in	22859398
immune	22859398
response	22859398
,	22859398
including	22859398
IL10	22859398
,	22859398
production	22859398
and	22859398
detoxification	22859398
of	22859398
reactive	22859398
oxygen	22859398
species	22859398
,	22859398
and	22859398
repair	22859398
of	22859398
oxidative	22859398
DNA	22859398
damage	22859398
with	22859398
risk	22859398
of	22859398
recurrence	22859398
after	22859398
surgery	22859398
for	22859398
localized	22859398
prostate	22859398
cancer	22859398
.	22859398

METHODS	22859398
:	22859398
We	22859398
conducted	22859398
a	22859398
nested	22859398
case	22859398
-	22859398
control	22859398
study	22859398
of	22859398
men	22859398
who	22859398
had	22859398
a	22859398
radical	22859398
prostatectomy	22859398
in	22859398
1993	22859398
to	22859398
2001	22859398
.	22859398

A	22859398
total	22859398
of	22859398
484	22859398
recurrence	22859398
cases	22859398
and	22859398
484	22859398
controls	22859398
were	22859398
matched	22859398
on	22859398
age	22859398
,	22859398
race	22859398
,	22859398
and	22859398
pathologic	22859398
stage	22859398
and	22859398
grade	22859398
.	22859398

Germline	22859398
DNA	22859398
was	22859398
extracted	22859398
from	22859398
paraffin	22859398
-	22859398
embedded	22859398
unaffected	22859398
lymph	22859398
nodes	22859398
.	22859398

We	22859398
genotyped	22859398
candidate	22859398
single	22859398
-	22859398
nucleotide	22859398
polymorphisms	22859398
(	22859398
SNP	22859398
)	22859398
in	22859398
IL10	22859398
,	22859398
CRP	22859398
,	22859398
GPX1	22859398
,	22859398
GSR	22859398
,	22859398
GSTP1	22859398
,	22859398
hOGG1	22859398
,	22859398
IL1B	22859398
,	22859398
IL1RN	22859398
,	22859398
IL6	22859398
,	22859398
IL8	22859398
,	22859398
MPO	22859398
,	22859398
NOS2	22859398
,	22859398
NOS3	22859398
,	22859398
SOD1	22859398
,	22859398
SOD2	22859398
,	22859398
SOD3	22859398
,	22859398
TLR4	22859398
,	22859398
and	22859398
TNF	22859398
and	22859398
tagging	22859398
SNPs	22859398
in	22859398
IL10	22859398
,	22859398
CRP	22859398
,	22859398
GSR	22859398
,	22859398
IL1RN	22859398
,	22859398
IL6	22859398
,	22859398
NOS2	22859398
,	22859398
and	22859398
NOS3	22859398
.	22859398

We	22859398
used	22859398
conditional	22859398
logistic	22859398
regression	22859398
to	22859398
estimate	22859398
OR	22859398
and	22859398
95%	22859398
confidence	22859398
intervals	22859398
(	22859398
CI	22859398
)	22859398
.	22859398

RESULTS	22859398
:	22859398
The	22859398
minor	22859398
allele	22859398
(	22859398
A	22859398
)	22859398
in	22859398
IL10	22859398
rs1800872	22859398
,	22859398
known	22859398
to	22859398
produce	22859398
less	22859398
interleukin	22859398
-	22859398
10	22859398
(	22859398
IL	22859398
-	22859398
10	22859398
)	22859398
,	22859398
was	22859398
associated	22859398
with	22859398
a	22859398
higher	22859398
risk	22859398
of	22859398
recurrence	22859398
(	22859398
OR	22859398
=	22859398
1	22859398
.	22859398
76	22859398
,	22859398
95%	22859398
CI	22859398
:	22859398
1	22859398
.	22859398
00	22859398
-	22859398
3	22859398
.	22859398
10	22859398
)	22859398
,	22859398
and	22859398
the	22859398
minor	22859398
allele	22859398
(	22859398
G	22859398
)	22859398
in	22859398
rs1800896	22859398
,	22859398
known	22859398
to	22859398
produce	22859398
more	22859398
IL	22859398
-	22859398
10	22859398
,	22859398
was	22859398
associated	22859398
with	22859398
a	22859398
lower	22859398
risk	22859398
of	22859398
recurrence	22859398
(	22859398
OR	22859398
=	22859398
0	22859398
.	22859398
66	22859398
,	22859398
95%	22859398
CI	22859398
:	22859398
0	22859398
.	22859398
48	22859398
-	22859398
0	22859398
.	22859398
91	22859398
)	22859398
.	22859398

We	22859398
also	22859398
observed	22859398
associations	22859398
for	22859398
candidate	22859398
SNPs	22859398
in	22859398
CRP	22859398
,	22859398
GSTP1	22859398
,	22859398
and	22859398
IL1B	22859398
.	22859398

A	22859398
common	22859398
IL10	22859398
haplotype	22859398
and	22859398
2	22859398
common	22859398
NOS2	22859398
haplotypes	22859398
were	22859398
associated	22859398
with	22859398
recurrence	22859398
.	22859398

CONCLUSION	22859398
:	22859398
Variation	22859398
in	22859398
IL10	22859398
,	22859398
CRP	22859398
,	22859398
GSTP1	22859398
,	22859398
IL1B	22859398
,	22859398
and	22859398
NOS2	22859398
was	22859398
associated	22859398
with	22859398
prostate	22859398
cancer	22859398
recurrence	22859398
independent	22859398
of	22859398
pathologic	22859398
prognostic	22859398
factors	22859398
.	22859398

IMPACT	22859398
:	22859398
This	22859398
study	22859398
supports	22859398
that	22859398
genetic	22859398
variation	22859398
in	22859398
immune	22859398
response	22859398
and	22859398
oxidation	22859398
influence	22859398
prostate	22859398
cancer	22859398
recurrence	22859398
risk	22859398
and	22859398
suggests	22859398
genetic	22859398
variation	22859398
in	22859398
these	22859398
pathways	22859398
may	22859398
inform	22859398
prognosis	22859398
.	22859398
Large	21684788
contiguous	21684788
gene	21684788
deletions	21684788
in	21684788
Sjogren	21684788
-	21684788
Larsson	21684788
syndrome	21684788
.	21684788

Sjogren	21684788
-	21684788
Larsson	21684788
syndrome	21684788
(	21684788
SLS	21684788
)	21684788
is	21684788
an	21684788
autosomal	21684788
recessive	21684788
disorder	21684788
characterized	21684788
by	21684788
ichthyosis	21684788
,	21684788
mental	21684788
retardation	21684788
,	21684788
spasticity	21684788
and	21684788
mutations	21684788
in	21684788
the	21684788
ALDH3A2	21684788
gene	21684788
for	21684788
fatty	21684788
aldehyde	21684788
dehydrogenase	21684788
,	21684788
an	21684788
enzyme	21684788
that	21684788
catalyzes	21684788
the	21684788
oxidation	21684788
of	21684788
fatty	21684788
aldehyde	21684788
to	21684788
fatty	21684788
acid	21684788
.	21684788

More	21684788
than	21684788
70	21684788
mutations	21684788
have	21684788
been	21684788
identified	21684788
in	21684788
SLS	21684788
patients	21684788
,	21684788
including	21684788
small	21684788
deletions	21684788
or	21684788
insertions	21684788
,	21684788
missense	21684788
mutations	21684788
,	21684788
splicing	21684788
defects	21684788
and	21684788
complex	21684788
nucleotide	21684788
changes	21684788
.	21684788

We	21684788
now	21684788
describe	21684788
2	21684788
SLS	21684788
patients	21684788
whose	21684788
disease	21684788
is	21684788
caused	21684788
by	21684788
large	21684788
contiguous	21684788
gene	21684788
deletions	21684788
of	21684788
the	21684788
ALDH3A2	21684788
locus	21684788
on	21684788
17p11	21684788
.	21684788
2	21684788
.	21684788

The	21684788
deletions	21684788
were	21684788
defined	21684788
using	21684788
long	21684788
distance	21684788
inverse	21684788
PCR	21684788
and	21684788
microarray	21684788
-	21684788
based	21684788
comparative	21684788
genomic	21684788
hybridization	21684788
.	21684788

A	21684788
24	21684788
-	21684788
year	21684788
-	21684788
old	21684788
SLS	21684788
female	21684788
was	21684788
homozygous	21684788
for	21684788
a	21684788
352	21684788
-	21684788
kb	21684788
deletion	21684788
involving	21684788
ALDH3A2	21684788
and	21684788
4	21684788
contiguous	21684788
genes	21684788
including	21684788
ALDH3A1	21684788
,	21684788
which	21684788
codes	21684788
for	21684788
the	21684788
major	21684788
soluble	21684788
protein	21684788
in	21684788
cornea	21684788
.	21684788

Although	21684788
lacking	21684788
corneal	21684788
disease	21684788
,	21684788
she	21684788
showed	21684788
severe	21684788
symptoms	21684788
of	21684788
SLS	21684788
with	21684788
uncommon	21684788
deterioration	21684788
in	21684788
oral	21684788
motor	21684788
function	21684788
and	21684788
loss	21684788
of	21684788
ambulation	21684788
.	21684788

The	21684788
other	21684788
19	21684788
-	21684788
month	21684788
-	21684788
old	21684788
female	21684788
patient	21684788
was	21684788
a	21684788
compound	21684788
heterozygote	21684788
for	21684788
a	21684788
1	21684788
.	21684788
44	21684788
-	21684788
Mb	21684788
contiguous	21684788
gene	21684788
deletion	21684788
and	21684788
a	21684788
missense	21684788
mutation	21684788
(	21684788
c	21684788
.	21684788
407C	21684788
>	21684788
T	21684788
,	21684788
P136L	21684788
)	21684788
in	21684788
ALDH3A2	21684788
.	21684788

These	21684788
studies	21684788
suggest	21684788
that	21684788
large	21684788
gene	21684788
deletions	21684788
may	21684788
account	21684788
for	21684788
up	21684788
to	21684788
5%	21684788
of	21684788
the	21684788
mutant	21684788
alleles	21684788
in	21684788
SLS	21684788
.	21684788

Geneticists	21684788
should	21684788
consider	21684788
the	21684788
possibility	21684788
of	21684788
compound	21684788
heterozygosity	21684788
for	21684788
large	21684788
deletions	21684788
in	21684788
patients	21684788
with	21684788
SLS	21684788
and	21684788
other	21684788
inborn	21684788
errors	21684788
of	21684788
metabolism	21684788
,	21684788
which	21684788
has	21684788
implications	21684788
for	21684788
carrier	21684788
testing	21684788
and	21684788
prenatal	21684788
diagnosis	21684788
.	21684788
Pharmacogenetic	25589620
Analysis	25589620
of	25589620
INT	25589620
0144	25589620
Trial	25589620
:	25589620
Association	25589620
of	25589620
Polymorphisms	25589620
with	25589620
Survival	25589620
and	25589620
Toxicity	25589620
in	25589620
Rectal	25589620
Cancer	25589620
Patients	25589620
Treated	25589620
with	25589620
5	25589620
-	25589620
FU	25589620
and	25589620
Radiation	25589620
.	25589620

PURPOSE	25589620
:	25589620
We	25589620
tested	25589620
whether	25589620
18	25589620
polymorphisms	25589620
in	25589620
16	25589620
genes	25589620
(	25589620
GSTP1	25589620
,	25589620
COX2	25589620
,	25589620
IL10	25589620
,	25589620
EGFR	25589620
,	25589620
EGF	25589620
,	25589620
FGFR4	25589620
,	25589620
CCDN1	25589620
,	25589620
VEGFR2	25589620
,	25589620
VEGF	25589620
,	25589620
CXCR2	25589620
,	25589620
IL8	25589620
,	25589620
MMP3	25589620
,	25589620
ICAM1	25589620
,	25589620
ERCC1	25589620
,	25589620
RAD51	25589620
,	25589620
and	25589620
XRCC3	25589620
)	25589620
would	25589620
predict	25589620
disease	25589620
-	25589620
free	25589620
survival	25589620
(	25589620
DFS	25589620
)	25589620
,	25589620
overall	25589620
survival	25589620
(	25589620
OS	25589620
)	25589620
,	25589620
and	25589620
toxicity	25589620
in	25589620
the	25589620
INT0144	25589620
trial	25589620
,	25589620
which	25589620
was	25589620
designed	25589620
to	25589620
investigate	25589620
different	25589620
postoperative	25589620
regimens	25589620
of	25589620
5	25589620
-	25589620
fluorouracil	25589620
(	25589620
5	25589620
-	25589620
FU	25589620
)	25589620
-	25589620
based	25589620
chemoradiation	25589620
(	25589620
CRT	25589620
)	25589620
in	25589620
locally	25589620
advanced	25589620
rectal	25589620
cancers	25589620
:	25589620
Arm	25589620
1	25589620
consisted	25589620
of	25589620
bolus	25589620
5	25589620
-	25589620
FU	25589620
followed	25589620
by	25589620
5	25589620
-	25589620
FU	25589620
protracted	25589620
venous	25589620
infusion	25589620
(	25589620
PVI	25589620
)	25589620
with	25589620
radiotherapy	25589620
;	25589620
arm	25589620
2	25589620
was	25589620
induction	25589620
and	25589620
concomitant	25589620
PVI	25589620
5	25589620
-	25589620
FU	25589620
with	25589620
radiotherapy	25589620
and	25589620
arm	25589620
3	25589620
was	25589620
induction	25589620
and	25589620
concomitant	25589620
bolus	25589620
5	25589620
-	25589620
FU	25589620
with	25589620
radiotherapy	25589620
.	25589620

EXPERIMENTAL	25589620
DESIGN	25589620
:	25589620
DNA	25589620
from	25589620
746	25589620
stage	25589620
II	25589620
/	25589620
III	25589620
rectal	25589620
patients	25589620
enrolled	25589620
in	25589620
the	25589620
Southwest	25589620
Oncology	25589620
Group	25589620
(	25589620
SWOG	25589620
)	25589620
S9304	25589620
phase	25589620
III	25589620
trial	25589620
was	25589620
analyzed	25589620
.	25589620

Genomic	25589620
DNA	25589620
was	25589620
extracted	25589620
from	25589620
formalin	25589620
-	25589620
fixed	25589620
,	25589620
paraffin	25589620
-	25589620
embedded	25589620
(	25589620
FFPE	25589620
)	25589620
tumor	25589620
tissue	25589620
.	25589620

The	25589620
polymorphisms	25589620
were	25589620
analyzed	25589620
using	25589620
direct	25589620
DNA	25589620
-	25589620
sequencing	25589620
or	25589620
polymerase	25589620
chain	25589620
reaction	25589620
-	25589620
restriction	25589620
fragment	25589620
length	25589620
polymorphism	25589620
(	25589620
PCR	25589620
-	25589620
RFLP	25589620
)	25589620
.	25589620

RESULTS	25589620
:	25589620
GSTP1	25589620
-	25589620
Ile105Val	25589620
(	25589620
rs1695	25589620
)	25589620
was	25589620
significantly	25589620
associated	25589620
with	25589620
DFS	25589620
and	25589620
OS	25589620
and	25589620
its	25589620
effect	25589620
did	25589620
not	25589620
vary	25589620
by	25589620
treatment	25589620
arm	25589620
.	25589620

The	25589620
five	25589620
-	25589620
year	25589620
DFS	25589620
and	25589620
OS	25589620
were	25589620
53%	25589620
and	25589620
58%	25589620
,	25589620
respectively	25589620
,	25589620
for	25589620
G	25589620
/	25589620
G	25589620
,	25589620
66%	25589620
and	25589620
72%	25589620
for	25589620
G	25589620
/	25589620
A	25589620
,	25589620
and	25589620
57%	25589620
and	25589620
66%	25589620
for	25589620
A	25589620
/	25589620
A	25589620
patients	25589620
.	25589620

In	25589620
arm	25589620
2	25589620
,	25589620
IL8	25589620
-	25589620
251A	25589620
/	25589620
A	25589620
genotype	25589620
(	25589620
rs4073	25589620
)	25589620
was	25589620
associated	25589620
with	25589620
a	25589620
lower	25589620
risk	25589620
of	25589620
toxicities	25589620
(	25589620
P	25589620
=	25589620
0	25589620
.	25589620
04	25589620
)	25589620
.	25589620

The	25589620
VEGFR2	25589620
H472Q	25589620
Q	25589620
/	25589620
Q	25589620
genotype	25589620
(	25589620
rs1870377	25589620
)	25589620
was	25589620
associated	25589620
with	25589620
a	25589620
higher	25589620
risk	25589620
of	25589620
grade	25589620
3	25589620
-	25589620
5	25589620
proximal	25589620
upper	25589620
gastrointestinal	25589620
tract	25589620
(	25589620
PUGIT	25589620
)	25589620
mucositis	25589620
(	25589620
P	25589620
=	25589620
0	25589620
.	25589620
04	25589620
)	25589620
in	25589620
arm	25589620
2	25589620
.	25589620

However	25589620
,	25589620
in	25589620
arm	25589620
1	25589620
,	25589620
this	25589620
genotype	25589620
was	25589620
associated	25589620
with	25589620
a	25589620
lower	25589620
risk	25589620
of	25589620
PUGIT	25589620
mucositis	25589620
(	25589620
P	25589620
=	25589620
0	25589620
.	25589620
004	25589620
)	25589620
.	25589620

CONCLUSION	25589620
:	25589620
rs1695	25589620
may	25589620
be	25589620
prognostic	25589620
in	25589620
patients	25589620
with	25589620
rectal	25589620
cancer	25589620
treated	25589620
with	25589620
adjuvant	25589620
CRT	25589620
.	25589620

rs4073	25589620
and	25589620
rs1870377	25589620
may	25589620
exhibit	25589620
different	25589620
associations	25589620
with	25589620
toxicity	25589620
,	25589620
according	25589620
to	25589620
the	25589620
5	25589620
-	25589620
FU	25589620
schedule	25589620
.	25589620
Genetic	16288197
homogeneity	16288197
for	16288197
inherited	16288197
congenital	16288197
microcoria	16288197
loci	16288197
in	16288197
an	16288197
Asian	16288197
Indian	16288197
pedigree	16288197
.	16288197

PURPOSE	16288197
:	16288197
Congenital	16288197
microcoria	16288197
is	16288197
a	16288197
rare	16288197
autosomal	16288197
dominant	16288197
developmental	16288197
disorder	16288197
of	16288197
the	16288197
iris	16288197
associated	16288197
with	16288197
myopia	16288197
and	16288197
juvenile	16288197
open	16288197
angle	16288197
glaucoma	16288197
.	16288197

Linkage	16288197
to	16288197
the	16288197
chromosomal	16288197
locus	16288197
13q31	16288197
-	16288197
q32	16288197
has	16288197
previously	16288197
been	16288197
reported	16288197
in	16288197
a	16288197
large	16288197
French	16288197
family	16288197
.	16288197

In	16288197
the	16288197
current	16288197
study	16288197
,	16288197
a	16288197
three	16288197
generation	16288197
Asian	16288197
Indian	16288197
family	16288197
with	16288197
15	16288197
congenital	16288197
microcoria	16288197
(	16288197
pupils	16288197
with	16288197
a	16288197
diameter	16288197
<	16288197
2	16288197
mm	16288197
)	16288197
affected	16288197
members	16288197
was	16288197
studied	16288197
for	16288197
linkage	16288197
to	16288197
candidate	16288197
microsatellite	16288197
markers	16288197
at	16288197
the	16288197
13q31	16288197
-	16288197
q32	16288197
locus	16288197
.	16288197

METHODS	16288197
:	16288197
Twenty	16288197
-	16288197
four	16288197
members	16288197
of	16288197
the	16288197
family	16288197
were	16288197
clinically	16288197
examined	16288197
and	16288197
genomic	16288197
DNA	16288197
was	16288197
extracted	16288197
.	16288197

Microsatellite	16288197
markers	16288197
at	16288197
13q31	16288197
-	16288197
q32	16288197
were	16288197
PCR	16288197
amplified	16288197
and	16288197
run	16288197
on	16288197
an	16288197
ABI	16288197
Prism	16288197
310	16288197
genetic	16288197
analyzer	16288197
and	16288197
genotyped	16288197
with	16288197
the	16288197
GeneScan	16288197
analysis	16288197
.	16288197

Two	16288197
point	16288197
and	16288197
multipoint	16288197
linkage	16288197
analyses	16288197
were	16288197
performed	16288197
using	16288197
the	16288197
MLINK	16288197
and	16288197
SUPERLINK	16288197
programs	16288197
.	16288197

RESULTS	16288197
:	16288197
Peak	16288197
two	16288197
point	16288197
LOD	16288197
scores	16288197
of	16288197
3	16288197
.	16288197
5	16288197
,	16288197
4	16288197
.	16288197
7	16288197
,	16288197
and	16288197
5	16288197
.	16288197
3	16288197
were	16288197
found	16288197
co	16288197
-	16288197
incident	16288197
with	16288197
consecutive	16288197
markers	16288197
D13S154	16288197
,	16288197
DCT	16288197
,	16288197
and	16288197
D13S1280	16288197
.	16288197

Multipoint	16288197
analysis	16288197
revealed	16288197
a	16288197
4	16288197
cM	16288197
region	16288197
encompassing	16288197
D13S1300	16288197
to	16288197
D13S1280	16288197
where	16288197
the	16288197
LOD	16288197
remains	16288197
just	16288197
over	16288197
6	16288197
.	16288197
0	16288197
Thus	16288197
we	16288197
confirm	16288197
localization	16288197
of	16288197
the	16288197
congenital	16288197
microcoria	16288197
locus	16288197
to	16288197
chromosomal	16288197
locus	16288197
13q31	16288197
-	16288197
q32	16288197
.	16288197

In	16288197
addition	16288197
,	16288197
eight	16288197
individuals	16288197
who	16288197
had	16288197
both	16288197
microcoria	16288197
and	16288197
glaucoma	16288197
were	16288197
screened	16288197
for	16288197
glaucoma	16288197
genes	16288197
:	16288197
myocilin	16288197
(	16288197
MYOC	16288197
)	16288197
,	16288197
optineurin	16288197
(	16288197
OPTN	16288197
)	16288197
and	16288197
CYP1B1	16288197
.	16288197

Using	16288197
direct	16288197
sequencing	16288197
a	16288197
point	16288197
mutation	16288197
(	16288197
144	16288197
G	16288197
>	16288197
A	16288197
)	16288197
resulting	16288197
in	16288197
a	16288197
Q48H	16288197
substitution	16288197
in	16288197
exon	16288197
1	16288197
of	16288197
the	16288197
MYOC	16288197
gene	16288197
was	16288197
observed	16288197
in	16288197
five	16288197
of	16288197
the	16288197
eight	16288197
glaucoma	16288197
patients	16288197
,	16288197
but	16288197
not	16288197
in	16288197
unaffected	16288197
family	16288197
members	16288197
and	16288197
100	16288197
unrelated	16288197
controls	16288197
.	16288197

CONCLUSIONS	16288197
:	16288197
We	16288197
have	16288197
confirmed	16288197
the	16288197
localization	16288197
of	16288197
the	16288197
congenital	16288197
microcoria	16288197
locus	16288197
(	16288197
MCOR	16288197
)	16288197
to	16288197
13q31	16288197
-	16288197
q32	16288197
in	16288197
a	16288197
large	16288197
Asian	16288197
Indian	16288197
family	16288197
and	16288197
conclude	16288197
that	16288197
current	16288197
information	16288197
suggests	16288197
this	16288197
is	16288197
a	16288197
single	16288197
locus	16288197
disorder	16288197
and	16288197
genetically	16288197
homogeneous	16288197
.	16288197

When	16288197
combined	16288197
with	16288197
the	16288197
initial	16288197
linkage	16288197
paper	16288197
our	16288197
haplotype	16288197
and	16288197
linkage	16288197
data	16288197
map	16288197
the	16288197
MCOR	16288197
locus	16288197
to	16288197
a	16288197
6	16288197
-	16288197
7	16288197
cM	16288197
region	16288197
between	16288197
D13S265	16288197
and	16288197
D13S1280	16288197
.	16288197

The	16288197
DCT	16288197
locus	16288197
,	16288197
a	16288197
member	16288197
of	16288197
the	16288197
tyrosinase	16288197
family	16288197
involved	16288197
in	16288197
pigmentation	16288197
,	16288197
maps	16288197
within	16288197
this	16288197
region	16288197
.	16288197

Data	16288197
presented	16288197
here	16288197
supports	16288197
the	16288197
hypothesis	16288197
that	16288197
congenital	16288197
microcoria	16288197
is	16288197
a	16288197
potential	16288197
risk	16288197
factor	16288197
for	16288197
glaucoma	16288197
,	16288197
although	16288197
this	16288197
observation	16288197
is	16288197
complicated	16288197
by	16288197
the	16288197
partial	16288197
segregation	16288197
of	16288197
MYOC	16288197
Q48H	16288197
(	16288197
1q24	16288197
.	16288197
3	16288197
-	16288197
q25	16288197
.	16288197
2	16288197
)	16288197
,	16288197
a	16288197
mutation	16288197
known	16288197
to	16288197
be	16288197
associated	16288197
with	16288197
glaucoma	16288197
in	16288197
India	16288197
.	16288197

Fine	16288197
mapping	16288197
and	16288197
candidate	16288197
gene	16288197
analysis	16288197
continues	16288197
with	16288197
the	16288197
hope	16288197
that	16288197
characterizing	16288197
the	16288197
micocoria	16288197
gene	16288197
will	16288197
lead	16288197
to	16288197
a	16288197
better	16288197
understanding	16288197
of	16288197
microcoria	16288197
and	16288197
glaucoma	16288197
causation	16288197
.	16288197

The	16288197
relationship	16288197
between	16288197
microcoria	16288197
,	16288197
glaucoma	16288197
,	16288197
and	16288197
the	16288197
MYOC	16288197
Q48H	16288197
mutation	16288197
in	16288197
this	16288197
family	16288197
is	16288197
discussed	16288197
.	16288197
Chemokine	20034406
CCL2	20034406
and	20034406
its	20034406
receptor	20034406
CCR2	20034406
are	20034406
increased	20034406
in	20034406
the	20034406
hippocampus	20034406
following	20034406
pilocarpine	20034406
-	20034406
induced	20034406
status	20034406
epilepticus	20034406
.	20034406

BACKGROUND	20034406
:	20034406
Neuroinflammation	20034406
occurs	20034406
after	20034406
seizures	20034406
and	20034406
is	20034406
implicated	20034406
in	20034406
epileptogenesis	20034406
.	20034406

CCR2	20034406
is	20034406
a	20034406
chemokine	20034406
receptor	20034406
for	20034406
CCL2	20034406
and	20034406
their	20034406
interaction	20034406
mediates	20034406
monocyte	20034406
infiltration	20034406
in	20034406
the	20034406
neuroinflammatory	20034406
cascade	20034406
triggered	20034406
in	20034406
different	20034406
brain	20034406
pathologies	20034406
.	20034406

In	20034406
this	20034406
work	20034406
CCR2	20034406
and	20034406
CCL2	20034406
expression	20034406
were	20034406
examined	20034406
following	20034406
status	20034406
epilepticus	20034406
(	20034406
SE	20034406
)	20034406
induced	20034406
by	20034406
pilocarpine	20034406
injection	20034406
.	20034406

METHODS	20034406
:	20034406
SE	20034406
was	20034406
induced	20034406
by	20034406
pilocarpine	20034406
injection	20034406
.	20034406

Control	20034406
rats	20034406
were	20034406
injected	20034406
with	20034406
saline	20034406
instead	20034406
of	20034406
pilocarpine	20034406
.	20034406

Five	20034406
days	20034406
after	20034406
SE	20034406
,	20034406
CCR2	20034406
staining	20034406
in	20034406
neurons	20034406
and	20034406
glial	20034406
cells	20034406
was	20034406
examined	20034406
using	20034406
imunohistochemical	20034406
analyses	20034406
.	20034406

The	20034406
number	20034406
of	20034406
CCR2	20034406
positive	20034406
cells	20034406
was	20034406
determined	20034406
using	20034406
stereology	20034406
probes	20034406
in	20034406
the	20034406
hippocampus	20034406
.	20034406

CCL2	20034406
expression	20034406
in	20034406
the	20034406
hippocampus	20034406
was	20034406
examined	20034406
by	20034406
molecular	20034406
assay	20034406
.	20034406

RESULTS	20034406
:	20034406
Increased	20034406
CCR2	20034406
was	20034406
observed	20034406
in	20034406
the	20034406
hippocampus	20034406
after	20034406
SE	20034406
.	20034406

Seizures	20034406
also	20034406
resulted	20034406
in	20034406
alterations	20034406
to	20034406
the	20034406
cell	20034406
types	20034406
expressing	20034406
CCR2	20034406
.	20034406

Increased	20034406
numbers	20034406
of	20034406
neurons	20034406
that	20034406
expressed	20034406
CCR2	20034406
was	20034406
observed	20034406
following	20034406
SE	20034406
.	20034406

Microglial	20034406
cells	20034406
were	20034406
more	20034406
closely	20034406
apposed	20034406
to	20034406
the	20034406
CCR2	20034406
-	20034406
labeled	20034406
cells	20034406
in	20034406
SE	20034406
rats	20034406
.	20034406

In	20034406
addition	20034406
,	20034406
rats	20034406
that	20034406
experienced	20034406
SE	20034406
exhibited	20034406
CCR2	20034406
-	20034406
labeling	20034406
in	20034406
populations	20034406
of	20034406
hypertrophied	20034406
astrocytes	20034406
,	20034406
especially	20034406
in	20034406
CA1	20034406
and	20034406
dentate	20034406
gyrus	20034406
.	20034406

These	20034406
CCR2	20034406
+	20034406
astroctytes	20034406
were	20034406
not	20034406
observed	20034406
in	20034406
control	20034406
rats	20034406
.	20034406

Examination	20034406
of	20034406
CCL2	20034406
expression	20034406
showed	20034406
that	20034406
it	20034406
was	20034406
elevated	20034406
in	20034406
the	20034406
hippocampus	20034406
following	20034406
SE	20034406
.	20034406

CONCLUSION	20034406
:	20034406
The	20034406
data	20034406
show	20034406
that	20034406
CCR2	20034406
and	20034406
CCL2	20034406
are	20034406
up	20034406
-	20034406
regulated	20034406
in	20034406
the	20034406
hippocampus	20034406
after	20034406
pilocarpine	20034406
-	20034406
induced	20034406
SE	20034406
.	20034406

Seizures	20034406
also	20034406
result	20034406
in	20034406
changes	20034406
to	20034406
CCR2	20034406
receptor	20034406
expression	20034406
in	20034406
neurons	20034406
and	20034406
astrocytes	20034406
.	20034406

These	20034406
changes	20034406
might	20034406
be	20034406
involved	20034406
in	20034406
detrimental	20034406
neuroplasticity	20034406
and	20034406
neuroinflammatory	20034406
changes	20034406
that	20034406
occur	20034406
following	20034406
seizures	20034406
.	20034406
Ubiquitin	28472177
carboxyl	28472177
-	28472177
terminal	28472177
esterase	28472177
L1	28472177
(	28472177
UCHL1	28472177
)	28472177
is	28472177
associated	28472177
with	28472177
stem	28472177
-	28472177
like	28472177
cancer	28472177
cell	28472177
functions	28472177
in	28472177
pediatric	28472177
high	28472177
-	28472177
grade	28472177
glioma	28472177
.	28472177

Pediatric	28472177
high	28472177
-	28472177
grade	28472177
gliomas	28472177
represent	28472177
8	28472177
-	28472177
12%	28472177
of	28472177
all	28472177
primary	28472177
tumors	28472177
of	28472177
the	28472177
nervous	28472177
system	28472177
in	28472177
children	28472177
.	28472177

Five	28472177
-	28472177
year	28472177
survival	28472177
for	28472177
these	28472177
pediatric	28472177
aggressive	28472177
tumors	28472177
is	28472177
poor	28472177
(	28472177
15	28472177
-	28472177
35%	28472177
)	28472177
indicating	28472177
the	28472177
need	28472177
to	28472177
develop	28472177
better	28472177
treatments	28472177
for	28472177
pediatric	28472177
high	28472177
-	28472177
grade	28472177
gliomas	28472177
.	28472177

In	28472177
this	28472177
work	28472177
we	28472177
used	28472177
SF188	28472177
and	28472177
SJ	28472177
-	28472177
GBM2	28472177
cell	28472177
lines	28472177
to	28472177
study	28472177
the	28472177
function	28472177
of	28472177
the	28472177
ubiquitin	28472177
carboxyl	28472177
-	28472177
terminal	28472177
esterase	28472177
L1	28472177
(	28472177
UCHL1	28472177
)	28472177
,	28472177
a	28472177
deubiquitinase	28472177
de	28472177
-	28472177
regulated	28472177
in	28472177
several	28472177
cancers	28472177
,	28472177
in	28472177
pediatric	28472177
high	28472177
-	28472177
grade	28472177
gliomas	28472177
.	28472177

UCHL1	28472177
depletion	28472177
in	28472177
SF188	28472177
and	28472177
SJ	28472177
-	28472177
GBM2	28472177
glioma	28472177
cells	28472177
was	28472177
associated	28472177
with	28472177
decreased	28472177
cell	28472177
proliferation	28472177
and	28472177
invasion	28472177
,	28472177
along	28472177
with	28472177
a	28472177
reduced	28472177
ability	28472177
to	28472177
grow	28472177
in	28472177
soft	28472177
agar	28472177
and	28472177
to	28472177
form	28472177
spheres	28472177
(	28472177
i	28472177
.	28472177
e	28472177
.	28472177

self	28472177
-	28472177
renewal	28472177
measure	28472177
)	28472177
.	28472177

A	28472177
70%	28472177
reduction	28472177
in	28472177
Wnt	28472177
signaling	28472177
was	28472177
also	28472177
observed	28472177
in	28472177
the	28472177
SF188	28472177
and	28472177
SJ	28472177
-	28472177
GBM2	28472177
UCHL1	28472177
knockdowns	28472177
(	28472177
KDs	28472177
)	28472177
using	28472177
a	28472177
TCF	28472177
-	28472177
dependent	28472177
TOPflash	28472177
reporter	28472177
assay	28472177
.	28472177

Transcriptome	28472177
comparisons	28472177
of	28472177
UCHL1	28472177
KDs	28472177
versus	28472177
vector	28472177
control	28472177
identified	28472177
a	28472177
list	28472177
of	28472177
306	28472177
differentially	28472177
expressed	28472177
genes	28472177
(	28472177
at	28472177
least	28472177
2	28472177
-	28472177
fold	28472177
change	28472177
;	28472177
p	28472177
<	28472177
0	28472177
.	28472177
05	28472177
)	28472177
which	28472177
included	28472177
genes	28472177
known	28472177
to	28472177
be	28472177
involved	28472177
in	28472177
cancer	28472177
like	28472177
ACTA2	28472177
,	28472177
POSTN	28472177
,	28472177
LIF	28472177
,	28472177
FBXL7	28472177
,	28472177
FBXW11	28472177
,	28472177
GDF15	28472177
,	28472177
HEY2	28472177
,	28472177
but	28472177
also	28472177
potential	28472177
novel	28472177
genes	28472177
such	28472177
us	28472177
IGLL5	28472177
,	28472177
ABCA4	28472177
,	28472177
AQP3	28472177
,	28472177
AQP4	28472177
,	28472177
CALB1	28472177
,	28472177
and	28472177
ALK	28472177
.	28472177

Bioinformatics	28472177
gene	28472177
ontology	28472177
(	28472177
GO	28472177
)	28472177
analysis	28472177
of	28472177
these	28472177
306	28472177
genes	28472177
revealed	28472177
significant	28472177
enrichment	28472177
in	28472177
""""	28472177
signal	28472177
peptides	28472177
""""	28472177
,	28472177
""""	28472177
extracellular	28472177
matrix	28472177
""""	28472177
and	28472177
""""	28472177
secreted	28472177
proteins	28472177
""""	28472177
GO	28472177
Terms	28472177
.	28472177

""""	28472177
Angiogenesis	28472177
and	28472177
blood	28472177
vessel	28472177
development	28472177
""""	28472177
,	28472177
""""	28472177
neuron	28472177
differentiation	28472177
/	28472177
development	28472177
""""	28472177
,	28472177
cell	28472177
adhesion	28472177
""""	28472177
,	28472177
and	28472177
""""	28472177
cell	28472177
migration	28472177
""""	28472177
also	28472177
showed	28472177
significant	28472177
enrichment	28472177
in	28472177
our	28472177
GO	28472177
analysis	28472177
.	28472177

Top	28472177
canonical	28472177
pathways	28472177
identified	28472177
by	28472177
Ingenuity	28472177
Pathway	28472177
Analysis	28472177
(	28472177
IPA	28472177
)	28472177
included	28472177
""""	28472177
Clathrin	28472177
-	28472177
mediated	28472177
Endocytosis	28472177
Signaling	28472177
""""	28472177
(	28472177
p	28472177
=	28472177
5	28472177
.	28472177
14x10	28472177
-	28472177
4	28472177
)	28472177
,	28472177
""""	28472177
Virus	28472177
Entry	28472177
via	28472177
Endocytic	28472177
Pathways	28472177
""""	28472177
(	28472177
p	28472177
=	28472177
6	28472177
.	28472177
15x	28472177
10	28472177
-	28472177
4	28472177
)	28472177
,	28472177
and	28472177
""""	28472177
High	28472177
Mobility	28472177
Group	28472177
-	28472177
Box	28472177
1	28472177
(	28472177
HMGB1	28472177
)	28472177
Signaling	28472177
""""	28472177
(	28472177
p	28472177
=	28472177
6	28472177
.	28472177
15x10	28472177
-	28472177
4	28472177
)	28472177
.	28472177

While	28472177
FGF2	28472177
,	28472177
IL1B	28472177
,	28472177
TNF	28472177
and	28472177
PDGFB	28472177
were	28472177
predicted	28472177
as	28472177
top	28472177
upstream	28472177
regulators	28472177
(	28472177
p	28472177
<	28472177
2x10	28472177
-	28472177
16	28472177
)	28472177
of	28472177
the	28472177
UCHL1	28472177
KD	28472177
-	28472177
associated	28472177
transcriptome	28472177
.	28472177

Aberrant	28472177
expression	28472177
of	28472177
UCHL1	28472177
in	28472177
pediatric	28472177
high	28472177
-	28472177
grade	28472177
gliomas	28472177
may	28472177
promote	28472177
cell	28472177
invasion	28472177
,	28472177
transformation	28472177
,	28472177
and	28472177
self	28472177
-	28472177
renewal	28472177
properties	28472177
,	28472177
at	28472177
least	28472177
in	28472177
part	28472177
,	28472177
by	28472177
modulating	28472177
Wnt	28472177
/	28472177
Beta	28472177
catenin	28472177
activity	28472177
.	28472177

UCHL1	28472177
might	28472177
act	28472177
as	28472177
an	28472177
oncogene	28472177
in	28472177
glioma	28472177
within	28472177
the	28472177
gene	28472177
network	28472177
that	28472177
imparts	28472177
stem	28472177
-	28472177
like	28472177
characteristics	28472177
to	28472177
these	28472177
cancer	28472177
cells	28472177
.	28472177
Langerin	10661407
,	10661407
a	10661407
novel	10661407
C	10661407
-	10661407
type	10661407
lectin	10661407
specific	10661407
to	10661407
Langerhans	10661407
cells	10661407
,	10661407
is	10661407
an	10661407
endocytic	10661407
receptor	10661407
that	10661407
induces	10661407
the	10661407
formation	10661407
of	10661407
Birbeck	10661407
granules	10661407
.	10661407

We	10661407
have	10661407
identified	10661407
a	10661407
type	10661407
II	10661407
Ca2	10661407
+	10661407
-	10661407
dependent	10661407
lectin	10661407
displaying	10661407
mannose	10661407
-	10661407
binding	10661407
specificity	10661407
,	10661407
exclusively	10661407
expressed	10661407
by	10661407
Langerhans	10661407
cells	10661407
(	10661407
LC	10661407
)	10661407
,	10661407
and	10661407
named	10661407
Langerin	10661407
.	10661407

LC	10661407
are	10661407
uniquely	10661407
characterized	10661407
by	10661407
Birbeck	10661407
granules	10661407
(	10661407
BG	10661407
)	10661407
,	10661407
which	10661407
are	10661407
organelles	10661407
consisting	10661407
of	10661407
superimposed	10661407
and	10661407
zippered	10661407
membranes	10661407
.	10661407

Here	10661407
,	10661407
we	10661407
have	10661407
shown	10661407
that	10661407
Langerin	10661407
is	10661407
constitutively	10661407
associated	10661407
with	10661407
BG	10661407
and	10661407
that	10661407
antibody	10661407
to	10661407
Langerin	10661407
is	10661407
internalized	10661407
into	10661407
these	10661407
structures	10661407
.	10661407

Remarkably	10661407
,	10661407
transfection	10661407
of	10661407
Langerin	10661407
cDNA	10661407
into	10661407
fibroblasts	10661407
created	10661407
a	10661407
compact	10661407
network	10661407
of	10661407
membrane	10661407
structures	10661407
with	10661407
typical	10661407
features	10661407
of	10661407
BG	10661407
.	10661407

Langerin	10661407
is	10661407
thus	10661407
a	10661407
potent	10661407
inducer	10661407
of	10661407
membrane	10661407
superimposition	10661407
and	10661407
zippering	10661407
leading	10661407
to	10661407
BG	10661407
formation	10661407
.	10661407

Our	10661407
data	10661407
suggest	10661407
that	10661407
induction	10661407
of	10661407
BG	10661407
is	10661407
a	10661407
consequence	10661407
of	10661407
the	10661407
antigen	10661407
-	10661407
capture	10661407
function	10661407
of	10661407
Langerin	10661407
,	10661407
allowing	10661407
routing	10661407
into	10661407
these	10661407
organelles	10661407
and	10661407
providing	10661407
access	10661407
to	10661407
a	10661407
nonclassical	10661407
antigen	10661407
-	10661407
processing	10661407
pathway	10661407
.	10661407
Polymorphism	16051693
of	16051693
the	16051693
PEMT	16051693
gene	16051693
and	16051693
susceptibility	16051693
to	16051693
nonalcoholic	16051693
fatty	16051693
liver	16051693
disease	16051693
(	16051693
NAFLD	16051693
)	16051693
.	16051693

Phosphatidylethanolamine	16051693
N	16051693
-	16051693
methyltransferase	16051693
(	16051693
PEMT	16051693
)	16051693
catalyzes	16051693
phosphatidylcholine	16051693
synthesis	16051693
.	16051693

PEMT	16051693
knockout	16051693
mice	16051693
have	16051693
fatty	16051693
livers	16051693
,	16051693
and	16051693
it	16051693
is	16051693
possible	16051693
that	16051693
,	16051693
in	16051693
humans	16051693
,	16051693
nonalcoholic	16051693
fatty	16051693
liver	16051693
disease	16051693
(	16051693
NAFLD	16051693
)	16051693
might	16051693
be	16051693
associated	16051693
with	16051693
PEMT	16051693
gene	16051693
polymorphisms	16051693
.	16051693

DNA	16051693
samples	16051693
from	16051693
59	16051693
humans	16051693
without	16051693
fatty	16051693
liver	16051693
and	16051693
from	16051693
28	16051693
humans	16051693
with	16051693
NAFLD	16051693
were	16051693
genotyped	16051693
for	16051693
a	16051693
single	16051693
nucleotide	16051693
polymorphism	16051693
in	16051693
exon	16051693
8	16051693
of	16051693
PEMT	16051693
,	16051693
which	16051693
leads	16051693
to	16051693
a	16051693
V175M	16051693
substitution	16051693
.	16051693

V175M	16051693
is	16051693
a	16051693
loss	16051693
of	16051693
function	16051693
mutation	16051693
,	16051693
as	16051693
determined	16051693
by	16051693
transiently	16051693
transfecting	16051693
McArdle	16051693
-	16051693
RH7777	16051693
cells	16051693
with	16051693
constructs	16051693
of	16051693
wild	16051693
-	16051693
type	16051693
PEMT	16051693
open	16051693
reading	16051693
frame	16051693
or	16051693
the	16051693
V175M	16051693
mutant	16051693
.	16051693

Met	16051693
/	16051693
Met	16051693
at	16051693
residue	16051693
175	16051693
(	16051693
loss	16051693
of	16051693
function	16051693
SNP	16051693
)	16051693
occurred	16051693
in	16051693
67	16051693
.	16051693
9%	16051693
of	16051693
the	16051693
NAFLD	16051693
subjects	16051693
and	16051693
in	16051693
only	16051693
40	16051693
.	16051693
7%	16051693
of	16051693
control	16051693
subjects	16051693
(	16051693
P	16051693
<	16051693
0	16051693
.	16051693
03	16051693
)	16051693
.	16051693

For	16051693
the	16051693
first	16051693
time	16051693
we	16051693
report	16051693
that	16051693
a	16051693
polymorphism	16051693
of	16051693
the	16051693
human	16051693
PEMT	16051693
gene	16051693
(	16051693
V175M	16051693
)	16051693
is	16051693
associated	16051693
with	16051693
diminished	16051693
activity	16051693
and	16051693
may	16051693
confer	16051693
susceptibility	16051693
to	16051693
NAFLD	16051693
.	16051693
Mutation	21405999
screening	21405999
of	21405999
the	21405999
GUCA1B	21405999
gene	21405999
in	21405999
patients	21405999
with	21405999
autosomal	21405999
dominant	21405999
cone	21405999
and	21405999
cone	21405999
rod	21405999
dystrophy	21405999
.	21405999

Background	21405999
:	21405999
Heterozygous	21405999
mutations	21405999
in	21405999
GUCA1A	21405999
(	21405999
MIM	21405999
#	21405999
600364	21405999
)	21405999
have	21405999
been	21405999
identified	21405999
to	21405999
cause	21405999
autosomal	21405999
dominantly	21405999
inherited	21405999
cone	21405999
dystrophy	21405999
,	21405999
cone	21405999
rod	21405999
dystrophy	21405999
and	21405999
macular	21405999
dystrophy	21405999
.	21405999

However	21405999
,	21405999
the	21405999
role	21405999
of	21405999
GUCA1B	21405999
gene	21405999
mutations	21405999
in	21405999
inherited	21405999
retinal	21405999
disease	21405999
has	21405999
been	21405999
controversial	21405999
.	21405999

We	21405999
therefore	21405999
performed	21405999
a	21405999
mutation	21405999
analysis	21405999
of	21405999
the	21405999
GUCA1B	21405999
gene	21405999
in	21405999
a	21405999
clinically	21405999
well	21405999
characterized	21405999
group	21405999
of	21405999
patients	21405999
of	21405999
European	21405999
and	21405999
North	21405999
-	21405999
American	21405999
geographical	21405999
origin	21405999
with	21405999
autosomal	21405999
dominantly	21405999
inherited	21405999
cone	21405999
dystrophy	21405999
and	21405999
cone	21405999
rod	21405999
dystrophy	21405999
.	21405999

Material	21405999
and	21405999
Methods	21405999
:	21405999
Twenty	21405999
-	21405999
four	21405999
unrelated	21405999
patients	21405999
diagnosed	21405999
with	21405999
cone	21405999
dystrophy	21405999
or	21405999
cone	21405999
rod	21405999
dystrophy	21405999
according	21405999
to	21405999
standard	21405999
diagnostic	21405999
criteria	21405999
and	21405999
a	21405999
family	21405999
history	21405999
consistent	21405999
with	21405999
an	21405999
autosomal	21405999
dominant	21405999
mode	21405999
of	21405999
inheritance	21405999
were	21405999
included	21405999
in	21405999
the	21405999
study	21405999
.	21405999

Mutation	21405999
analysis	21405999
of	21405999
all	21405999
coding	21405999
exons	21405999
of	21405999
the	21405999
GUCA1B	21405999
gene	21405999
was	21405999
performed	21405999
by	21405999
polymerase	21405999
chain	21405999
reaction	21405999
amplification	21405999
of	21405999
genomic	21405999
DNA	21405999
and	21405999
subsequent	21405999
DNA	21405999
sequencing	21405999
.	21405999

Results	21405999
:	21405999
Three	21405999
different	21405999
sequence	21405999
variants	21405999
,	21405999
c	21405999
.	21405999
-	21405999
17T	21405999
>	21405999
C	21405999
,	21405999
c	21405999
.	21405999
171T	21405999
>	21405999
C	21405999
,	21405999
c	21405999
.	21405999
465G	21405999
>	21405999
T	21405999
were	21405999
identified	21405999
.	21405999

The	21405999
sequence	21405999
variant	21405999
c	21405999
.	21405999
465G	21405999
>	21405999
T	21405999
encodes	21405999
a	21405999
conservative	21405999
amino	21405999
acid	21405999
substitution	21405999
,	21405999
p	21405999
.	21405999
Glu155Asp	21405999
,	21405999
located	21405999
in	21405999
EF	21405999
-	21405999
hand	21405999
4	21405999
,	21405999
the	21405999
calcium	21405999
binding	21405999
site	21405999
of	21405999
GCAP2	21405999
protein	21405999
.	21405999

All	21405999
sequence	21405999
variants	21405999
were	21405999
previously	21405999
reported	21405999
in	21405999
healthy	21405999
subjects	21405999
.	21405999

Conclusion	21405999
:	21405999
The	21405999
absence	21405999
of	21405999
clearly	21405999
pathogenic	21405999
mutations	21405999
in	21405999
the	21405999
selected	21405999
patient	21405999
group	21405999
suggests	21405999
that	21405999
the	21405999
GUCA1B	21405999
gene	21405999
is	21405999
a	21405999
minor	21405999
cause	21405999
for	21405999
retinal	21405999
degenerations	21405999
in	21405999
Europeans	21405999
or	21405999
North	21405999
-	21405999
Americans	21405999
.	21405999
Negative	27292643
Selection	27292643
and	27292643
Chromosome	27292643
Instability	27292643
Induced	27292643
by	27292643
Mad2	27292643
Overexpression	27292643
Delay	27292643
Breast	27292643
Cancer	27292643
but	27292643
Facilitate	27292643
Oncogene	27292643
-	27292643
Independent	27292643
Outgrowth	27292643
.	27292643

Chromosome	27292643
instability	27292643
(	27292643
CIN	27292643
)	27292643
is	27292643
associated	27292643
with	27292643
poor	27292643
survival	27292643
and	27292643
therapeutic	27292643
outcome	27292643
in	27292643
a	27292643
number	27292643
of	27292643
malignancies	27292643
.	27292643

Despite	27292643
this	27292643
correlation	27292643
,	27292643
CIN	27292643
can	27292643
also	27292643
lead	27292643
to	27292643
growth	27292643
disadvantages	27292643
.	27292643

Here	27292643
,	27292643
we	27292643
show	27292643
that	27292643
simultaneous	27292643
overexpression	27292643
of	27292643
the	27292643
mitotic	27292643
checkpoint	27292643
protein	27292643
Mad2	27292643
with	27292643
Kras	27292643
(	27292643
G12D	27292643
)	27292643
or	27292643
Her2	27292643
in	27292643
mammary	27292643
glands	27292643
of	27292643
adult	27292643
mice	27292643
results	27292643
in	27292643
mitotic	27292643
checkpoint	27292643
overactivation	27292643
and	27292643
a	27292643
delay	27292643
in	27292643
tumor	27292643
onset	27292643
.	27292643

Time	27292643
-	27292643
lapse	27292643
imaging	27292643
of	27292643
organotypic	27292643
cultures	27292643
and	27292643
pathologic	27292643
analysis	27292643
prior	27292643
to	27292643
tumor	27292643
establishment	27292643
reveals	27292643
error	27292643
-	27292643
prone	27292643
mitosis	27292643
,	27292643
mitotic	27292643
arrest	27292643
,	27292643
and	27292643
cell	27292643
death	27292643
.	27292643

Nonetheless	27292643
,	27292643
Mad2	27292643
expression	27292643
persists	27292643
and	27292643
increases	27292643
karyotype	27292643
complexity	27292643
in	27292643
Kras	27292643
tumors	27292643
.	27292643

Faced	27292643
with	27292643
the	27292643
selective	27292643
pressure	27292643
of	27292643
oncogene	27292643
withdrawal	27292643
,	27292643
Mad2	27292643
-	27292643
positive	27292643
tumors	27292643
have	27292643
a	27292643
higher	27292643
frequency	27292643
of	27292643
developing	27292643
persistent	27292643
subclones	27292643
that	27292643
avoid	27292643
remission	27292643
and	27292643
continue	27292643
to	27292643
grow	27292643
.	27292643
Neuroprotective	25874935
effect	25874935
of	25874935
neuroserpin	25874935
in	25874935
oxygen	25874935
-	25874935
glucose	25874935
deprivation	25874935
-	25874935
and	25874935
reoxygenation	25874935
-	25874935
treated	25874935
rat	25874935
astrocytes	25874935
in	25874935
vitro	25874935
.	25874935

Neuroserpin	25874935
(	25874935
NSP	25874935
)	25874935
reportedly	25874935
exerts	25874935
neuroprotective	25874935
effects	25874935
in	25874935
cerebral	25874935
ischemic	25874935
animal	25874935
models	25874935
and	25874935
patients	25874935
;	25874935
however	25874935
,	25874935
the	25874935
mechanism	25874935
of	25874935
protection	25874935
is	25874935
poorly	25874935
understood	25874935
.	25874935

We	25874935
thus	25874935
attempted	25874935
to	25874935
confirm	25874935
neuroprotective	25874935
effects	25874935
of	25874935
NSP	25874935
on	25874935
astrocytes	25874935
in	25874935
the	25874935
ischemic	25874935
state	25874935
and	25874935
then	25874935
explored	25874935
the	25874935
relative	25874935
mechanisms	25874935
.	25874935

Astrocytes	25874935
from	25874935
neonatal	25874935
rats	25874935
were	25874935
treated	25874935
with	25874935
oxygen	25874935
-	25874935
glucose	25874935
deprivation	25874935
(	25874935
OGD	25874935
)	25874935
followed	25874935
by	25874935
reoxygenation	25874935
(	25874935
OGD	25874935
/	25874935
R	25874935
)	25874935
.	25874935

To	25874935
confirm	25874935
the	25874935
neuroprotective	25874935
effects	25874935
of	25874935
NSP	25874935
,	25874935
we	25874935
measured	25874935
the	25874935
cell	25874935
survival	25874935
rate	25874935
,	25874935
relative	25874935
lactate	25874935
dehydrogenase	25874935
(	25874935
LDH	25874935
)	25874935
release	25874935
;	25874935
we	25874935
also	25874935
performed	25874935
morphological	25874935
methods	25874935
,	25874935
namely	25874935
Hoechst	25874935
33342	25874935
staining	25874935
and	25874935
Annexin	25874935
V	25874935
assay	25874935
.	25874935

To	25874935
explore	25874935
the	25874935
potential	25874935
mechanisms	25874935
of	25874935
NSP	25874935
,	25874935
the	25874935
release	25874935
of	25874935
nitric	25874935
oxide	25874935
(	25874935
NO	25874935
)	25874935
and	25874935
TNF	25874935
-	25874935
alpha	25874935
related	25874935
to	25874935
NSP	25874935
administration	25874935
were	25874935
measured	25874935
by	25874935
enzyme	25874935
-	25874935
linked	25874935
immunosorbent	25874935
assay	25874935
.	25874935

The	25874935
proteins	25874935
related	25874935
to	25874935
the	25874935
NF	25874935
-	25874935
kappaB	25874935
,	25874935
ERK1	25874935
/	25874935
2	25874935
,	25874935
and	25874935
PI3K	25874935
/	25874935
Akt	25874935
pathways	25874935
were	25874935
investigated	25874935
by	25874935
Western	25874935
blotting	25874935
.	25874935

To	25874935
verify	25874935
the	25874935
cause	25874935
-	25874935
and	25874935
-	25874935
effect	25874935
relationship	25874935
between	25874935
neuroprotection	25874935
and	25874935
the	25874935
NF	25874935
-	25874935
kappaB	25874935
pathway	25874935
,	25874935
a	25874935
NF	25874935
-	25874935
kappaB	25874935
pathway	25874935
inhibitor	25874935
sc3060	25874935
was	25874935
employed	25874935
to	25874935
observe	25874935
the	25874935
effects	25874935
of	25874935
NSP	25874935
-	25874935
induced	25874935
neuroprotection	25874935
.	25874935

We	25874935
found	25874935
that	25874935
NSP	25874935
significantly	25874935
increased	25874935
the	25874935
cell	25874935
survival	25874935
rate	25874935
and	25874935
reduced	25874935
LDH	25874935
release	25874935
in	25874935
OGD	25874935
/	25874935
R	25874935
-	25874935
treated	25874935
astrocytes	25874935
.	25874935

It	25874935
also	25874935
reduced	25874935
NO	25874935
/	25874935
TNF	25874935
-	25874935
alpha	25874935
release	25874935
.	25874935

Western	25874935
blotting	25874935
showed	25874935
that	25874935
the	25874935
protein	25874935
levels	25874935
of	25874935
p	25874935
-	25874935
IKKBalpha	25874935
/	25874935
beta	25874935
and	25874935
P65	25874935
were	25874935
upregulated	25874935
by	25874935
the	25874935
OGD	25874935
/	25874935
R	25874935
treatment	25874935
and	25874935
such	25874935
effects	25874935
were	25874935
significantly	25874935
inhibited	25874935
by	25874935
NSP	25874935
administration	25874935
.	25874935

The	25874935
NSP	25874935
-	25874935
induced	25874935
inhibition	25874935
could	25874935
be	25874935
significantly	25874935
reversed	25874935
by	25874935
administration	25874935
of	25874935
the	25874935
NF	25874935
-	25874935
kappaB	25874935
pathway	25874935
inhibitor	25874935
sc3060	25874935
,	25874935
whereas	25874935
,	25874935
expressions	25874935
of	25874935
p	25874935
-	25874935
ERK1	25874935
,	25874935
p	25874935
-	25874935
ERK2	25874935
,	25874935
and	25874935
p	25874935
-	25874935
AKT	25874935
were	25874935
upregulated	25874935
by	25874935
the	25874935
OGD	25874935
/	25874935
R	25874935
treatment	25874935
;	25874935
however	25874935
,	25874935
their	25874935
levels	25874935
were	25874935
unchanged	25874935
by	25874935
NSP	25874935
administration	25874935
.	25874935

Our	25874935
results	25874935
thus	25874935
verified	25874935
the	25874935
neuroprotective	25874935
effects	25874935
of	25874935
NSP	25874935
in	25874935
ischemic	25874935
astrocytes	25874935
.	25874935

The	25874935
potential	25874935
mechanisms	25874935
include	25874935
inhibition	25874935
of	25874935
the	25874935
release	25874935
of	25874935
NO	25874935
/	25874935
TNF	25874935
-	25874935
alpha	25874935
and	25874935
repression	25874935
of	25874935
the	25874935
NF	25874935
-	25874935
kappaB	25874935
signaling	25874935
pathways	25874935
.	25874935

Our	25874935
data	25874935
also	25874935
indicated	25874935
that	25874935
NSP	25874935
has	25874935
little	25874935
influence	25874935
on	25874935
the	25874935
MAPK	25874935
and	25874935
PI3K	25874935
/	25874935
Akt	25874935
pathways	25874935
.	25874935

Genotype	21879313
rs8099917	21879313
near	21879313
the	21879313
IL28B	21879313
gene	21879313
and	21879313
amino	21879313
acid	21879313
substitution	21879313
at	21879313
position	21879313
70	21879313
in	21879313
the	21879313
core	21879313
region	21879313
of	21879313
the	21879313
hepatitis	21879313
C	21879313
virus	21879313
are	21879313
determinants	21879313
of	21879313
serum	21879313
apolipoprotein	21879313
B	21879313
-	21879313
100	21879313
concentration	21879313
in	21879313
chronic	21879313
hepatitis	21879313
C	21879313
.	21879313

The	21879313
life	21879313
cycle	21879313
of	21879313
the	21879313
hepatitis	21879313
C	21879313
virus	21879313
(	21879313
HCV	21879313
)	21879313
is	21879313
closely	21879313
related	21879313
to	21879313
host	21879313
lipoprotein	21879313
metabolism	21879313
.	21879313

Serum	21879313
levels	21879313
of	21879313
lipid	21879313
are	21879313
associated	21879313
with	21879313
the	21879313
response	21879313
to	21879313
pegylated	21879313
interferon	21879313
plus	21879313
ribavirin	21879313
(	21879313
PEG	21879313
-	21879313
IFN	21879313
/	21879313
RBV	21879313
)	21879313
therapy	21879313
,	21879313
while	21879313
single	21879313
nucleotide	21879313
polymorphisms	21879313
(	21879313
SNPs	21879313
)	21879313
around	21879313
the	21879313
human	21879313
interleukin	21879313
28B	21879313
(	21879313
IL28B	21879313
)	21879313
gene	21879313
locus	21879313
and	21879313
amino	21879313
acid	21879313
substitutions	21879313
in	21879313
the	21879313
core	21879313
region	21879313
of	21879313
the	21879313
HCV	21879313
have	21879313
been	21879313
reported	21879313
to	21879313
affect	21879313
the	21879313
efficacy	21879313
of	21879313
PEG	21879313
-	21879313
IFN	21879313
/	21879313
RBV	21879313
therapy	21879313
in	21879313
chronic	21879313
hepatitis	21879313
with	21879313
HCV	21879313
genotype	21879313
1b	21879313
infection	21879313
.	21879313

The	21879313
aim	21879313
of	21879313
this	21879313
study	21879313
was	21879313
to	21879313
elucidate	21879313
the	21879313
relationship	21879313
between	21879313
serum	21879313
lipid	21879313
and	21879313
factors	21879313
that	21879313
are	21879313
able	21879313
to	21879313
predict	21879313
the	21879313
efficacy	21879313
of	21879313
PEG	21879313
-	21879313
IFN	21879313
/	21879313
RB	21879313
therapy	21879313
,	21879313
with	21879313
specific	21879313
focus	21879313
on	21879313
apolipoprotein	21879313
B	21879313
-	21879313
100	21879313
(	21879313
apoB	21879313
-	21879313
100	21879313
)	21879313
in	21879313
148	21879313
subjects	21879313
with	21879313
chronic	21879313
HCV	21879313
G1b	21879313
infection	21879313
.	21879313

Our	21879313
results	21879313
demonstrated	21879313
that	21879313
both	21879313
the	21879313
aa	21879313
70	21879313
substitution	21879313
in	21879313
the	21879313
core	21879313
region	21879313
of	21879313
the	21879313
HCV	21879313
and	21879313
the	21879313
rs8099917	21879313
SNP	21879313
located	21879313
proximal	21879313
to	21879313
the	21879313
IL28B	21879313
were	21879313
independent	21879313
factors	21879313
in	21879313
determining	21879313
serum	21879313
apoB	21879313
-	21879313
100	21879313
and	21879313
low	21879313
-	21879313
density	21879313
lipoprotein	21879313
(	21879313
LDL	21879313
)	21879313
cholesterol	21879313
levels	21879313
.	21879313

A	21879313
significant	21879313
association	21879313
was	21879313
noted	21879313
between	21879313
higher	21879313
levels	21879313
of	21879313
apoB	21879313
-	21879313
100	21879313
(	21879313
P	21879313
=	21879313
1	21879313
.	21879313
1	21879313
10	21879313
(	21879313
-	21879313
3	21879313
)	21879313
)	21879313
and	21879313
LDL	21879313
cholesterol	21879313
(	21879313
P	21879313
=	21879313
0	21879313
.	21879313
02	21879313
)	21879313
and	21879313
the	21879313
subjects	21879313
having	21879313
Arg70	21879313
.	21879313

A	21879313
significant	21879313
association	21879313
was	21879313
also	21879313
observed	21879313
between	21879313
subjects	21879313
carrying	21879313
the	21879313
rs8099917	21879313
TT	21879313
responder	21879313
genotype	21879313
and	21879313
higher	21879313
levels	21879313
of	21879313
apoB	21879313
-	21879313
100	21879313
(	21879313
P	21879313
=	21879313
6	21879313
.	21879313
4	21879313
10	21879313
(	21879313
-	21879313
3	21879313
)	21879313
)	21879313
and	21879313
LDL	21879313
cholesterol	21879313
(	21879313
P	21879313
=	21879313
4	21879313
.	21879313
2	21879313
10	21879313
(	21879313
-	21879313
3	21879313
)	21879313
)	21879313
.	21879313

Our	21879313
results	21879313
suggest	21879313
that	21879313
apoB	21879313
-	21879313
100	21879313
and	21879313
LDL	21879313
cholesterol	21879313
are	21879313
markers	21879313
of	21879313
impaired	21879313
cellular	21879313
lipoprotein	21879313
pathways	21879313
and	21879313
/	21879313
or	21879313
host	21879313
endogenous	21879313
interferon	21879313
response	21879313
to	21879313
HCV	21879313
in	21879313
chronic	21879313
HCV	21879313
infection	21879313
.	21879313

In	21879313
particular	21879313
,	21879313
serum	21879313
apoB	21879313
-	21879313
100	21879313
concentration	21879313
might	21879313
be	21879313
an	21879313
informative	21879313
marker	21879313
for	21879313
judging	21879313
changes	21879313
in	21879313
HCV	21879313
-	21879313
associated	21879313
intracellular	21879313
lipoprotein	21879313
metabolism	21879313
in	21879313
patients	21879313
carrying	21879313
the	21879313
rs8099917	21879313
responder	21879313
genotype	21879313
.	21879313
Randomized	17151160
comparison	17151160
of	17151160
olanzapine	17151160
versus	17151160
risperidone	17151160
for	17151160
the	17151160
treatment	17151160
of	17151160
first	17151160
-	17151160
episode	17151160
schizophrenia	17151160
:	17151160
4	17151160
-	17151160
month	17151160
outcomes	17151160
.	17151160

OBJECTIVE	17151160
:	17151160
The	17151160
authors	17151160
compared	17151160
4	17151160
-	17151160
month	17151160
treatment	17151160
outcomes	17151160
for	17151160
olanzapine	17151160
versus	17151160
risperidone	17151160
in	17151160
patients	17151160
with	17151160
first	17151160
-	17151160
episode	17151160
schizophrenia	17151160
spectrum	17151160
disorders	17151160
.	17151160

METHOD	17151160
:	17151160
One	17151160
hundred	17151160
twelve	17151160
subjects	17151160
(	17151160
70%	17151160
male	17151160
;	17151160
mean	17151160
age	17151160
=	17151160
23	17151160
.	17151160
3	17151160
years	17151160
[	17151160
SD	17151160
=	17151160
5	17151160
.	17151160
1	17151160
]	17151160
)	17151160
with	17151160
first	17151160
-	17151160
episode	17151160
schizophrenia	17151160
(	17151160
75%	17151160
)	17151160
,	17151160
schizophreniform	17151160
disorder	17151160
(	17151160
17%	17151160
)	17151160
,	17151160
or	17151160
schizoaffective	17151160
disorder	17151160
(	17151160
8%	17151160
)	17151160
were	17151160
randomly	17151160
assigned	17151160
to	17151160
treatment	17151160
with	17151160
olanzapine	17151160
(	17151160
2	17151160
.	17151160
5	17151160
-	17151160
20	17151160
mg	17151160
/	17151160
day	17151160
)	17151160
or	17151160
risperidone	17151160
(	17151160
1	17151160
-	17151160
6	17151160
mg	17151160
/	17151160
day	17151160
)	17151160
.	17151160

RESULTS	17151160
:	17151160
Response	17151160
rates	17151160
did	17151160
not	17151160
significantly	17151160
differ	17151160
between	17151160
olanzapine	17151160
(	17151160
43	17151160
.	17151160
7%	17151160
,	17151160
95%	17151160
CI	17151160
=	17151160
28	17151160
.	17151160
8%	17151160
-	17151160
58	17151160
.	17151160
6%	17151160
)	17151160
and	17151160
risperidone	17151160
(	17151160
54	17151160
.	17151160
3%	17151160
,	17151160
95%	17151160
CI	17151160
=	17151160
39	17151160
.	17151160
9%	17151160
-	17151160
68	17151160
.	17151160
7%	17151160
)	17151160
.	17151160

Among	17151160
those	17151160
responding	17151160
to	17151160
treatment	17151160
,	17151160
more	17151160
subjects	17151160
in	17151160
the	17151160
olanzapine	17151160
group	17151160
(	17151160
40	17151160
.	17151160
9%	17151160
,	17151160
95%	17151160
CI	17151160
=	17151160
16	17151160
.	17151160
8%	17151160
-	17151160
65	17151160
.	17151160
0%	17151160
)	17151160
than	17151160
in	17151160
the	17151160
risperidone	17151160
group	17151160
(	17151160
18	17151160
.	17151160
9%	17151160
,	17151160
95%	17151160
CI	17151160
=	17151160
0%	17151160
-	17151160
39	17151160
.	17151160
2%	17151160
)	17151160
had	17151160
subsequent	17151160
ratings	17151160
not	17151160
meeting	17151160
response	17151160
criteria	17151160
.	17151160

Negative	17151160
symptom	17151160
outcomes	17151160
and	17151160
measures	17151160
of	17151160
parkinsonism	17151160
and	17151160
akathisia	17151160
did	17151160
not	17151160
differ	17151160
between	17151160
medications	17151160
.	17151160

Extrapyramidal	17151160
symptom	17151160
severity	17151160
scores	17151160
were	17151160
1	17151160
.	17151160
4	17151160
(	17151160
95%	17151160
CI	17151160
=	17151160
1	17151160
.	17151160
2	17151160
-	17151160
1	17151160
.	17151160
6	17151160
)	17151160
with	17151160
risperidone	17151160
and	17151160
1	17151160
.	17151160
2	17151160
(	17151160
95%	17151160
CI	17151160
=	17151160
1	17151160
.	17151160
0	17151160
-	17151160
1	17151160
.	17151160
4	17151160
)	17151160
with	17151160
olanzapine	17151160
.	17151160

Significantly	17151160
more	17151160
weight	17151160
gain	17151160
occurred	17151160
with	17151160
olanzapine	17151160
than	17151160
with	17151160
risperidone	17151160
:	17151160
the	17151160
increase	17151160
in	17151160
weight	17151160
at	17151160
4	17151160
months	17151160
relative	17151160
to	17151160
baseline	17151160
weight	17151160
was	17151160
17	17151160
.	17151160
3%	17151160
(	17151160
95%	17151160
CI	17151160
=	17151160
14	17151160
.	17151160
2%	17151160
-	17151160
20	17151160
.	17151160
5%	17151160
)	17151160
with	17151160
olanzapine	17151160
and	17151160
11	17151160
.	17151160
3%	17151160
(	17151160
95%	17151160
CI	17151160
=	17151160
8	17151160
.	17151160
4%	17151160
-	17151160
14	17151160
.	17151160
3%	17151160
)	17151160
with	17151160
risperidone	17151160
.	17151160

Body	17151160
mass	17151160
index	17151160
at	17151160
baseline	17151160
and	17151160
at	17151160
4	17151160
months	17151160
was	17151160
24	17151160
.	17151160
3	17151160
(	17151160
95%	17151160
CI	17151160
=	17151160
22	17151160
.	17151160
8	17151160
-	17151160
25	17151160
.	17151160
7	17151160
)	17151160
versus	17151160
28	17151160
.	17151160
2	17151160
(	17151160
95%	17151160
CI	17151160
=	17151160
26	17151160
.	17151160
7	17151160
-	17151160
29	17151160
.	17151160
7	17151160
)	17151160
with	17151160
olanzapine	17151160
and	17151160
23	17151160
.	17151160
9	17151160
(	17151160
95%	17151160
CI	17151160
=	17151160
22	17151160
.	17151160
5	17151160
-	17151160
25	17151160
.	17151160
3	17151160
)	17151160
versus	17151160
26	17151160
.	17151160
7	17151160
(	17151160
95%	17151160
CI	17151160
=	17151160
25	17151160
.	17151160
2	17151160
-	17151160
28	17151160
.	17151160
2	17151160
)	17151160
with	17151160
risperidone	17151160
.	17151160

CONCLUSIONS	17151160
:	17151160
Clinical	17151160
outcomes	17151160
with	17151160
risperidone	17151160
were	17151160
equal	17151160
to	17151160
those	17151160
with	17151160
olanzapine	17151160
,	17151160
and	17151160
response	17151160
may	17151160
be	17151160
more	17151160
stable	17151160
.	17151160

Olanzapine	17151160
may	17151160
have	17151160
an	17151160
advantage	17151160
for	17151160
motor	17151160
side	17151160
effects	17151160
.	17151160

Both	17151160
medications	17151160
caused	17151160
substantial	17151160
rapid	17151160
weight	17151160
gain	17151160
,	17151160
but	17151160
weight	17151160
gain	17151160
was	17151160
greater	17151160
with	17151160
olanzapine	17151160
.	17151160
Association	17166870
between	17166870
an	17166870
endoglin	17166870
gene	17166870
polymorphism	17166870
and	17166870
systemic	17166870
sclerosis	17166870
-	17166870
related	17166870
pulmonary	17166870
arterial	17166870
hypertension	17166870
.	17166870

Systemic	17166870
sclerosis	17166870
(	17166870
SSc	17166870
)	17166870
is	17166870
a	17166870
connective	17166870
tissue	17166870
disorder	17166870
characterized	17166870
by	17166870
early	17166870
generalized	17166870
microangiopathy	17166870
with	17166870
disturbed	17166870
angiogenesis	17166870
.	17166870

Endoglin	17166870
gene	17166870
(	17166870
ENG	17166870
)	17166870
encodes	17166870
a	17166870
transmembrane	17166870
glycoprotein	17166870
which	17166870
acts	17166870
as	17166870
an	17166870
accessory	17166870
receptor	17166870
for	17166870
the	17166870
transforming	17166870
growth	17166870
factor	17166870
-	17166870
beta	17166870
(	17166870
TGF	17166870
-	17166870
beta	17166870
)	17166870
superfamily	17166870
,	17166870
and	17166870
is	17166870
crucial	17166870
for	17166870
maintaining	17166870
vascular	17166870
integrity	17166870
.	17166870

A	17166870
6	17166870
-	17166870
base	17166870
insertion	17166870
in	17166870
intron	17166870
7	17166870
(	17166870
6bINS	17166870
)	17166870
of	17166870
ENG	17166870
has	17166870
been	17166870
reported	17166870
to	17166870
be	17166870
associated	17166870
with	17166870
microvascular	17166870
disturbance	17166870
.	17166870

OBJECTIVES	17166870
:	17166870
Our	17166870
objective	17166870
was	17166870
to	17166870
investigate	17166870
the	17166870
relationship	17166870
between	17166870
6bINS	17166870
and	17166870
the	17166870
vascular	17166870
complication	17166870
pulmonary	17166870
arterial	17166870
hypertension	17166870
(	17166870
PAH	17166870
)	17166870
in	17166870
SSc	17166870
in	17166870
a	17166870
French	17166870
Caucasian	17166870
population	17166870
.	17166870

METHODS	17166870
:	17166870
Two	17166870
hundred	17166870
eighty	17166870
SSc	17166870
cases	17166870
containing	17166870
29	17166870
/	17166870
280	17166870
having	17166870
PAH	17166870
diagnosed	17166870
by	17166870
catheterism	17166870
were	17166870
compared	17166870
with	17166870
140	17166870
patients	17166870
with	17166870
osteoarthritis	17166870
.	17166870

Genotyping	17166870
was	17166870
performed	17166870
by	17166870
polymerase	17166870
-	17166870
chain	17166870
-	17166870
reaction	17166870
-	17166870
based	17166870
fluorescence	17166870
and	17166870
direct	17166870
sequencing	17166870
of	17166870
genomic	17166870
DNA	17166870
.	17166870

RESULTS	17166870
:	17166870
The	17166870
polymorphism	17166870
was	17166870
in	17166870
Hardy	17166870
-	17166870
Weinberg	17166870
equilibrium	17166870
.	17166870

We	17166870
observed	17166870
a	17166870
significant	17166870
lower	17166870
frequency	17166870
of	17166870
6bINS	17166870
allele	17166870
in	17166870
SSc	17166870
patients	17166870
with	17166870
associated	17166870
PAH	17166870
compared	17166870
with	17166870
controls	17166870
[	17166870
10	17166870
.	17166870
3	17166870
vs	17166870
23	17166870
.	17166870
9%	17166870
,	17166870
P	17166870
=	17166870
0	17166870
.	17166870
01	17166870
;	17166870
odds	17166870
ratio	17166870
(	17166870
OR	17166870
)	17166870
0	17166870
.	17166870
37	17166870
,	17166870
95%	17166870
confidence	17166870
interval	17166870
(	17166870
CI	17166870
)	17166870
0	17166870
.	17166870
15	17166870
-	17166870
0	17166870
.	17166870
89	17166870
]	17166870
,	17166870
and	17166870
a	17166870
trend	17166870
in	17166870
comparison	17166870
with	17166870
SSc	17166870
patients	17166870
without	17166870
PAH	17166870
(	17166870
10	17166870
.	17166870
3	17166870
vs	17166870
20	17166870
.	17166870
3%	17166870
,	17166870
P	17166870
=	17166870
0	17166870
.	17166870
05	17166870
;	17166870
OR	17166870
:	17166870
0	17166870
.	17166870
45	17166870
,	17166870
95%	17166870
CI	17166870
:	17166870
0	17166870
.	17166870
19	17166870
-	17166870
1	17166870
.	17166870
08	17166870
)	17166870
.	17166870

Genotypes	17166870
carrying	17166870
allele	17166870
6bINS	17166870
were	17166870
also	17166870
less	17166870
frequent	17166870
in	17166870
SSc	17166870
patients	17166870
with	17166870
PAH	17166870
than	17166870
in	17166870
controls	17166870
(	17166870
20	17166870
.	17166870
7	17166870
vs	17166870
42	17166870
.	17166870
9%	17166870
,	17166870
P	17166870
=	17166870
0	17166870
.	17166870
02	17166870
)	17166870
.	17166870

CONCLUSIONS	17166870
:	17166870
Thus	17166870
the	17166870
frequency	17166870
of	17166870
6bINS	17166870
differs	17166870
between	17166870
SSc	17166870
patients	17166870
with	17166870
or	17166870
without	17166870
PAH	17166870
,	17166870
suggesting	17166870
the	17166870
implication	17166870
of	17166870
ENG	17166870
in	17166870
this	17166870
devastating	17166870
vascular	17166870
complication	17166870
of	17166870
SSc	17166870
.	17166870
Screening	15951966
for	15951966
exonic	15951966
copy	15951966
number	15951966
mutations	15951966
at	15951966
MSH2	15951966
and	15951966
MLH1	15951966
by	15951966
MAPH	15951966
.	15951966

BACKGROUND	15951966
:	15951966
Exonic	15951966
deletions	15951966
in	15951966
MSH2	15951966
and	15951966
MLH1	15951966
are	15951966
significant	15951966
contributors	15951966
to	15951966
the	15951966
mutation	15951966
spectrum	15951966
in	15951966
HNPCC	15951966
,	15951966
and	15951966
heterozygous	15951966
changes	15951966
in	15951966
exon	15951966
copy	15951966
number	15951966
are	15951966
not	15951966
detected	15951966
by	15951966
conventional	15951966
mutation	15951966
screening	15951966
methods	15951966
.	15951966

AIMS	15951966
:	15951966
We	15951966
aimed	15951966
to	15951966
develop	15951966
methods	15951966
for	15951966
screening	15951966
copy	15951966
number	15951966
changes	15951966
in	15951966
all	15951966
the	15951966
exons	15951966
of	15951966
the	15951966
MLH1	15951966
and	15951966
MSH2	15951966
genes	15951966
using	15951966
a	15951966
single	15951966
multiplex	15951966
amplifiable	15951966
probe	15951966
hybridisation	15951966
(	15951966
MAPH	15951966
)	15951966
assay	15951966
.	15951966

METHODS	15951966
:	15951966
We	15951966
developed	15951966
a	15951966
probe	15951966
set	15951966
consisting	15951966
of	15951966
probes	15951966
from	15951966
the	15951966
19	15951966
exons	15951966
of	15951966
MLH1	15951966
and	15951966
16	15951966
exons	15951966
of	15951966
MSH2	15951966
,	15951966
and	15951966
3	15951966
control	15951966
probes	15951966
,	15951966
and	15951966
applied	15951966
it	15951966
to	15951966
screening	15951966
for	15951966
deletions	15951966
and	15951966
duplications	15951966
using	15951966
fluorescent	15951966
detection	15951966
of	15951966
amplified	15951966
fragments	15951966
.	15951966

RESULTS	15951966
:	15951966
We	15951966
tested	15951966
73	15951966
DNA	15951966
samples	15951966
from	15951966
controls	15951966
and	15951966
50	15951966
from	15951966
HNPCC	15951966
patients	15951966
in	15951966
whom	15951966
no	15951966
point	15951966
mutations	15951966
had	15951966
been	15951966
found	15951966
,	15951966
and	15951966
detected	15951966
10	15951966
copy	15951966
number	15951966
changes	15951966
among	15951966
the	15951966
patient	15951966
samples	15951966
.	15951966

A	15951966
deletion	15951966
of	15951966
about	15951966
1	15951966
.	15951966
4	15951966
kb	15951966
including	15951966
exon	15951966
3	15951966
of	15951966
MSH2	15951966
was	15951966
confirmed	15951966
by	15951966
amplification	15951966
of	15951966
a	15951966
junction	15951966
fragment	15951966
,	15951966
and	15951966
was	15951966
shown	15951966
to	15951966
be	15951966
the	15951966
result	15951966
of	15951966
an	15951966
unequal	15951966
recombination	15951966
between	15951966
intronic	15951966
Alu	15951966
elements	15951966
.	15951966

CONCLUSIONS	15951966
:	15951966
MAPH	15951966
can	15951966
detect	15951966
exonic	15951966
copy	15951966
number	15951966
changes	15951966
in	15951966
MLH1	15951966
and	15951966
MSH2	15951966
in	15951966
DNA	15951966
from	15951966
HNPCC	15951966
patients	15951966
.	15951966

Since	15951966
finding	15951966
an	15951966
exonic	15951966
deletion	15951966
or	15951966
duplication	15951966
makes	15951966
full	15951966
sequence	15951966
analysis	15951966
unnecessary	15951966
,	15951966
it	15951966
may	15951966
be	15951966
most	15951966
cost	15951966
-	15951966
effective	15951966
to	15951966
pre	15951966
-	15951966
screen	15951966
samples	15951966
by	15951966
MAPH	15951966
or	15951966
MLPA	15951966
before	15951966
screening	15951966
for	15951966
point	15951966
mutations	15951966
.	15951966
